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FSP Section 11,000
Checklists and Illustrative Financial
Statements for Health Care Entities
Letter to Customers
Dear Valued Customer,
The following checklists and illustrative materials have been developed by the AICPA Accounting and Auditing Publications Staff to serve as nonauthoritative practice aids for use by preparers of financial statements and by practitioners who audit, review, or compile financial statements. The auditor’s and accountant’s report checklists address those requirements most likely to be encountered when reporting on financial
statements of a commercial corporation prepared in conformity with U.S. generally accepted accounting
principles.
Relevant financial statement reporting and disclosure guidance issued through September 30, 2010, has been
considered in the development of this edition of the checklist. The accounting guidance in this checklist has
been conformed to reflect reference to FASB Accounting Standards Codificatione as it existed on September
30, 2010.
Any guidance issued subsequent to September 30, 2010, has not been included in this checklist; therefore, if
your entity has a fiscal year-end after September 30, 2010, you need to consider the applicability of such
guidance. In determining the applicability of newly issued guidance, its effective date also should be considered.
Recognizing that many entities have December 31 year-ends and in an effort to assist those users, this checklist includes guidance issued through September 30, 2010, which may become effective by December 31,
2010. Additional questions appear and are indicated with an “A” or “B” reference. As determined by the
effective date or early implementation decision
●

entities for which this guidance has not been implemented should consider all questions with an
“A” reference (for example, question 1A, question 2A, and so on) and should place an “N/A” mark
by questions with a “B” reference.

●

entities for which this guidance has been implemented should consider all questions with a “B”
reference (for example, question 1B, question 2B, and so on) and should place an “N/A” mark by
questions with an “A” reference.

Therefore, based upon the year-end of the entities and the decision to early implement (if allowed), the
appropriate additional questions should be answered when provided.
We hope you find this checklist helpful as you perform your audit and compilation and review engagements. We would greatly appreciate your feedback on this checklist. You may e-mail these comments to
A&APublications@aicpa.org or write to
A&A Publications
AICPA
220 Leigh Farm Road
Durham, NC 27707-8110

FSP §11,000
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Description
.01 Health care entities may be classified by sponsorship or legal structure within the following broad
categories:
Not-for-profit business-oriented. These are essentially self-sustaining from fees charged for goods and
services. The fees charged by such entities generally are intended to help the entity maintain its selfsustaining status rather than to maximize profits for the owner’s benefit. Such entities often are
exempt from federal income taxes and may receive contributions of relatively small amounts from
resource providers that do not expect commensurate or proportionate pecuniary returns.
Not-for-profit nonbusiness-oriented. These are voluntary health and welfare entities as defined in Financial Accounting Standards Board (FASB) Statement No. 117, Financial Statements of Not-for-Profit
Organizations. Such entities are within the scope of AICPA Audit and Accounting Guide Not-forProfit Entities, rather than that of Audit and Accounting Guide Health Care Entities.
Governmental. Often called public health care entities, the entities are owned and operated by federal,
state, city, or county governments or other political subdivisions.
Investor- (or operator-) owned. These entities operate as stock corporations, partnerships, or sole proprietorships.
.02 Health care entities include, but are not limited to, the following:
●

Clinics, medical group practices, individual practitioners and practice associations, and other
ambulatory care entities

●

Continuing care retirement communities

●

Health maintenance organizations and similar prepaid health care plans

●

Home health agencies

●

Hospitals

●

Nursing homes that provide skilled, intermediate, and less intensive levels of health care

●

Parent companies, holding companies, and other entities that primarily plan, organize, and
oversee health care services

Applicability of These Checklists
.03 These checklists, and the illustrative financial statements included herein, follow the guidance contained in AICPA Audit and Accounting Guide Health Care Entities (with conforming changes as of June 1,
2010), referred to as “the guide.” These checklists and illustrative financial statements should be used for
not-for-profit business-oriented and investor-owned health care entities. These checklists do not apply to not-forprofit nonbusiness-oriented health care entities. For these types of entities, follow the guidance in AICPA Audit
and Accounting Guide Not-for-Profit Entities and the AICPA’s Checklists and Illustrative Financial Statements Not-for-Profit Entities.
.04 Not-for-profit health care providers that receive federal financial assistance may be required to have
an audit conducted in accordance with Office of Management and Budget (OMB) Circular A-133, Audits of
States, Local Governments, and Non-Profit Organizations. FSP section 11,300 includes guidance for auditors’
reports for audits performed under OMB Circular A-133.
.05 Although the guide also applies to state and local government-owned health care providers, these
checklists do not include disclosures or sample financial statements of government-owned providers. Chapter
1 of the guide discusses the application of generally accepted accounting principles (GAAP) to governmental
health care providers.

FSP §11,000.01
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Legislation and Regulation
.06 Significant aspects of health care entity operations are affected by government legislation and regulation with many states adopting laws governing the granting of licenses, as well as scope of services to be
rendered. In addition, many independent entities and governmental agencies, including Medicare and Medicaid, evaluate programs and services of health care entities to determine compliance with set standards.

Basic Financial Statements
.07 The financial reporting for not-for-profit business-oriented entities and investor-owned health care
enterprises generally is consistent except for transactions that clearly are not applicable. For example, notfor-profit business-oriented entities, by their nature, do not have shareholders’ equity. On the other hand,
investor-owned health care enterprises typically do not receive contributions.
.08 The basic financial statements of health care providers generally consist of a statement of financial
position or balance sheet, a statement of activities or income statement or statement of operations, a statement of changes in net assets (equity), a statement of cash flows, and notes to the financial statements. The
titles of the financial statements will depend upon the business form of the provider (that is, not-for-profit
and investor-owned). See the following chart:
Basic Financial Statements
Not-for-Profit
Business-Oriented Entity
Investor-Owned Entity
Balance Sheet/Statement of Financial Position
Statement of Operations/Statement of
Activities
Statement of Changes in Net Assets
Statement of Cash Flows

Balance Sheet
Statement of Operations/Income Statement
Statement of Changes in Equity
Statement of Cash Flows

General
.09 This publication includes the following information:
●

Financial Statements and Notes Checklist (FSP section 11,100)—For use by preparers of financial statements and by practitioners who audit or compile them as they evaluate the adequacy
of disclosures.

●

Auditors’ Reports Checklist (FSP section 11,200)—For use by auditors in reporting on audited
financial statements.

●

Auditors’ Reports Checklist for Audits Performed in Accordance With Government Auditing
Standards and OMB Circular A-133 (FSP section 11,300).

●

Illustrative Financial Statement Formats (FSP section 11,400)—Formats commonly used to
present financial statements for both not-for-profit business-oriented and investor-owned health care
entities.

.10 These checklists and illustrative materials are intended to be used in connection with engagements
of nonpublic entities and are not intended to be used in connection with audits of public entities that are
required to be audited under standards set by the Public Company Accounting Oversight Board (PCAOB).
.11 These checklists are applicable to not-for-profit business-oriented and investor-owned health care entities.
Although financial reporting for these types of entities is generally consistent, there are requirements that
apply to only not-for-profit business-oriented entities and those that apply to only investor-owned enterprises. Symbols have been used to indicate the applicability of presentation and disclosure requirements to
these types of entities. Not-for-profit business-oriented entities should complete all disclosure items denoted
with a star (.). Investor-owned entities should complete all disclosure items denoted with a diamond (l).

FSP §11,000.11
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.12 These checklists and illustrative materials have been developed by the AICPA Accounting and Auditing Publications staff to serve as nonauthoritative practice aids for use by preparers of financial statements and by practitioners who audit or compile them. The auditor’s and accountant’s report checklists
address those requirements most likely to be encountered when reporting on financial statements of a notfor-profit business-oriented or investor-owned health care entity prepared in conformity with U.S. GAAP. They
do not include reporting requirements relating to other matters such as internal control or agreed-upon
procedures. The financial statement and notes checklist includes disclosure considerations applicable to notfor-profit business-oriented and investor-owned health care entities in preparing financial statements in conformity with U.S. GAAP.
.13 Users of the financial statements and notes checklist should remember that it is a disclosure checklist
only and not a comprehensive U.S. GAAP application or measurement checklist. Accordingly, application
and measurement issues related to preparing financial statements in conformity with U.S. GAAP are not
included in the checklist.
.14 The AICPA Accounting and Auditing Publications staff has included guidance from the FASB Accounting Standards Codificatione (ASC) as it existed September 30, 2010. Questions are derived primarily from
the content of the “Presentation” (section 45) and “Disclosure” (section 50) sections of FASB ASC. The AICPA Accounting and Auditing Publications staff has included presentation and disclosure items deemed
most likely to be encountered when reporting on the financial statements of a not-for-profit business-oriented
or investor-owned health care entity prepared in conformity with U.S. GAAP. Thus, not all paragraphs of the
“Presentation” and “Disclosure” sections of FASB ASC have been included. Users should evaluate whether
circumstances exist for which the relevant presentation and disclosure guidance is not provided in these
checklists and illustrative materials and refer directly to FASB ASC as appropriate. These checklists and
illustrative materials note significant areas where presentation and disclosure paragraphs were deemed too
specific for this general publication and, where noted, users are urged to consult FASB ASC as necessary.
.15 The checklists and illustrative financial statements should be used by, or under the supervision of,
persons having adequate technical training and proficiency in the application of U.S. GAAP, generally accepted auditing standards, and other relevant technical guidance.
.16 In some cases, this checklist uses the term additional presentation information or additional disclosure
information to further illustrate an item. In such cases, the information contained under those headings continues to be authoritative guidance and is included to further clarify a presentation or disclosure requirement or to add additional useful information.
.17 Relevant financial statement reporting and disclosure guidance issued through September 30, 2010,
has been considered in the development of this edition of the checklist. This includes relevant guidance
issued up to and including the following:
●
●
●

●

●
●

FASB Accounting Standards Updates issued through September 30, 2010
Statement on Auditing Standards No. 120, Required Supplementary Information (AICPA,
Professional Standards, vol. 1, AU sec. 558)
Interpretation No. 4, “Appropriateness of Identifying No Significant Deficiencies or No
Material Weaknesses in an Interim Communication,” of AU section 325, Communicating
Internal Control Related Matters Identified in an Audit (AICPA, Professional Standards, vol. 1,
AU sec. 9325 par. .11–.13)
Statement of Position 09-1, Performing Agreed-Upon Procedures Engagements That Address the
Completeness, Accuracy, or Consistency of XBRL-Tagged Data (AICPA, Technical Practice Aids,
AUD sec. 14,440)
Statement on Standards for Attestation Engagements No. 16, Reporting on Controls at a
Service Organization (AICPA, Professional Standards, vol. 1, AT sec. 801)
Interpretation No. 8, “Including a Description of Tests of Controls or Other Procedures, and
the Results Thereof, in an Examination Report,” of AT section 101, Attest Engagements
(AICPA, Professional Standards, vol. 1, AT sec. 9101 par. .70–.72)
(continued)

FSP §11,000.12

5

Checklists and Illustrative Financial Statements for Health Care Entities

●

Statement on Standards for Accounting and Review Services No. 19, Compilation and Review
Engagements (AICPA, Professional Standards, vol. 2)
Interpretation No. 31, “Preparation of Financial Statements for Use by an Entity’s Auditors,”
of AR section 100, Compilation and Review of Financial Statements (AICPA, Professional
Standards, vol. 2, AR sec. 9100 par. .136–.137)

●

.18 Any guidance issued subsequent to September 30, 2010, has not been included in this checklist;
therefore, if your entity has a fiscal year-end after September 30, 2010, you need to consider the applicability
of such guidance. In determining the applicability of newly issued guidance, its effective date should also
be considered.
.19 These checklists contain numerous references to authoritative accounting and auditing guidance.
Abbreviations and acronyms used in such references include the following:
AAG-NPO5 AICPA Audit and Accounting Guide Not-for-Profit Entities (with conforming changes
as of March 1, 2010)
AU5
Reference to a section number in AICPA Professional Standards for U.S. auditing
standards that are applicable to nonissuers
AUD5
Reference to a section number in AICPA Technical Practice Aids, Statements of
Position—Auditing and Attestation
FASB ASC5 Reference to a topic, subtopic, section, or paragraph in Financial Accounting
Standards Board Accounting Standards Codificatione
.20 On June 30, 2009, FASB issued FASB Statement No. 168, The FASB Accounting Standards Codificatione and the Hierarchy of Generally Accepted Accounting Principles—a replacement of FASB Statement No. 162,
which is codified in FASB ASC 105, Generally Accepted Accounting Principles. On the effective date of this
statement, FASB ASC became the authoritative source of U.S. accounting and reporting standards for nongovernmental entities, in addition to guidance issued by the SEC. At that time, FASB ASC superseded all
then-existing, non-SEC accounting and reporting standards for nongovernmental entities. Once effective, all
other nongrandfathered, non-SEC accounting literature not included in FASB ASC became nonauthoritative.
This statement became effective for financial statements issued for interim and annual periods ending after
September 15, 2009. See the FASB website at www.fasb.org for further information.

Instructions
.21 Within these checklists are a number of questions or statements that are accompanied by references
to applicable authoritative guidance. The financial statements and notes checklist is organized into nine
discrete sections. Disclosures listed in the “Presentation,” “Assets,” “Liabilities,” “Equity,” “Revenue,” and
“Expenses” sections are common to most not-for-profit business-oriented and investor-owned health care entities.
Those listed in the “Broad Transactions,” “Continuing Care Retirement Communities,” and “OMB Circular
A-133 Requirements” sections are required when circumstances dictate.
.22 The checklists provide spaces for checking off or initialing each question or point to indicate that it
has been considered. Carefully review the topics listed and consider whether they represent potential disclosure items for the reporting entity for which you are preparing or auditing financial statements. Users
should check or initial
●

Yes—If the disclosure is required and has been made appropriately.

●

No—If the disclosure is required but has not been made.

●

N/A (Not Applicable)—If the disclosure is not applicable to the entity.

.23 It is important that the effect of any “No” response be considered on the auditor’s or accountant’s
report. For audited financial statements, a “No” response that is material to the financial statements may
warrant a departure from an unqualified opinion as discussed in paragraphs .20–.64 of AU section 508,
Reports on Audited Financial Statements (AICPA, Professional Standards, vol. 1). If a “No” response is indicated,

FSP §11,000.23
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the Accounting and Auditing Publications staff recommends that a notation be made in the margin to explain why the disclosure was not made (for example, because the item was not considered to be material to
the financial statements).
.24 Users may find it helpful to use the right margin for certain other remarks and comments as appropriate, including the following:
a.

For each disclosure for which a “Yes” is indicated, a notation as to where the disclosure is
located in the financial statements and a cross-reference to the applicable working papers where
the support to a disclosure may be found

b.

For items marked as “N/A,” the reasons for which they do not apply in the circumstances of
the particular report

c.

For each disclosure for which a “No” response is indicated, a notation as to why the disclosure
was not made (for example, because the item was not considered to be material to the financial
statements)

.25 This checklist includes guidance mandatorily effective for annual reporting periods ending on or
before September 30, 2010. Recognizing that many entities have December 31 year-ends, this checklist also
includes guidance issued through September 30, 2010, that may become effective for annual reporting periods ending on or before December 31, 2010, either because of the effective date or an entity’s decision to
early adopt (where permitted). Any guidance included herein not yet mandatorily effective for annual reporting periods ending on or before September 30, 2010, is described in footnotes within each section of the
checklist where applicable.
.26 Where this aforementioned type of dual guidance is provided, the checklist questions are segregated
into those denoted with “A” references and those denoted with “B” references. Checklist questions pertaining to guidance mandatorily effective for annual reporting periods ending on or before September 30, 2010,
absent an entity’s decision to early adopt any superseding guidance (where applicable and permissible), are
denoted with “A” references. Entities to which the “A” references apply should place an “N/A” mark in
the related checklist questions denoted with a “B” reference. Checklist questions pertaining to guidance
issued through September 30, 2010, that may become effective for entities with annual reporting periods
ending on or before December 31, 2010, either because of the effective date or an entity’s decision to early
adopt (where permitted), are denoted with a “B” reference. Entities to which the “B” references apply should
place an “N/A” mark by questions denoted with an “A” reference. Therefore, depending upon your entity’s
(ies’) year-end(s) and decision(s) to early adopt (where permitted), the appropriate alternative questions
should be answered when provided.
.27 These checklists and illustrative materials have been prepared by the AICPA staff. They have not
been reviewed, approved, disapproved, or otherwise acted on by any senior technical committee of the
AICPA and do not represent official positions or pronouncements of the AICPA.
.28 The use of these or any other checklists requires the exercise of individual professional judgment.
These checklists are not substitutes for the original authoritative guidance. Users of these checklists and
illustrative materials are urged to refer directly to applicable authoritative guidance when appropriate. The
checklists and illustrative materials may not include all disclosures and presentation items promulgated, nor
do they represent minimum standards or requirements. Additionally, users of the checklists and illustrative
materials are encouraged to tailor them as required to meet specific circumstances of each particular engagement. As an additional resource, users may call the AICPA Technical Hotline at 877-242-7212.
.29 We hope you find this checklist helpful as you perform your audit and compilation and review
engagements. We would greatly appreciate your feedback on this checklist. You may e-mail your comments
to AandAPublications@aicpa.org.

FSP §11,000.24
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Recognition
.30
AICPA Staff
Anne Mundinger, CPA
Technical Manager
Accounting and Auditing Publications
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FSP Section 11,100
Financial Statements and Notes Checklist
.01 Checklist Questionnaire. This financial statement disclosure checklist is organized into sections. Carefully review the topics listed and consider whether they represent potential disclosure items for the entity
for which you are preparing, compiling, reviewing, or auditing financial statements. Place a check mark by
the topics or sections that are applicable and complete those sections of the checklist. Other sections may be
marked “N/A” or left blank. For example, if the entity had a change in accounting principle, place a check
mark by the section “Accounting Changes” and complete that section of the checklist. On the other hand, if
the entity did not have a change in accounting principle, do not place a check mark by “Accounting
Changes” and skip that section when completing the checklist.
Place U by
Sections
Applicable
I.

II.

Presentation
A.
Presentation of Financial Statements—Overall (Financial
Accounting Standards Board [FASB] Accounting Standards
Codification [ASC] 205-10)
B.
Presentation of Discontinued Operations in the Financial
Statements (FASB ASC 205-20)
C.
Presentation of the Balance Sheet—Overall (FASB ASC 210-10)
D.
Presentation of Offsetting in the Balance Sheet (FASB ASC 210-20)
E.
Presentation of Comprehensive Income (FASB ASC 220-10)
F.
Presentation of the Income Statement (FASB ASC 225-10)
G.
Presentation of Extraordinary and Unusual Items in the Income
Statement (FASB ASC 225-20)
H.
Income Statement Business Interruption (FASB ASC 225-30)
I.
Presentation of the Statement of Cash Flows (FASB ASC 230-10)
J.
Presentation of the Notes to Financial Statements (FASB ASC 23510)
K.
Presentation of Accounting Changes and Error Corrections (FASB
ASC 250-10)
L.
Presentation of Changing Prices (FASB ASC 255-10)
M.
Presentation of Earnings Per Share (FASB ASC 260-10)
N.
Presentation Regarding Interim Reporting (FASB ASC 270-10)
O.
Presentation Regarding Income Taxes for Interim Reporting (FASB
ASC 270-740)
P.
Presentation of Risks and Uncertainties (FASB ASC 275-10)
Q.
Presentation Regarding Segment Reporting (FASB ASC 280-10)
Assets
A.
Receivables (FASB ASC 310-10)
B.
Nonrefundable Fees and Other Costs (FASB ASC 310-20)
C.
Loans and Debt Securities Acquired With Deteriorated Credit
Quality (FASB ASC 310-30)
D.
Troubled Debt Restructurings by Creditors (FASB ASC 310-40)
E.
Investments—Debt and Equity Securities (FASB ASC 320-10)
F.
Investments—Equity Method and Joint Ventures (FASB ASC 32310)
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Place U by
Sections
Applicable
G.
H.
I.
J.
K.

III.

IV.

V.

VI.

Cost Method Investments (FASB ASC 325-20)
Investments in Insurance Contracts (FASB ASC 325-30)
Inventory (FASB ASC 330-10)
Capitalized Advertising Costs (FASB ASC 340-20)
Insurance Contracts That Do Not Transfer Insurance Risks (FASB
ASC 340-30)
L.
Goodwill (FASB ASC 350-20)
M.
General Intangibles Other Than Goodwill (FASB ASC 350-30)
N.
Property, Plant, and Equipment (FASB ASC 360-10)
Liabilities
A.
Liabilities—Overall (FASB ASC 405-10)
B.
Insurance-Related Assessment Liabilities (FASB ASC 405-30)
C.
Asset Retirement and Environmental Obligations (FASB ASC 41020)
D.
Asset Retirement and Environmental Obligations—Environmental
Obligations (FASB ASC 410-30)
E.
Exit or Disposal Cost Obligations (FASB ASC 420-10)
F.
Commitments (FASB ASC 440-10)
G.
Loss Contingencies (FASB ASC 450-20)
H.
Gain Contingencies (FASB ASC 450-30)
I.
Guarantees (FASB ASC 460-10)
J.
Debt—Overall (FASB ASC 470-10)
K.
Debt—Debt With Conversion and Other Options (FASB ASC 47020)
L.
Participating Mortgage Loans (FASB ASC 470-30)
M.
Debt Modifications and Extinguishments (FASB ASC 470-50)
N.
Troubled Debt Restructuring by Debtors (FASB ASC 470-60)
O.
Distinguishing Liabilities From Equity (FASB ASC 480-10)
Equity
A.
Equity (FASB ASC 505-10)
B.
Treasury Stock (FASB ASC 505-30)
C.
Equity-Based Payments to Nonemployees (FASB ASC 505-50)
Revenue
A.
Revenue Recognition—Products (FASB ASC 605-15)
B.
Revenue Recognition—Services (FASB ASC 605-20)
C.
Multiple Element Arrangements (FASB ASC 605-25)
D.
Milestone Method Revenue Recognition (FASB ASC 605-28)
E.
Gains and Losses—Revenue Recognition (FASB ASC 605-40)
F.
Principal Agent Considerations—Revenue Recognition (FASB ASC
605-45)
G.
Customer Payments and Incentives (FASB ASC 605-50)
Expenses
A.
Compensation (FASB ASC 710-10)
B.
Nonretirement Postemployment Benefits (FASB ASC 712-10)
C.
Defined Benefit Plans—Compensation (FASB ASC 715-20)
D.
Defined Benefit Plans—Other Postretirement (FASB ASC 715-60)
E.
Defined Contribution Plans (FASB ASC 715-70)
F.
Multiemployer Plans (FASB ASC 715-80)
G.
Stock Compensation (FASB ASC 718-10)
H.
Employee Stock Ownership Plans (FASB ASC 718-40)
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Place U by
Sections
Applicable
I.
J.
K.
L.
M.
N.
O.

VII.

VIII.
IX.

Insurance Costs (FASB ASC 720-20)
Advertising Costs (FASB ASC 720-35)
Research and Development Expenses (FASB ASC 730-10)
Research and Development Arrangements (FASB ASC 730-20)
Income Taxes (FASB ASC 740-10)
Intraperiod Tax Allocations (FASB ASC 740-20)
Income Taxes—Other Considerations or Special Areas (FASB ASC
740-30)
P.
Income Taxes—Interim Reporting (FASB ASC 740-270)
Broad Transactions
A.
Business Combinations (FASB ASC 805-10)
B.
Identifiable Assets and Liabilities, and Any Noncontrolling
Interest—Business Combinations (FASB ASC 805-20)
C.
Goodwill or Gain From Bargain Purchase, Including Consideration
Transferred (FASB ASC 805-30)
D.
Business Combinations—Related Issues (FASB ASC 805-50)
E.
Collaborative Arrangements (FASB ASC 808-10)
F.
Consolidation (FASB ASC 810-10)
G.
Derivatives and Hedging (FASB ASC 815-10)
H.
Embedded Derivatives (FASB ASC 815-15)
I.
Fair Value Hedging (FASB ASC 815-25)
J.
Cash Flow Hedges (FASB ASC 815-30)
K.
Net Investment Hedges (FASB ASC 815-35)
L.
Contracts in Entity’s Own Equity (FASB ASC 815-40)
M.
Weather Derivatives (FASB ASC 815-45)
N.
Fair Value Measurements and Disclosures (FASB ASC 820-10)
O.
Financial Instruments (FASB ASC 825-10)
P.
Financial Instruments—Registration Payment Arrangements (FASB
ASC 825-20)
Q.
Foreign Currency Transactions (FASB ASC 830-20)
R.
Foreign Currency Matters—Translation of Financial Statements
(FASB ASC 830-30)
S.
Capitalization of Interest (FASB ASC 835-20)
T.
Imputation of Interest (FASB ASC 835-30)
U.
Leases—Overall (Lessees) (FASB ASC 840-10)
V.
Operating Leases (Lessees) (FASB ASC 840-20)
W.
Capital Leases (Lessees) (FASB ASC 840-30)
X.
Sale-Leaseback Transactions (Lessees) (FASB ASC 840-40)
Y.
Leases—Overall (Lessors) (FASB ASC 840-10)
Z.
Operating Leases (Lessors) (FASB ASC 840-20)
AA.
Capital Leases (Lessors) (FASB ASC 840-30)
BB.
Nonmonetary Transactions (FASB ASC 845-10)
CC.
Related Party Disclosures (FASB ASC 850-10)
DD.
Reorganizations (FASB ASC 852-10 and FASB ASC 852-20)
EE.
Subsequent Events (FASB ASC 855-10)
FF.
Transfers and Servicing (FASB ASC 860-10)
GG.
Sales of Financial Assets (FASB ASC 860-20)
HH.
Secured Borrowing and Collateral (FASB ASC 860-30)
II.
Servicing Assets and Liabilities (FASB ASC 860-50)
Continuing Care Retirement Communities
OMB Circular A-133 Requirements
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I. Presentation
Yes
A.

Presentation of Financial Statements—Overall (FASB ASC 205-10)
Presentation
. 1.

Has the not-for-profit entity properly reported the following:
a.

Assets and liabilities classified in order of liquidity and
financial flexibility?

b.

Net assets classified in three groups—permanently restricted, temporarily restricted and unrestricted (based
on the existence of donor-imposed restrictions and the
nature of those restrictions)?

c.

Items of revenues, expenses, gains and losses, aggregated and classified as increases or decreases in permanently restricted, temporarily restricted or unrestricted net assets?

d.

Cash receipts and cash payments classified as resulting
from investing, financing, or operating activities?
[FASB ASC 958-205-45-2]

Expirations of Donor Imposed Restrictions
. 2.

Are net assets released from restriction, such as those related
to the fulfillment of time or purpose restrictions, reported
separately in the financial statements or disclosed in the
notes?
[FASB ASC 958-205-45-9]

. 3.

Has the entity properly recognized the expiration of a donorimposed restriction on a contribution in the period in which
the restriction expires, with the exception of donor-imposed
restrictions on long-lived assets which should be recognized
when the asset is placed in service? (Note: According to FASB
ASC 954-210-50-1, not-for-profit, business oriented health
care entities are prohibited from implying a time restriction
that expires over the useful life of a donated long-lived asset.)
[FASB ASC 954-205-45 par. 8–9]

Other
.l 4.

FSP §11,100.01

Has the entity properly presented, for a full presentation in
conformity with accounting principles generally accepted in
the United States (U.S. GAAP), the following financial statements:
a.

Statement of financial position (balance sheet?

b.

Statement of activities (statement of income operations/income statement)?

c.

Statement of changes in net assets (retained earnings or
changes in shareholders’ equity)? (Note: The statement
of changes in net assets (equity) may be combined with
the statement of activities per FASB ASC 954-225-45-1.)

d.

Statement of cash flows?

e.

Description of accounting policies?

No

N/A
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Yes
f.

No

N/A

Notes to the financial statements?
[FASB ASC 954-205-45-1]

.l 5.

Has the entity properly presented each financial statement
with a suitable title?
[Common Practice]

.l 6.

Has the entity properly presented a reference to the notes,
which are an integral part of the financial statements?
[Common Practice]

Endowments
. 7.

If losses in prior periods reduced the assets of a donor-restricted endowment fund below the level required by the donor stipulations or law, are gains that restore the fair value of
the assets of the endowment fund to the required level classified as increases in unrestricted net assets?
[FASB ASC 958-205-45-24]

. 8.

If the governing board determines that the relevant law requires the entity to retain permanently some portion of gains
on investment assets of endowment funds, is that amount reported as an increase in permanently restricted net assets?
[FASB ASC 958-205-45-21]

. 9.

In the absence of such a law or a donor’s explicit or clear implicit permanent restriction, is net appreciation reported as
unrestricted if the endowment’s income is unrestricted, or
temporarily restricted if the endowment’s income is temporarily restricted by the donor?
[FASB ASC 958-205-45-34]

. 10.

For not-for-profit entities with endowment funds in states
with UMIFA-based legislation: Unless the not-for-profit entity has made the election described in question 13 that follows, does the not-for-profit entity report income and gains
on donor-restricted endowment funds as
a.

increases in permanently restricted net assets if a donor’s explicit restriction or a law that extends a donor’s
restriction to the gains requires those gains to be held
permanently (for example, if a donor states that a specific investment must be held in perpetuity, the gains
on that security are subject to that same permanent restriction unless the donor states otherwise)?

b.

increases in temporarily restricted net assets if a donor’s explicit restriction or a law that extends a donor’s
restriction to the gains requires those gains to be used
for a particular purpose or at a particular future time
(gains are temporarily restricted if the investment income of a donor restricted endowment fund is temporarily restricted by the donor)?

c.

increases in unrestricted net assets if neither of the preceding questions 10a–b is applicable to the gains?

FSP §11,100.01
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Yes
. 11.

For not-for-profit entities with endowment funds in states
with UPMIFA-based legislation: unless the not-for-profit entity has made the election described in question 12 that follows, does the not-for-profit entity report income and gains
on donor-restricted endowment funds as
a.

increases in permanently restricted net assets if a donor’s explicit restriction or a law that extends a donor’s
restriction to the gains requires those gains to be held
permanently (for example, if a donor states that a specific investment must be held in perpetuity, the gains
on that security are subject to that same permanent restriction unless the donor states otherwise)?

b.

increases in temporarily restricted net assets if the preceding question 11a is not applicable to the gains?
[FASB ASC 958-205-45-31 and FASB ASC 958-205-45
par. 16–21A]

. 12.

This question is for investments that are not held in donorrestricted endowment funds: Unless the not-for-profit entity
has made the election described in question 13 that follows,
does the not-for-profit entity report investment income and
gains as increases in unrestricted net assets unless donors
otherwise restrict those income and gains?
[FASB ASC 958-320-45 par. 1–3]

. 13.

If the not-for-profit entity has elected to report investment income and gains as increases in unrestricted net assets if the
restrictions are met in the same period, are

. 14.

. 15.

FSP §11,100.01

a.

investment income and gains on which restriction have
not been met reported as described in the preceding
questions 10, 11, or 12, as applicable?

b.

investment income and gains on which restrictions are
met reported as increases in unrestricted net assets?
[FASB ASC 958-320-45-3]

If a not-for-profit entity reports gains and investment income
that are limited to specific uses by donor-imposed restrictions
as increases in unrestricted net assets because the restrictions
are met in the same reporting period as the gains and income
are recognized, does the not-for-profit entity
a.

have a similar policy for reporting contributions received?

b.

report consistently from period to period?

c.

disclose its accounting policy?
[FASB ASC 958-320-45-3]

In the absence of donor stipulations or law to the contrary,
does the not-for-profit entity report losses on investments and
donor-restricted endowment funds as

No

N/A
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Yes
a.

decreases in permanently restricted net assets if subject
to a donor’s explicit permanent restriction or a law that
extends a donor’s permanent restriction to the losses
(for example, if a donor states that a specific investment
must be held in perpetuity, the losses on that security
are subject to that same permanent restriction unless
the donor states otherwise)?

b.

decreases in temporarily restricted net assets to the extent that donor-imposed temporary restrictions on net
appreciation of a donor-restricted endowment fund
have not been met before the loss occurs?

c.

decreases in unrestricted net assets if losses exceed the
temporarily restricted net appreciation of a donor-restricted endowment fund or if the investments are not
subject to donor-imposed restrictions?
[FASB ASC 958-205-45 par. 22–24 and FASB ASC 958205-45-18]

No

N/A

Split-Interest Agreements
Presentation
. 16.

Are assets and liabilities recognized under split-interest
agreements disclosed separately from other assets and liabilities in the statement of financial position or in the related
notes?
[FASB ASC 958-30-45-6]

. 17.

If a split-interest gift contains an embedded derivative (charitable remainder unitrusts with period-certain payments or
period-certain-plus-life-dependent payments and certain lead
interest trusts), is the embedded derivative reported at fair
value?
[FASB ASC 958-30-30-9]

. 18.

Is contribution revenue and changes in the value of split-interest agreements recognized under such agreements disclosed as separate line items in the statement of activities or
in the related notes?
[FASB ASC 958-30-45-7]

. 20.

Is contribution revenue recognized under split-interest agreements classified as
a.

permanently restricted net assets, if the donor has permanently restricted the not-for-profit entity’s use of its
interest?

b.

unrestricted net assets, if the not-for-profit entity has
the immediate right to use its interest without restrictions?

c.

temporarily restricted net assets, if not classified as permanently restricted or unrestricted net assets?
[FASB ASC 958-30-45-1]
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Yes
Disclosure
. 21.

Do the notes to the financial statements include the following
disclosures related to split-interest agreements:
a.

A description of the general terms of existing split-interest agreements?

b.

The basis used for recognized assets?

c.

The discount rates and actuarial assumptions used in
calculating present value?

d.

The existence of any legally mandated reserves?

e.

The existence of any limitations placed by state law,
such as limitations on the instruments in which resources are invested?

f.

The disclosures required by the “Fair Value Option”
subsection of FASB ASC 825-10-50, if a not-for-profit
entity elects the fair value option as described in FASB
ASC 958-30-35-2?

g.

The disclosures required by paragraphs 1–2 of FASB
ASC 820-10-50 in the format described in FASB ASC
820-10-50-8, if the assets and liabilities of split-interest
agreements are measured at fair value on a recurring
basis in periods after initial recognition?
[FASB ASC 958-30-50 par. 1–2]

Comparative Financial Statements
Presentation
.l 22.

Has the entity properly presented the statement of financial
position, the income statement, and the statement of changes
in equity for one or more preceding years, as well as for the
current year?
[FASB ASC 205-10-45-2]

.l 23.

Has the entity properly presented appropriate explanations
of changes related to any differences in the manner of or basis
for presenting corresponding items for two or more periods?
[FASB ASC 205-10-45-3]

.l 24.

Has the entity properly presented, or at least referred to, if
issuing comparative statements, notes and other disclosures
in the financial statements of the preceding year(s) in the current year, to the extent that they continue to be of significance?
[FASB ASC 205-10-45-4]

. 25.

If prior year information is summarized and does not include
the minimum information required by FASB ASC 958, is the
nature of the prior year information described by appropriate
titles and in the notes in the financial statements of the notfor-profit entity?
[FASB ASC 958-205-45-8]

FSP §11,100.01
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Yes

No

N/A

Disclosure
Changes Affecting Comparability
.l 26.

Has the entity properly disclosed information that will explain a change in the manner of or basis for presenting corresponding items for two or more periods (for example, any
change in practice that affects comparability of financial statements must be disclosed), if changes have occurred?
[FASB ASC 205-10-50-1]

Fund Raising
. 27.

If the entity includes within its financial statements a ratio of
fund-raising expenses to amounts raised, has it disclosed how
that ratio was computed?
[FASB ASC 958-205-50-3]

The following table summarizes the titles used to describe the statement of assets, liabilities, and equity
in the financial statements a sample of public entities surveyed by the AICPA. Reprinted from the
AICPA’s Accounting Trends & Techniques, 2010, 64th edition (product no. 0099010 [paperback] or WATXX [online]).
BALANCE SHEET TITLE
2009
2008
2007
2006
Balance sheet
476
478
577
578
Statement of financial position
24
22
23
21
Statement of financial condition
—
—
—
1
Total entities
500
500
600
600
2008–2009 based on 500 entities surveyed; 2006–2007 based on 600 entities surveyed.
B.

Presentation of Discontinued Operations in the Financial Statements (FASB ASC 205-20)
Presentation

.l 1.

Has the entity properly presented, as discontinued operations, the results of operations of a component of an entity (as
that phrase is defined in FASB ASC glossary) that either has
been disposed of or is classified as held for sale under the
requirements of FASB ASC 360-10-45-9, in accordance with
FASB ASC 205-20-45-3 if both of the following conditions are
met:
a.

The operations and cash flows of the component have
been (or will be) eliminated from the ongoing operations of the entity as a result of the disposal transaction?

b.

The entity will not have any significant continuing involvement in the operations of the component after the
disposal transaction?
[FASB ASC 205-20-45-1]
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Yes
.l 2.

Has the entity properly presented, in a period in which a
component of an entity either has been disposed of or is classified as held for sale, in the income statement for current and
prior periods, the results of operations of the component (including any gain or loss recognized in accordance with FASB
ASC 360-10-35-40 and 360-10-40-5), in discontinued operations?
[FASB ASC 205-20-45-3]

.l 3.

Has the entity properly presented the results of operations of
a component of an entity classified as held for sale in discontinued operations in the period(s) in which they occur?
[FASB ASC 205-20-45-3]

.l 4.

Has the entity properly presented the results of discontinued
operations, less applicable income taxes (benefit), as a separate component of income before extraordinary items?
[FASB ASC 205-20-45-3]

.l 5.

Has the entity properly presented the gain or loss recognized
on the disposal either on the face of the income statement or
in the notes to the financial statements?
[FASB ASC 205-20-45-3]

.l 6.

Has the entity properly presented adjustments to amounts
previously reported in discontinued operations that are directly related to the disposal of a component of an entity in a
prior period and classified them separately in the current period in discontinued operations?
[FASB ASC 205-20-45-4]

Allocation of Interest to Discontinued Operations
.l 7.

Has the entity properly presented, as allocated to discontinued operations, interest on debt that is to be assumed by the
buyer and interest on debt that is required to be repaid as a
result of a disposal transaction?
[FASB ASC 205-20-45-6]

Disposal Group Classified as Held for Sale
.l 8.

Has the entity properly presented the assets and liabilities of
a disposal group that is classified as held for sale separately
in the asset and liability sections, respectively, of the statement of financial position? (Note: These assets and liabilities
should not be offset and presented as a single amount. Further, major classes of assets and liabilities classified as held
for sale should be separately disclosed either on the face of
the statement of financial position or in the notes to the financial statements.)
[FASB ASC 205-20-45-10]

Disclosure
.l 9.

FSP §11,100.01

Has the entity properly disclosed the following information
in the notes to the financial statement that cover the period in
which a long-lived asset (disposal group) either has been sold
or is classified as held for sale under the requirements of
FASB ASC 360-10-45-9:

No

N/A
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Yes

.l 10.

a.

A description of the facts and circumstances leading to
the expected disposal, the expected manner and timing
of that disposal, and, if not separately presented on the
face of the statement, the carrying amount(s) of the major classes of assets and liabilities included as part of a
disposal group?

b.

The gain or loss recognized in accordance with FASB
ASC 360-10-35-40 and FASB ASC 360-10-40-5 and if not
separately presented on the face of the income statement, the caption in the income statement that includes
that gain or loss?

c.

If applicable, amounts of revenue and pretax profit or
loss reported in discontinued operations?

d.

If applicable, the segment in which the long-lived asset
(disposal group) is reported under FASB ASC 280?
[FASB ASC 205-20-50-1]

No

N/A

Has the entity properly disclosed the major classes of assets
and liabilities classified as held for sale either on the face of
the statement of financial position or in the notes to the financial statements?
[FASB ASC 205-20-50-2]

Change to a Plan of Sale
.l 11.

Has the entity properly disclosed, if the entity decides not to
sell a long-lived asset previously classified as held for sale,
and either FASB ASC 360-10-35-44 or FASB ASC 360-10-35-45
applies, is a description of the facts and circumstances leading to the decision to change the plan to sell the long-lived
asset (disposal group) and its effect on the results of operations for the period and any prior periods in the notes to the
financial statements that include the period of that decision?
[FASB ASC 205-20-50-3]

Continuing Cash Flows
.l 12.

Has the entity properly disclosed the following, for each discontinued operation that generates continuing cash flows:
a.

The nature of the activities that give rise to continuing
cash flows?

b.

The period of time continuing cash flows are expected
to be generated?

c.

The principal factors used to conclude that the expected
continuing cash flows are not direct cash flows of the
disposed component?
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Yes

.l 13.

d.

Additionally, for each discontinued operation in which
the ongoing entity will engage in a “continuation of activities” with the disposed component after its disposal
and for which the amounts presented in continuing operations after the disposal transaction include a continuation of revenues and expenses that were intraentity
transactions before the disposal transaction, are those
intraentity amounts before the disposal transaction disclosed for all periods for comparability purposes?

e.

Are the types of continuing involvement, if any, that
the entity will have after the disposal transaction disclosed in the period in which the operations are initially classified as discontinued?
[FASB ASC 205-20-50-4 and FASB ASC 205-20-55 par.
9–12]

If the occurrence of a significant event or circumstance at any
time during the assessment period results in an expectation
that the criteria for reporting discontinued operations in
FASB ASC 205-20-45-1 will be met by the end of the assessment period, is the component’s operations presented as discontinued operations?
[FASB ASC 205-20-55-22]

Adjustments to Previously Reported Amounts
.l 14.

Has the entity properly disclosed the nature and amount of
adjustments to amounts previously reported in discontinued
operations that are directly related to the disposal of a component of an entity in a prior period?
[FASB ASC 205-20-50-5]

Continuing Involvement by Ongoing Entity
.l 15.

Has the entity properly disclosed, for each discontinued operation in which the ongoing entity will engage in a continuation of activities with the disposed component after its disposal, and for which the amounts presented in continuing
operations after the disposal transaction include a continuation of revenues and expenses that were intraentity transactions (eliminated in consolidated financial statements) before
the disposal transaction, intraentity amounts before the disposal transaction for all periods presented? Further, has the
entity properly disclosed the types of continuing involvement, if any, that the entity will have after the disposal transaction? (That information should be disclosed in the period in
which operations are initially classified as discontinued.)
[FASB ASC 205-20-50-6]

Endowments
. 16.

Has the not-for-profit entity disclosed information to enable
users of financial statements to understand all of the following about its endowment funds (both donor restricted and
board designated:
a.

FSP §11,100.01

Net asset classification?

No

N/A
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Yes

. 17.

. 18.

b.

Net asset composition?

c.

Changes in net asset composition?

d.

Spending policies?

e.

Related investment policies?
[FASB ASC 958-205-50-1A]

No

N/A

Has the not-for-profit disclosed the following for each period
for which it presents financial statements:
a.

A description of the governing board’s interpretation of
the law or laws that underlie the not-for-profit entity’s
net asset classification of donor-restricted endowment
funds?

b.

A description of the not-for-profit entity’s policies for
the appropriation of endowment assets for expenditures (its endowment spending policies)?

c.

A description of the not-for-profit entity’s endowment
investment policies, including all of the following:
i.

Return objectives and risk parameters?

ii.

How those objectives relate to the not-for-profit
entity’s endowment spending policies?

iii.

The strategies employed for achieving those objectives?

d.

The composition of the not-for-profit entity’s endowment by net asset class at the end of the period, in total
and by type of endowment fund, showing donor-restricted endowment funds separately from board-designated endowment funds?

e.

A reconciliation of the beginning and ending balance of
the not-for-profit entity’s endowment, in total and by
net asset class, including, at a minimum, all of the following line items that apply:
i.

Investment return, separated into investment income (for example, interest, dividends, rents) and
net appreciation or depreciation of investments?

ii.

Contributions?

iii.

Amounts appropriated for expenditure?

iv.

Reclassifications?

v.

Other changes?
[FASB ASC 958-205-50-1B]

Has the not-for-profit disclosed, for each period for which a
statement of financial position is presented, the aggregate
amount of the deficiencies for all donor-restricted endowment funds for which the fair value of the assets at the reporting date is less than the level required by donor stipulations or law?
[FASB ASC 958-205-50-2]
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Yes
C.

Presentation of the Balance Sheet—Overall (FASB ASC 210-10)
Presentation

.l 1.

For classified balance sheets, are assets and liabilities segregated into current and noncurrent classifications with totals
presented for current assets and current liabilities?
[FASB ASC 210-10-45]

.l 2.

Are assets not expected to be realized during the current operating cycle classified as noncurrent?
[FASB ASC 210-10-45 par. 3–4]

. 3.

Does the statement of financial position/balance sheet report
total assets, liabilities, and net assets, as well as separate
amounts for each of the three classes of net assets, with captions used to describe their meanings as explained in FASB
ASC 958-210-45?
[FASB ASC 958-210-45-1]

.l 4.

Is any cash restricted as to withdrawal or use for other than
current operations excluded from current assets? (See FASB
ASC 954-305-45-1 for additional detail.)
[FASB ASC 210-10-45-4]

.l 5.

If a classified balance sheet is presented, is a total for current
liabilities shown?
[FASB ASC 210-10-45-5]

. 6.

Does the entity provide information about liquidity by one or
more of the following presentations:
a.

Sequencing assets according to their nearness of conversion to cash and sequencing liabilities according to
the nearness of their maturity and resulting use of
cash?

b.

Classifying assets and liabilities as current and noncurrent?

c.

Disclosing in notes to financial statements relevant information about the liquidity or maturity of assets and
liabilities, including restrictions on the use of particular
assets?
[FASB ASC 958-210-45-8]

. 7.

Has the entity properly eliminated interfund receivables and
payables?
[FASB ASC 954-210-45-3]

. 8.

Has the entity properly reported internally designated funds
separately from externally designated funds either on the face
of the balance sheet or in the notes to the financial statements?
[FASB ASC 954-210-45-3]

. 9.

Are cash or other assets received with a donor-imposed restriction that limits their use to long-term purposes reported
separately from assets that are unrestricted and available for
current use?
[FASB ASC 958-210-45-6]
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Yes
. 10.

Does the not-for-profit entity provide information about the
nature and amounts of different types of permanent restrictions and temporary restrictions by reporting their amounts
on the face of the statement of financial position or by including relevant details in notes to financial statements?
[FASB ASC 958-210-45-9]

.l 11.

Are personal funds of patients, residents, and others under
an agency arrangement reported as unrestricted assets and
corresponding liabilities in the balance sheet/statement of financial position?
[FASB ASC 954-305-45-4]

.l 12.

Are bank overdrafts reclassified to and presented separately
in current liabilities?
[Common Practice]

.l 13.

Are held checks (those written before but not released until
after the balance sheet date) reclassified to accounts payable?
[Common Practice]

.l 14.

Are current portions of debt obligations presented as current
liabilities?
[FASB ASC 210-10-45-9]

. 15.

Are encumbrances, appropriations of fund balances, unspecified reserves, general or unspecified business risks, and
other commitments not meeting the criteria of FASB ASC
450-20-25 not reported as expenses or liabilities? (Note: These
may be reported as segregations of net assets on the statement of financial position.)
[FASB ASC 450-20-25-2; FASB ASC 958-210-45-11]

No

N/A

Disclosure
.l 16.

Has the entity properly disclosed the amounts at which current assets are stated, supplemented by information that reveals, for the various classifications of inventory items, the
basis upon which their amounts are stated, and where practicable, an indication of the method of determining the cost?
[FASB ASC 210-10-50-1]

. 17.

Has the not-for-profit entity disclosed all of the following, if
present, in the notes to financial statements:
a.

Unusual circumstances, such as special borrowing arrangements, requirements imposed by resource providers that cash be held in separate accounts, and known
significant liquidity problems?

b.

The fact that the not-for-profit has not maintained appropriate amounts of cash and cash equivalents to comply with donor-imposed restrictions?

c.

Information about significant limits resulting from contractual agreements with suppliers, creditors, and others, including the existence of loan covenants?
[FASB ASC 958-210-50-2]
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Yes
. 18.

Has the not-for-profit entity disclosed all of the following, if
present, in the notes to financial statements if not provided
on the face of the statement of financial position:
a.

A description of the kind of asset whose use is limited?

b.

Information about the nature and amount of limitations
on the use of cash and cash equivalents?

c.

Contractual limitations on the use of particular assets?

d.

Information about the nature and amounts of different
types of permanent restrictions?

e.

Information about the nature and amounts of different
types of temporary restrictions?
[FASB ASC 958-210-50-3; FASB ASC 958-210-45 par. 6,
7(a), 7(b), 9, and 10]

. 19.

Has the not-for-profit entity disclosed, in the notes to the financial statements relevant information about the liquidity or
maturity of assets and liabilities, including restrictions on the
use of particular items, unless that information is provided on
the face of the statement of financial position?
[FASB ASC 958-210-50-1]

. 20.

Are internally designated funds reported separately from externally designated funds, in accordance with FASB ASC 958210-45-4? (If the form of the assets is not evident from the
description on the balance sheet, the form of the assets should
be disclosed in the notes to the financial statements.)
[FASB ASC 954-210-50-2]

.l 21.

If a concentration of credit risk arises from deposits in excess
of federally insured limits, is it disclosed?
[FASB ASC 958-320-50-3]

D.

Presentation of Offsetting in the Balance Sheet (FASB ASC 21010)
Presentation
Right of Setoff

.l 1.

E.

Has the entity properly presented and exercised its option, if
it has a valid right of setoff, to offset the related asset and
liability and present the net amount?
[FASB ASC 210-20-45-2]

Presentation of Comprehensive Income (FASB ASC 220-10)
Presentation
Reporting Comprehensive Income
l 1.

FSP §11,100.01

Has the entity properly presented a full set of financial statements for the period which include (a) financial position at
the end of the period, (b) earnings (net income) for the period,
(c) comprehensive income (total nonowner changes in equity)
for the period, (d) cash flows during the period, and (e) investments by and distributions to owners during the period?
[FASB ASC 220-10-45-3]

No

N/A
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Yes
l 2.

No

N/A

Has the entity properly presented all components of comprehensive income in the financial statements in the period in
which they are recognized and presented them with the components of other comprehensive income (OCI)?
[FASB ASC 220-10-45-5]

Classifications Within Comprehensive Income
l 3.

Has the entity properly presented an amount for net income,
even if the entity has no items of OCI and does not present
that fact?
[FASB ASC 220-10-45-6]

Alternative Formats for Reporting Comprehensive Income
l 4.

Has the entity properly presented comprehensive income and
its components in a financial statement that is displayed with
the same prominence as other financial statements that constitute a full set of financial statements?
[FASB ASC 220-10-45-8]

l 5.

Has the entity properly presented the components of OCI and
total comprehensive income below the total for net income in
a statement that reports results of operations or in a separate
statement of comprehensive income that begins with net income? (Note: This subtopic does not require a specific format,
but the preceding presentation is encouraged.)
[FASB ASC 220-10-45-9]

l 6.

Has the entity properly presented the components of OCI either net of related tax effects, or before related tax effects with
one amount shown for the aggregate tax effect related to the
total of OCI items?
[FASB ASC 220-10-45-11]

l 7.

Has the entity properly presented the amount of income tax
expense or benefit allocated to each component of OCI (including reclassification adjustments) on the face of the statement in which those components are displayed or presented
in the notes to the financial statements?
[FASB ASC 220-10-45-12]

Reporting OCI in the Equity Section of a Statement of Financial Position
l 8.

Has the entity properly presented the total of OCI for a period, transferred to a component of equity, separately from
retained earnings and additional paid-in-capital in the balance sheet with a descriptive title such as “accumulated other
comprehensive income?”
[FASB ASC 220-10-45-14]

l 9.

Has the entity properly presented accumulated balances for
each classification within accumulated OCI on the face of the
balance sheet, in the statement of changes in shareholders’ equity, or in the notes?
[FASB ASC 220-10-45-14]
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Interim-Period Reporting
l 10.

F.

Has the entity properly presented a total for comprehensive
income in condensed financial statements of interim periods?
[FASB ASC 220-10-45-18]

Presentation of the Income Statement (FASB ASC 225-10)
Presentation
l 1.

Has the entity properly presented all items of profit and loss
recognized during the period, with the sole exception of error
corrections as addressed in FASB ASC 250, Accounting
Changes and Error Corrections, in order to present net income?
[FASB ASC 225-10-45-1]

. 2.

Does the statement of activities/operations or statement of
changes in net assets report the amount of change in net assets for the period for the entity as a whole (using a descriptive term such as change in net assets or change in equity),
and does that amount articulate to the net assets reported in
the statement of financial position?
[FASB ASC 958-225-45 par. 1–2]

. 3.

Does the statement of activities/operations or the statement
of changes in net assets report the amount of change in permanently restricted net assets, temporarily restricted net assets, and unrestricted net assets for the period?
[FASB ASC 958-225-45-1]

. 4.

Does the statement of activities/operations report the following:

. 5.
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a.

Revenues as increases in unrestricted net assets, unless
the use of the assets received is limited by donor-imposed restrictions?

b.

Expenses as decreases in unrestricted net assets?

c.

Events that simultaneously increase one class of net assets and decrease another (reclassifications), including
expiration of donor-imposed restrictions, separately
from revenues, expenses, gains, and losses?

d.

Events that simultaneously increase one class of net assets and decrease another (reclassifications), including
expiration of donor-imposed restrictions, separately
from revenues, expenses, gains, and losses?

e.

Gains and losses as increases or decreases in unrestricted net assets unless a donor or law temporarily or
permanently restrict their use?
[FASB ASC 958-225-45 par. 4–8]

Are revenues and expenses (arising from ongoing activities
associated with health care services) displayed as gross
amounts?
[FASB ASC 958-225-45-14]

No

N/A
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Yes
. 6.

If the entity elects to report investment revenues net of related expenses (that is, custodial fees, and internal and external investment advisory costs), does the entity disclose the
amount of expenses, either on the face of the statement of activities or in the notes to the financial statements?
[FASB ASC 958-225-45-14]

. 7.

If the entity reports an intermediate measure of operations
(for example, excess or deficit of operating revenues over expenses), is this intermediate measure reported only in a financial statement that, at a minimum, reports the change in unrestricted net assets for the period? (Example 1 in FASB ASC
958-225-55-5 illustrates a statement of unrestricted revenues,
expenses, and other changes in unrestricted net assets that
subdivides all transactions and other events and circumstances to make an operating and nonoperating distinction.)
[FASB ASC 958-225-45-10]

. 8.

If the entity reports net gains and losses on its statement of
activities/operations, do these net amounts result from peripheral or incidental transactions or from events largely beyond the control of the entity and its management?
[FASB ASC 958-225-45 par. 15–17]

. 9.

Does the statement of activities/operations include a performance indicator that reports results of operations and that is
clearly labeled with a descriptive term such as revenues over
expenses, revenues and gains over expenses and losses,
earned income, or performance earnings?
[FASB ASC 954-225-45-4]

. 10.

Does the not-for-profit entity report the performance indicator in a statement that also presents the total changes in unrestricted net assets? (Note: Other changes in net assets may
be presented separately or in the same statement.)
[FASB ASC 954-225-45-4]

. 11.

Does the entity report the following items separately from the
performance indicator:
a.

Transactions with owners acting in that capacity?

b.

Equity transfers involving other entities that control the
reporting entity, are controlled by the reporting entity,
or are under common control with the reporting entity?

c.

Receipt of restricted contributions, including temporary
restrictions (such as time or purpose) or permanent restrictions?

d.

Contributions of (and assets released from donor restrictions related to) long-lived assets?

No

N/A
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Yes

. 12.

e.

Items that are required to be reported in or reclassified
from other comprehensive income, such as minimum
pension liabilities in accordance with FASB ASC 71530; foreign currency translation adjustments and the effective portion of the gain or loss on derivative instruments designated and qualifying as cash flow hedging
instruments pursuant to paragraphs 1–2 of FASB ASC954-815-25?

f.

Items that are required to be reported separately under
specialized not-for-profit standards. These include extraordinary items, the effect of discontinued operations,
and the cumulative effect of accounting changes; and
unrealized gains and losses on investments not restricted by donors or by law (except for those investments classified as trading securities) and investment
returns restricted by donors or by law, as required by
FASB ASC 954-320-45-1?

g.

Unrealized gains and losses on investments on other
than trading securities, in accordance with FASB ASC
954-320-45-1b?

h.

Investment returns restricted by donors or by law?

i.

Investment losses that decrease unrestricted net assets
if those losses reduce the assets of a donor restricted
endowment fund below the required level, as described
in FASB ASC 958-205-45-22?

j.

Investment gains that increase unrestricted net assets if
those gains restore the fair value of the assets of a donor restricted endowment fund to the required level, as
described in FASB ASC 958-205-45-22?

k.

An inherent contribution that increases temporarily restricted net assets as described in FASB ASC 954-80545-2.
[FASB ASC 954-225-45-7]

Has the entity properly excluded equity transfers from the
performance indicator and separately as changes in net assets?
[FASB ASC 954-225-45-2]

Disclosure
. 13.

If the entity’s use of the term operations is not apparent from
the details provided on the face of the statement of activities,
does a note to the financial statements describe the nature of
the reported measure of operations or the items excluded
from operations?
[FASB ASC 958-225-50-1(a)]

. 14.

Do the notes to the financial statements include a description
of the nature and composition of the performance indicator?
[FASB ASC 954-225-50-1]
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No

N/A
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Yes
. 15.

G.

No

N/A

If an intermediate measure of operations is reported and its
use is not apparent from the details provided on the face of
the statement, has the entity included a note to the financial
statements describing the nature of the reported measure of
operations or the items excluded from operations?
[FASB ASC 954-225-50-2]

Presentation of Extraordinary and Unusual Items in the Income
Statement (FASB ASC 225-20)
Presentation
Presentation of Extraordinary Items

.l 1.

Has the entity properly presented extraordinary items segregated from the results of ordinary operations and shown separately in the income statement, with disclosure of the nature
and amounts thereof?
[FASB ASC 225-20-45-9]

.l 2.

Has the entity properly presented extraordinary items (including applicable income taxes) segregated and following
income before extraordinary items and before net income?
[FASB ASC 225-20-45-10]

.l 3.

Has the entity properly presented the caption “extraordinary
items” to identify and present separately the effects of events
and transactions, other than disposals of components of an
entity, that meet the criteria for classification as extraordinary
as discussed in paragraphs 1–6 of FASB ASC 225-20-45?
(Note: The nature of an extraordinary event or transaction
and the principal items entering into the determination of an
extraordinary gain or loss should be described.)
[FASB ASC 225-20-45-11]

.l 4.

Has the entity properly presented earnings per share (EPS)
data for extraordinary items either on the face of the income
statement or in the related notes, as prescribed by FASB ASC
260-10-45?
[FASB ASC 225-20-45-12]

Adjustment of Amounts Reported in Prior Periods
.l 5.

Has the entity properly presented any extraordinary items
that were reported in prior periods and that have been adjusted during the current period, including separate presentation concerning year of origin, nature, and amount, and
have those items been classified separately in the current period as an extraordinary item?
[FASB ASC 225-20-45-13]
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Presentation of Unusual or Infrequently Occurring Items
.l 6.

Has the entity properly presented material events or transactions that are either unusual in nature or of infrequent occurrence, but not both (and therefore not meeting the criteria for
extraordinary items), (a) as a separate component of income
from continuing operations and (b) accompanied by disclosure of the nature and financial effects of each event?
[FASB ASC 225-20-45-16]

Disclosure
Unusual or Infrequently Occurring Items
.l 7.

Has the entity properly disclosed the nature and financial effects of each event or transaction that is unusual in nature or
occurs infrequently, but not both, on the face of the income
statement, or alternatively, in notes to the financial statements?
[FASB ASC 225-20-50-3]

Interim Reporting
.l 8.

H.

Has the entity properly disclosed extraordinary items separately and included in the determination of net income for the
interim period or periods in which they occurred?
[FASB ASC 225-20-50-4]

Income Statement Business Interruption (FASB ASC 225-30)
Disclosure

.l 1.

I.

Has the entity disclosed the following information in the
notes to the financial statements in the period(s) in which
business interruption insurance recoveries are recognized:
a.

The nature of the event resulting in business interruption losses?

b.

The aggregate amount of business interruption insurance recoveries recognized during the period and the
line item(s) in the statement of operations in which
those recoveries are classified (including amounts reported as an extraordinary item pursuant to FASB ASC
225-20?
[FASB ASC 225-30-50-1]

Presentation of the Statement of Cash Flows (FASB ASC 230-10)
Presentation
Cash and Cash Equivalents

.l 1.
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Has the entity properly presented the change during the period in cash and cash equivalents and present an explanation
for the change?
[FASB ASC 230-10-45-4]

No

N/A
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Yes

No

N/A

Cash Flows From Investing Activities
.l 2.

Has the entity properly presented cash flows from purchases,
sales, and maturities of available-for-sale securities as cash
flows from investing activities and presented these amounts
as gross amounts in the statement of cash flows?
[FASB ASC 230-10-45-11]

Cash Flows From Operating Activities
.l 3.

Has the entity properly presented cash payments made to
settle an asset retirement obligation in the statement of cash
flows as an operating activity?
[FASB ASC 230-10-45-17(e)]

Acquisitions and Sales of Certain Securities and Loans
.l 4.

Has the entity properly presented cash receipts and cash payments resulting from purchase and sales of securities classified as trading securities, as prescribed in FASB ASC 320, Investments—Debt and Equity Securities, based on the nature and
purpose for which the securities were acquired?
[FASB ASC 230-10-45-19]

.l 5.

Has the entity properly presented cash receipts and cash payments resulting from the purchase or sale of securities and
other assets that were acquired for resale and that are being
carried at market value in a trading account as operating cash
flows?
[FASB ASC 230-10-45-20]

.l 6.

Has the entity properly presented cash receipts and cash payments resulting from the purchase or sale of loans that were
acquired for resale and that are being carried at market value
or at the lower of cost or market values as operating cash
flows?
[FASB ASC 230-10-45-21]

Reporting Operating, Investing, and Financing Activities
.l 7.

Has the entity properly presented, in the statement of cash
flows, net cash provided or used by the operating, investing,
and financing activities and the effect of those flows on cash
and cash equivalents during the period in a manner that reconciles beginning and ending cash and cash equivalents?
(Note: Although not required, the entity may present separate presentation of cash flows pertaining to extraordinary
items or discontinued operations in those categories provided
that the presentation is consistent for all periods effective.)
[FASB ASC 230-10-45-24]

.l 8.

Has the entity properly presented the following, if the direct
method of reporting net cash flow from operating activities,
as encouraged by FASB ASC 230-10-45-25, is used:
a.

Cash received from customers?

b.

Interest and dividends received?

c.

Other operating cash receipts?
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Yes
d.

Cash paid to employees and suppliers?

e.

Interest paid?

f.

Income taxes paid and, separately, the cash that would
have been paid for income taxes if increases in the
value of equity instruments issued under share-based
payment arrangements that are not recognizable as a
cost of goods or services for accounting purposes also
had not been deductible in determining taxable income
(FASB ASC 230-10-45-14[e])?

g.

Other operating cash payments (if any)?
[FASB ASC 230-10-45-25]

No

Reconciliation of Net Income and Net Cash Flow From Operating
Activities
.l 9.

Has the entity properly presented, if the direct method of reporting net cash flow from operating activities is not used,
the net cash flow from operating activities indirectly, by adjusting net income to reconcile it to net cash flow from operating activities?
[FASB ASC 230-10-45-28]

.l 10.

Has the entity properly presented a reconciliation of net income to net cash flow from operating activities, including
separate reporting of all major classes of reconciling items?
[FASB ASC 230-10-45-29]

.l 11.

Has the entity properly presented, if the direct method is
used, a separate reconciling schedule to reconcile net income
to net cash flow from operating activities?
[FASB ASC 230-10-45-30]

.l 12.

Has the entity properly presented, if the indirect method is
used, a separate reconciling schedule to reconcile net income
to net cash flow from operating activities either within the
statement of cash flows or in a separate schedule, with the
statement of cash flows presenting only the net cash flow
from operating activities?
[FASB ASC 230-10-45-31]

The following table summarizes the methods used to report cash flows from operating
activities in the financial statements of a sample of public entities surveyed by the
AICPA. Reprinted from the AICPA’s Accounting Trends & Techniques, 2010, 64th edition
(product no. 0099010 [paperback] or WAT-XX [online]).
METHOD OF REPORTING CASH FLOWS FROM OPERATING ACTIVITIES
2009
2008
2007
2006
Indirect method
495
495
594
594
Direct method
5
5
6
6
Total entities
500
500
600
600
2008–2009 based on 500 entities surveyed; 2006–2007 based on 600 entities surveyed.
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Yes

No

N/A

Disclosure
Cash Equivalents Policy
.l 13.

Has the entity properly disclosed the accounting policy for
determining which items are treated as cash equivalents?
[FASB ASC 230-10-50-1]

Interest and Income Taxes Paid
.l 14.

Has the entity properly disclosed, if the indirect method of
reporting net cash flow from operating activities is used, the
amounts of interest paid (net of amounts capitalized) and income taxes paid during the period in related disclosures?
[FASB ASC 230-10-50-2]

Noncash Investing and Financing Activities
.l 15.

Has the entity properly disclosed investing and financing activities that affect recognized assets or liabilities, but that do
not result in cash receipts or cash payments in the period?
[FASB ASC 230-10-50-3]

.l 16.

Has the entity properly disclosed only the cash portion of any
transactions that are part cash and part noncash in the statement of cash flows, or if there are a significant amount of
transactions, elsewhere in the financial statements with clear
reference to the statement of cash flows?
[FASB ASC 230-10-50 par. 5–6]

J.

Presentation of the Notes to Financial Statements (FASB ASC 23510)

The following table lists accounting policies that were most frequently included in the summary of
accounting policies of a sample of public entities surveyed by the AICPA. Reprinted from the
AICPA’s Accounting Trends & Techniques, 2010, 64th edition (product no. 0099010 [paperback] or
WAT-XX [online]).
DISCLOSURE OF ACCOUNTING POLICIES
Number of Companies
2009
2008
2007
2006
Revenue recognition
485
486
587
590
Consolidation policy
477
481
561
570
Use of estimates
476
469
582
567
Property
475
453
570
572
Cash equivalents
474
475
551
546
Depreciation methods
456
469
513
514
Amortization of intangibles
456
451
548
540
Interperiod tax allocation
449
438
534
508
Impairment
436
415
517
546
Financial instruments
435
440
502
506
Inventory pricing
429
416
506
514
Stock-based compensation
414
408
493
507
(continued)
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Translation of foreign currency
Nature of operations
Earnings per share calculation
Accounts receivable
Advertising costs
Employee benefits
Research and development costs
Credit risk concentrations
Fiscal years
Environmental costs
Capitalization of interest

2009
383
365
297
349
244
229
185
181
150
129
98

2008
376
363
300
333
250
195
172
190
145
131
86

2007
445
376
351
381
293
217
228
213
165
145
102

2008–2009 based on 500 entities surveyed; 2006–2007 based on 600 entities surveyed.
Disclosure
What to Disclose
.l 1.

Do the disclosures for the entity properly identify and describe all significant accounting principles followed by the reporting entity and the methods of applying those principles
that materially affect the determination of financial position,
cash flows, and results of operations?
[FASB ASC 235-10-50-3]

.l 2.

Has the entity properly disclosed the following information,
when those principles and methods identified in FASB ASC
235-10-50-3 include all instances in which there
a.

is a selection from existing acceptable alternatives?

b.

are principles and methods peculiar to the industry in
which the reporting entity operates, even if such principles and methods are predominantly followed in that
industry?

c.

are unusual or innovative applications of U.S. GAAP?
[FASB ASC 235-10-50-3]

Avoid Duplicate Details of Disclosures
.l 3.

Has the entity properly not disclosed duplicating details (for
example, composition of inventories or of plant assets) presented elsewhere as a part of the financial statements?
[FASB ASC 235-10-50-5]

Format
.l 4.
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Has the entity properly disclosed a description of all significant accounting policies of the reporting entity, presented as
either a separate summary preceding the notes to the financial statements or as the initial note under the same or similar
title?
[FASB ASC 235-10-50-6]

No
2006
428
286
368
386
288
185
224
211
168
144
92

N/A
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Yes
K.

No

N/A

Presentation of Accounting Changes and Error Corrections (FASB
ASC 250-10)

The following table lists accounting changes that were most frequently reported in the financial
statements of a sample of public entities surveyed by the AICPA. Reprinted from the AICPA’s
Accounting Trends & Techniques, 2010, 64th edition (product no. 0099010 [paperback] or WAT-XX
[online]).
ACCOUNTING CHANGES
Number of Companies
2009
2008
2007
2006
Noncontrolling interests
96
*
*
*
Fair value measurements
51
175
2
—
Business combinations
46
*
*
*
Defined benefit pension and postretirement
plans
44
59
138
303
Financial instruments with debt and equity
characteristics
20
*
*
*
Derivatives and hedging activities
18
5
—
—
Earnings per share
17
*
*
*
Income tax uncertainties
5
161
369
1
Inventories
4
4
3
8
Prior period financial statement misstatement
3
6
10
18
Consolidation of variable interest entities
3
—
—
—
Impairment or disposal of long-lived assets
2
1
—
2
Asset retirement obligation
2
—
—
29
Servicing of financial assets
2
—
—
4
Stock based compensation
—
—
42
437
N/C 5 Not compiled. Line item was not included in table for year shown.
2008–2009 based on 500 entities surveyed; 2006–2007 based on 600 entities surveyed.
*

Presentation
Change in Reporting Entity
.l 1.

If a change in reporting entity results in financial statements
that are, in effect, the statements of a different reporting entity, has the change been applied retrospectively to all periods presented?
[FASB ASC 250-10-45-21]
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Yes
Changes in Accounting Principle
l 2.

If a public company that regularly reports interim information makes an accounting change during the fourth quarter of
its fiscal year and does not report the data specified by FASB
ASC 270-10-50-1, in a separate fourth-quarter report or in its
annual report, does the entity include disclosure of the effects
of the accounting change on interim-period results, as required by FASB ASC 250-10-50-1, in a note to the annual financial statements for the fiscal year in which the change is
made?
[FASB ASC 250-10-45-15]

Note: According to FASB ASC 250-10-45-14, a change in accounting
principle made in an interim period should be reported by retrospective
application in accordance with FASB ASC 250-10-45-5. However, the impracticability exception in FASB ASC 250-10-45-9 may not be applied to
prechange interim periods of the fiscal year in which the change is
made. When retrospective application to prechange interim periods is
impracticable, the desired change may only be made as of the beginning
of a subsequent fiscal year.
Disclosure
.l 3.

FSP §11,100.01

Has the entity properly disclosed the following in the fiscal,
and interim, if applicable, period in which a change in accounting principle is made (not required for subsequent periods): (Note: If a change accounting principle has no material
effect in the period of change but is reasonably certain to have
a material effect in later periods, the disclosures in item [a]
should be provided whenever the financial statements of the
period of change are presented)?
a.

The nature of and reason for the change in accounting
principle, including an explanation of why the newly
adopted accounting principle is preferable?

b.

The method of applying the change, including all of the
following:
i.

A description of the prior-period information
that has been retrospectively adjusted, if any?

ii.

The effect of the change on income from continuing operations, net income (or other appropriate
captions of changes in the applicable net assets or
performance indicator), any other affected financial statement line item, and any affected pershare amounts for the current period and any
prior periods retrospectively adjusted? Presentation of the effect on financial statement subtotals
and totals other than income from continuing operations and net income (or other appropriate
captions of changes in the applicable net assets or
performance indicator) is not required.

No

N/A

37

Financial Statements and Notes Checklist

Yes

c.

.l 4.

iii.

The cumulative effect of the change on retained
earnings or other components of equity or net assets in the statement of financial position as of the
beginning of the earliest period presented?

iv.

If retrospective application to all prior periods is
impracticable, disclosure of the reasons therefore,
and a description of the alternative method used
to report the change (see paragraphs 5–7 of FASB
ASC 250-10-45)?

No

N/A

If indirect effects of a change in accounting principle
are recognized,
i.

a description of the indirect effects of a change in
accounting principle, including the amounts that
have been recognized in the current period, and
the related per-share amounts, if applicable?

ii.

unless impracticable, the amount of the total recognized indirect effects of the accounting change
and the related per-share amounts, if applicable,
that are attributable to each prior period presented?
[FASB ASC 250-10-50 par. 1–2]

Has the entity properly disclosed in the fiscal year in which a
new accounting principle is adopted, financial information
reported for interim periods after the date of adoption, which
includes disclosure of the effect of the change on income from
continuing operations, net income (or other appropriate captions of changes in the applicable net assets or performance
indicator), and related per-share amounts, if applicable, for
those post change interim periods?
[FASB ASC 250-10-50-3]

Change in Accounting Estimate1
.l 5.

Has the entity properly disclosed the effect on income from
continuing operations, net income (or other appropriate captions of changes in the applicable net assets or performance
indicator), and any related per-share amounts of the current
period for a change in estimate that affects several future periods, such as a change in service lives of depreciable assets?
(Note: Disclosure of those effects is not necessary for estimates made each period in the ordinary course of accounting
for items such as uncollectible accounts or inventory obsolescence unless the effect of a change in the estimate is material.)
[FASB ASC 250-10-50-4]

.l 6.

When the entity effects a change in estimate by changing an
accounting principle, are the disclosures required by questions 2–3 made?
[FASB ASC 250-10-50-4]

1
Per Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 250-10-50-5, the disclosure provisions for a
change in accounting estimate are not required for revisions resulting from a change in a valuation technique or its application.
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Yes
.l 7.

When the entity has a change in estimate that does not have
a material effect in the period of change but is reasonably certain to have a material effect in later periods, is a description
of that change in estimate disclosed whenever the financial
statements of the period of change are presented?
[FASB ASC 250-10-50-4]

Change in Reporting Entity
.l 8.

When there has been a change in the reporting entity, do the
financial statements of the period of the change, provide a
description of the nature of the change, and the reason for it?
[FASB ASC 250-10-50-6]

.l 9.

Is the effect of the change on income before extraordinary
items, net income (or other appropriate captions of changes
in the applicable net assets or performance indicator), OCI,
and any related per-share amounts disclosed for all periods
presented?
[FASB ASC 250-10-50-6]

.l 10.

If a change in reporting entity does not have a material effect
in the period of change but is reasonably certain to have a
material effect in later periods, the nature of and reason for
the change disclosed whenever the financial statements of the
period of change are presented?
[FASB ASC 250-10-50-6]

Correction of an Error in Previously Issued Financial Statements
.l 11.

When financial statements are restated to correct an error, has
the entity disclosed that its previously issued financial statements have been restated, along with a description of the nature of the error? Does the entity also properly disclose the
following:
a.

The effect of the correction on each financial statement
line item and any per-share amounts affected for each
prior period presented?

b.

The cumulative effect of the change on retained earnings or other appropriate components of equity or net
assets in the statement of financial position, as of the
beginning of the earliest period presented?
[FASB ASC 250-10-50-7]

.l 12.

Has the entity properly disclosed, if prior period adjustments
have been recorded, the resulting effects (both gross and net
of applicable income tax) on the net income of prior periods
in the annual report for the year in which the adjustments are
made and in interim reports, if applicable, issued during that
year subsequent to the date of recording the adjustments?
(Note: The entity should not repeat the disclosures in subsequent periods.)
[FASB ASC 250-10-50 par. 8 and 10]

.l 13.

Has the entity properly disclosed the following prior-period
adjustments and restatements (see also FASB ASC 205-10-45
and FASB ASC 205-10-50-1):
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Yes
a.

For single period financial statements, the effects (including applicable income taxes) of such restatement
on the balance of retained earnings at the beginning of
the period and on the net income of the immediately
preceding period?

b.

For multiple-period financial statements, the effects (including applicable income taxes) for each of the periods
included in the statements, in total and by class, of the
correction on change in net assets for each of the periods presented?
[FASB ASC 250-10-50-9]

No

N/A

Error Correction Related to Prior Interim Periods of the Current Fiscal Year
l 14.

L.

If the entity prepares interim reporting and an adjustment related to a prior period of the current fiscal year has been
made, has the entity properly disclosed both of the following:
a.

The effect on income from continuing operations, net
income, and related per-share amounts for each prior
interim period of the current fiscal year?

b.

Income from continuing operations, net income, and related per-share amounts for each prior interim period
restated in accordance with FASB ASC 250-10-45-26?
[FASB ASC 250-10-50-11]

Presentation of Changing Prices (FASB ASC 255-10)
Disclosure

.l 1.

M.

Although not required, has the entity properly disclosed, as
encouraged, supplementary information on the effects of
changing prices?
[FASB ASC 255-10-50-1]

Presentation of Earnings Per Share (FASB ASC 260-10)2
Presentation
Additional Presentation Information

For entities that have issued common stock or potential common stock, if those securities trade in a public
market either on a stock exchange or in the over-the-counter market, including securities quoted only locally
or regionally, as discussed in FASB ASC 260-10-15-2, see FASB ASC 260-10-45 for information on proper
presentation.
Disclosure
l 1.

Has the entity properly disclosed the following for each period for which an income statement is presented:

2
Per FASB ASC 260-10-15-2, the guidance in FASB ASC 260, Earnings Per Share, requires presentation of earnings per share (EPS) by
all entities that have issued common stock or potential common stock (that is, securities such as options, warrants, convertible securities,
or contingent stock agreements) if those securities trade in a public market either on a stock exchange (domestic or foreign) or in the overthe-counter market, including securities quoted only locally or regionally. FASB ASC 260 also requires presentation of EPS by an entity
that has made a filing or is in the process of filing with a regulatory agency in preparation for the sale of those securities in a public
market.
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Yes

l 2.

a.

A reconciliation of the numerators and denominators of
the basic and diluted per share computations for income from continuing operations?

b.

The effect that has been given to preferred dividends in
arriving at income available to common shareholders’
in computing basic EPS?

c.

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic EPS in the future that were not included in the computation of diluted EPS because to do so would have
been antidilutive for the period(s) presented?
[FASB ASC 260-10-50-1]

No

N/A

Has the entity properly disclosed, for the latest period for
which an income statement is presented, a description of any
transaction that occurred after the end of the most recent period but before the financial statements were issued or are
available to be issued (as discussed in FASB ASC 855-10-25)
that would have changed materially the number of common
shares or potential common shares outstanding at the end of
the period if the transaction had occurred before the end of
the period?
[FASB ASC 260-10-50-2]

Presentation Regarding Interim Reporting (FASB ASC 270-10)3

N.

Disclosure
l 1.

Has the entity properly disclosed the following, at a minimum, if the publicly traded entity reports summarized financial information at interim dates (including reports on the
fourth quarter):
a.

Sales or gross revenues, provision for income taxes, extraordinary items (including related income tax effects),
net income, and comprehensive income?

b.

Basic and diluted EPS data for each period presented,
determined in accordance with the provisions of FASB
ASC 260?

3
In July 2010, FASB issued Accounting Standards Update (ASU) No. 2010-20, Receivables (Topic 310): Disclosures about the Credit Quality
of Financing Receivables and the Allowance for Credit Losses. The effective dates are as follows:

a.

b.

For publicly traded companies:
i.

The “Pending Content” for disclosures as of the end of a reporting period are effective for the first interim or annual
reporting period ending on or after December 15, 2010 (that is, December 31, 2010, for public entities with calendar yearends).

ii.

The “Pending Content” for disclosures about activity that occurs during a reporting period is effective for the first interim
or annual reporting period beginning on or after December 15, 2010 (that is, January 1, 2011, for public entities with
calendar year-ends).

For nonpublic entities, the “Pending Content” is effective for the first annual reporting period ending on or after December 15,
2011 (that is, December 31, 2011, for entities with calendar year-ends).

This checklist has not been updated to include the presentation and disclosure requirements of ASU No. 2010-20.
Readers can refer to the full text of the ASU on the FASB website at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition and open effective date information discussed in FASB ASC 31010-65-2.
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Yes
c.

Seasonal revenue, costs, or expenses?

d.

Significant changes in estimates or provisions for income taxes?

e.

Disposal of a component of an entity and extraordinary, unusual or infrequently occurring items?

f.

Contingent items?

g.

Changes in accounting principles or estimates?

h.

Significant changes in financial position?

i.

All of the following information about reportable operating segments determined according to the provisions of FASB ASC 280, including provisions related to
restatement of segment information in previously issued financial statements:

j.

i.

Revenues from external customers?

ii.

Intersegment revenues?

iii.

A measure of segment profit or loss?

iv.

Total assets for which there has been a material
change from the amount disclosed in the last annual report?

v.

A description of differences from the last annual
report in the basis of segmentation or in the
measurement of segment profit or loss?

vi.

A reconciliation of the total of the reportable segments’ measures of profit or loss to the entity’s
consolidated income before income taxes, extraordinary items, and discontinued operations?

No

N/A

All of the following information about defined benefit
pension plans and other defined benefit postretirement
benefit plans, disclosed for all periods presented pursuant to the provisions of FASB ASC 715-20:
i.

The amount of net periodic benefit cost recognized, for each period for which a statement of
income is presented, showing separately the service cost component, the interest cost component,
the expected return on plan assets for the period,
the gain or loss component, the prior service cost
or credit component, the transition asset or obligation component, and the gain or loss recognized due to a settlement or curtailment?
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Yes
ii.

The total amount of the employer’s contributions
paid, and expected to be paid, during the current
fiscal year, if significantly different from amounts
previously disclosed pursuant to FASB ASC 71520-50-1. Estimated contributions may be presented in the aggregate combining all of the following: (1) contributions required by funding
regulations or laws, (2) discretionary contributions, and (3) noncash contributions?

k.

The information about the use of fair value to measure
assets and liabilities recognized in the statement of financial position pursuant to paragraphs 1–6 of FASB
ASC 820-10-50?

l.

The information about derivative instruments as required by FASB ASC 815-10-50, 815-20-50, 815-25-50,
815-30-50, and 815-35-50?

m.

The information about fair value of financial instruments as required by FASB ASC 825-10-50?

n.

The information about certain investments in debt and
equity securities as required by FASB ASC 320-10-50
and 942-320-50?

o.

The information about other-than-temporary impairments as required by FASB ASC 320-10-50, 325-20-50,
and 958-320-50?
[FASB ASC 270-10-50-1]

l 2.

Has the entity properly disclosed, if the reporting entity is a
publicly traded company and if interim financial data and
disclosures are not separately reported for the fourth quarter,
accounting changes made during the fourth quarter, disposals of segments of a business, extraordinary, unusual, or infrequently occurring items recognized in the fourth quarter,
and the aggregate effect of year-end adjustments that are material to the results of that quarter in a note to the financial
statements?
[FASB ASC 270-10-50-2]

l 3.

Has the entity properly disclosed the impact of the financial
results for interim periods of the matters discussed in paragraphs 12–16 of FASB ASC 270-10-45 and paragraphs 5–6 of
FASB ASC 270-10-50?
[FASB ASC 270-10-50-3]

l 4.

Has the entity properly disclosed, as encouraged but not required, balance sheet and cash flow data been for the interim
periods?
[FASB ASC 270-10-50-4]

l 5.

Has the entity properly disclosed extraordinary items separately and included them in the determination of net income
for the period in which they occurred?
[FASB ASC 270-10-50-5]
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Yes
l 6.

O.

No

N/A

Has the entity properly disclosed, in the same manner required for annual reports, contingencies and other uncertainties that could be expected to affect the fairness of presentation of financial data at an interim date been?
[FASB ASC 270-10-50-6]

Presentation Regarding Income Taxes for Interim Reporting
(FASB ASC 270-740)
Additional Presentation and Disclosure Information

See the “Income Taxes” section of this checklist for information on the presentation and disclosure requirements under FASB ASC 270-740.
P.

Presentation of Risks and Uncertainties (FASB ASC 275-10)
Disclosure
Nature of Operations

.l 1.

Has the entity properly disclosed a description of the major
products or services the entity sells or provides and it principal markets, including the locations of those markets?
[FASB ASC 275-10-50-2]

.l 2.

If the entity operates in more than one business, has the entity
properly disclosed information indicating the relative importance of its operations in each business and the basis for this
determination (assets, revenues, and earnings)?
[FASB ASC 275-10-50-2]

Use of Estimates in the Preparation of Financial Statements
.l 3.

Has the entity properly disclosed in the financial statements
an explanation that the preparation of financial statements in
conformity with U.S. GAAP requires the use of managements’ estimates?
[FASB ASC 275-10-50-4]

Certain Significant Estimates
.l 4.

Has the entity properly disclosed if, based on known information available to the entity before the issuance of the financial statements, it is reasonably possibly that estimates in the
financial statements will change in the near term (as defined
by the FASB ASC glossary as a period of time not to exceed
one year from the date of the financial statements) and the
effects will be material, discussion (including an estimate of
the effect of the change in condition, situation, or set of circumstances that existed at the date of the financial statements) in the financial statements of these facts and circumstances?
[FASB ASC 275-10-50-6]
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Yes
.l 5.

No

N/A

Has the entity properly disclosed, if the criteria in FASB ASC
275-10-50-8 are met, that it is at least reasonably possible that
a change in an entity’s estimate of its liability could occur in
the near term? (Note: If the estimate involves a loss contingency under FASB ASC 450-20, the disclosure should also include an estimate of the possible loss or range of loss, or state
that such estimate cannot be made.)
[FASB ASC 275-10-50-9]

Current Vulnerability Due to Certain Concentrations
.l 6.

Q.

Has the entity properly disclosed, if the entity has concentrations that exist at the date of the financial statements, that
those concentrations make the entity vulnerable to the risk of
a near term severe impact, and it is at least reasonably possible that the events that could cause the severe impact will
occur in the near term, further including information that is
adequate to inform users of the general nature of the risk associated with the concentration?
[FASB ASC 275-10-50 par. 16 and 20]

Presentation Regarding Segment Reporting (FASB ASC 280-10)
Additional Disclosure Information

Per FASB ASC 280-10-15-2, the guidance in this topic applies to all public entities, with certain exceptions
outlined in FASB ASC 280-10-15-3; however, entities other than public entities are also encouraged to provide the disclosures described in this section.
Disclosure
Operating Segments—Disclosure Requirements—General Information
l 1.

Has the public entity properly disclosed the following for
each period for which an income statement is presented:
a.

Factors used to identify the public entity’s reportable
segments, including the basis of organization (for example, whether management has chosen to organize
the reporting entity around differences in products and
services, geographic areas, regulatory environments, or
a combination of factors and whether operating segments have been aggregated)?

b.

Types of products and services from which each reportable segment derives its revenues?
[FASB ASC 280-10-50-21]

Operating Segments—Disclosure Requirements—Information
About Profit or Loss and Assets
l 2.
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Yes
l 3.

N/A

Has the public entity properly disclosed the following for
each reportable segment, if the specified amounts are included in the measure of segment profit or loss reviewed by
the chief operating decision maker or are otherwise regularly
provided to the chief operating decision maker:
a.

Revenues from external customers?

b.

Revenues from transactions with other operating segments of the reporting entity?

c.

Interest revenue?

d.

Interest expense?

e.

Depreciation, depletion, and amortization expense?

f.

Unusual items as described in FASB ASC 225-20-45-16?

g.

Equity in the net income of investees accounted for by
the equity method?

h.

Income tax expense or benefit?

i.

Extraordinary items?

j.

Significant noncash items other than depreciation, depletion, and amortization expense?
[FASB ASC 280-10-50-22]

l 4.

Has the public entity properly disclosed, unless a segment
has no or immaterial financial operations, interest revenue
separately from interest expense for each reportable segment
(unless a majority of the segment’s revenues are from interest
and the chief operating decision maker relies primarily on net
interest revenue to assess the performance of the segment and
make decisions about resources to be allocated to the segment)? (In that situation, a public entity may report that segment’s interest revenue net of its interest expense and disclose that it has done so.)
[FASB ASC 280-10-50 par. 22–24]

l 5.

Has the public entity properly disclosed the following specified amounts if (a) they included in the determination of segment assets reviewed by the chief operating decision maker
or (b) are otherwise regularly provided to the chief operating
decision maker, even if not included in that measure of segment assets, for each reportable segment:

l 6.

No

i.

The amount of investment in equity method investees?

ii.

Total expenditures for additions to long-lived assets
other than any of the following: financial instruments,
long term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, or deferred tax assets?
[FASB ASC 280-10-50-25]

Has the public entity properly disclosed the fact that, and the
reason behind the fact, if it has no asset information to disclose for a reportable segment?
[FASB ASC 280-10-50-26]
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Operating Segments—Disclosure Requirements—Information
About Profit or Loss and Assets—Measurement
l 7.

Has the public entity properly provided an explanation of the
measurements of segment profit or loss and segment assets
for each reportable segment and disclosed all of the following:
a.

The basis of accounting for any transactions between
reportable segments?

b.

The nature of any differences between the reporting entity’s consolidated income before taxes, extraordinary
items, discontinued operations, and the cumulative effect of changes in accounting principle?

c.

The nature of any differences between the measurements of the reportable segments’ assets and the reporting entity’s consolidated assets?

d.

The nature of any changes from prior periods in the
measurement methods used to determine reported segment profit or loss and the effect, if any, of those
changes on the measure of segment profit or loss?

e.

The nature and effect of any asymmetrical allocations
to segments?
[FASB ASC 280-10-50-29]

Operating Segments—Disclosure Requirements—Reconciliations
l 8.

Has the public entity properly disclosed reconciliations of the
totals of the reportable segments’ revenues, measures of
profit or loss, assets, and every other significant item of information disclosed to corresponding consolidated amounts
presented with all significant reconciling items separately
identified and described?
[FASB ASC 280-10-50 par. 30–31]

Operating Segments—Disclosure Requirements—Interim Period Information
l 9.
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Has the public entity properly disclosed the following information about each reportable segment in condensed financial
statements of interim periods for current quarter and year-todate amounts:
a.

Revenues from external customers?

b.

Intersegment revenues?

c.

A measure of segment profit or loss?

d.

Total assets for which there has been a material change
from the amount disclosed in the last annual report?

e.

A description of differences from the last annual report
in the basis of segmentation or in the basis of measurement of segment profit or loss?

No

N/A
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Yes
f.

No

N/A

A reconciliation of the total of the reportable segments’
measures of profit or loss to the public entity’s consolidated income before income taxes, extraordinary items,
and discontinued operations? If a public entity allocates
items such as income taxes and extraordinary items to
segments, the public entity may choose to reconcile the
total of the segments’ measures of profit or loss to consolidated income after those items. Significant reconciling items should be separately identified and described
in that reconciliation.
[FASB ASC 280-10-50 par. 32–33]

Operating Segments—Disclosure Requirements—Restatements of
Previously Reported Information
l 10.

Has the public entity properly disclosed corresponding information for prior periods restated and the fact that the corresponding items of segment information for earlier periods
have been restated, if the reporting entity changes the structure of its internal organization in a manner that changes the
composition of its reportable segments?
[FASB ASC 280-10-50-34]

l 11.

Has the public entity properly disclosed, in the year in which
a change in the structure of its internal organization in a manner that changes the composition of its reportable segments
occurs and the corresponding information for prior periods is
not restated, segment information for the current period under both the old basis and the new basis?
[FASB ASC 280-10-50-35]

Operating Segments—Disclosure Requirements—Information
About Products and Services
l 12.

Has the public entity properly disclosed the revenues from
external customers for each product and service or each
group of similar products and services, unless it is impracticable to do so? If impracticable, has that fact been disclosed?
[FASB ASC 280-10-50-40]

Operating Segments—Disclosure Requirements—Information
About Geographic Areas
l 13.

Has the public entity properly disclosed the following information about its geographical information, unless it is impracticable to do so? If impracticable, has that fact been disclosed?
a.

Revenues from external customers (i) attributed to the
reporting entity’s country of domicile and (ii) attributed to all foreign countries in total from which the reporting entity derives revenue?

b.

Revenues from external customers attributed to an individual foreign country, if material?

c.

The basis for attributing revenues from external customers to individual countries?
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Yes
d.

Long-lived assets other than financial instruments, long
term customer relationships of a financial institution,
mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets (i) located in the
reporting entity’s country of domicile and (ii) located in
all foreign countries in total in which the reporting entity holds assets?

e.

Long-lived assets as described question 13(d) preceding
in an individual foreign country, if material?
[FASB ASC 280-10-50-41]

No

N/A

Operating Segments—Disclosure Requirements—Information
About Major Customers
l 14.

Has the public entity properly disclosed information about
the extent of its reliance on its major customers (those
amounting to 10 percent or more of the entity’s revenue)?
[FASB ASC 280-10-50-42]

II. Assets
A.

Receivables (FASB ASC 310-10)4, 5
Presentation
Loans or Trade Receivables

.l 1.

Has the entity properly presented receivables held for sale as
a separate balance sheet amount, which is not included with
other loans or trade receivables? (Note: Major categories of
loans or trade receivables should be presented separately either in the balance sheet or in the notes to the financial statements.)
[FASB ASC 310-10-45-2]

.l 2.

Has the entity properly recorded receivables net of an allowance for doubtful accounts?
[FASB ASC 954-310-45-1]

4
In December 2009, FASB issued ASU No. 2009-16, Transfers and Servicing (Topic 860): Accounting for Transfers of Financial Assets. This
update is to incorporate FASB Statement No. 166, Accounting for Transfers of Financial Assets—an amendment of FASB Statement No. 140,
into the codification. ASU No. 2009-16 represents a revision to the provisions of former FASB Statement No. 140, Accounting for Transfers
and Servicing of Financial Assets and Extinguishment of Liabilities—a replacement of FASB Statement No. 125, and requires more information
about transfers of financial assets, including securitization transactions, and where entities have continuing exposure to the risks related
to transferred financial assets. It eliminates the concept of a “qualifying special-purpose entity,” changes the requirements for derecognizing financial assets, and requires additional disclosures. This ASU should be applied as of the beginning of each reporting entity’s first
annual reporting period that begins after November 15, 2009 (that is, January 1, 2010, for entities with calendar year-ends). Early adoption
is not permitted.

This checklist has been updated to include the presentation and disclosure requirements of ASU No. 2009-16.
Readers can refer to the full text of the ASU on the FASB website at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition and open effective date information discussed in FASB ASC 86010-65-3.
5

See footnote 3.
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Yes
.l 3.

No

N/A

Although the aggregate amount of receivables may include
balances due from patients and third party payors (including
final settlements and appeals), has the entity properly reported separately in the financial statements the amounts due
from third-party payors for retroactive adjustments of items
such as final settlements or appeals?
[FASB ASC 954-310-45-1]

Foreclosed or Repossessed Assets
.l 4.

Has the entity properly presented foreclosed or repossessed
assets as a separate balance sheet amount or included in other
assets on the balance sheet with separate disclosures in the
notes to the financial statements? (Note: Certain returned or
repossessed assets, such as inventory, should not be classified
separately if the assets subsequently are to be utilized by the
entity in operations.)
[FASB ASC 310-10-45-3]

Allowances
.l 5.

Has the entity properly presented allowances for uncollectible receivables as deductions from the related receivables?
[FASB ASC 310-10-45-4]

Unearned Discounts
.l 6.

Has the entity properly presented unearned discounts (other
than cash or quantity discounts and similar items), finance
charges, and interest included in the face amounts of receivables as a deduction from the related receivables?
[FASB ASC 310-10-45-8]

Receivables from Officers, Employees, or Affiliates
.l 7.

Has the entity properly presented accounts and notes receivable from officers, employees, and affiliated entities separately (with appropriate disclosures), and not included under
a general heading such as “notes receivable” or “accounts receivable?”
[FASB ASC 310-10-45-13]

Disclosure
Loans or Trade Receivables
.l 8.

Has the entity properly disclosed the following in the accounting policy note disclosure:
a.

The basis of accounting for loans, trade receivables, and
lease financings, including those classified as held for
sale?

b.

The method used in determining the lower of cost or
fair value of nonmortgage loans held for sale (that is
aggregate or individual asset basis)?
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c.

The classification and method of accounting for interest-only strips, loans, other receivables, or retained interests in securitizations that can be contractually prepaid or otherwise settled in a way that the holder
would not recover substantially all of its recorded investment?

d.

The method for recognizing interest income on loan
and trade receivables, including a statement about the
entity’s policy for treatment of related fees and costs,
including the method of amortizing net deferred fees or
costs?
[FASB ASC 310-10-50-2]

.l 9.

Has the entity properly disclosed the major categories of loan
or trade receivables separately in the balance sheet or in the
notes to the financial statements?
[FASB ASC 310-10-50-3]

.l 10.

Has the entity properly disclosed any allowance for credit
losses, allowance for doubtful accounts, and, as applicable,
any unearned income, any unamortized premiums and discounts, and any net unamortized deferred fees and costs in
the financial statements?
[FASB ASC 310-10-50-4]

.l 11.

Is the carrying amount of loans, trade receivables, securities,
and financial instruments that serve as collateral for borrowings disclosed pursuant to FASB ASC 860-30-50-1(b) for nonpublic entities and pursuant to FASB ASC 860-30-50-4(b) for
public entities?
[FASB ASC 310-10-50-5]

.l 12.

With regard to contractual adjustments and third-party settlements, does the provider identify and explain the estimated
amounts that are receivable?
[FASB ASC 954-310-50-1]

Nonaccrual and Past Due Loans and Trade Receivables
.l 13.
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Has the entity properly disclosed the following in the accounting policy note disclosure:
a.

The policy for placing loans and trade receivables, if
applicable, on nonaccrual status (or discontinuing accrual of interest)?

b.

The policy for recording payments received on nonaccrual loans and trade receivables, if applicable?

c.

The policy for resuming accrual of interest?

d.

The policy for charging off uncollectible loans and
trade receivables?

e.

The policy for determining past due or delinquency
status (that is, whether past due status is based on how
recently payments have been received or contractual
terms)?
[FASB ASC 310-10-50-6]

No

N/A
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Yes
.l 14.

Has the entity properly disclosed the recorded investment in
loans (and trade receivables if applicable) on nonaccrual
status as of each balance sheet date in the notes to the financial statements?
[FASB ASC 310-10-50-7]

.l 15.

Has the entity properly disclosed the recorded investment in
loans, and trade receivables, if applicable, past due 90 days
or more and still accruing?
[FASB ASC 310-10-50-7]

No

N/A

Accounting Policies for Credit Losses and Doubtful Accounts
.l 16.

Has the entity properly disclosed, in addition to the loss contingencies disclosures required by FASB ASC 450-20, a description of the accounting policies and methodology the entity used to estimate its allowance for loan losses, allowance
for doubtful accounts, and any liability for off-balance sheet
credit losses, and related charges for loan, trade receivable, or
other credit losses, including a description of the factors that
influenced management’s judgment? (Note: The entity may
also include a discussion of risk elements relevant to particular categories of financial instruments.)
[FASB ASC 310-10-50-9]

Allowance for Credit Losses Related to Loans
.l 17.

Has the entity properly disclosed, as applicable, the activity
in the total allowance for credit losses related to loans, including the balance in the allowance at the beginning and end of
each period, additions charged to operations, direct writedowns charged against the allowance, and recoveries of
amounts previously charged off?
[FASB ASC 310-10-50-12]

Impaired Loans
.l 18.

Has the entity properly disclosed, either in the body of the
financial statements or in the accompanying notes, the following information about loans that meet the definition of an
impaired loan in paragraphs 16–17 of FASB ASC 310-10-35:
a.

b.

As of the date of each statement of financial position
presented, the total recorded investment in the impaired loans at the end of each period and
i.

the amount of that recorded investment for
which there is a related allowance for credit
losses determined in accordance with FASB ASC
310-10-35 and the amount of that allowance?

ii.

the amount of that recorded investment for
which there is no related allowance for credit
losses determined in accordance with FASB ASC
310-10-35?

The creditor’s policy for recognizing interest income on
impaired loans, including how cash receipts are recorded?
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Yes
c.

For each period for which results of operations are presented, the average recorded investment in the impaired loans during each period, the related amount of
interest income recognized during the time within that
period that the loans were impaired, and, unless not
practicable, the amount of interest income recognized
using a cash-basis method of accounting during the
time within that period the loans were impaired?
[FASB ASC 310-10-50 par. 15–16]

Loss Contingencies
.l 19.

Has the entity properly disclosed loss contingencies, as described in FASB ASC 460-10-50-2 (see question 1 in “Guarantees (FASB ASC 460-10)”), even though the possibility of loss
may be remote?
[FASB ASC 310-10-50-22]

Risks and Uncertainties
.l 20.

Has the entity properly disclosed concentrations that meet
the requirements of FASB ASC 275-10-50-16? (Note: Certain
loan products have contractual terms that expose entities to
risks and uncertainties that fall into one or more categories,
as discussed in FASB ASC 275-10-50-1.)
[FASB ASC 275-10-50-16; 310-10-50-25]

. 21.

Do entities that receive unconditional promises to give disclose the following:
a.

The amounts of promises receivable in less than one
year, in one to five years, and in more than five years?

b.

The amount of any allowance for uncollectible promises receivable?
[FASB ASC 958-310-50-1]

. 22.

Have amounts determined to be uncollectible when the contributions receivable were initially measured been excluded
from the allowance for uncollectible promises to give? (Note:
Illustrated in FASB ASC 958-605-55-22.)
[FASB ASC 958-310-50-2]

. 23.

If unconditional promises to give are subsequently measured
at fair value, have the disclosures in the following paragraphs
been made in the notes to financial statements:

FSP §11,100.01

a.

The disclosures required by paragraphs 1–2 of FASB
ASC 820-10-50 in the format described in FASB ASC
820-10-50-8?

b.

The disclosures required by paragraphs 28–31 of FASB
ASC 825-10-50?

c.

The disclosures required by FASB ASC 825-10-50-32, if
an election to report unconditional promises to give is
made after initial recognition pursuant to FASB ASC
825-10-25-4(e)?
[FASB ASC 958-310-50-3]

No

N/A
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Yes
. 24.

B.

No

N/A

Do entities that receive conditional promises to give disclose
the following:
a.

The total of the amounts promised?

b.

A description and amount for each group of promises
having similar characteristics (such as amount of promises conditioned on establishing new programs, completing a new building, and raising matching gifts by a
specified date)?
[FASB ASC 958-310-50-4]

Nonrefundable Fees and Other Costs (FASB ASC 310-20)
Presentation
Balance Sheet Presentation

.l 1.

Has the entity properly presented the unamortized balance of
loan origination, commitment, and other fees and costs and
purchase premiums and discounts that are being recognized
as an adjustment of yield pursuant to FASB ASC 310-20 on
the balance sheet as a part of the loan balance to which it
relates?
[FASB ASC 310-20-45-1]

.l 2.

Has the entity properly presented commitment fees that meet
the criteria of FASB ASC 310-20-35-2 as deferred income in
the financial statements?
[FASB ASC 310-20-45-2]

Income Statement Clarification
.l 3.

Has the entity properly presented amounts of loan origination, commitment, and other fees and costs recognized as an
adjustment of yield as a part of interest income? (Note: Amortization of other fees, such as commitment fees that are being amortized on a straight-line basis over the commitment
period or included in income when the commitment expires,
should be presented as service fee income.)
[FASB ASC 310-20-45-3]

Disclosure
Net Fees and Costs
.l 4.

Has the entity properly disclosed, in the summary of significant accounting policies, a description of the method for recognizing interest income on loan and trade receivables, including a statement about the entity’s policy for treatment of
related fees and costs, including the method of amortizing net
deferred fees or costs included in the notes to the financial
statements?
[FASB ASC 310-20-50-1]

.l 5.

If the entity anticipates prepayments in applying the interest
method, has the entity disclosed the policy and any significant assumptions underlying the prepayment estimates?
[FASB ASC 310-20-50-2]
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Yes
.l 6.

Has the entity properly disclosed the unamortized net fees
and costs as a part of each loan category? (Note: Additional
disclosures such as unamortized net fees and costs may be
included in the footnotes to the financial statements if the
lender believes that such information is useful to the users of
financial statements.)
[FASB ASC 310-20-50-3]

.l 7.

Has the entity properly disclosed, with respect to credit card
fees and costs, for both purchased and originated credit
cards, the net amount capitalized at the balance sheet date
and the amortization period(s)?
[FASB ASC 310-20-50-4]

C.

Loans and Debt Securities Acquired With Deteriorated Credit
Quality (FASB ASC 310-30)
Presentation
Accretable Yield

.l 1.

Has the entity properly not presented in the balance sheet the
amount of the loan’s accretable yield or the loan’s contractually required payments receivable in excess of the amount of
its cash flows expected at acquisition?
[FASB ASC 310-30-45-1]

Disclosure
Footnote Disclosures for Loans
.l 2.

Has the entity properly disclosed in the notes to financial
statements how prepayments are considered in the determination of contractual cash flows and cash flows expected to
be collected?
[FASB ASC 310-30-50-1]

.l 3.

Has the entity properly disclosed, for each balance sheet presented, the following information about loans within the
scope of FASB ASC 310-30:
a.
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Separately for both those loans that are accounted for
as debt securities and those loans that are not accounted for as debt securities,
i.

the outstanding balance and related carrying
amount at the beginning and end of the period?

ii.

the amount of accretable yield at the beginning
and end of the period, reconciled for additions,
accretion, disposals of loans, and reclassifications
to or from nonaccretable difference during the
period?

iii.

for loans acquired during the period, the contractually required payments receivable, cash flows
expected to be collected, and fair value at the acquisition date?

No

N/A
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Yes
iv.

b.

.l 4.

D.

No

N/A

for those loans within the scope of FASB ASC
310-30 for which the income recognition model is
not applied in accordance with FASB ASC 31030-35-3, the carrying amount at the acquisition
date for loans acquired during the period and the
carrying amount of all loans at the end of the period?

Further, for those loans that are not accounted for as
debt securities, has the entity disclosed
i.

the amount of (1) any expense recognized pursuant to FASB ASC 310-30-35-10(a) and (2) any
reductions of the allowance recognized pursuant
to FASB ASC 310-30-35-10(b)(1) for each period
for which an income statement is presented?

ii.

the amount of the allowance for uncollectible accounts at the beginning and end of the period?
[FASB ASC 310-30-50-2]

For financial instruments, are significant concentrations of
credit risk arising from receivables disclosed?
[FASB ASC 954-310-50-2]

Troubled Debt Restructurings by Creditors (FASB ASC 310-40)
Disclosure6
Creditor Disclosure of Troubled Debt Restructurings

6

.l 1.

Has the entity properly disclosed the amount of commitments, if any, to lend additional funds to debtors owing receivables whose terms have been modified in troubled debt
restructurings either in the body of the financial statements
or in the notes thereto as of the date of each balance sheet
presented?
[FASB ASC 310-40-50-1]

.l 2.

Has the entity properly disclosed, or not disclosed, information established by FASB ASC 310-10-50-15(a) and 310-10-5015(c) in the years after a loan restructuring (restructured in a
troubled debt restructuring involving a modification of
terms) if the restructuring agreement for the impaired loan (a)
specifies an interest rate equal to or greater than the rate that
the creditor was willing to accept at the time of restructuring
for a new loan with comparable risk, and (b) the loan is not
impaired based on the terms specified by the restructuring
agreement? (Note: This exception should be applied consistently to all loans restructured in a troubled debt restructuring that meet the criteria in this paragraph.)
[FASB ASC 310-40-50 par. 2–3]

.l 3.

Has the amount of writedown and recorded investment of a
loan modified in a troubled debt restructuring been disclosed
in the year of writedown?
[FASB ASC 310-40-50-4]

See footnote 3.
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Yes
Loan Restructured Into Two (or More) Loan Agreements
.l 4.

E.

As related to a loan restructured in a troubled debt restructuring into two (or more) loan agreements, has the entity separately considered the restructured loans in years after the restructuring when assessing the applicability of the disclosures
in FASB ASC 310-10-50-15(a) and FASB ASC 310-10-50-15(c)?
[FASB ASC 310-40-50-5]

Investments—Debt and Equity Securities (FASB ASC 320-10)
Presentation
Balance Sheet Classification

.l 1.

.l 2.

Has the entity properly presented any investments in available-for-sale securities and trading securities separately from
similar assets that are subsequently measured using another
measurement attribute on the face of the statement of financial position and, in doing so, does the entity
a.

present the aggregate of those fair value and non-fairvalue amounts in the same line item and parenthetically disclose the amount of fair value included in the
aggregate amount?

b.

present two separate line items to display the fair value
and non-fair-value carrying amounts?
[FASB ASC 320-10-45-1]

If the entity presents a classified statement of financial position, has the entity properly presented all individual held-tomaturity securities, individual available-for-sale securities,
and individual trading securities as either current or noncurrent, as appropriate, under the current asset and current liability provisions of FASB ASC 210-10-45?
[FASB ASC 320-10-45-2]

Income Statement Classification
.l 3.

Has the entity properly presented gains and losses that have
accumulated before the transfer consistently with realized
gains and losses for the category from which the security is
being transferred, and not the category into which the security is being transferred?
[FASB ASC 320-10-45-7]

Other-Than-Temporary Impairment
.l 4.
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Has the entity properly presented, in a period in which the
entity determines that a security’s decline in fair value below
its amortized cost basis is other than temporary, the total
other-than-temporary impairment in the statement of earnings with an offset for the amount of the total other-than-temporary impairment that is recognized in OCI, in accordance
with FASB ASC 320-10-35-34D?
[FASB ASC 320-10-45-8A]

No

N/A
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Yes

No

N/A

Other Comprehensive Income
.l 5.

Has the entity properly presented subsequent increases in the
fair value of available-for-sale securities in OCI pursuant to
FASB ASC 320-10-35-1(b) and FASB ASC 320-10-45-8? (Note:
Subsequent decreases in fair value, if not an other-than-temporary impairment, should also be included in OCI.)
[FASB ASC 320-10-45-9]

Other Than Temporary Impairment
.l 6.

Has the entity properly presented, in the financial statement
in which the components of accumulated OCI are reported,
amounts recognized therein related to held-to-maturity and
available-for-sale debt securities for which a portion of an
other-than-temporary impairment has been recognized in
earnings?
[FASB ASC 320-10-45-9A]

Cash Flow Presentation
.l 7.

Has the entity properly presented cash flows from purchases,
sales, and maturities of available-for-sale securities and heldto-maturity securities as cash flows from investing activities
and presented them at gross for each security classification in
the statement of cash flows?
[FASB ASC 320-10-45-11]

.l 8.

Has the entity properly presented cash flows from purchases,
sales, and maturities of trading securities as cash flows based
on the nature and purpose for which the securities were acquired (generally, operating activities) in the statement of
cash flows?
[FASB ASC 320-10-45-11]

General
. 9.

Are realized gains and losses; unrealized gains and losses;
dividend, interest, and other similar investment income; and
other than temporary impairment losses reported in the statement of activities as increases or decreases in unrestricted net
assets or in temporarily restricted net assets or in permanently restricted net assets, depending on the existence of or
lack of donor restrictions or law?
[FASB ASC 958-320-45 par. 1–2]

. 10.

Have the following investment returns been included in the
performance indicator:
a.

Dividend, interest, and other similar investment income?

b.

Realized gains and losses?

c.

Unrealized gains and losses on trading securitites (as
defined in FASB ASC 320)?
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Yes
d.

. 11.

Other than temporary impairment losses? (Note: Unrealized gains and losses on other than trading securities should be excluded from the performance indicator. For examples of other items that should be
reported separately from the performance indicator, see
FASB ASC 954-225-45-7.)
[FASB ASC 954-320-45-1]

Have gains and investment income that are limited to specific
uses by donor-imposed restrictions reported as increases in
unrestricted net assets, if (a) the restrictions are met in the
same reporting period as the gains and income are recognized, provided that the not-for-profit entity has a similar
policy for reporting contributions received, (b) reports consistently from period to period, and (c) discloses it accounting
policy.
[FASB ASC 958-320-45-3 and FASB ASC 954-320-45-2]

Disclosure
.l 12.

Has the entity properly disclosed the major security types,
based on the nature and risks of each security? (Note: In determining whether disclosure for a particular security type is
necessary and whether it is necessary to further separate a
particular security type into greater detail, the entity should
consider all of the following: [a] [shared] activity or business
sector, [b] vintage, [c] geographic concentration, [d] credit
quality, and [e] economic characteristics.)
[FASB ASC 320-10-50-1B]

. 13.

For the most recent period for which a statement of financial
position is presented, does the entity disclose the nature of
and carrying amount for every individual investment or
group of investments that represents a significant concentration of market risk?
[FASB ASC 958-320-50-3]

. 14.

For each period for which a statement of financial position is
presented, has the not-for-profit entity disclosed the aggregate carrying amount of investments by major types, for example, equity securities, U.S. Treasury securities, corporate
debt securities, mortgage-backed securities, oil and gas properties, and real estate?
[FASB ASC 958-320-50-2]

. 15.

For cost-method investments, does the entity disclose all of
the following additional information, if applicable, as of each
date for which a statement of financial position is presented
in its annual financial statements:
a.
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The composition of investment return including, at a
minimum, investment income, net realized gains or
losses on investments reported at other than fair value,
and net gains or losses on investments reported at fair
value?

No

N/A
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Yes

. 16.

b.

A reconciliation of investment return to amounts reported in the statement of activities if investment return is separated into operating and nonoperating
amounts?

c.

A description of the policy used to determine the
amount that is included in the measure of operations
and a discussion of circumstances leading to a change,
if any, in that policy?
[FASB ASC 958-320-50-1]

No

N/A

For the most recent period for which a statement of financial
position is presented, does the not-for-profit entity disclose
the nature of and carrying amount for every individual investment or group of investments that represents a significant
concentration of market risk (that may result from the nature
of the investments, a lack of diversity of industry, currency,
or geographic location)?
[FASB ASC 958-320-50-3]

Securities Classified as Available for Sale
.l 17.

.l 18.

Has the entity properly disclosed, for securities classified as
available for sale, all of the following by major security type,
as of each date for which a statement of financial position is
presented: (Note: Investments in mutual funds that invest
only in U.S. government debt securities may be shown separately rather than grouped with other equity securities.)
a.

Amortized cost basis?

b.

Aggregate fair value?

c.

Total other-than-temporary impairment recognized in
accumulated OCI?

d.

Total gains for securities with net gains in accumulated
OCI?

e.

Total losses for securities with net losses in accumulated OCI?

f.

Information about the contractual maturities of those
securities as of the date of the most recent statement of
financial position reported? (Note: Maturity information may be combined in appropriate groupings. Further, securities not due at a single maturity date, such
as mortgage backed securities, may be disclosed separately rather than allocated over several maturity
groupings.)
[FASB ASC 320-10-50 par. 2–4]

Has the entity properly disclosed the following by major security type, for securities classified as held-to-maturity as of
each date for which a statement of financial position is presented:
a.

Amortized cost basis?

b.

Aggregate fair value?
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Yes
c.

Gross unrecognized holding gains?

d.

Gross unrecognized holding losses?

e.

Net carrying amount?

f.

Total other-than-temporary impairment recognized in
accumulated OCI?

g.

Gross gains and losses in accumulated OCI for any derivatives that hedged the forecasted acquisition of the
held-to-maturity securities?

h.

Information about the contractual maturities of those
securities as of the date of the most recent statement of
financial position presented?
[FASB ASC 320-10-50-5]

No

N/A

Impairment of Securities
.l 19.

Has the entity properly disclosed, for all investments in an
unrealized loss position, including those that fall within the
scope of FASB ASC 325-40, for which other-than-temporary
impairments have not been recognized in earnings (including
investments for which a portion of an other-than-temporary
impairment has been recognized in OCI), the following in its
interim and annual financial statements:
a.

As of each date for which a statement of financial position is presented, quantitative information, aggregated by category of investment—each major security
type that the entity discloses in accordance with FASB
ASC 320-10 and cost-method investments—in tabular
form (Note: These disclosures should be segregated by
those investments that have been in a continuous unrealized loss position7 for less than 12 months and those
that have been in a continuous unrealized loss position
for 12 months or longer.),
i.

the aggregate related fair value of investments
with unrealized losses?

ii.

the aggregate amount of unrealized losses (that
is, the amount by which cost basis exceeds fair
value)?

7

Per FASB ASC 320-10-50-8, the reference point for determining how long an investment has been in a continuous unrealized loss
position is the balance sheet date of the reporting period in which the impairment is identified. The continuous unrealized loss position
ceases upon either of the following:
●

The recognition of the total amount by which amortized cost basis exceeds fair value as an other-than-temporary impairment
in earnings

●

The investor becoming aware of a recovery of fair value up to (or beyond) the cost of the investment during the period
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Yes
b.

No

N/A

As of the date of the most recent statement of financial
position, additional information (in narrative form) that
provides sufficient information to allow financial statement users to understand the quantitative disclosures
and the information that the entity considered (both
positive and negative) in reaching the conclusion that
the impairment or impairments are not other than temporary? (Note: The disclosures may be aggregated by
investment categories, but individually significant unrealized losses generally should not be aggregated.)
(See FASB ASC 320-10-50-6 for example disclosures.)
[FASB ASC 320-10-50 par. 6–7]

.l 20.

Has the entity properly disclosed, for interim and annual periods in which an other-than-temporary impairment of a debt
security is recognized and only the amount related to a credit
loss was recognized in earnings, by major security type, the
methodology and significant inputs used to measure the
amount related to credit loss? (Examples of significant inputs
include default rates, delinquency rates, percentage of nonperforming assets, loan-to-collateral-value ratios, third-party
guarantees, current levels of subordination, vintage, geographic concentration and credit ratings.)
[FASB ASC 320-10-50-8A]

.l 21.

Has the entity properly disclosed, in tabular format, a rollforward of the amount related to credit losses recognized in
earnings in accordance with FASB ASC 320-10-35-34D, for interim and annual periods, including, at a minimum,
a.

the beginning balance of the amount related to credit
losses on debt securities held by the entity at the beginning of the period for which a portion of an other-thantemporary impairment was recognized in OCI?

b.

additions for the amount related to the credit loss for
which an other-than-temporary impairment was not
previously recognized?

c.

reductions for securities sold during the period (realized)?

d.

reductions for securities for which the amount previously recognized in OCI was recognized in earnings
because the entity intends to sell the security or more
likely than not will be required to sell the security before recovery of its amortized cost basis?

e.

if the entity does not intend to sell the security and it is
not more likely than not that the entity will be required
to sell the security before recovery of its amortized cost
basis, additional increases to the amount related to the
credit loss for which an other-than-temporary impairment was previously recognized?

FSP §11,100.01

62

Health Care Entities

Yes
f.

reductions for increases in cash flows expected to be
collected that are recognized over the remaining life of
the security?

g.

the ending balance of the amount related to credit
losses on debt securities held by the entity at the end of
the period for which a portion of an other-than-temporary impairment was recognized in OCI?
[FASB ASC 320-10-50-8B]

Sales, Transfers, and Related Matters That Occurred During the Period
.l 22.

.l 23.
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Has the entity properly disclosed the following for each period for which an income statement is presented:
a.

The proceeds from sales of available-for-sale securities
and gross realized gains and losses that have been included in earnings as a result of those sales?

b.

The basis on which the cost of a security sold or the
amount reclassified out of accumulated OCI into earnings was determined (that is, specific identification, average cost, or other method used)?

c.

The gross gains and losses included in earnings from
transfers of securities from the available-for-sale category to the trading category?

d.

The amount of the net unrealized holding gain or loss
on available-for-sale securities for the period that has
been included in accumulated OCI and the amount of
gains and losses reclassified out of accumulated OCI
into earnings for the period?

e.

The portion of trading gains and losses for the period
that relates to trading securities still held at the reporting date?
[FASB ASC 320-10-50-9]

Has the entity properly disclosed the following for any sales
of or transfers from securities classified as held-to-maturity
for each period for which an income statement is presented:
(Note: FASB ASC 320-10-25-14 sets forth the conditions under
which sales of debt securities may be considered as maturities
for the purposes of these disclosures.)
a.

Net carrying amount of the sold or transferred security?

b.

The net gain or loss in accumulated OCI for any derivative that hedged the forecasted acquisition of the heldto-maturity security?

c.

Related realized or unrealized gain or loss?

d.

The circumstances leading to the decision to sell or
transfer the security?
[FASB ASC 320-10-50 par. 10–11]

No

N/A
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Yes
F.

No

N/A

Investments—Equity Method and Joint Ventures (FASB ASC 32310)
Presentation
l 1.

For investments in common stock accounted for by the equity
method, is the investor’s share of earnings shown as a single
amount except for investee extraordinary items and its share
of accounting changes reported in the financial statements?
[FASB ASC 323-10-45 par. 1–2]

Disclosure
General
l 2.

Has the entity properly disclosed the following for investments in common stock accounted for by the equity method:
a.

The name of each investee and their percentage of ownership of common stock? (Note: Disclosure should include the names of any significant investee entities in
which the investor holds 20 percent or more of the voting stock, but the common stock is not accounted for
on the equity method, together with the reasons why
the equity method is not considered appropriate, and
the names of any significant investee corporations in
which the investor holds less than 20 percent of the voting stock and the common stock is accounted for on the
equity method, together with the reasons why the equity method is considered appropriate.)

b.

The accounting policies of the investor with respect to
investments in common stock?

c.

The difference between the amount at which an investment is carried and the amount of underlying equity in
net assets, and the accounting treatment of this difference?

d.

For investments in common stock for which a quoted
market price is available, the aggregate value of each
identified investment based on the quoted market
price? (This is not required for investments in common
stock of subsidiaries.)

e.

For investments in common stock of corporate joint
ventures or other investments accounted for under the
equity method which is in the aggregate material in relation to the financial position or results of operations
of an investor, summarized information as to assets, liabilities, and results of operation of the investees as appropriate?

f.

Material effects of possible conversions of outstanding
convertible securities, exercises, or contingent issuances?
[FASB ASC 323-10-50-3]
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Yes
G.

Cost Method Investments (FASB ASC 325-20)
Presentation
. 1.

Has the entity properly presented property held for investment purposes as part of investments?
[FASB ASC 954-325-45-1]

Disclosure
. 2.

.l 3.

FSP §11,100.01

For each period for which a statement of financial position is
presented, are the following disclosures made on the face of
the financial statements or in the notes thereto:
a.

The basis for determining the carrying amount for
other investments?

b.

The method(s) and significant assumptions used to estimate the fair values of investments other than financial instruments if those other investments are reported
at fair value?

c.

The information required by FASB ASC 320-10-50-6(a)
if the not-for-profit entity holds cost-method investments that are in an unrealized loss position for which
impairment losses have not been recognized?

d.

The information required by FASB ASC 325-20-50-1, in
question 3 that follows?
[FASB ASC 958-325-50-2]

For cost-method investments, does the entity disclose all of
the following additional information, if applicable, as of each
date for which a statement of financial position is presented
in its annual financial statements:
a.

The aggregate carrying amount of all cost-method investments?

b.

The aggregate carrying amount of cost-method investments that the entity did not evaluate for impairment
(see FASB ASC 325-20-35)?

c.

The fact that the fair value of a cost-method investment
is not estimated if there are no identified events or
changes in circumstances that may have a significant
adverse effect on the fair value of the investment, and
any one of the following:
i.

The entity determined, in accordance with paragraphs 16–19 of FASB ASC 825-10-50, that it is
not practicable to estimate the fair value of the
investment?

ii.

The entity is exempt from estimating fair value
under FASB ASC 825?

iii.

The entity is exempt from estimating interim fair
values because it does not meet the FASB ASC
definition of a publicly traded company?
[FASB ASC 325-20-50-1]

No

N/A
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Yes
.l 4.

H.

No

N/A

Has the entity properly disclosed, for cost-method investments, the following additional information, if applicable, as
of each date for which a statement of financial position is presented in its annual financial statements:
a.

The aggregate carrying amount of all cost-method investments?

b.

The aggregate carrying amount of cost-method investments that the entity did not evaluate for impairment
(see FASB ASC 325-20-35)?

c.

The fact that the fair value of a cost-method investment
is not estimated if there are no identified events or
changes in circumstances that may have a significant
adverse effect on the fair value of the investment, and
any one of the following:
i.

The entity determined, in accordance with paragraphs 16–19 of FASB ASC 825-10-50, that it is
not practicable to estimate the fair value of the
investment?

ii.

The entity is exempt from estimating fair value
under FASB ASC 825?

iii.

the entity is exempt from estimating interim fair
values because it does not meet the FASB ASC
definition of a publicly traded company?
[FASB ASC 325-20-50-1]

Investments in Insurance Contracts (FASB ASC 325-30)
Presentation
Life Settlement Contract—Statement of Financial Position

.l 1.

Has the entity properly presented, to accomplish separate reporting, its investments that are remeasured at fair value on
the face of the statement of financial position separately from
those accounted for under the investment method by either
of the following:
a.

Displaying separate line items on the statement of financial position for the fair value method and investment method carrying amounts?

b.

Presenting the aggregate of those fair value method
and investment method carrying amounts and parenthetically disclosing the amount of those investments
accounted for under the fair value method included in
the aggregate amount?
[FASB ASC 325-30-45-1]
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Life Settlement Contract—Income Statement
.l 2.

.l 3.

Has the entity properly presented, to accomplish separate reporting, the investment income from its investments in life
settlement contracts that are remeasured at fair value on the
face of the income statement separately from the investment
income from those accounted for under the investment
method by either of the following:
a.

Displaying separate line items on the income statement
for the investment income from the investments in life
settlement contracts that are accounted for under the
fair value method and investment method?

b.

Presenting the aggregate of the investment income in
life settlement contracts and parenthetically disclosing
the investment income from those investments accounted for under the fair value method that are included in the aggregate amount?
[FASB ASC 325-30-45-3]

Has the entity properly presented, if applying the fair value
method, premiums paid and life insurance proceeds received
on the same financial reporting line as the changes in fair
value?
[FASB ASC 325-30-45-4]

Life Settlement Contract—Statement of Cash Flows
.l 4.

Has the entity properly presented cash receipts and cash payments related to life settlement contracts pursuant to FASB
ASC 230, Statement of Cash Flows, based on the nature and
purpose for which the life settlements were acquired?
[FASB ASC 325-30-45-5]

Disclosure
General
.l 5.

Has the entity properly disclosed when contractual restrictions on the ability to surrender a policy exist?
[FASB ASC 325-30-50-1]

Life Settlement Contract
.l 6.

Has the entity properly disclosed its accounting policy for life
settlement contracts including the classification of cash receipts and cash disbursements in the statement of cash flows?
(Note: The disclosure requirements in FASB ASC 325-30-50
do not eliminate disclosure requirements included in elsewhere in FASB ASC, including other disclosure requirements
on the use of fair value.)
[FASB ASC 325-30-50 par. 2–3]

Life Settlement Contract—Investment Method
.l 7.
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Has the entity properly disclosed the following for life settlements contracts accounted for under the investment method
based on the remaining life expectancy for each of the first
five succeeding years from the date of the statement of financial position and thereafter, as well as in the aggregate:

No

N/A

67

Financial Statements and Notes Checklist

Yes
a.

The number of life settlement contracts?

b.

The carrying value of the life settlement contracts?

c.

The face value (death benefits) of the life insurance policies underlying the contracts?
[FASB ASC 325-30-50-4]

.l 8.

Has the entity properly disclosed the life insurance premiums
anticipated to be paid for each of the five succeeding fiscal
years to keep the life settlement contracts in force as of the
date of the most recent statement of financial position presented?
[FASB ASC 325-30-50-5]

.l 9.

Has the entity properly disclosed, if the entity becomes aware
of new or updated information that causes it to change its
expectations on the timing of the realization of proceeds from
the investments in life settlement contracts, the nature of the
information and the related effect on the timing of the realization of proceeds from the life settlement contracts, including disclosing significant changes to the amounts disclosed in
accordance with FASB ASC 325-30-50-4? (Note: The investor
is not required to actively seek out new or updated information to update the assumptions used in determining the remaining life expectancy of the life settlement contracts.)
[FASB ASC 325-30-50-6]

No

N/A

Life Settlement Contract—Fair Value Method
.l 10.

Has the entity properly disclosed the method(s) and significant assumptions used to estimate the fair value of investments in life settlement contracts, including any mortality assumptions?
[FASB ASC 325-30-50-7]

.l 11.

Has the entity properly disclosed the following for life settlement contracts accounted for under the fair value method
based on remaining life expectancy for each of the first five
succeeding years from the date of the statement of financial
position and thereafter, as well as in the aggregate:
a.

The number of life settlement contracts?

b.

The carrying value of the life settlement contracts?

c.

The face value (death benefits) of the life insurance policies underlying the contracts?
[FASB ASC 325-30-50-8]

.l 12.

Has the entity properly disclosed the reasons for changes in
its expectation of the timing of the realization of the investments in life settlement contracts, including disclosing significant changes to the amounts disclosed in accordance with
FASB ASC 325-30-50-8?
[FASB ASC 325-30-50-9]

.l 13.

Has the investor (entity) properly disclosed the following for
each reporting period presented in the income statement:

FSP §11,100.01

68

Health Care Entities

Yes

I.

a.

The gains or losses recognized during the period on investments sold during the period?

b.

The unrealized gains or losses recognized during the
period on investments that are still held at the date of
the statement of financial position?
[FASB ASC 325-30-50-10]

Inventory (FASB ASC 330-10)
Disclosure
Basis for Stating Inventories

.l 1.

Has the entity properly disclosed the basis of stating inventories and has that basis been consistently applied? Whenever
a significant change is made therein, has the entity disclosed
the nature of the change and, if material, the effect on income?
[FASB ASC 330-10-50-1]

Losses From Application of Lower of Cost or Market
.l 2.

Has the entity properly disclosed information regarding substantial and unusual losses which have resulted from the application of the rule of lower of costs or market (normally as
a charge separately identified from the consumed inventory
costs described as cost of goods sold)?
[FASB ASC 330-10-50-2]

Goods Stated Above Cost
.l 3.

Has the entity properly disclosed if goods are stated above
cost?
[FASB ASC 330-10-50-3]

Stating Inventories at Sales Prices
.l 4.

Has the entity properly disclosed if goods are stated at sales
prices?
[FASB ASC 330-10-50-4]

Losses on Firm Purchase Commitments
.l 5.

J.

Has the entity properly disclosed net losses on firm purchase
commitments for goods for inventory, separately in the income statement?
[FASB ASC 330-10-50-5]

Capitalized Advertising Costs (FASB ASC 340-20)
Presentation
Presentation of Qualifying Direct-Response Advertising Assets

.l 1.

Has the entity properly presented direct-response advertising
costs as assets net of accumulated amortization, if those costs
meet the recognition criteria as capitalized assets of FASB
ASC 340-20-25-4?
[FASB ASC 340-20-45-1]

Disclosure
.l 2.
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Has the entity properly disclosed the following related to advertising:

No

N/A
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K.

a.

The accounting policy for reporting advertising, indicating whether such costs are expensed as incurred or
expensed the first time the advertising takes place?

b.

A description of direct-response-advertising reported
as assets (if any), the related accounting policy, and the
amortization method and period?

c.

The amount charged to advertising expense for each
statement of income presented, with separate disclosure of amounts, if any, representing a write-down of
capitalized advertising costs to net realizable value?

d.

The amount of advertising reported as assets in each
balance sheet presented?
[FASB ASC 340-20-50-1]

No

N/A

Insurance Contracts That Do Not Transfer Insurance Risks (FASB
ASC 340-30)
Presentation
Deposit Asset and Liability

.l 1.

Has the entity properly presented deposit assets and liabilities on the gross basis, unless the right of offset exists as defined in FASB ASC 210-20?
[FASB ASC 340-30-45-1]

Insurance and Reinsurance Contracts That Transfer Only Significant Timing Risk and Insurance and Reinsurance Contracts That
Transfer Neither Timing nor Significant Underwriting Risk
.l 2.

Has the entity properly presented changes in the carrying
amount of the deposit as interest income or interest expense?
[FASB ASC 340-30-45-2]

Insurance and Reinsurance Contracts that Transfer Only Significant
Underwriting Risk
.l 3.

Has the entity properly presented the changes in the recorded
amount of the deposit, other than the unexpired portion of
the coverage provided, arising from an insurance or reinsurance contract that transfers only significant underwriting risk
in an insured’s income statement as an offset against the loss
recorded by the insured that will be reimbursed under the
insurance or reinsurance contract and in an insurer’s income
statement as an incurred loss?
[FASB ASC 340-30-45-3]

.l 4.

Has the entity properly presented the reduction in the deposit
related to the unexpired portion of the coverage provided as
an adjustment to incurred loss?
[FASB ASC 340-30-45-4]

.l 5.

Has the entity (if not an insurance entity) properly presented
the reduction in the deposit related to the unexpired portion
of the coverage provided as an expense?
[FASB ASC 340-30-45-5]
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Disclosure
Deposit Asset and Liability
.l 6.

Has the entity properly disclosed a description of the contracts accounted for as deposits and the separate amounts of
total deposit assets and total deposit liabilities reported in the
statement of financial position?
[FASB ASC 340-30-50-1]

Insurance and Reinsurance Contracts That Transfer Only Underwriting Risk
.l 7.

L.

Has the entity properly disclosed the following regarding the
changes in the recorded amount of the deposit arising from
an insurance or reinsurance contract that transfers only significant underwriting risk:
a.

The present values of initial expected recoveries that
will be reimbursed under the insurance or reinsurance
contracts that have been recorded as an adjustment to
incurred losses?

b.

Any adjustment of amounts initially recognized for expected recoveries and the individual components of the
adjustment (meaning, interest accrual, the present
value of additional expected recoveries, and the present
value of reductions in expected recoveries) disclosed
separately?

c.

The amortization expense attributable to the expiration
of coverage provided under the contract?
[FASB ASC 340-30-50-2]

Goodwill (FASB ASC 350-20)
Presentation
l 1.

Has the entity properly presented the aggregate amount of
goodwill as a separate line item in the statement of financial
position?
[FASB ASC 350-20-45-1]

l 2.

Has the entity properly presented the aggregate amount of
goodwill impairment losses as a separate line item in the income statement before the subtotal “income from continuing
operations” (or similar caption) unless a goodwill impairment loss is associated with a discontinued operation?
[FASB ASC 350-20-45-2]

l 3.

Has the entity properly presented a goodwill impairment loss
associated with a discontinued operation (on a net-of-tax basis) within the results of discontinued operations?
[FASB ASC 350-20-45-3]
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Yes

No

N/A

Disclosure
Information for Each Period for Which a Statement of Financial Position Is Presented
l 4.

Has the entity properly disclosed any changes in the carrying
amount of goodwill during the period, including showing the
following separately, (see example 3 in FASC ASC 350-20-5524):8
a.

The gross amount and accumulated impairment losses
at the beginning of the period?

b.

Additional goodwill recognized during the period, except goodwill included in a disposal group that, on acquisition, meets the criteria to be classified as held for
sale in accordance with FASB ASC 360-10-45-9?

c.

Adjustments resulting from the subsequent recognition
of deferred tax assets during the period in accordance
with paragraphs 2–4 of FASB ASC 805-740-25 and
FASB ASC 805-740-45-2?

d.

Goodwill included in a disposal group classified as
held for sale in accordance with FASB ASC 360-10-45-9
and goodwill derecognized during the period without
having previously been reported in a disposal group
classified as held for sale?

e.

Impairment losses recognized during the period in accordance with FASB ASC 350-10?

f.

Net exchange differences arising during the period in
accordance with FASB ASC 830, Foreign Currency Matters?

g.

Any other changes in the carrying amounts during the
period?

h.

The gross amount and accumulated impairment losses
at the end of the period?
[FASB ASC 350-20-50-1]

Goodwill Impairment Loss
l 5.

Has the entity properly disclosed, for each goodwill impairment loss recognized, the following information in the notes
to the financial statement that include the period in which the
impairment loss is recognized:
a.

A description of the facts and circumstances leading to
the impairment?

8
Entities that report segment information in accordance with FASB ASC 280, Segment Reporting, should provide this information about
goodwill in total and for each reportable segment and should disclose any significant changes in the allocation of goodwill by reportable
segment. If any portion of goodwill has not yet been allocated to a reporting unit at the date the financial statements are issued, that
unallocated amount and the reasons for not allocating that amount should be disclosed.
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M.

b.

The amount of the impairment loss and the method of
determining the fair value of the associated reporting
unit (whether based on quoted market prices, prices of
comparable businesses, a present value or other valuation technique, or a combination thereof)?

c.

If a recognized impairment loss is an estimate that has
not yet been finalized (refer to paragraphs 18–19 of
FASB ASC 350-20-35), that fact and the reasons therefore and, in subsequent periods, the nature and amount
of any significant adjustments made to the initial estimate of the impairment loss?
[FASB ASC 350-20-50-2]

General Intangibles Other Than Goodwill (FASB ASC 350-30)
Presentation

.l 1.

At a minimum, are all intangible assets aggregated and presented as a separate line item in the statement of financial
position? (This requirement does not preclude presentation of
individual intangible assets or classes of intangible assets as
separate line items.)
[FASB ASC 350-30-45-1]

.l 2.

Are amortization expense and impairment losses for intangible assets presented in income statement line items within
continuing operations as deemed appropriate for each entity?
[FASB ASC 350-30-45-2]

Disclosure
Disclosures in the Period of Acquisition
.l 3.

Has the entity properly disclosed, for intangible assets acquired either individually or with a group of assets (in either
an asset acquisition or business combination), all of the following in the notes to financial statements in the period of
acquisition: (Note: The following information also should be
disclosed separately for each material business combination
or in the aggregate for individually immaterial business combinations that are material collectively, if the aggregate fair
values of intangible assets, other than goodwill, are significant.)
a.

b.
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For intangible assets subject to amortization, all of the
following:
i.

The total amount assigned and the amount assigned to any major intangible asset class?

ii.

The amount of any significant residual value, in
total and by major intangible asset class?

iii.

The weighted-average amortization period, in total and by major intangible asset class?

For intangible assets not subject to amortization, the total amount assigned and the amount assigned for each
major intangible asset class?

No

N/A
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Yes
c.

The amount of research and development assets acquired in a transaction other than a business combination and written off in the period and the line item in
the income statement in which the amounts written off
are aggregated?

d.

For intangible assets with renewal or extension terms,
the weighted-average period before the next renewal or
extension (both explicit and implicit), by major asset
class?
[FASB ASC 350-30-50-1]

No

N/A

Disclosures for Each Period for Which a Statement of Financial Position is Presented
.l 4.

Has the entity properly disclosed the following information
in the financial statements or notes to the financial statements, for each period for which a statement of financial position is presented:
a.

For intangible assets subject to amortization, all of the
following:
i.

The gross carrying amount and accumulated amortization, in total and by major intangible asset
class?

ii.

The aggregate amortization expense for the period?

iii.

The estimated aggregate amortization expense
for each of the five succeeding fiscal years?

b.

For intangible assets not subject to amortization, the total carrying amount and the carrying amount for each
major intangible asset class?

c.

The entity’s accounting policy on the treatment of costs
incurred to renew or extend the term of a recognized
intangible asset?

d.

For intangible assets that have been renewed or extended in the period for which a statement of financial
position is presented, both of the following:
i.

For entities that capitalize renewal or extension
costs, the total amount of costs incurred in the
period to renew or extend the term of a recognized intangible asset, by major intangible asset
class?

ii.

The weighted-average period before the next renewal or extension (both explicit and implicit),
by major intangible asset class?
[FASB ASC 350-30-50-2]
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Disclosures Relating to Impairment Loss
.l 5.

Has the entity properly disclosed, for each impairment loss
recognized related to an intangible asset, the following information in the notes to the financial statements that include
the period in which the impairment loss is recognized:
a.

A description of the impaired intangible asset and the
facts and circumstances leading to the impairment?

b.

The amount of the impairment loss and the method for
determining fair value?

c.

The caption in the income statement in which the impairment loss is aggregated?

d.

If applicable, the segment in which the impaired intangible asset is reported under FASB ASC 280?
[FASB ASC 350-30-50-3]

Renewal or Extension of an Intangible Asset’s Legal or Contractual
Life
.l 6.

N.

Has the entity properly disclosed, for recognized intangible
assets, information that enables users of financial statements
to assess the extent to which the expected future cash flows
associated with the asset are affected by the entity’s intent or
ability (or both intent and ability) to renew or extend the arrangement?
[FASB ASC 350-30-50-4]

Property, Plant, and Equipment (FASB ASC 360-10)
Presentation
Impairment of Long-Lived Assets—Impairment of Long-Lived Assets Classified as Held and Used—Presentation of Impairment Loss
for Long-Lived Assets to Be Held and Used

.l 1.

Is an impairment loss recognized for a long-lived asset (asset
group) to be held and used included in income from continuing operations before income taxes in the income statement?
If a subtotal such as income from operations is presented,
does it include the amount of the loss?
[FASB ASC 360-10-45-4]

.l 2.

If a long-lived asset is to be disposed of other than by sale,
does it continue to be classified as held and used until it is
disposed of?
[FASB ASC 360-10-45-15]

FSP §11,100.01

No

N/A

75

Financial Statements and Notes Checklist

Yes

No

N/A

Impairment of Long-Lived Assets—Impairment of Long-Lived Assets Classified as Held and Used—Presentation of Disposal Gains
or Losses in Continuing Operations
l 3.

Is a gain or loss that is recognized on the sale of a long-lived
asset (disposal group) that is not a component of an entity
included in income from continuing operations before income taxes in the income statement? (Note: If a subtotal such
as “income from operations” is presented, it should include
the amounts of those gains or losses.)
[FASB ASC 360-10-45-5]

Change of Classification After Balance Sheet Date but Before Issuance of Financial Statements
.l 4.

Has the entity properly presented, if the held for sale criteria
were met after the balance sheet date but before the financial
statements were issued or were available to be issued, the
long-lived asset as held and used in those financial statements when issued or available to be issued?
[FASB ASC 360-10-45-13]

Disclosure
Other Property and Equipment Disclosures
. 5.

. 6.

. 7.

Are the following policies related to property and equipment
disclosed by the not-for-profit entity, in the notes to financial
statements:
a.

The capitalization policy adopted?

b.

The capitalization policy for collections (capitalization,
prospective capitalization, or no capitalization)?

c.

The basis of valuation of property, plant, and equipment—for example, cost for purchased items and fair
value for contributed items?
[FASB ASC 958-360-50-1]

Have separate disclosures been made for the following:
a.

Nondepreciable assets?

b.

Property and equipment not held for use in operations,
for example, items held for sale or for investment purposes or construction in process?

c.

Improvements to leased facilities and equipment?
[FASB ASC 958-360-50-2]

Has disclosure been made regarding the liquidity of property, plant, and equipment, including information about limitations on their use, such as the following:
a.

Property, plant, and equipment pledged as collateral or
otherwise subject to lien?

b.

Donor or legal limitations on the use of or proceeds
from the disposal of plant, property, and equipment?
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c.

Property, plant, and equipment acquired with restricted assets if title may revert to another party, such
as a resource provider?

d.

The terms of exchange transactions (other than lease
transactions), such as federal contracts, in which the resource provider retains legal title during the term of the
arrangement but it is probable that the not-for-profit
entity will be permitted to keep the assets when the arrangement terminates?
[FASB ASC 958-360-50 par. 3–4]

. 8.

If not presented separately on the face of the statement of financial position pursuant to FASB ASC 958-360-45-4, has the
amount capitalized for works of art, historical treasures, and
similar assets that do not meet the definition of a collection,
been disclosed?
[FASB ASC 958-360-50-5]

. 9.

If the not-for-profit entity does not recognize and capitalize
its collections or capitalizes collections prospectively, has it
disclosed its collections, including their relative significance
and its stewardship policies for those collections? (If collection items not capitalized are deaccessed during the period, it
also should describe the items given away, damaged, destroyed, lost, or otherwise deaccessed during the period or
disclose their fair value.)
[FASB ASC 958-360-50-6]

.l 10.

Has the entity properly disclosed the following regarding the
depreciation method or methods used in the financial statements or notes thereto:

.l 11.
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a.

Depreciation expense for the period?

b.

Balances of major classes of depreciable assets, by nature or function, at the balance sheet date?

c.

Accumulated depreciation, either by major class of depreciable assets or in total, at the balance sheet date?

d.

A general description of the method or methods used
in computing depreciation with respect to major classes
of depreciable assets?
[FASB ASC 360-10-50-1]

Is the following information disclosed in the notes to the financial statements that include the period in which an impairment loss is recognized:
a.

A description of the impaired long-lived asset (asset
group) and the facts and circumstances leading to the
impairment?

b.

If not separately presented on the face of the statement,
the amount of the impairment loss and the caption in
the income statement that includes the loss?

No

N/A
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Yes

. 12.

c.

The method or methods for determining fair value
(whether based on a quoted market price, prices for
similar assets, or another valuation technique)?

d.

If applicable, the segment in which the impaired longlived asset (asset group) is reported under FASB ASC
280?
[FASB ASC 360-10-50-2]

No

N/A

Has the entity disclosed whether or not it implies a time restriction that expires over the useful life of the donated assets
if those long-lived assets are received without stipulations
about how long the donated asset must be used or are acquired with gifts of cash or other assets restricted for those
acquisitions?
[FASB ASC 958-360-50-1]

III. Liabilities
Liabilities—Overall (FASB ASC 405-10)
. 1.
In addition to disclosures required by FASB ASC 450-20-50,
has the entity disclosed in the notes to financial statements a
schedule of unconditional promises to give that shows the total amount separated into amounts payable in each of the
next five years, the aggregate amount due in more than five
years, and for unconditional promises to give that are reported using present value techniques, the unamortized discount?
[FASB ASC 958-405-50-1]
.l 2.
If the entity is a provider of prepaid health care services, is
the basis for accruing health care costs and significant business and contractual arrangements with hospitals, physicians,
and other associated entities disclosed?
[FASB ASC 954-405-50-2]
B.
Insurance-Related Assessment Liabilities (FASB ASC 405-30)
Disclosure
.l 1.
Has the entity properly disclosed, for insurance-related assessments,
a.
if amounts relating to insurance-related assessments
have been discounted, has the entity disclosed in the
financial statements the undiscounted amounts of the
liability and any related asset for premium tax offsets
or policy surcharges as well as the discount rate used?
b.
if amounts have not been discounted, has the entity disclosed in the financial statements the amounts of the
liability, any related asset for premium tax offsets or
policy surcharges, the periods over which the assessments are expected to be paid, and the period over
which the recorded premium tax offsets or policy surcharges are expected to be realized?
[FASB ASC 405-30-50-1]
A.
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.l 2.

With regard to contractual adjustments and third-party settlements, does the entity identify and explain the estimated
amounts payable?
[FASB ASC 954-405-50-1]
C.
Asset Retirement and Environmental Obligations (FASB ASC 41020)
Presentation
.l 1.
Has the entity properly presented accretion expense as an operating item in the statement of income? (Note: The entity
may use any descriptor for accretion expense so long as it
conveys the underlying nature of the expense.)
[FASB ASC 410-20-45-1]
Disclosure
.l 2.
Has the entity properly disclosed the following information
about its asset retirement obligations:
a.
A general description of the asset retirement obligations and the associated long-lived assets?
b.
The fair value of assets that are legally restricted
for purposes of settling asset retirement obligations?
c.
A reconciliation of the beginning and ending aggregate carrying amount of asset retirement obligations showing separately the changes attributable to (1) liabilities incurred in the current
period, (2) liabilities settled in the current period,
(3) accretion expense, and (4) revisions in estimated cash flows, whenever there is a significant
change in one or more of those four components
during the reporting period?
[FASB ASC 410-20-50-1]
.l 3.
Has the entity properly disclosed, if the fair value of an asset
retirement obligation cannot be reasonably estimated, that
fact and the reasons therefore?
[FASB ASC 410-20-50-2]
D.
Asset Retirement and Environmental Obligations—Environmental Obligations (FASB ASC 410-30)
Presentation
General
.l 1.
Has the entity properly not presented environmental remediation obligations as extraordinary? (Note: Environmental remediation obligations are not events that are unusual in nature.)
[FASB ASC 410-30-45-3]
.l 2.
Has the entity properly presented environmental remediation
costs as a charge against operations, rather than non-operating expenses?
[FASB ASC 410-30-45-4]
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.l 3.

.l

.l

.l

.l

.l

.l

Has the entity properly presented any earnings on assets that
are reflected on the entity’s financial statements and are earmarked for funding environmental liabilities as investment
income?
[FASB ASC 410-30-45-4]
4.
Has the entity properly presented environmental remediation
expenses and related recoveries attributable to discontinued
operations, accounted for in accordance with FASB ASC 20520, as discontinued operations?
[FASB ASC 410-30-45-5]
Disclosure
Disclosures That Are Required
5.
Has the entity properly disclosed whether the accrual for environmental remediation liabilities is measured on a discounted basis? (Note: If the entity utilizes present-value
measurement techniques, additional disclosures are appropriate. See FASB ASC 410-30-50-7.)
[FASB ASC 410-30-50-4]
6.
Has the entity properly disclosed, with respect to recorded
accruals for environmental remediation loss contingencies
and assets for third-party recoveries related to environmental
remediation obligations, if any portion of the accrued obligation is discounted, the undiscounted amount of the obligation, and the discount rate used in the present-value determinations?
[FASB ASC 410-30-50-7]
Disclosures That Are Encouraged But Not Required
7.
Has the entity properly disclosed any events, situations, or
sets of circumstances that generally trigger recognition of loss
contingencies that have arisen out of the entity’s environmental remediation-related obligations, as well as the entity’s policy concerning the timing of recognition of recoveries?
[FASB ASC 410-30-50-8]
8.
Has the entity properly disclosed additional specific disclosures, as necessary, with respect to environmental remediation loss contingencies that would be useful to further users’
understanding of the entity’s financial statements?
[FASB ASC 410-30-50-9]
9.
Has the entity properly disclosed the following encouraged,
but not required, items:
a.
The estimated time frame of disbursements for recorded amounts if expenditures are expected to continue over the long term?
b.
The estimated time frame for realization of recognized
probable recoveries, if realization is not expected in the
near term?
c.
If an estimate of the probable or reasonably possible
loss or range of loss cannot be made, the reasons why
it cannot be made?
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Yes
d.

If information about the reasonably possible loss or the
recognized and additional reasonably possible loss for
an environmental remediation obligation related to an
individual site is relevant to an understanding of the
financial position, cash flows, or results of operations
of the entity, the following with respect to the site:
i.
The total amount accrued for the site?
ii.
The nature of any reasonably possible loss contingency or additional loss, and an estimate of
the possible loss or the fact that an estimate cannot be made and the reasons why it cannot be
made?
iii.
Whether other potentially responsible parties are
involved and the entity’s estimated share of the
obligation?
iv.
The status of regulatory proceedings?
v.
The estimated time frame for resolution of the
contingency?
[FASB ASC 410-30-50-10]
.l 10. Has the entity properly disclosed the estimated time frame
for resolution of the uncertainty as to the amount of the loss?
[FASB ASC 410-30-50-11]
.l 11. Has the entity properly disclosed the following encouraged,
but not required, items in the income statement:
a.
The amount recognized for environmental remediation
loss contingencies in each period?
b.
The amount of any recovery from third parties that is
credited to environmental remediation costs in each period?
c.
The income statement caption in which environmental
remediation costs and credits are included?
[FASB ASC 410-30-50-12]
Disclosure Related to Loss Contingencies
.l 12. Has the entity properly disclosed, in the financial statements,
a contingency conclusion that addresses the estimated total
unrecognized exposure to environmental remediation and
other loss contingencies?
[FASB ASC 410-30-50-14]
.l 13. Has the entity properly disclosed a description of the general
applicability and impact of environmental laws and regulations upon their business and how the existence of such laws
and regulations may give rise to loss contingencies for future
environmental remediation?
[FASB ASC 410-30-50-17]
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Exit or Disposal Cost Obligations (FASB ASC 420-10)
Presentation
.l 1.
Has the entity properly presented the cumulative effect of a
change resulting from a revision to either the timing or the
amount of estimated cash flows in the same line item(s) in the
income statement used when the related costs were recognized initially in the period of change?
[FASB ASC 420-10-45-1]
.l 2.
Has the entity properly presented costs associated with an
exit or disposal activity that involves a discontinued operation in the results of discontinued operations in accordance
with FASB ASC 205-20-45?
[FASB ASC 420-10-45-2]
.l 3.
Has the entity properly presented costs associated with an
exit or disposal activity that does not involve a discontinued
operation in income from continuing operations before income taxes, for example, in a subtotal such as “income from
operations?”
[FASB ASC 420-10-45-3]
.l 4.
Has the entity properly presented accretion expense separately from interest cost in the income statement?
[FASB ASC 420-10-45-5]
Disclosure
.l 5.
Has the entity properly disclosed the following information
in notes to the financial statements that include the period in
which an exit or disposal activity is initiated and any subsequent period until the activity is completed:
a.
A description of the exit or disposal activity, including
the facts and circumstances leading to the expected activity and the expected completion date?
b.
For each major type of cost associated with the activity
(for example, one-time termination benefits, contract
termination costs, and other associated costs),
i.
the total amount expected to be incurred in connection with the activity, the amount incurred in
the period, and the cumulative amount incurred
to date?
ii.
a reconciliation of the beginning and ending liability balances showing separately the changes
during the period attributable to costs incurred
and charged to expense, costs paid or otherwise
settled, and any adjustments to the liability with
an explanation of the reason(s) therefore?
c.
The line item(s) in the income statement in which the
costs in item (b) are aggregated?
d.
For each reportable segment, as defined in FASB ASC
280-10-50-10,
i.
the total amount of costs expected to be incurred
in connection with the activity?
ii.
the amount incurred in the period?

E.
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No
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iii.

F.

the cumulative amount incurred to date, net of
any adjustments to the liability with an explanation of the reason(s) why?
e.
If a liability for a cost associated with the activity is not
recognized because fair value cannot be reasonably estimated, that fact and the reasons why?
[FASB ASC 420-10-50-1]
Commitments (FASB ASC 440-10)

The following table lists the types of contingencies (loss and gain) and commitments that were most
commonly reported in the financial statements of a sample of public entities surveyed by the AICPA.
Reprinted from the AICPA’s Accounting Trends & Techniques, 2010, 64th edition (product no. 0099010
[paperback] or WAT-XX [online]).
CONTINGENCIES
Number of Companies
2009
2008
2007
2006
Loss Contingencies
Litigation
379
404
4489
476
Environmental
203
225
266
263
Possible tax assessments
145
166
185
117
Insurance
132
160
176
152
Government investigations
95
122
153
138
Other—described
63
66
45
70
Gain Contingencies
Operating loss carryforward
429
423
499
496
Tax credits and other tax credit
carryforwards
273
255
278
265
Capital loss carryforward
69
65
83
85
Plaintiff litigation
44
55
40
40
Alternative minimum tax carryforward
42
40
51
57
Investment credit carryforward
8
11
9
6
Asset sale receivable
7
8
10
11
Charitable contribution carryforward
7
5
7
6
Potential tax refund
4
4
12
5
Other—described
6
3
6
5
2008–2009 based on 500 entities surveyed; 2006–2007 based on 600 entities surveyed.
Disclosure
.l 1.
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Has the entity properly disclosed, notwithstanding more explicit disclosures required elsewhere in FASB ASC, all of the
following in the financial statements:
a.

Unused letters of credit?

b.

Long-term leases?

c.

Assets pledged for security for loans?
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d.

Pension plans?

e.

The existence of cumulative preferred stock dividends
in arrears?

f.

Commitments, including the following:
i.

A commitment for plant acquisition?

ii.

An obligation to reduce debts?

iii.

An obligation to maintain working capital?

iv.

An obligation to restrict dividends?
[FASB ASC 440-10-50-1]

No

N/A

Unconditional Purchase Obligations
.l 2.

Has the entity properly disclosed any unconditional purchase
obligations, exhibiting all of the following characteristics, in
accordance with FASB ASC 440-10-50-4 (if not on the balance
sheet), or in accordance with FASB ASC 440-10-50-6 (if recorded on the balance sheet):
a.

It is noncancelable, or cancelable only in any of the following circumstances:
i.

Upon the occurrence of some remote contingency?

ii.

With the permission of the other party?

iii.

If a replacement agreement is signed between the
same parties?

iv.

Upon payment of a penalty in an amount such
that continuation of the agreement appears reasonably assured?

b.

It was negotiated as part of arranging financing for the
facilities that will provide the contracted goods or services or for costs related to those goods or services (for
example, carrying costs for contracted goods)? A purchaser is not required to investigate whether a supplier
used an unconditional purchase obligation to help secure financing, if the purchaser would otherwise be unaware of that fact.

c.

It has a remaining term in excess of one year?
[FASB ASC 440-10-50-2]

Unconditional Purchase Obligations—Unrecognized Commitments
.l 3.

Has the entity properly disclosed the following for long term
unconditional purchase obligations that are not recorded in
the purchaser’s balance sheet: (Note: These disclosures may
be omitted only if the aggregate commitment for all such obligations not disclosed is immaterial.)
a.

Nature and term of the obligations?

b.

Amount of the fixed and determinable portion of the
obligations as of the date of the latest balance sheet presented in the aggregate and, if determinable, for each
of the next five years?
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.l 4.

c.

Nature of any variable components of the obligation?

d.

Amounts of purchases under the obligations for each
year for which an income statement is presented?
[FASB ASC 440-10-50-4]

Has the entity properly disclosed, as encouraged, but not required, the amount of imputed interest necessary to reduce
the unconditional purchase obligation(s) to present value?
[FASB ASC 440-10-50-5]

Unconditional Purchase Obligations—Recognized Commitments
.l 5.

G.

Has the entity properly disclosed, for unconditional purchase
obligations that meet the criteria of FASB ASC 440-10-50-2
and that have been recognized on the purchaser’s balance
sheet, for each of the 5 years following the date of the latest
balance sheet presented, the aggregate amount of payments?
[FASB ASC 440-10-50-6]

Loss Contingencies (FASB ASC 450-20)9
Disclosure
Accruals for Loss Contingencies

9

.l 1.

Has the entity properly disclosed the nature, and in some circumstances, the amount accrued, if necessary for the financial
statements not to be misleading, for loss contingencies that
are probable and estimable? (Note: The terminology used
should be descriptive of the nature of the accrual, such as estimated liability or liability of an estimated amount. Further,
the term reserve should not be used and is limited to an
amount of unidentified or unsegregated assets held or retained for a specific purpose.)
[FASB ASC 450-20-50-1]

.l 2.

Has the entity properly disclosed the following, if it is at least
reasonably possible that the loss estimate will change in the
near term and the change would be material to the financial
statements:

See footnote 3.
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a.

The nature of the uncertainty?

b.

An indication that it is at least reasonably possible that
a change in the estimate will occur in the near term?

c.

An estimate of the possible loss or range of loss, or a
statement that such an estimate cannot be made?

d.

A disclosure of the facts that cause the estimate to be
sensitive to change? (Note: This disclosure is encouraged, but not required.)
[FASB ASC 450-20-50-2]

No

N/A
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N/A

Unrecognized Contingencies10
.l 3.

.l 4.

Has the entity properly disclosed the contingency if there is
at least a reasonable possibility that a loss or an additional
loss may have been incurred and either of the following conditions exists:
a.

An accrual is not made for a loss contingency because
any of the conditions in FASB ASC 450-20-25-2 are not
met?

b.

An exposure to loss exists in excess of the amount accrued pursuant to the provisions of FASB ASC 450-2030-1?
[FASB ASC 450-20-50-3]

Has the entity properly disclosed the following for unrecognized loss contingencies when there is at least a reasonable
possibility that a loss or an additional loss has been incurred:
a.

The nature of the contingency?

b.

An estimate of the possible loss or range of loss, or a
statement that such an estimate cannot be made?
[FASB ASC 450-20-50-4]

.l 5.

Has the entity properly disclosed information for contingencies for which there is a reasonable possibility that a loss may
have been incurred even though information may not indicate that it is probable that an asset had been impaired or a
liability had been incurred at the date of the financial statements?
[FASB ASC 450-20-50-5]

.l 6.

Has the entity properly disclosed a loss contingency involving any unasserted claim or assessment, if and only if, (a) it is
considered probable that a claim will be asserted and (b) there
is a reasonable possibility that the outcome will be unfavorable? (Note: The disclosures in FASB ASC 450-20-50-4 should
be provided.)
[FASB ASC 450-20-50-6]

. 7.

Have issues of noncompliance with donor-imposed restrictions been disclosed if (a) there is a reasonable possibility that
a material contingent liability has been incurred or (b) there
is at least a reasonable possibility that the noncompliance
could lead to a material loss of revenue or cause the entity to
be unable to continue as a going concern?
[FASB ASC 958-450-50-2]

10

In August 2010, FASB issued ASU No. 2010-24, Health Care Entities (Topic 954): Presentation of Insurance Claims and Related Insurance
Recoveries (a consensus of the FASB Emerging Issues Task Force), which clarifies that a health care entity should not net insurance recoveries
against a related claim liability, and the amount of the claim liability should be determined without consideration of insurance recoveries.
The “Pending Content” is effective for the first annual reporting period ending on or after December 15, 2011 (that is, December 31, 2011,
for entities with calendar year ends).
This checklist has not been updated to include the presentation and disclosure requirements in ASU No. 2010-24.
This guidance is labeled as “Pending Content” due to the transition and open effective date information discussed in FASB ASC
954-450-65-1. Readers can refer to the full text of the ASU on the FASB website at www.fasb.org.

FSP §11,100.01

86

Health Care Entities

Yes
. 8.

If the noncompliance (see question 11) results from the notfor-profit entity’s failure to maintain an appropriate composition of assets in amount needed to comply with donor restrictions, have the amounts and circumstances been
disclosed?
[FASB ASC 958-450-50-3]

.l 9.

Has the health care entity disclosed their program of medical
malpractice insurance coverage?
[FASB ASC 954-450-50-1]

.l 10.

If the health care entity discounts accrued malpractice claims,
has it disclosed the amount of accrued malpractice claims that
are discounted and the interest rate or rates used to discount
those claims?

Losses Arising After the Date of the Financial Statements
.l 11.

H.

Has the entity properly disclosed a loss or a loss contingency
arising after the date of the entity’s financial statements (but
before those financial statements are issued), if applicable. If
such a disclosure is required, have the following been provided:
a.

The nature of the contingency?

b.

An estimate of the possible loss or range of loss, or a
statement that such an estimate cannot be made?
[FASB ASC 450-20-50-9]

Gain Contingencies (FASB ASC 450-30)
Disclosure

.l 1.

I.

Has the entity properly disclosed, with care to avoid any misleading implications about likelihood of realization, any gain
contingencies?
[FASB ASC 450-30-50-1]

Guarantees (FASB ASC 460-10)
Presentation

.l 1.
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Has an accrual for credit loss on a financial instrument with
off-balance sheet risk been recorded separately from a valuation account related to a recognized financial instrument?
[FASB ASC 460-30-45-1]

No

N/A

87

Financial Statements and Notes Checklist

Yes
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N/A

Disclosure11
Information About Each Guarantee or Group of Similar Guarantees—Loss Contingencies
.l 2.

Has the entity properly disclosed the existence of a loss contingency, even though the possibility of loss may be remote?
(Examples may include: guarantees of indebtedness of others,
including indirect guarantees of indebtedness of others, obligations of commercial banks under standby letters of credit,
guarantees to repurchase receivables that have been sold or
otherwise assigned, and other agreements that in substance
have the same guarantee characteristic.)
[FASB ASC 460-10-50-2]

.l 3.

Has the entity properly disclosed the nature and amount of
the guarantee disclosed as a result of FASB ASC 460-10-50-2?
[FASB ASC 460-10-50-3]

Information About Each Guarantee or Group of Similar Guarantees—Disclosures About a Guarantor’s Obligation
.l 4.

Has the entity properly disclosed the following information
about each guarantee, or each group of similar guarantees,
even if the likelihood of the guarantor’s having to make any
payments under the guarantee is remote:
a.

The nature of the guarantee, including the following:
i.

The approximate term of the guarantee?

ii.

How the guarantee arose?

iii.

The events or circumstances that would require
the guarantor to perform under the guarantee?

iv.

The current status (that is, as of the date of the
statement of financial position) of the payment or
performance risk of the guarantee?

v.

If the entity uses internal groupings for the purposes of item (iv), how those groupings are determined and used for managing risk?

b.

The maximum potential amount of future payments
(undiscounted) the guarantor could be required to
make under the guarantee?

c.

If the terms of the guarantee provide for no limitation
to the maximum potential future payments under the
guarantee, is that fact disclosed?

11
Per FASB ASC 460-10-50-5, the disclosure requirements of this subsection of FASB ASC do not eliminate or affect the disclosure
requirements of the following:

●

The requirements of the “General” subsection of FASB ASC 825-10-50

●

The requirements of FASB ASC 450-20-50 paragraphs 3–4 that an entity disclose a contingent loss that has a reasonable
possibility of occurring

●

The requirements of the “Disclosure” subsections of FASB ASC 815, Derivatives and Hedging

●

The requirements of FASB ASC 275-10-50 that an entity disclose information about risks and uncertainties that could significantly affect the amounts reported in the financial statements in the near term
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d.

If the guarantor is unable to develop an estimate of the
maximum potential amount of future payments under
its guarantee, are the reasons why the maximum potential amount cannot be estimated disclosed?

e.

The current carrying amount of the liability, if any, for
the guarantor’s obligations under the guarantee, including the amount, if any, recognized under FASB
ASC 450-20-30, regardless of whether the guarantee is
freestanding or embedded in another contract?

f.

The nature of

g.

i.

any recourse provisions that would enable the
guarantor to recover from third parties any of the
amounts paid under the guarantee?

ii.

any assets held either as collateral or by third
parties that, upon the occurrence of any triggering event or condition under the guarantee, the
guarantor can obtain and liquidate to recover all
or a portion of the amounts paid under the guarantee?

If estimable, the approximate extent to which the proceeds from liquidation of those assets would be expected to cover the maximum potential amount of future payments under the guarantee?
[FASB ASC 460-10-50-4]

Product Warranties
.l 5.
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For product warranties and other guarantee contracts required to be disclosed by FASB ASC 460-10-15-9, is has the
entity properly disclosed the following information:
a.

The information required to be disclosed by FASB ASC
460-10-50-4, except that a guarantor is not required to
disclose the maximum potential amount of future payments in FASB ASC 460-10-50-4(b)?

b.

The guarantor’s accounting policy and methodology
used in determining its liability for product warranties
(including any liability associated with extended warranties)?

c.

A tabular reconciliation of the changes in the guarantor’s aggregate product warranty liability for the reporting period?

d.

Does the tabular reconciliation present
i.

the beginning balance of the aggregate product
warranty liability?

ii.

the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty?

No

N/A
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Yes

J.

iii.

the aggregate changes in the liability for accruals
related to product warranties issued during the
reporting period, and the aggregate changes in
the liability for accruals related to preexisting
warranties, including adjustments related to
changes in estimates?

iv.

the ending balance of the aggregate product warranty liability?
[FASB ASC 460-10-50-8]

No

N/A

Debt—Overall (FASB ASC 470-10)
Presentation
Additional Presentation Information

Due to the vast differences in debt presentation concerns, readers should see FASB ASC 470-10-45 for information on the proper presentation of debt related items for their particular entity.
.l 1.

Are short term obligations expected to be refinanced reclassified to long term liabilities?
[FASB ASC 470-10-45 par. 13–14]

.l 2.

Are borrowings outstanding under revolving credit agreements that include both a subjective acceleration clause and a
requirement to maintain a lock-box arrangement, whereby remittances from the borrower’s customers reduce the debt outstanding, classified as short term obligations?
[FASB ASC 470-10-45-5]

.l 3.

Has an entity classified long-term debt as noncurrent, unless
both of the following conditions exist:

.l 4.

a.

A covenant violation that gives the lender the right to
call the debt has occurred at the balance sheet date, or
would have occurred absent a loan modification?

b.

It is probable that the entity will not be able to cure the
default within the next 12 months?
[FASB ASC 470-10-45-1]

Are long term obligations that are or will be callable by the
creditor, either because the debtor’s violation of the debt
agreement at the balance-sheet date makes the obligation callable or because the violation, if not cured within a specified
grace period, will make the obligation callable, classified as
current unless either of the following conditions is met:
a.

The creditor has waived or subsequently lost the right
to demand repayment for more than one year (or operating cycle, if longer) from the balance-sheet date?

b.

The obligation contains a grace period within which the
debtor may cure the violation, and it is probable that
the violation will be cured within that period, thus preventing the violation from becoming callable?
[FASB ASC 470-10-45-11]
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Yes

No

N/A

Disclosure
Disclosure of Long-Term Obligations
.l 5.

Has the entity properly disclosed, for each of the five years
following the date of the latest balance sheet presented, the
combined aggregate amount of maturities and sinking fund
requirements for all long-term borrowings?
[FASB ASC 470-10-50-1]

.l 6.

Has the entity properly disclosed the circumstances related to
any callable debt, as defined in FASB ASC 470-10-45-11, that
is classified as a long-term liability (or, in the case of an unclassified balance sheet, is included as a long-term liability in
the disclosure of debt maturities)?
[FASB ASC 470-10-50-2]

Subjective Acceleration Clauses
.l 7.

Has the entity properly disclosed any long term debt agreements subject to a subjective acceleration clause unless the
likelihood of the acceleration of the due date is remote?
[FASB ASC 470-10-50-3]

Short-Term Obligations Expected to be Refinanced
.l 8.

Has the entity properly disclosed any short-term obligations
that are excluded from current liabilities and a general description of the financing agreement and the terms of any
new obligation incurred or expected to be incurred or equity
securities issued or expected to be issued as a result of a refinancing?
[FASB ASC 470-10-50-4]

Summary Disclosure of Securities Outstanding
.l 9.

K.

Has the entity properly disclosed interest rates, maturities,
conversion features, and other significant terms (for example,
subordinated features) of long term debt, pursuant to FASB
ASC 505-10-50-3 (See question 3 in “Equity [FASB ASC 50510]”)?
[FASB ASC 470-10-50-5]

Debt—Debt With Conversion and Other Options (FASB ASC 47020)12
Presentation
Income Statement Classification
l 1.

12

Has the entity properly not presented any expense recognized on the date of conversion of convertible debt related to
a beneficial conversion feature as extraordinary?
[FASB ASC 470-20-45-1]

In October 2010, FASB issued ASU No. 2009-15, Accounting for Own-Share Lending Arrangements in Contemplation of Convertible Debt
Issuance or Other Financing—a consensus of the FASB Emerging Issues Task Force. This update is the result of the consensus of Emerging
Issues Task Force Issue No. 09-1, “Accounting for Own-Share Lending Arrangements in Contemplation of Convertible Debt Issuance,”
which clarified how an entity should account for a share-lending arrangement that is entered into in contemplation of a convertible debt
(continued)
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Yes
l 2.

No

N/A

Has the entity properly not presented any expense recognized
on the date of conversion of convertible debt related to an
inducement offer as extraordinary?
[FASB ASC 470-20-45-2]

Own-Share Lending Arrangements Issued in Contemplation of
Convertible Debt Issuance
l 3B.

(Accounting Standards Update [ASU] No. 2009-15, Accounting for Own-Share Lending Arrangements in Contemplation of Convertible Debt Issuance or Other Financing—a
consensus of the FASB Emerging Issues Task Force) Has the
entity properly not presented loaned shares in the calculation
of basic and diluted EPS, unless default of the share-lending
arrangement occurs? (Note: If dividends on the loaned shares
are not reimbursed to the entity, any amounts, including contractual [accumulated] dividends and participation rights in
undistributed earnings, attributable to the loaned shares
should be deducted in computing income available to common shareholders, in a manner consistent with the two-class
method in FASB ASC 260-10-45-60B.)
[“Pending Content” in FASB ASC 470-20-45-2A]

Disclosure
Own-Share Lending Arrangements Issued in Contemplation of
Convertible Debt Issuance
l 4.

(ASU No. 2009-15) Has the entity properly disclosed the following when it has entered into a share-lending arrangement
on its own shares in contemplation of a convertible debt offering or other financing:
a.

A description of any outstanding share-lending arrangements on the entity’s own stock?

b.

All significant terms of the share-lending arrangement
including (i) the number of shares, (ii) the term, (iii) the
circumstances under which cash settlement would be
required, and (iv) any requirements for the counterparty to provide collateral?

c.

The entity’s reason for entering into the share-lending
arrangement?

d.

The fair value of the outstanding loaned shares as of
the balance sheet date?

e.

The treatment of the share-lending arrangement for the
purposes of calculating EPS?

offering and the effect the share-lending arrangement has on the calculation of EPS. ASU No. 2009-15 is effective for financial statements
issued for fiscal years beginning on or after December 15, 2009 (that is, January 1, 2010, for entities with calendar year-ends), and interim
periods within those fiscal years for arrangements outstanding as of the beginning of those fiscal years. Early adoption is not permitted.
This checklist has been updated to include the presentation and disclosure requirements of ASU No. 2009-15.
Readers can refer to the full text of the ASU on the FASB website at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition and open effective date information discussed in FASB ASC 47020-65-3.
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f.

The unamortized amount of the issuance costs associated with the share-lending arrangement at the balance
sheet date?

g.

The classification of the issuance costs associated with
the share-lending arrangement at the balance sheet
date?

h.

The amount of interest cost recognized relating to the
amortization of the issuance cost associated with the
share-lending arrangement for the reporting period?

i.

Any amounts of dividends paid related to the loaned
shares that will not be reimbursed?
[“Pending Content” in FASB ASC 470-20-50-2A]

l 5.

(ASU No. 2009-15) If the entity has entered into a share-lending arrangement on its own shares in contemplation of a convertible debt offering or other financing has it properly disclosed the items required by FASB ASC 505, Equity?
[“Pending Content” in FASB ASC 470-20-50-2B]

l 6.

(ASU No. 2009-15) Has the entity properly disclosed, in the
period in which it concludes that it is probable that the counterparty to its share-lending arrangement will default, the
amount of expense reported in the statement of earnings related to the default? (Note: The entity should disclose, in any
subsequent period, any material changes in the amount of expense as a result of changes in the fair value of the entity’s
shares or the probable recoveries. Further, it default is probable, but has not yet occurred, the entity should disclose the
number of shares related to the share-lending arrangement
that will be reflected in basic and diluted EPS when the counterparty defaults.)
[“Pending Content” in FASB ASC 470-20-50-2C]

No

N/A

Cash Conversion Options13
l 7.

l 8.

Has the entity properly disclosed, as of each date for which a
statement of financial position is presented, the following:
a.

The carrying amount of the equity component?

b.

The principal amount, unamortized discount, and net
carrying amount for the liability component?
[FASB ASC 470-20-50-4]

Has the entity properly disclosed, as of the date of the most
recent statement of financial position that is presented, the
following:
a.

13

The remaining period over which any discount on the
liability component with be amortized?

Per FASB ASC 470-20-50-3, the entity should provide the incremental disclosures required by the guidance in FASB ASC 470-20 in
annual financial statements for convertible debt instruments that are within the scope of the “Cash Conversions” subsections of FASB
ASC 470-20 that were outstanding during any of the periods presented.
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Yes

.l 9.

L.

b.

The conversion price and the number of shares on
which the aggregate consideration to be delivered upon
conversion is determined?

c.

All of the following information about derivative transactions entered into (in connection with the issuance of
instruments within the scope of the “Cash Conversions” subsections of FASB ASC 470-20-50, regardless
of whether such derivative transactions are accounted
for as assets, liabilities, or equity instruments):
i.

The terms of those derivative transactions?

ii.

How those derivative transactions relate to the
instruments (within the scope of the “Cash Conversions” subsections of FASB ASC 470-20-50)?

iii.

The number of shares underlying the derivative
transactions?

iv.

The reasons for entering into those derivative
transactions?
[FASB ASC 470-20-50-5]

No

N/A

Has the entity properly disclosed, as of each date for which a
statement of financial position is presented, the following:
a.

The effective interest rate on the liability component for
the period?

b.

The amount of interest cost recognized for the period
relating to both the contractual interest coupon and amortization of the discount on the liability component?
[FASB ASC 470-20-50-6]

Participating Mortgage Loans (FASB ASC 470-30)
Presentation

.l 1.

Has the entity properly included the amortization of the debt
discount relating to the participation liability in interest expense?
[FASB ASC 470-30-45-1]

.l 2.

Has the entity properly presented the debt extinguishment
gain or loss from the extinguishment of a participating mortgage loan as required by FASB ASC 470-50-40-2? (Note: This
subtopic does not preclude these gains or losses that meet the
criteria of FASB ASC 225, Income Statement, from being classified as extraordinary.)
[FASB ASC 470-30-45 par. 2–3]

Disclosure
.l 3.

If the entity has borrowed funds in the form of participating
mortgage loans, has it properly disclosed the following in the
financial statements:
a.

The aggregate amount of participating mortgage obligations at the balance-sheet date, with separate disclosure of the aggregate participation liabilities and related debt discounts?
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Yes
b.

M.

No

N/A

Terms of the participations by the lender in either the
appreciation in the market value of the mortgaged real
estate project or the results of operations of the mortgaged real estate project, or both?
[FASB ASC 470-30-50-1]

Debt Modifications and Extinguishments (FASB ASC 470-50)14, 15
Disclosure

.l 1A.

Has the entity properly disclosed if debt was considered to be
extinguished by in-substance defeasance under the provisions of FASB Statement No. 76, Extinguishment of Debt, prior
to the effective date of FASB Statement No. 125, Accounting
for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities, a general description of the transaction and
the amount of debt that is considered extinguished at the end
of the period so long as that debt remains outstanding?
[FASB ASC 470-50-50-1]

.l 1B.

(ASU No. 2009-16, Transfers and Servicing [Topic 860]: Accounting for Transfers of Financial Assets) Has the entity
properly disclosed, if debt was considered to be extinguished
by in-substance defeasance under the provisions of FASB
Statement No. 76 prior to the effective date of FASB Statement No. 125, a general description of the transaction and the
amount of debt that is considered extinguished at the end of
each period that debt remains outstanding?
[“Pending Content” in FASB ASC 470-50-50-1]

N.

Troubled Debt Restructuring by Debtors (FASB ASC 470-60)
Disclosure

.l 1.

.l 2.

Has the entity properly disclosed the following, related to a
troubled debt restructuring occurring during the current period:
a.

A description of the principal changes in terms, the major features of settlement, or both? (Note: Separate restructurings within a fiscal period for the same category
of payables may be grouped for disclosure purposes.)

b.

Aggregate gain on restructuring of payables?

c.

Aggregate net gain or loss on transfers of assets recognized during the period?

d.

Per-share amount of the aggregate gain on restructuring of payables?
[FASB ASC 470-60-50-1]

Has the entity properly disclosed the following, related to
periods after a troubled debt restructuring:

14
Per FASB ASC 470-50-45 paragraphs 2–3, gains and losses from extinguishment of debt that meet the criteria in FASB ASC 225-20
are not precluded from being classified as extraordinary items. However, any charges to earnings resulting from application of FASB
ASC 470-50-40-21(c) should not be classified as extraordinary.
15

See footnote 4.
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Yes

O.

a.

The extent to which amounts contingently payable are
included in the carrying amount of restructured payables pursuant to the provisions of FASB ASC 470-60-357?

b.

If required by paragraphs 1–6 and 9–10 of FASB ASC
450-20-50, total amounts contingently payable on restructured payables and conditions under which those
amounts would become payable or forgiven?
[FASB ASC 470-60-50-2]

No

N/A

Distinguishing Liabilities From Equity (FASB ASC 480-10)16
Presentation
Additional Presentation Information

For those entities for which FASB Statement No. 150, Accounting for Certain Financial Instruments with Characteristics of Both Liabilities and Equity, applies, please reference FASB ASC at www.fasb.org for the presentation items relevant to your entity.
Disclosure
Additional Disclosure Information
For those entities for which FASB Statement No. 150 applies, please reference FASB ASC at www.fasb.org
for the disclosure items relevant to your entity.
.l 1.

Has the entity properly disclosed the following (if it issues
financial instruments within the scope of FASB ASC 480-1025):
a.

The nature and terms of the financial instruments?

16

In November 2003, FASB issued FASB Staff Position (FSP) FAS 150-3, Effective Date, Disclosures, and Transition for Mandatorily
Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests under FASB Statement No. 150, to clarify and defer specific implementation of the provisions of FASB Statement No. 150, Accounting for Certain Financial
Instruments with Characteristics of both Liabilities and Equity.
FASB Statement No. 150 as issued is effective for mandatorily redeemable financial instruments of nonpublic entities for the first
fiscal period beginning after December 15, 2003. For mandatorily redeemable instruments of other entities, FASB Statement No. 150 as
issued is effective for financial instruments entered into or modified after May 31, 2003, and for all other instruments for interim periods
beginning after June 15, 2003.
FSP FAS 150-3 deferred the effective date for mandatorily redeemable financial instruments issued by nonpublic entities that are
not Securities and Exchange Commission (SEC) registrants, as follows:
a.

For instruments that are mandatorily redeemable on fixed dates for amounts that either are fixed or are determined by reference
to an interest rate index, currency index, or another external index, the classification, measurement, and the disclosure provisions of FASB ASC 480-10-50 and the presentation provisions of FASB ASC 480-10-45 were effective for fiscal periods beginning
after December 15, 2004.

b.

For all other financial instruments that are mandatorily redeemable, the classification, measurement, and disclosure provisions
of FASB ASC 480-10-50 and the presentation provisions of FASB ASC 480-10-45 are deferred indefinitely pending further FASB
action.

Readers should review this FSP or the relevant transition guidance to understand the various effective dates of FASB Statement No. 150,
as discussed in FASB ASC 480-10-65-1.
This checklist has been updated to include the presentation and disclosure requirements of FSP FAS 150-3.
Readers can refer to the full text of the statement on the FASB website at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition and open effective date information discussed in FASB ASC 48010-65-1.
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Yes
b.

.l 2.

No

N/A

The rights and obligations embodied in those instruments, including both:
i.

settlement alternatives, if any, in the contract,
and

ii.

the entity that controls the settlement alternatives?
[FASB ASC 480-10-50-1]

Has the entity properly disclosed the following for all outstanding financial instruments (within the scope of FASB
ASC 480-10) and for each settlement alternative:
a.

The amount that would be paid, or the number of
shares that would be issued and their fair value, determined under the conditions specified in the contract if
the settlement were to occur at the reporting date?

b.

How changes in the fair value of the issuer’s equity
shares would affect those settlement amounts (for example, “the issuer is obligated to issue an additional x
shares or pay an additional y dollars in cash for each
$1 decrease in the fair value of one share”)?

c.

The maximum amount that the issuer could be required to pay to redeem the instrument by physical settlement, if applicable?

d.

The maximum number of shares that could be required
to be issued, if applicable?

e.

That a contract does not limit the amount that the issuer could be required to pay or the number of shares
that the issuer could be required to issue, if applicable?

f.

For a forward contract or an option indexed to the issuer’s equity shares, the forward price or option strike
price, the number of issuer’s shares to which the contract is indexed, and the settlement date or dates of the
contract, as applicable?
[FASB ASC 480-10-50-2]

IV. Equity
A.

Equity (FASB ASC 505-10)

The following table summarizes the titles used to describe the equity section in the financial statements
of a sample of public entities surveyed by the AICPA. Reprinted from the AICPA’s Accounting Trends
& Techniques, 2010, 64th edition (product no. 0099010 [paperback] or WAT-XX [online]).
TITLE OF STOCKHOLDERS’ EQUITY SECTION
2009
2008
2007
2006
Stockholders’ equity
256
258
307
299
Shareholders’ equity
179
181
225
233
(continued)
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Yes

Shareowners’ equity
Common stockholders’ equity
Common shareholders’ equity
Term deficit or deficiency in title
Other or no title
Total entities

No

2009
16
5
5
1
22

2008
17
5
1
18
13

2007
17
6
4
24
10

2006
16
6
4
27
7

16

500

600

600

N/A

2008–2009 based on 500 entities surveyed; 2006–2007 based on 600 entities surveyed.
Presentation
Receivables for Issuance of Equity
l 1.

Has the entity properly presented a note received as a contribution to equity as an offset against stock in the equity section? (Note: Such notes may be recorded as an asset if collected in cash before the financial statements are issued or are
available to be issued.)
[FASB ASC 505-10-45-2]

Disclosure
l 2.

Has the entity properly disclosed changes in the separate account comprising shareholders’ equity (in addition to retained earnings) and changes in the number of shares of equity securities during at least the most recent annual fiscal
period and any subsequent interim period presented? (Note:
This disclosure may take the form of separate statements or
may be made in the basic financial statements or in the notes.)
[FASB ASC 505-10-50-2]

l 3.

Has the entity properly disclosed information about the pertinent rights and privileges of the various securities outstanding, including mandatory redemption requirements, in summary form? (Note: Examples of information to be included
are dividend and liquidation preferences, participation rights,
call prices and dates, and conversion or exercise prices or
rates and pertinent date. See FASB ASC 505-10-50-3 for more
examples of disclosures.)
[FASB ASC 505-10-50-3]

Securities With Preferences
l 4.

Has the entity properly disclosed, for preferred stock that has
a preference in involuntary liquidation considerably in excess
of par or stated value of the shares, the liquidation preference
in the equity section of the balance sheet in the aggregate,
either parenthetically or “in short,” rather than on a per share
basis or in the notes to the financial statements?
[FASB ASC 505-10-50-4]

l 5.

Has the entity properly disclosed the following on the face of
the balance sheet or in the notes to the financial statements:
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Yes
a.

The aggregate or per-share amounts at which preferred
stock may be called or are subject to redemption
through sinking-fund operations or otherwise?

b.

The aggregate and per-share amounts of arrearages in
cumulative preferred dividends?
[FASB ASC 505-10-50-5]

Convertible Securities
l 6.

Has the entity properly disclosed, for contingently convertible securities that disclose the significant quantitative and
qualitative terms of the conversion features to enable users of
the financial statements to understand the circumstances of
the contingency and the potential impact of conversion, including:
a.

events or changes in circumstances that would cause
the contingency to be met and any significant features
necessary to understand the conversion rights and the
timing of those rights (for example, the periods in
which [i] the contingency might be met and [ii] the securities may be converted if the contingency is met)?

b.

the conversion price and the number of shares into
which the security is potentially convertible?

c.

events or changes in circumstances, if any, that could
adjust or change the contingency, conversion price, or
number of shares, including significant terms of those
changes?

d.

the manner of settlement upon conversion and any alternative settlement methods (for example, cash,
shares, or a combination)?
[FASB ASC 505-10-50-6]

l 7.

Has the entity properly disclosed, in order to meet the requirements of FASB ASC 505-10-50-6, the possible conversion
prices and dates as well as other significant terms for each
convertible instrument?
[FASB ASC 505-10-50-7]

l 8.

Has the entity properly disclosed, in the footnotes to the financial statements, the terms of the transaction (as referred to
in FASB ASC 505-10-50-6), including the excess of the aggregate fair value of the instruments that the holder would receive at conversion over the proceeds received and the period
over which the discount is amortized?
[FASB ASC 505-10-50-8]

l 9.

Has the entity properly disclosed whether the shares that
would be issued if the contingently convertible securities
were converted are included in the calculation of diluted EPS,
and the reasons why or why not?
[FASB ASC 505-10-50-9]
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Yes

B.

l 10.

Although not required, has the entity disclosed information
about derivative instruments entered into in connection with
the issuance of the contingently convertible securities that
may be useful in terms of fully explaining the potential impact of the contingently convertible securities? (Note: Information might include the terms of those derivative instruments, including the terms of settlement, how those
instruments relate to the contingently convertible securities,
and the number of shares underlying the derivative instruments.)
[FASB ASC 505-10-50-10]

l 11.

For debt with conversion and other options, has the entity
considered incremental disclosures in accordance with FASB
ASC 470-20-10-2 and paragraphs 2–6 of FASB ASC 470-20-50?
[FASB ASC 505-10-50-10A]

l 12.

Has the entity properly disclosed, for redeemable stock, the
amount of redemption requirements, separately by issue or
combined, for all issues of capital stock that are redeemable
at fixed or determinable prices on fixed or redeemable dates
in each of the five years following the date of the latest balance sheet?
[FASB ASC 505-10-50-11]

No

N/A

Treasury Stock (FASB ASC 505-30)

The following table summarizes the presentations of treasury stock in the balance sheets of a sample
of public entities surveyed by the AICPA. Reprinted from the AICPA’s Accounting Trends & Techniques,
2010, 64th edition (product no. 0099010 [paperback] or WAT-XX [online]).
TREASURY STOCK—BALANCE SHEET PRESENTATION
2009
2008
2007
2006
Common Stock
Cost of treasury stock shown as stockholders’
equity deduction
316
318
371
381
Cost of treasury stock deducted from stock of
the same class
5
10
6
8
Par or stated value of treasury stock deducted
from issued stock of the same class
19
20
20
14
Other
—
2
1
2
Total presentations
340
350
398
405
Preferred Stock
Cost of treasury stock shown as stockholders’
equity deduction
Other
Total presentations

—
—
—

—
—
—

—
1
1

3
2
5
(continued)
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Yes

Number of Entities
Disclosing treasury stock
Not disclosing treasury stock
Total entities

2009

2008

2007

2006

340
160
500

350
150
500

398
202
600

408
192
600

2008–2009 based on 500 entities surveyed; 2006–2007 based on 600 entities surveyed.
Presentation
l 1.

Has the entity properly presented, if the entity purchased
stock for purposes other than retirement or if ultimate disposition has not yet been decided, the cost separately as a deduction from the total of capital stock, additional paid-in capital, and retained earnings, or has it been presented in
accordance with paragraphs 7–10 of FASB ASC 505-30-30?
[FASB ASC 505-30-45-1]

Disclosure
Disclosures Relating to State Laws
l 2.

Has the entity made appropriate disclosures regarding state
laws that may affect or restrict the entity’s ability to repurchase its own outstanding common stock?
[FASB ASC 505-30-50-2]

Disclosures Relating to Allocation of Repurchase Price
l 3.

C.

Has the entity made proper disclosures if treasury shares are
purchased at a stated price significantly in excess of the current market price of the shares, including the allocation of the
amounts paid and the accounting treatment for such
amounts?
[FASB ASC 505-30-50 par. 3–4]

Equity-Based Payments to Nonemployees (FASB ASC 505-50)
Presentation
l 1.

Has the entity properly not presented an asset, other than a
note or receivable, received in return for fully vested, nonforfeitable equity instruments, that are issued at the date of an
agreement for goods or services, as a contra-equity of the equity instrument?
[FASB ASC 505-50-45-1]

Disclosure
Grantor Disclosures
l 2.
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Has the entity properly disclosed, to the extent that the disclosures are important to an understanding of the effects of
the transactions on the financial statements, information
about goods or services, other than employee services, acquired in a share-based payment transaction?
[FASB ASC 505-50-50-1]

N/A
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Yes

No

N/A

Grantee Disclosures
l 3.

Has the entity properly disclosed, in accordance with paragraphs 1–2 of FASB ASC 845-10-50, in each period’s financial
statements, the amount of gross operating revenue recognized as a result of nonmonetary transactions addressed by
the guidance of FASB ASC 505-50?
[FASB ASC 505-50-50-2]

V. Revenue
The following table summarizes the titles used to describe the income statement in the financial
statements of a sample of public entities surveyed by the AICPA. Reprinted from the AICPA’s
Accounting Trends & Techniques, 2010, 64th edition (product no. 0099010 [paperback] or WAT-XX
[online]).
INCOME STATEMENT TITLE
2009
2008
2007
2006
Income
242
227
264
252
Operations
181
195
244
260
Earnings
70
74
89
87
Other
7
4
3
1
Total entities

500

500

600

600

2008–2009 based on 500 entities surveyed; 2006–2007 based on 600 entities surveyed.
A.

Revenue Recognition—Products (FASB ASC 605-15)
Presentation
General

.l 1.

B.

Has the entity properly presented revenue and cost of sales,
reduced for any estimated returns, for sales made with a right
of return which meet the criteria in FASB ASC 605-15-25-1?
[FASB ASC 605-15-45-1]

Revenue Recognition—Services (FASB ASC 605-20)17
Presentation
General

.l 1.

Has the entity properly classified revenue based on the type
of service rendered or contracted to be rendered?
[FASB ASC 954-605-45-1]

17
In August 2010, FASB issued ASU No. 2010-23, Health Care Entities (Topic 954): Measuring Charity Care for Disclosure—a consensus of
the FASB Emerging Issues Task Force. The “Pending Content” is effective for the first annual reporting period ending on or after December
15, 2011 (that is, December 31, 2011, for entities with calendar year-ends).

This checklist has not been updated to include the presentation and disclosure requirements of ASU No. 2010-23.
Readers can refer to the full text of the ASU on the FASB website at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition and open effective date information discussed in FASB ASC 954605-65-1.
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Yes
.l 2.

Has the entity properly excluded charity care from gross revenue?
[FASB ASC 954-605-45-2]

.l 3.

Has the entity properly reported service revenue, including
patient service revenue, net of contractual and other adjustments in the statement of operations?
[FASB ASC 954-605-45-2]

.l 4.

Has the entity properly reported separately significant revenue earned under capitation arrangements?
[FASB ASC 954-605-45-3]

Contributions and Pledges
. 5.

Does the entity distinguish between contributions received
with permanent restrictions, those received with temporary
restrictions, and those received without donor-imposed restrictions, so that they are reported as support increasing permanently restricted net assets, temporarily restricted net assets, or unrestricted net assets, respectively?
[FASB ASC 958-605-45 par. 3–4]

. 6.

If donor-restricted contributions whose restrictions are met in
the same reporting period are reported as unrestricted support, pursuant to FASB ASC 958-605-45-4, is such treatment
consistent from period to period and is the policy disclosed?
[FASB ASC 958-360-50-1]

. 7.

Does the entity report receipt of unconditional promises to
give with payments due in future periods as restricted support, unless explicit donor stipulations or circumstances surrounding the receipt of the promise make clear that the donor
intended the contribution to be used to support activities of
the current period?
[FASB ASC 958-605-45-5]

. 8.

Does an entity that receives unconditional promises to give
measured using present value techniques report the subsequent accrual of the interest element recognized as contribution income (FASB ASC 958-310-35-6) as an increase in either
temporarily restricted or permanently restricted net assets if
the underlying promise to give is donor restricted?
[FASB ASC 958-310-45-2]

Disclosure
. 9.

Has the not-for-profit entity made disclosure if it reports contributions with donor-imposed restrictions as unrestricted
support, in accordance with FASB ASC 958-605-45-4?
[FASB ASC 958-605-50-2]

Other
.l 10.
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Have the notes to the financial statements disclosed the methods of revenue recognition (for example, policies related to
capitation revenue, patient service revenues, or contributions)?
[FASB ASC 954-605-50-1]

No

N/A
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Yes

No

N/A

Estimated and Final Settlements Under Rate Setting Systems
.l 11.

Has the entity properly disclosed the differences between
original estimates and subsequent revisions (including final
settlements) under retrospective rate setting methods?
[FASB ASC 954-605-50-2]

Charity Care
.l 12.

Has the entity properly disclosed management’s policy for
providing charity care, as well as the level of charity care provided? (Note: Such disclosure is generally made in the notes
to the financial statements and is measured based on the provider’s rates, costs, units of service, or other statistical measure.)
[FASB ASC 954-605-50-3]

Donated Materials, Facilities, and Services
. 13.

If donated materials merely pass through the entity to its
charitable beneficiaries, and the entity is only an agent or intermediary for the donors, has that donation been excluded
from contribution revenues?
[FASB ASC 958-605-55-13]

. 14.

If the not-for-profit entity receives contributed services, does
it disclose the following:
a.

A description of the programs or activities for which
those services were used?

b.

The nature and extent of contributed services received
for the period?

c.

The amount recognized as revenues for the period?

d.

The fair value of contributed services received but not
recognized, if practicable (optional)?

e.

Nonmonetary information such as the number and
trends of donated hours received or service outputs
provided by volunteer efforts (optional)?

f.

Dollar amount of contributions raised by volunteers
(optional)?
[FASB ASC 958-605-50-1]

Receivables for Issuance of Equity
l 15.

Has the entity properly disclosed the amount of revenue and
expense recognized from advertising barter transactions for
each income statement period presented?
[FASB ASC 605-20-50-1]
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Yes
C.

No

N/A

Multiple Element Arrangements (FASB ASC 605-25)
Disclosure18

.l 1.

D.

Has the entity properly disclosed the following in regard to
revenue arrangements with multiple deliverables:
a.

Its accounting policy for recognition of revenue from
multiple-deliverable arrangements (for example,
whether deliverables are separable into units of accounting)?

b.

The description and nature of such arrangements, including performance, cancellation, termination, or refund-type provisions?
[FASB ASC 605-25-50-1]

Milestone Method Revenue Recognition (FASB ASC 605-28)
Disclosure19
Additional Disclosure Information

If the entity has elected to early adopt ASU No. 2010-17, Revenue Recognition—Milestone Method (Topic 605):
Milestone Method of Revenue Recognition—a consensus of the FASB Emerging Issues Task Force, see FASB ASC
605-28-50 for required disclosures.

18

In October 2009, FASB issued ASU No. 2009-13, Revenue Recognition (Topic 605): Multiple-Deliverable Revenue Arrangements—a consensus of the FASB Emerging Issues Task Force. This update amends FASB ASC 605-25 to separate consideration in multiple-deliverable
arrangements; establish a selling-price hierarchy for determining the selling price of a deliverable; replace the term fair value in the
revenue allocation guidance with selling price; eliminate the residual method of allocation, and require that a vendor determine its best
estimate of selling price in a manner that is consistent with that used to determine the price to sell the deliverable on a standalone basis.
This ASU should be applied on a prospective basis for revenue arrangements entered into or materially modified in fiscal years beginning
on or after June 15, 2010 (that is, January 1, 2011, for entities with calendar year-ends), unless the entity elects to adopt this ASU on a
retroactive basis in accordance with FASB ASC 605-25-65-1(e). Early application is permitted.
This checklist has not been updated to include the presentation and disclosure requirements of ASU No. 2009-13.
Readers can refer to the full text of the ASU on the FASB website at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition and open effective date information discussed in FASB ASC 60525-65-1.
19
In April 2010, FASB issued ASU No. 2010-17, Revenue Recognition—Milestone Method (Topic 605): Milestone Method of Revenue Recognition—a consensus of the FASB Emerging Issues Task Force. ASU No. 2010-17 provides guidance on applying the milestone method to
milestone payments for achieving specified performance measures when those payments are related to uncertain future events. The
scope of this ASU is limited to transactions involving research or development if the milestone payment is to be recognized in its entirety
in the period the milestone is achieved. Entities can make an accounting policy election to recognize arrangement consideration received
for achieving specified performance measures during the period in which the milestones are achieved, provided certain criteria are met.
Although the milestone method is an accounting policy election, other methods that would result in recognizing a milestone in its entirety
during the period in was achieved would not be acceptable for milestones if the criteria are not met. This ASU should be applied on a
prospective basis for milestones achieved fiscal years beginning on or after June 15, 2010 (that is, January 1, 2011, for entities with calendar
year-ends), unless the entity elects to adopt this ASU on a retroactive basis in accordance with FASB ASC 250, Accounting Changes and
Error Corrections. Early application is permitted.

This checklist has not been updated to include the presentation and disclosure requirements of ASU No. 2010-17.
Readers can refer to the full text of the ASU on the FASB website at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition and open effective date information discussed in FASB ASC 60528-65-1.
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Yes
E.

No

N/A

Gains and Losses—Revenue Recognition (FASB ASC 605-40)
Presentation

.l 1.

F.

Has the entity properly presented any gain or loss resulting
from an involuntary conversion of a nonmonetary asset in accordance with the provisions of FASB ASC 225-20?
[FASB ASC 605-40-45-1]

Principal Agent Considerations—Revenue Recognition (FASB
ASC 605-45)
Presentation
Overall Considerations of Reporting Revenue Gross as a Principal
Versus Net as an Agent

.l 1.

Has the entity used sound judgment in determining whether
to report revenue on either (a) the gross amount billed to a
customer because it has earned revenue (as a principal) from
the dale of the goods or services, or (b) the net amount retained because it has earned a commission or fee as an agent?
(See FASB ASC 605-45-45 paragraphs 3 and 15 for indicators
of gross and net reporting, respectively.)
[FASB ASC 605-45-45-1]

Shipping and Handling Fees and Costs
.l 2.

Has the entity properly not presented shipping and handling
costs as a deduction from revenues?
[FASB ASC 605-45-45-21]

Reimbursements Received for Out-of-Pocket Expenses Incurred
.l 3.

Has the entity properly presented reimbursements received
for out-of-pocket expenses incurred as revenue in the income
statement?
[FASB ASC 605-45-45-23]

Disclosure
Gross Transaction Volumes
.l 4.

Although not required, has the entity properly disclosed
gross transaction volume for those revenues reported as net?
(Note: Such disclosure can be made parenthetically in the income statement or in the notes to the financial statements, but
they should not be characterized as revenues, nor should they
be reported in a column that sums to net income or loss.)
[FASB ASC 605-45-50-1]

Shipping and Handling Fees and Costs
.l 5.

In addition to disclosing the accounting policy decision regarding the classification of shipping and handling costs, has
the entity properly disclosed both the amounts if significant
and if not included in the cost of sales, and the line item(s) on
the income statement where included?
[FASB ASC 605-45-50-2]

FSP §11,100.01

106

Health Care Entities

Yes

No

N/A

Taxes Collected From Customers and Remitted to Governmental
Authorities

G.

l 6.

Has the entity properly disclosed the accounting policy decision regarding the presentation of taxes within the scope of
FASB ASC 605-45-15-2(e), either on a gross basis (included in
revenues and costs) or a net basis (excluded from revenues),
disclosed pursuant to FASB ASC 235-10?
[FASB ASC 605-45-50-3]

l 7.

Has the entity properly disclosed the amount of taxes that are
reported on a gross basis in interim and annual financial
statements for each period for which an income statement is
presented, if significant? (Note: The disclosure of these taxes
may be done on an aggregate basis.)
[FASB ASC 605-45-50-4]

Customer Payments and Incentives (FASB ASC 605-50)
Presentation
Additional Presentation Information

For entities involved in providing customers sales incentives or other consideration, see FASB ASC 605-5045 for further presentation information, including circumstances under which that consideration is either
●

an adjustment of the selling prices of the vendor’s product or services and therefore characterized
as a reduction of revenue when recognized in the vendor’s income statement, or

●

a cost incurred by the vendor for assets or services received from the customer and therefore characterized as a cost or expense when recognized in the vendor’s income statement.
Disclosure
Service Provider’s Accounting for Consideration Given to a Manufacturer or Reseller of Equipment
.l 1.

Has the entity properly disclosed, if the entity is a service
provider and provides incentives to a third-party manufacturer or reseller that ultimately benefits the service provider’s
customer, this fact?
[FASB ASC 605-50-50-1]

Transfer Specifying Transferor or its Affiliate as Beneficiary
. 2.

FSP §11,100.01

If an entity transferred assets to a recipient entity in an equity
transaction, has it disclosed the following information for
each period for which a statement of financial position is presented:
a.

The identity of the recipient entity to which the transfer
was made?

b.

Whether variance power was granted to the recipient
entity and, if so, a description of the terms of the variance power?

c.

The terms under which amounts will be distributed to
the resource provider or its affiliate?

107

Financial Statements and Notes Checklist

Yes
d.

No

N/A

The aggregate amount recognized in the statement of
financial position for those transfers and whether that
amount is recorded as an interest in the net assets of
the recipient entity or as another asset (for example, as
a beneficial interest in assets held by others or a refundable advance)?
[FASB ASC 958-605-50-6]

VI. Expenses
A.

Compensation (FASB ASC 710-10)
Presentation
Additional Presentation Information

For entities with rabbi trusts, as discussed in FASB ASC 710-10-25-15, see FASB ASC 710-10-45 for information on proper presentation.
Disclosure
Compensated Absences
.l 1.

B.

Has the entity properly disclosed, if the entity meets the conditions for recognizing a liability for compensated absences
in subparagraphs 1(a)–1(c) of FASB ASC 710-10-2520 and does
not accrue a liability because the amount cannot be reasonably estimated, that fact?
[FASB ASC 710-10-50-1]

Nonretirement Postemployment Benefits (FASB ASC 712-10)
Disclosure
Other Postemployment Benefits

.l 1.

20

If the entity does not accrue an obligation for other postemployment benefits in accordance with FASB ASC 450-20-25-2
or FASB ASC 710-10-25-1 because the amount cannot be reasonably estimated, has the entity properly disclosed that fact?
[FASB ASC 712-10-50-2]

FASB ASC 710-10-25 paragraph 1(a)–1(c) reads:
An employer shall accrue a liability for employees’ compensation for future absences if all of the following conditions are met:
a.

The employer’s obligation relating to employees’ rights to receive compensation for future absences is attributable to
employees’ services already rendered.

b.

The obligation relates to rights that vest or accumulate. Vested rights are those for which the employer has an obligation
to make payment even if an employee terminates; thus, they are not contingent on an employee’s future service. Accumulate means that earned but unused rights to compensated absences may be carried forward to one or more periods
subsequent to that in which they are earned, even though there may be a limit to the amount that can be carried forward.

c.

Payment of the compensation is probable.
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Yes
C.

No

N/A

Defined Benefit Plans—Compensation (FASB ASC 715-20)21, 22
Presentation

.l 1.

If the entity sponsors one or more defined benefit pension
plans or one or more defined benefit other postretirement
plans, has the entity separately presented, for pension plans
and other postretirement benefit plans, the funded status of
the plans and the amounts recognized in the statement of financial position, showing separately the assets and current
and noncurrent liabilities recognized?
[FASB ASC 715-20-45-2]

.l 2.

If the entity presents a classified statement of financial position, has the entity properly presented the liability for an underfunded plan as a current liability, a noncurrent liability, or
a combination of both? (Note: The current portion is the
amount by which the actuarial present value of benefits included in the benefit obligation payable in the next 12
months, or operating cycle, if longer, exceeds the fair value of
plan assets and that the amount classified as a current liability is limited to the amount of the plan’s unfunded status recognized in the employer’s statement of financial position.)
[FASB ASC 715-20-45-3]

.l 3.

If the entity presents a classified statement of financial position, has the entity properly presented the asset for an overfunded plan as a noncurrent asset?
[FASB ASC 715-20-45-3]

Disclosure
Additional Disclosure Information
FASB ASC 715-20-50 contains disclosures for both nonpublic and public companies. See the following section, “Public Entity Disclosures,” for required disclosures specific to public entities.
Disclosures by Nonpublic Entities
. 4A.

Has the entity properly disclosed separately for pension
plans and other postretirement benefit plans, if the entity
sponsors one or more defined benefit pension plans or one or
more other defined benefit postretirement plans:

21

Paragraphs 1–2 of FASB ASC 715-30-50, regarding defined benefit plans, refer to FASB ASC 715-20-50 for the disclosure requirements
applicable to FASB ASC 715-30-50.
22
In January 2010, FASB issued ASU No. 2010-06, Fair Value Measurements and Disclosures (Topic 820): Improving Disclosures about Fair
Value Measurements. This ASU establishes new disclosure requirements regarding transfers in and out of levels 1 and 2 of the fair value
hierarchy and activity in level 3 fair value measurements. It also clarifies certain existing disclosures within FASB ASC 820-10-50
regarding level of disaggregation and inputs and valuation techniques. The amendments in this ASU will be effective for interim and
annual reporting periods beginning after December 15, 2009 (that is, January 1, 2010, for entities with calendar year-ends), except for the
disclosures in the level 3 fair value measurement roll forward. Those disclosures are effective for fiscal years beginning after December
15, 2010 (that is, January 1, 2011, for entities with calendar year-ends), and for interim periods within those fiscal years.

This checklist has been updated to include the presentation and disclosure requirements of ASU No. 2010-06.
Readers can refer to the full text of the ASU on the FASB website at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition and open effective date information discussed in FASB ASC 60528-65-1.
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Yes
a.

The benefit obligation, fair value of plan assets, and
funded status of the plan?

b.

Employer contributions, participant contributions, and
benefits paid?

No

N/A

Additional Disclosure Information
The objectives of the disclosures about postretirement benefit plan assets are to provide users of financial
statements with an understanding of the following:
●

How investment allocation decisions are made, including the factors that are pertinent to an understanding of investment policies and strategies

●

The major category of plan assets

●

The inputs and valuation techniques used to measure the fair value of plan assets

●

The effect of fair value measurements using significant unobservable inputs (level 3) on changes in
the plan assets for the period

●

Significant concentrations of risk within plan assets
c.

Considering the items in the preceding “Additional
Disclosure Information,” has the entity provided:
i.

A narrative description of investment policies
and strategies, including target allocation percentages or range of percentages considering the
major categories of plan assets disclosed pursuant to item (ii), as of the latest statement of financial position presented (on a weighted-average
basis for employers with more than one plan),
and other factors that are pertinent to an understanding of those policies and strategies such as
investment goals, risk management practices,
permitted and prohibited investments including
the use of derivatives, diversification, and the relationship between plan assets and benefit obligations?

ii.

The fair value of each major category of plan assets as of each date for which a statement of financial position is presented? (Note: Asset categories are based on the nature and risks of assets
in the entity’s plan[s].)

iii.

A narrative description of the basis used to determine the overall expected long-term rate-of-return-on-assets assumption, such as the general
approach used, the extent to which the overall
rate-of-return-on-assets assumption was based
on historical returns, the extent to which adjustments were made to those historical returns in
order to reflect expectations of future returns,
and how those adjustments were determined?
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Yes
iv.

Information that enables users of financial statements to assess the inputs and valuation techniques used to develop fair value measurements
of plan assets at the reporting date? To meet this
objective, has the entity properly disclosed the
following:
(1)

The level within the fair value hierarchy in
which the fair value measurements in their
entirety fall, segregating fair value measurements using quoted prices in active
markets for identical assets or liabilities
(level 1), significant other observable inputs (level 2), and significant unobservable
inputs (level 3)?

(2)

For fair value measurements of plan assets
using significant unobservable inputs
(level 3), a reconciliation of the beginning
and ending balances, separately presenting
changes during the period attributable to
the following:

(3)

FSP §11,100.01

(a)

Actual return on plan assets?

(b)

Purchases, sales, and settlements,
net?

(c)

Transfers in or out, or both, of level
3?

Information about the valuation technique(s) and inputs used to measure fair
value and a discussion of changes in valuation techniques and inputs, if any, during
the period?

d.

For defined benefit pension plans, the accumulated
benefit obligation?

e.

The benefits (as of the date of the latest statement of
financial position presented) expected to be paid in
each of the next five fiscal years, and in the aggregate
for the five fiscal years thereafter? The expected benefits should be estimated based on the same assumptions used to measure the entity’s benefit obligation at
the end of the year and should include benefits attributable to estimated future employee service.

f.

The employer’s best estimate, as soon as it can reasonably be determined, of contributions expected to be
paid to the plan during the next fiscal year beginning
after the date of the latest statement of financial position presented? Estimated contributions may be presented in the aggregate combining any of the following:
(i) contributions required by funding regulations or
laws, (ii) discretionary contributions, and (iii) noncash
contributions.

No

N/A
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Yes
g.

The amounts recognized in the statements of financial
position, showing separately the postretirement benefit
assets and current and noncurrent postretirement benefit liabilities?

h.

Separately, the net gain or loss and net prior service
cost or credit recognized in OCI for the period pursuant
to FASB ASC 715-30-35 paragraphs 11 and 21 and
FASB ASC 715-60-35 paragraphs 16 and 25 and reclassification adjustments of OCI for the period, as those
amounts, including amortization of the net transition
asset or obligation, are recognized as components of net
periodic benefit cost?

i.

The amounts in accumulated OCI that have not yet
been recognized as components of net periodic benefit
cost, showing separately the net gain or loss, net prior
service cost or credit, and net transition asset or obligation?

j.

On a weighted-average basis, all of the following assumptions used in the accounting for the plans, specifying in a tabular format, the assumptions used to determine the benefit obligation and the assumptions
used to determine net benefit cost:
i.

Assumed discount rates (refer to FASB ASC 71530-35-45 for a discussion of representationally
faithful disclosure)?

ii.

Rates of compensation increase (for pay-related
plans)?

iii.

Expected long term rates of return on plan assets?

k.

The assumed health care cost trend rate(s) for the next
year used to measure the expected cost of benefits covered by the plan (gross eligible charges), and a general
description of the direction and pattern of change in the
assumed trend rates thereafter, together with the ultimate trend rate(s) and when that rate is expected to be
achieved?

l.

If applicable, the amounts and types of securities of the
employer and related parties included in plan assets,
the approximate amount of future annual benefits of
plan participants covered by insurance contracts, including annuity contracts, issued by the employer or
related parties, and any significant transactions between the employer or related parties and the plan during the period?

m.

The nature and effect of significant nonroutine events,
such as amendments, combinations, divestitures, curtailments, and settlements?

No

N/A
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Yes
n.

The amounts in accumulated OCI expected to be recognized as components of net periodic benefit cost over
the fiscal year that follows the most recent annual statement of financial position presented, showing separately the net gain or loss, net prior service cost or
credit, and net transition asset or obligation?

o.

The amount and timing of any plan assets expected to
be returned to the employer during the 12 month period, or operating cycle if longer, that follows the most
recent annual statement of financial position presented?

p.

The amount of net periodic benefit cost recognized?
[FASB ASC 715-20-50-5]

Note (ASU No. 2010-06, Fair Value Measurements and Disclosures (Topic 820): Improving Disclosures about Fair
Value Measurements): ASU No. 2010-06 affects FASB ASC
715-20-50-5, question 4A, preceding, in the following manner:
Throughout the paragraph, the term major category was replaced with the term class. As such, entities that have adopted
the provisions of ASU No. 2010-06 should consider the disclosure requirements contained in question 4A with this change
in mind.
[“Pending Content” in FASB ASC 715-20-50-5]
Interim Disclosure Requirements for Nonpublic Entities
. 5.

Has the entity properly disclosed, in interim periods for
which a complete set of financial statement is presented, the
total amount of the employer’s contributions paid, and expected to be paid, during the current fiscal year, if significantly different than amounts previously disclosed pursuant
to FASB ASC 715-20-50-5(f)?23 (Note: Estimated contributions
may be presented in the aggregate by combining [a] contributions required by regulations or laws, [b] discretionary contributions, and [c] noncash contributions.)
[FASB ASC 715-20-50-7]

Disclosures Related to Expected Rate of Return on Plan Assets
.l 6.

23

If the entity has changed the previously disclosed weightedaverage expected long-term rate of return for plan assets,
based on a subsequent interim measurement of both pension
or other postretirement plan assets and obligations, has the
entity disclosed the beginning and more recently assumed
rate, or a properly weighted combination of the two?
[FASB ASC 715-20-50-8]

See question 4A(f) in the “VI.C. Defined Benefit Plans—Compensation (FASB ASC 715-20)” section.
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Yes

No

N/A

Disclosures Related to Japanese Governmental Settlement Transactions
Additional Disclosure Information
For entities with activities regarding accounting for Japanese governmental settlement transactions, see paragraphs 9–10 of FASB ASC 715-20-50 for disclosure requirements.
Public Entity Disclosure
Disclosures by Public Entities
l 7A.

Has the public entity properly disclosed the following items,
separately for pension plans and other postretirement benefits, if the entity is a sponsor of one or more defined benefit
pension plans or one or more defined benefit other postretirement plans: (Note: Amounts related to the entity’s results
of operations should be disclosed for each period for which a
statement of income is presented and amounts related to the
entity’s statement of financial position for each statement of
financial position presented.)
a.

b.

A reconciliation of beginning and ending balances of
the benefit obligation, showing separately, if applicable, the effects during the period attributable to each of
the following: (Note: For defined benefit pension plans,
the benefit obligation is the projected benefit obligation
and for defined other postretirement plans, the benefit
obligation is the accumulated postretirement benefit
obligation.)
i.

Service cost?

ii.

Interest cost?

iii.

Contribution by plan participants?

iv.

Actuarial gains and losses?

v.

Foreign currency exchange rates? (Note: The effects of foreign currency exchange rate changes
that are to be disclosed are those applicable to
plans of a foreign operation whose functional
currency is not the reporting currency pursuant
to FASB ASC 830-10-45.)

vi.

Benefits paid?

vii.

Plan amendments?

viii.

Business combinations?

ix.

Divestitures?

x.

Curtailments, settlements, and special and contractual termination benefits?

A reconciliation of the beginning and ending balances
of the fair value of plan assets showing separately, if
applicable, the effects during the period attributable to
each of the following:
i.

Actual return on plan assets?
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Yes

c.

ii.

Foreign currency exchange rates?

iii.

Contribution by the employer?

iv.

Contributions by plan participants?

v.

Benefits paid?

vi.

Business combinations?

vii.

Divestitures?

viii.

Settlements?

No

N/A

The funded status of the plans and the amounts recognized in the statement of financial position, showing
separately the assets and current and noncurrent liabilities?
Additional Disclosure Information

The objectives of the disclosures about postretirement benefit plan assets are to provide users of financial
statements with an understanding of the following:
●

How investment allocation decisions are made, including the factors that are pertinent to an understanding of investment policies and strategies

●

The major category of plan assets

●

The inputs and valuation techniques used to measure the fair value of plan assets

●

The effect of fair value measurements using significant unobservable inputs (level 3) on changes in
the plan assets for the period

●

Significant concentrations of risk within plan assets
d.
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Considering the items in the preceding “Additional
Disclosure Information,” has the entity provided the
following:
i.

A narrative description of investment policies
and strategies, including target allocation percentages or range of percentages considering the
major categories of plan assets disclosed pursuant to item (ii), as of the latest statement of financial position presented (on a weighted-average
basis for employers with more than one plan),
and other factors that are pertinent to an understanding of those policies and strategies such as
investment goals, risk management practices,
permitted and prohibited investments including
the use of derivatives, diversification, and the relationship between plan assets and benefit obligations?

ii.

The fair value of each major category of plan assets as of each date for which a statement of financial position is presented? (Note: Asset categories are based on the nature and risks of assets
in the entity’s plan[s].)
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Yes
iii.

A narrative description of the basis used to determine the overall expected long-term rate-of-return-on-assets assumption, such as the general
approach used, the extent to which the overall
rate-of-return-on-assets assumption was based
on historical returns, the extent to which adjustments were made to those historical returns in
order to reflect expectations of future returns,
and how those adjustments were determined?

iv.

Information that enables users of financial statements to assess the inputs and valuation techniques used to develop fair value measurements
of plan assets at the reporting date? To meet this
objective, has the entity properly disclosed the
following:
(1)

The level within the fair value hierarchy in
which the fair value measurements in their
entirety fall, segregating fair value measurements using quoted prices in active
markets for identical assets or liabilities
(level 1), significant other observable inputs (level 2), and significant unobservable
inputs (level 3)?

(2)

For fair value measurements of plan assets
using significant unobservable inputs
(level 3), a reconciliation of the beginning
and ending balances, separately presenting
changes during the period attributable to
the following:

(3)

(a)

Actual return on plan assets?

(b)

Purchases, sales, and settlements,
net?

(c)

Transfers in, out, or both of level 3?

No

N/A

Information about the valuation technique(s) and inputs used to measure fair
value and a discussion of changes in valuation techniques and inputs, if any, during
the period?

e.

The accumulated benefit obligation? (For defined benefit pension plans)

f.

The benefits expected to be paid in each of the next five
fiscal years, and in the aggregate for the five fiscal years
thereafter? (Note: The expected benefits should be estimated based on the same assumptions used to measure
the entity’s benefit obligation at the end of the year and
should include benefits attributable to estimated future
employee service.)
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g.

The entity’s best estimate, as soon as it can reasonably
be determined, of contributions expected to be paid to
the plan during the next fiscal year beginning after the
date of the latest statement of financial position presented. (Note: Estimated contributions may be presented in the aggregate combining [i] contributions required by funding regulations or laws, [ii] discretionary
contributions, and [iii] noncash contributions.)

h.

The amount of net benefit cost recognized, showing
separately all of the following:
i.

The service cost component?

ii.

The interest cost component?

iii.

The expected return on plan assets for the period?

iv.

The gain or loss component?

v.

The prior service cost or credit component?

vi.

The transition asset or obligation component?

vii.

The gain or loss recognized due to settlements or
curtailments?

i.

Separately the net gain or loss and net prior service cost
or credit recognized in OCI for the period pursuant to
FASB ASC 715-30-35 paragraphs 11 and 21 and FASB
ASC 715-60-35 paragraphs 16 and 25 and reclassification adjustments of OCI for the period, as those
amounts, including amortization of the net transition
asset or obligation, are recognized as components of net
periodic benefit cost?

j.

The amounts in accumulated OCI that have not yet
been recognized as components of net periodic benefit
cost, showing separately the net gain or loss, net prior
service cost or credit, and net transition asset or obligation?

k.

On a weighted-average basis, the assumptions used in
the accounting for the plans, specifying in a tabular format, the assumptions used to determine the benefit obligation and the assumptions used to determine net
benefit cost including (i) assumed discount rates, (ii)
rates of compensation increase (for pay-related plans),
and (iii) expected long-term rates of return on plan assets?

l.

The assumed health care cost trend rate(s) for the next
year used to measure the expected cost of benefits covered by the plan (gross eligible charges), and a general
description of the direction and pattern of change in the
assumed trend rates thereafter, together with the ultimate trend rate(s) and when that rate is expected to be
achieved?

No

N/A
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Yes
m.

The effect of a one-percentage-point increase and the
effect of a one-percentage-point decrease in the assumed health care cost trend rates on the aggregate of
the service and interest cost components of net periodic
postretirement health care benefit costs and the accumulated postretirement benefit obligation for health
care benefits?

n.

If applicable, the amounts and types of securities of the
employer and related parties included in plan assets,
the approximate amount of future annual benefits of
plan participants covered by insurance contracts, including annuity contracts issued by the employer or related parties, and any significant transactions between
the employer or related parties and the plan during the
period?

o.

If applicable, any alternative method used to amortize
prior service amounts or net gains and losses pursuant
to FASB ASC 715-30-35-13 and 715-30-35-25 or FASB
ASC 715-60-35-18 and 715-60-35-31?

p.

If applicable, any substantive commitment, such as past
practice or a history of regular benefit increases, used
as the basis for accounting for the benefit obligation?

q.

If applicable, the cost of providing special or contractual termination benefits recognized during the period
and a description of the nature of the event?

r.

An explanation of any significant change in the benefit
obligation or plan assets not otherwise apparent in the
other disclosures required by FASB ASC 715-20-50?

s.

The amounts in accumulated OCI expected to be recognized as components of net periodic benefit cost over
the fiscal year that follows the most recent annual statement of financial position presented, showing separately the net gain or loss, net prior service cost or
credit, and net transition asset or obligation?

t.

The amount and timing of any plan assets expected to
be returned to the employer during the 12-month period, or operating cycle if longer, that follows the most
recent annual statement of financial position presented?
[FASB ASC 715-20-50-1]

No

N/A
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Yes

No

N/A

Note (ASU No. 2010-06): ASU No. 2010-06 affects FASB ASC
715-20-50-1, question 7A, in the following manner: (a)
throughout the paragraph, the term major category was replaced with the term class and (b) the following statement was
added to item 7A(d)(ii): “For additional guidance on determining appropriate classes of plan assets, see FASB ASC 82010-50-2A.” As such, public entities that have adopted the provisions of ASU No. 2010-06 should consider the disclosure
requirements contained in question 7A with these changes in
mind.
[“Pending Content” in FASB ASC 715-20-50-1]
l 8.

Has the public entity properly aggregated the disclosures, as
required by FASB ASC 715-20-50, for all of the entity’s defined benefit pension plans and for all of the entity’s other
defined benefit postretirement plans, unless disaggregating in
groups is considered to provide useful information or is otherwise required by paragraphs 3–4 of FASB ASC 715-20-50
(discussed subsequently)?
[FASB ASC 715-20-50-2]
Additional Disclosure Information

Disclosures about pension plans with assets in excess of the accumulated benefit obligation generally may
be aggregated with disclosures about pension plans with accumulated benefit obligations in excess of assets.
The same aggregation is permitted for other postretirement benefit plans. If aggregate disclosures are presented, an employer should disclose both of the following:
●

The aggregate benefit obligation and aggregate fair value of plan assets for plans with benefit obligations in excess of plan assets as of the measurement date of each statement of financial position
presented, and

●

The aggregate pension accumulated benefit obligation and aggregate fair value of plan assets for
pension plans with accumulated benefit obligations in excess of plan assets
[FASB ASC 715-20-50-3]
U.S. reporting entities may combine disclosures about pension plans or other postretirement benefit plans
outside the United States with those for U.S. plans unless the benefit obligations of the plans outside the
United States are significant relative to the total benefit obligation and those plans use significantly different
assumptions. A foreign reporting entity that prepares financial statements in conformity with U.S. GAAP
should apply the preceding guidance to its domestic and foreign plans.
[FASB ASC 715-20-50-4]
Interim Disclosure Requirements for Publicly Traded Entities
l 9.

Has the public entity properly disclosed the following information for its interim financial statements that include a
statement of income:
a.
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The amount of net benefit cost recognized, for each period for which a statement of income is presented,
showing separately each of the following:
i.

The service cost component?

ii.

The interest cost component?
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Yes

b.

D.

iii.

The expected return on plan assets for the period?

iv.

The gain or loss component?

v.

The prior service cost or credit component?

vi.

The transition asset or obligation component?

vii.

The gain or loss recognized due to a settlement
or curtailment?

No

N/A

The total amount of the employer’s contributions paid,
and expected to be paid, during the current fiscal year,
if significantly different from amounts previously disclosed pursuant to FASB ASC 715-20-50-1(g)?24 Estimated contributions may be presented in the aggregate
combining all of the following: (i) contributions required by funding regulations or laws, (ii) discretionary
contributions, and (iii) noncash contributions.
[FASB ASC 715-20-50-6]

Defined Benefit Plans—Other Postretirement (FASB ASC 715-60)
Disclosure
Medicare Prescription Drug, Improvement, and Modernization Act

.l 1.

.l 2.

24

Has the entity properly disclosed the following, if the entity
is including for the first time, in interim or annual financial
statements, the effects of the Medicare subsidy in measuring
the accumulated postretirement benefit obligation and in
measuring net periodic postretirement benefit cost:
a.

The reduction in the accumulated postretirement benefit obligation for the subsidy related to benefits attributed to past service?

b.

The effect of the subsidy on the measurement of net periodic postretirement benefit cost for the current period? (Note: That effect includes any amortization of
the actuarial gain, noted in question 1[a], as a component of the net amortization called for by paragraphs
29–30 of FASB ASC 715-60-35, the reduction in current
period service cost due to the subsidy, and the resulting
reduction in interest cost on the accumulated postretirement benefit obligation as a result of the subsidy.)

c.

Any other disclosures required by FASB ASC 715-2050-1(r)?
[FASB ASC 715-60-50-3]

Has the entity properly disclosed, for purposes of the disclosures required by paragraphs 1(a) and 1(f) of FASB ASC 71520-50, gross benefit payments (paid and expected, respectively), including prescription drug benefits, and separately
the gross amount of the Medicare subsidy receipts (received
and expected, respectively)?
[FASB ASC 715-60-50-4]

See question 7A(g) in the “VI.C. Defined Benefit Plans—Compensation (FASB ASC 715-20)” section.
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Yes
.l 3.

E.

Until the entity is able to determine whether benefits provided by its plan are actuarially equivalent (as defined in the
act), has the entity properly disclosed the following in the financial statements for interim or annual periods:
a.

The existence of the Medicare Prescription Drug, Improvement, and Modernization Act?

b.

That measures of the accumulated postretirement benefit obligation or net periodic postretirement benefit
cost do not reflect any amount associated with the subsidy because the employer is unable to conclude
whether the benefits provided by the plan are actuarially equivalent to Medicare Part D under the act?
[FASB ASC 715-60-50-6]

Defined Contribution Plans (FASB ASC 715-70)
Disclosure

.l 1.

F.

Has the entity properly disclosed the amount of cost recognized for defined contribution pension plans and for other
defined contribution postretirement benefit plans for all periods presented separately from the amount of cost recognized
for defined benefit plans? (Note: The disclosures should include a description of the nature and effect of any significant
changes during the period affecting comparability, such as a
change in the rate of employer contributions, a business combination, or a divestiture.)
[FASB ASC 715-70-50-1]

Multiemployer Plans (FASB ASC 715-80)
Disclosure

.l 1.

Has the entity properly disclosed the amount of contributions
to multiemployer plans for each annual period for which a
statement of income is presented? (Note: An entity may disclose total contributions to multiemployer plans without disaggregating the amounts attributable to pension plans and
other postretirement benefit plans. The disclosures should include a description of the nature and effect of any changes
affecting comparability, such as a change in the rate of employer contributions, a business combination, or a divestiture.)
[FASB ASC 715-80-50-1]

.l 2.

Has the entity properly disclosed if it is either probable or
reasonably possible that (a) an employer would withdraw
from the plan under circumstances that would give rise to an
obligation, or (b) an entity’s contribution to the fund would
be increased during the remainder of the contract period to
make up a shortfall in the funds necessary to maintain the
negotiated level of benefit coverage (a “maintenance of benefits” clause), the provisions of FASB ASC 450?
[FASB ASC 715-80-50-2]
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N/A
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Yes
G.

No

N/A

Stock Compensation (FASB ASC 718-10)
Disclosure
l 1.

l 2.

Has the entity properly disclosed, if the entity has one or
more share-based payment arrangements, information that
enables users of the financial statements to understand (Note:
This information is not required for interim disclosure.)
a.

the nature and terms of such arrangements that existed
during the period and the potential effects of those arrangements on shareholders?

b.

the effect of compensation cost arising from sharebased payment arrangements on the income statement?

c.

the method of estimating the fair value of the goods or
services received, or the fair value of the equity instruments granted (or offered to grant), during the period?

d.

the cash flow effects resulting from share-based payment arrangements?
[FASB ASC 718-10-50-1]

Has the entity properly disclosed the following, at a minimum, with regards to stock-based compensation: (Note: In
some circumstances, an entity may need to disclose information beyond the following to achieve the disclosure objectives.)
a.

A description of the share-based payment arrangement(s), including the general terms of awards under
the arrangement(s), such as
i.

the requisite service period(s) and any other substantive conditions (including those related to
vesting)?

ii.

the maximum contractual term of equity (or liability) share options or similar instruments?

iii.

the number of shares authorized for awards of
equity share options or other equity instruments?

b.

The method it uses for measuring compensation cost
from share-based payment arrangements with employees?

c.

For the most recent year for which an income statement
is provided, both of the following:
i.

The number and weighted-average exercise
prices (or conversion ratios) for (1) shares outstanding at the beginning of the year, (2) shares
outstanding at the end of the year, (3) shares exercisable or convertible at the end of the year,
and (4) those during the year that were granted,
exercised or converted, forfeited or expired?
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Yes
ii.

d.

e.

f.
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The number and weighted-average grant-date
fair value (or calculated value for a nonpublic entity that uses that method or intrinsic value for
awards measured pursuant to FASB ASC 718-1030-21) of equity instruments not specified in item
(c)(i), for those (1) nonvested at the beginning of
the year, (2) nonvested at the end of the year, and
(3) those during the year that were granted,
vested or forfeited?

For each year for which an income statement is provided
i.

the weighted average grant-date fair values (or
calculated value for a nonpublic entity that uses
that method or intrinsic value for awards measured at that value pursuant to paragraphs 21–22
of FASB ASC 718-10-30) of equity options or
other equity instruments granted during the
year?

ii.

value of shares vested during the year?

For fully vested share options (or share units) and share
options expected to vest at the date of the latest statement of financial position
i.

the number, weighted-average exercise price (or
conversion ratio), aggregate intrinsic value (except for nonpublic entities), and weighted-average remaining contractual term of options (or
share units) outstanding?

ii.

the number, weighted-average exercise price (or
conversion ratio), aggregate intrinsic value (except for nonpublic entities), and weighted-average remaining contractual term of options (or
share units) currently exercisable (or convertible)?

For each year for which an income statement is presented, both of the following (an entity that uses the
intrinsic value method pursuant to paragraphs 21–22 of
FASB ASC 718-10-30 is not required to disclose the following information for awards accounted for under
that method):
i.

A description of the method used during the year
to estimate the fair value (or calculated value) of
awards under share-based payment arrangements?

ii.

A description of the significant assumptions used
during the year to estimate the fair value (or calculated value) of share-based compensation
awards, including (if applicable)

No

N/A
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Yes
(1)

expected term of share options and similar
instruments, including a discussion of the
method used to incorporate the contractual
term of the instruments and employees’ expected exercise and postvesting employment termination behavior into the fair
value (or calculated value) of the instrument?

(2)

expected volatility of the entity’s shares
and the method used to estimate it? (An
entity that uses a method that employs different volatilities during the contractual
term should disclose the range of expected
volatilities used and the weighted-average
expected volatility. A nonpublic entity that
uses the calculated value method should
disclose the reasons why it is not practicable for it to estimate the expected volatility
of its share price, the appropriate industry
sector index that it has selected, the reasons
for selecting that particular index, and how
it has calculated historical volatility using
that index.)

(3)

expected dividends? (An entity that uses a
method that employs different dividend
rates during the contractual term should
disclose the range of expected dividends
used and the weighted-average expected
dividends.)

(4)

risk-free rate(s)? (An entity that uses a
method that employs different risk-free
rates should disclose the range of risk-free
rates used.)

(5)

discount for post-vesting restrictions and
the method for estimating it?

g.

Has the entity, if the entity grants equity or liability instruments under multiple share-based payment arrangements with employees, provided the information
specified in items (a)–(f) of this question separately for
different types of awards to the extent that the differences in the characteristics of the awards make separate
disclosure important to an understanding of the entity’s use of share-based compensation?

h.

For each year for which an income statement is presented, both of the following:
i.

No

N/A

Total compensation cost for share-based payment
arrangements (including recognized in income as
well as the total recognized tax benefit related
thereto and capitalized as part of the cost of an
asset)?
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Yes
ii.

No

N/A

A description of the significant modifications, including the terms of the modifications, the number of employees affected, and the total incremental compensation cost resulting from the
modifications?

i.

As of the latest balance sheet date presented, the total
compensation cost related to nonvested awards not yet
recognized and the weighted-average period over
which it is expected to be recognized?

j.

If not separately disclosed elsewhere, the amount of
cash received from exercise of share options and similar instruments granted under share-based payment arrangements and the tax benefit realized from stock options exercised during the annual period?

k.

If not separately disclosed elsewhere, the amount of
cash used to settle equity instruments granted under
share-based payment arrangements?

l.

Description of the entity’s policy, if any, for issuing
shares upon share option exercise (or share unit conversion), including the source of those shares (that is,
new shares or treasury shares). If as a result of its policy, an entity expects to repurchase shares in the following annual period, the entity should disclose an estimate of the amount (or a range, if more appropriate)
of shares to be repurchased during that period?
[FASB ASC 718-10-50-2]
Additional Disclosure Information

In addition to the information required by FASB ASC 718-10-50, the entity may disclose supplemental information that it believes would be useful to investors and creditors, such as a range of values calculated on
the basis of different assumptions, provided that the supplemental information is reasonable and does not
lessen the prominence and credibility of the information required by FASB ASC 718-10-50. The alternative
assumptions should be described to enable users of the financial statements to understand the basis for the
supplemental information.
[FASB ASC 718-10-50-4]
H.

Employee Stock Ownership Plans (FASB ASC 718-40)
Presentation
Earnings Per Share
l 1.
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Has the entity properly presented dividends on preferred
stock held by an employee stock ownership plan as a deduction from net income net of any applicable tax benefit when
computing both basic and diluted EPS (if that preferred stock
is considered outstanding)?
[FASB ASC 718-40-45-1]
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Yes

No

N/A

Issuance of Shares or the Sale of Shares to an Employee Stock Ownership Plan
l 2.

Has the entity properly presented, as a separate balance sheet
item, the issuance of shares or the sale of treasury shares to
an employee stock ownership plan when the issuance or sale
occurred and presented a corresponding charge to unearned
employee stock ownership plan shares?
[FASB ASC 718-40-45-2]

Disclosure
l 3.

Has an entity that sponsors an employee stock ownership
plan properly disclosed the following information about the
plan:
a.

A description of the plan, the basis for determining
contributions, including the employee groups covered,
and the nature and effect of significant matters affecting comparability of information for all periods presented? (Note: For leveraged employee stock ownership plans and pension reversion employee stock
ownership plans, the description should include the basis for releasing shares and how dividends on allocated
and unallocated shares are used.)

b.

A description of the accounting policies followed for
employee stock ownership plan transactions, including
the method of measuring compensation, the classification of dividends on employee stock ownership plan
shares, and the treatment of employee stock ownership
plan shares for EPS computations? (Note: If the entity
has both old employee stock ownership plan shares for
which it does not adopt the guidance in FASB ASC 71840 and new employee stock ownership plan shares for
which the guidance in FASB ASC 718-40 is required,
the accounting policies for both blocks of shares shall
be described.)

c.

The amount of compensation cost recognized during
the period?

d.

The number of allocated shares, committed-to-be-released shares, and suspense shares held by the employee stock ownership plan at the balance sheet date?
(Note: If the disclosure should be made separately for
shares accounted for under FASB ASC 718-40 and for
grandfathered employee stock ownership plan shares.)

e.

The fair value of unearned employee stock ownership
plan shares at the balance sheet date for shares accounted for under FASB ASC 718-40? (Note: This disclosure does not apply to old employee stock ownership plan shares that are not accounted for under FASB
ASC 718-40.)
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Yes

I.

f.

The existence and nature of any repurchase obligation,
including disclosure of the fair value of the shares allocated as of the balance sheet date which are subject to
the repurchase obligation?

g.

The amount and treatment in the EPS computation of
the tax benefit related to dividends paid to any employee stock ownership plan, if material?
[FASB ASC 718-40-50-1]

Insurance Costs (FASB ASC 720-20)
Presentation
Stop-Loss Insurance Contracts

.l 1.

Has the entity properly included stop-loss insurance premiums in health care costs, net of recoveries?
[FASB ASC 954-720-45-1]

Disclosure
Retrospectively Rated Premiums
.l 2.

With regards to retrospectively rated premiums, has the entity disclosed the following:
a.

That it is insured under a retrospectively rated policy?

b.

That premiums are accrued based on the ultimate cost
of the experience to date of a group of entities?
[FASB ASC 954-720-50-1]

Captive Insurance Entities
.l 3.

With regards to medical malpractice claims insured by captive insurance entities, has the entity disclosed the following:
a.

That it is insured under a retrospectively rated policy
of a multiprovider captive insurance entity?

b.

That premiums are accrued based on the captive insurance entity’s experience to date?
[FASB ASC 954-720-50-2]

Multiprovider Captive Insurance Entities
.l 4.
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For entities that are insured by a multiprovider captive insurance entity, have the following been disclosed:
a.

That it is ensured by such an entity?

b.

Its ownership percentage in the captive entity?

c.

The method for accounting for its investment in, and
the operations of, the captive entity?
[FASB ASC 954-720-50-3]

No

N/A
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Yes

No

N/A

Claims-Made Contracts
.l 5.

Has the entity properly disclosed, when it changes from occurrence-based insurance claims-made insurance or elects to
significantly reduce or eliminate its insurance coverage, the
items required by paragraphs 3–6 of FASB ASC 450-20-50,25 if
it is at least reasonably possible that a loss has been incurred?
[FASB ASC 720-20-50-1]

Other
l 6.

For publicly held entities and entities with public accountability, such as governments, are circumstances disclosed in
which
a.

b.

.l 7.

they are exposed to risks of future material loss related
to
i.

torts?

ii.

theft of, damage to, expropriation of, or destruction of assets?

iii.

business interruption?

iv.

errors or omissions?

v.

injuries to employees?

vi.

acts of God?

those risks have not been transferred to unrelated third
parties through insurance? (Encouraged, but not required.)

In considering those matters to be disclosed that relate to certain uninsured risks of future material loss as described in
FASB ASC 720-20, has the entity considered the following:
a.

The actual and potential effects of losses from such
risks on the entity’s historical or planned operations,
including exposure to losses from claims, curtailment
of research and development or manufacturing, or contraction or cessation of other activities, such as discontinuance of a product line?

b.

Comparison of current insurance coverage by major
categories of risk to coverage in prior periods, without
necessarily quantifying such coverage or change in coverage?

c.

Recent claims experience?

d.

A description of the reporting entity’s risk management
programs? (Encouraged, but not required.)

Other Expenses
. 8.

Has the not-for-profit disclosed the following other expenses:
a.

25

Total fund-raising expenses?

See questions 3–6 of the “III.F. Loss Contingencies (FASB ASC 450-20)” section.
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Yes

. 9.

J.

b.

Total program expenses and information about why total program expenses disclosed in the notes do not articulate with the statement of activities? (Pursuant to
FASB ASC 958-720-45-5, this disclosure is only required
if the components of total program expenses are not evident from the details provided on the face of the statement of activities.)

c.

The amount of income tax expense and the nature of
the activities that generated the taxes? (Only required if
the not-for-profit incurs income tax expense.)
[FASB ASC 958-720-50-1]

Has the not-for-profit disclosed the following related to fundraising:
a.

The types of activities for which joint costs have been
incurred?

b.

A statement that such costs have been allocated?

c.

The total amount allocated during the period and the
portion allocated to each functional expense category?
[FASB ASC 958-720-50-2]

Advertising Costs (FASB ASC 720-35)
Disclosure

.l 1.

K.

Has the entity properly disclosed the following related to advertising costs:
a.

The accounting policy for reporting whether such costs
are expensed as incurred or the first time the advertising takes place?

b.

The total amount charged to advertising expense for
each income statement presented?
[FASB ASC 720-35-50-1]

Research and Development Expenses (FASB ASC 730-10)
Disclosure

.l 1.

L.

Has the entity properly disclosed the total research and development costs charged to expense in each period for which
an income statement is presented? (Note: This disclosure
should include research and development costs incurred for
a computer software product to be sold, leased, or otherwise
marketed.)
[FASB ASC 730-10-50-1]

Research and Development Arrangements (FASB ASC 730-20)
Disclosure

.l 1.
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Has the entity properly disclosed the following, for research
and development arrangements to perform research and development for others which are accounted for under FASB
ASC 730-20:

No

N/A
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Yes

.l 2.

M.

a.

The terms of significant agreements under the research
and development arrangement (including royalty arrangements, purchase provisions, license agreements,
and commitments to provide additional funding) as of
the date of each balance sheet presented?

b.

The amount of compensation earned and costs incurred
under such contracts for each period for which an income statement is presented?
[FASB ASC 730-20-50-1]

No

N/A

Has the entity properly disclosed each research and development arrangement separately, if such separate disclosure is
necessary to understand the effects on the financial statements? (Note: Aggregation of similar arrangements, by type,
may be appropriate.)
[FASB ASC 730-20-50-3]

Income Taxes (FASB ASC 740-10)
Presentation
Deferred Tax Assets
l 1.

Has the entity properly presented separately, in a classified
statement of financial position, the deferred tax assets and liabilities into a current amount and a noncurrent amount?
(Note: Deferred tax assets and liabilities should be classified
as current or noncurrent based on the classification of the related asset or liability for financial reporting.)
[FASB ASC 740-10-45-4]

l 2.

Has the entity properly allocated the valuation allowance for
a particular tax jurisdiction, properly allocated between current and noncurrent deferred tax assets for that tax jurisdiction on a pro rata basis?
[FASB ASC 740-10-45-5]

l 3.

Has the entity properly presented, for a particular tax-paying
component of the entity and within a particular tax jurisdiction, all current deferred tax assets and liabilities offset and
as a single amount and all noncurrent tax assets and liabilities
in the same manner? (Note: The entity should not offset deferred tax liabilities and assets attributable to different taxpaying components of the entity or to different tax jurisdictions.)
[FASB ASC 740-10-45-6]

Deferred Tax Accounts Not Related to an Asset or Liability
l 4.

Has the entity properly presented and classified deferred tax
assets not related to an asset or liability for financial reporting
(see paragraphs 25–26 of FASB ASC 740-10-25), including
those related to carryforwards, according to the expected reversal date of the temporary difference?
[FASB ASC 740-10-45-9]
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Yes

No

N/A

Tax Accounts, Other Than Deferred—Unrecognized Tax Benefits
l 5.

If the entity presents a classified statement of financial position, has the entity properly classified a liability associated
with an unrecognized tax benefit as a current liability (or the
amount of a net operating loss carryforward or amount refundable is reduced) to the extent the entity anticipates payment (or receipt) of cash within one year or the operating cycle, if longer? (Note: The liability for unrecognized tax
benefits (or reduction in amounts refundable) should not
been combined with deferred tax liabilities or assets.)
[FASB ASC 740-10-45-11]

l 6.

Has the entity properly not presented and classified a liability
recognized for an unrecognized tax benefit as a deferred tax
liability, unless it arose from a taxable temporary difference?
[FASB ASC 740-10-45-12]

l 7.

Has the entity properly not presented, as offset, cash or other
assets against a tax liability or other amount owing to governmental bodies, except as noted in FASB ASC 210-20-45-6?26
[FASB ASC 740-10-45-13]

Income Statement Presentation of Certain Measurement Changes to
Income Tax Accounts—Changes in Tax Laws or Rates
l 8.

Has the entity properly presented changes to deferred tax accounts, as required by FASB ASC 740-10-35-4, for the effect of
a change in tax laws or rates in income from continuing operations for the period that includes the enactment date?
[FASB ASC 740-10-45-15]

Income Statement Presentation of Certain Measurement Changes to
Income Tax Accounts—Changes in the Tax Status of an Entity
l 9.

Has the entity properly presented changes as a result of recognition or derecognition of a deferred tax account, as required by FASB ASC 740-10-25-32 and FASB ASC 740-10-406, due to a change in tax status, included in income from
continuing operations?
[FASB ASC 740-10-45-19]

Disclosure
Additional Disclosure Information
FASB ASC 740-10-50 contains disclosures for both nonpublic and public companies. See the following “Public Entity Disclosures” section of this checklist for required disclosures specific to public entities.

26
The offset of cash or other assets against the tax liability or other amounts owing to governmental bodies should not be acceptable
except in the following circumstance.

Most securities issued by governments are not by their terms designed specifically for the payment of taxes and, accordingly, should
not be deducted from taxes payable on the balance sheet. The only exception to this general principle occurs when it is clear that a
purchase of securities is in substance an advance payment of taxes that will be payable in the relatively near future, so that in the special
circumstances the purchase is tantamount to the prepayment of taxes.
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Yes

No

N/A

General
l 10.

Are disclosures appropriate regarding the tax-exempt status
and any other significant tax matters?
[FASB ASC 954-740-50-1]

Statement of Financial Position Related Disclosures
l 11.

Has the entity properly disclosed the components of the net
deferred tax asset or liability recognized in the statement of
financial position, as follows:
a.

The total of all deferred tax liabilities (measured as described in FASB ASC 740-10-30-5[b])?

b.

The total of all deferred tax assets (measured as described in [c] and [d] of FASB ASC 740-10-30-5)?

c.

The total valuation allowance recognized for deferred
tax assets (measured as described in FASB ASC 740-1030-5[e])?
[FASB ASC 740-10-50-2]

l 12.

Has the entity properly disclosed the net change in the total
valuation allowance during the year?
[FASB ASC 740-10-50-2]

l 13.

Has the entity properly disclosed the following:

l 14.

a.

The amounts and expiration dates of operating loss and
tax credit carryforwards for tax purposes?

b.

Any portion of the valuation allowance for deferred tax
assets for which subsequently recognized tax benefits
will be credited directly to contributed capital?
[FASB ASC 740-10-50-3]

Has the entity properly disclosed the change in the entity’s
tax status for year 2 and the effects of that change, if material,
if a change in the entity’s tax status becomes effective after
year-end in year 2 but before the financial statements for year
1 are issued or are available to be issued?
[FASB ASC 740-10-50-4]

Statement of Financial Position Related Disclosures—Nonpublic
Entities
.l 15.

Has the entity properly disclosed the types of significant temporary differences and carryforwards? (Note: The entity may
omit disclosures of the tax effects of each type.)
[FASB ASC 740-10-50-8]

Income Statement Related Disclosures
l 16.

Has the entity properly disclosed the following significant
components of income tax expense attributable to continuing
operations for each year presented: (Note: The components
that follow are not exhaustive.)
a.

Current tax expense (or benefit)?

b.

Deferred tax expense (or benefit) (exclusive of the effects of other components in this list)?
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Yes

l 17.

c.

Investment tax credits?

d.

Government grants (to the extent recognized as a reduction of income tax expense)?

e.

The benefits of operating loss carryforwards?

f.

Tax expense that results from allocating certain tax benefits directly to contributed capital?

g.

Adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax
status of the reporting entity?

h.

Adjustments of the beginning-of-the-year balance of a
valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future
years (for example, any acquisition-date income tax
benefits or expenses recognized from changes in the acquirer’s valuation allowance for its previously existing
deferred tax assets as a result of a business combination
[see FASB ASC 805-740-30-3])?
[FASB ASC 740-10-50-9]

Has the entity properly disclosed the amount of income tax
expense or benefit allocated to continuing operations and the
amounts separately allocated to other items (in accordance
with the intraperiod tax allocation provisions of paragraphs
2–14 of FASB ASC 740-20-45 and FASB ASC 852-740-45-3) for
each year for which those items are presented?
[FASB ASC 740-10-50-10]

Income Tax Expense Compared to Statutory Expectations—Nonpublic Entities
l 18.

Has the entity properly disclosed the nature of significant
items required to reconcile the reported amount of income tax
expense attributable to continuing operations for the year to
the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income
from continuing operations? (Note: A numerical reconciliation is not required.)
[FASB ASC 740-10-50-13]

Income Tax Expense Compared to Statutory Expectations—All Entities
l 19.

If not otherwise evident, has the entity properly disclosed the
nature and effect of any other significant matter affecting
comparability of information for all periods presented?
[FASB ASC 740-10-50-14]

Unrecognized Tax Benefit Related Disclosures
l 20.
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each annual reporting period presented:

No
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Yes
a.

The total amounts of interest and penalties recognized
in the statement of operations and the total amounts of
interest and penalties recognized in the statement of financial position?

b.

For positions for which it is reasonably possible that the
total amounts of unrecognized tax benefits will significantly increase or decrease within 12 months of the reporting date,

c.

i.

the nature of the uncertainty?

ii.

the nature of the event that could occur in the
next 12 months that would cause the change?

iii.

an estimate of the range of the reasonably possible change or a statement that an estimate of the
range cannot be made?

No

N/A

A description of tax years that remain subject to examination by major tax jurisdictions?
[FASB ASC 740-10-50-15]

Entities With Separately Issued Financial Statements That Are
Members of a Consolidated Tax Return
l 21.

If the entity is a member of a group that files a consolidated
tax return, has the entity properly disclosed the following
items in its separately issued financial statements:
a.

The aggregate amount of current and deferred tax expense for each income statement presented and the
amount of any tax-related balances due to or from affiliates as of the date of each balance sheet presented?

b.

The principal provisions of the method by which the
consolidated amount of current and deferred tax expense is allocated to members of the group and the nature and effect of any changes in that method (and in
determining related balances to or from affiliates) during the years for which the disclosures in item (a) are
presented?
[FASB ASC 740-10-50-17]

Policy-Related Disclosures—Interest and Penalty Recognition
Policies
l 22.

Has the entity properly disclosed its policy on classification
of interest and penalties in accordance with FASB ASC 74010-45-25 in the footnotes to the financial statements? (Note:
Interest may be classified as either income taxes or interest
expense and penalties may be classified as income taxes or
another expense. These determinations are based on the policy election of the entity.)
[FASB ASC 740-10-50-19]
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Yes
Policy-Related Disclosures—Investment Tax Credit Recognition
Policy
l 23.

Has the entity properly disclosed its policy on accounting for
investment tax credits and amounts involved, if material?
(Note: FASB ASC 740-10-25-46 identifies the deferral method
and the flow-through method as acceptable methods of accounting for investment tax credits.)
[FASB ASC 740-10-50-20]

Public Entity Disclosures
Statement of Financial Position Related to Disclosures
l 24.

Has the public entity properly disclosed the approximate tax
effect of each type of temporary difference and carryforward
that gives rise to a significant portion of deferred tax liabilities and deferred tax assets (before allocation of valuation allowances)?
[FASB ASC 740-10-50-6]

Income Tax Expense Compared to Statutory Expectations
l 25.

Has the public entity properly disclosed a reconciliation using percentages or dollar amounts of the reported amount of
income tax expense attributable to continuing operations for
the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations? (Note: The statutory
tax rates should be the regular tax rates if there are alternative
tax systems. Further the estimated amount and nature of each
significant reconciling item should be disclosed.)
[FASB ASC 740-10-50-12]

Unrecognized Tax Benefit Related Disclosures
l 26.

Has the entity properly disclosed the following at the end of
each annual reporting period presented:
a.
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A tabular reconciliation of the total amount of unrecognized tax benefits at the beginning and the end of the
period that includes, at a minimum, the following:
i.

The gross amounts of the increases and decreases
in unrecognized tax benefits as a result of tax positions taken during the prior period?

ii.

The gross amounts of increases and decreases in
unrecognized tax benefits as a result of tax positions taken during the current period?

iii.

The amounts of decreases in the unrecognized
tax benefits relating to settlements with taxing
authorities?

iv.

Reductions to unrecognized tax benefits as a result of a lapse of the applicable statute of limitations?

No

N/A
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Yes
b.

No

N/A

The total amount of unrecognized tax benefits that, if
recognized, would affect the effective tax rate?
[FASB ASC 740-10-50-15A]

Public Entities Not Subject to Income Tax
l 27.

N.

Has the public entity properly disclosed the fact, if applicable,
that it is not subject to income taxes because its income is
taxed directly to its owners, as well as the net difference between the tax bases and the reported amounts of the entity’s
assets and liabilities?
[FASB ASC 740-10-50-16]

Intraperiod Tax Allocations (FASB ASC 740-20)
Presentation
l 1.

O.

Has the entity properly presented the income tax expense or
benefit for the year, allocated among the following:
a.

Continuing operations?

b.

Discontinued operations?

c.

Extraordinary items?

d.

OCI?

e.

Items charged or credited directly to shareholders’ equity?
[FASB ASC 740-20-45-2]

Income Taxes—Other Considerations or Special Areas (FASB ASC
740-30)
Disclosure
Undistributed Earnings of Subsidiaries and Corporate Joint Ventures
l 1.

Has the entity properly disclosed the following whenever a
deferred tax liability is not recognized because of the exceptions to comprehensive recognition of deferred taxes related
to subsidiaries and corporate joint ventures:
a.

A description of the types of temporary differences for
which a deferred tax liability has not been recognized
and the types of events that would cause those temporary differences to become taxable?

b.

The cumulative amount of each type of temporary difference?
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Yes
c.

The amount of the unrecognized deferred tax liability
for temporary differences related to investments in foreign subsidiaries and foreign corporate joint ventures
that are essentially permanent in duration if determination of that liability is practicable or a statement that
determination is not practicable? (Note: Whereas FASB
ASC 740-30-25-14 prohibits recognition of a tax benefit
for tax deductions or favorable tax rates attributable to
future dividends of undistributed earnings for which a
deferred tax liability has not been recognized, favorable
tax treatment would be reflected in measuring that unrecognized deferred tax liability for disclosure purposes.)

d.

The amount of the deferred tax liability for temporary
differences other than those in question 1(c) (that is, undistributed domestic earnings) that is not recognized in
accordance with the provisions of FASB ASC 740-30-2518?
[FASB ASC 740-30-50-2]

No

N/A

Income Taxes—Interim Reporting (FASB ASC 740-270)

P.

Disclosure
l 1.

Has the entity properly disclosed the reasons for significant
variations in the customary relationship between income tax
expense and pretax accounting income in the interim period
financial statements if they are not otherwise apparent from
the financial statements or from the nature of the entity’s
business?
[FASB ASC 740-270-50-1]

VII. Broad Transactions
A.

Business Combinations (FASB ASC 805-10)27
Mergers and Acquisitions
Note: FASB ASC 958-805 provides standards for the information a
not-for-profit entity provides in its financial reports about a combination with one or more other not-for-profit entities, businesses, or
nonprofit activities. It requires the not-for-profit entity to determine
whether the combination is a merger or an acquisition and to apply
(continued)

27
In January 2010, FASB issued ASU No. 2010-02, Consolidation (Topic 810): Accounting and Reporting for Decreases in Ownership of a
Subsidiary—a Scope Clarification. The amendments in this ASU clarify that the scope of the decrease in ownership provisions of FASB ASC
810-10 and related guidance applies to all of the following:

●

A subsidiary or group of assets that is a business or nonprofit activity

●

A subsidiary that is a business or nonprofit activity that is transferred to an equity method investee or joint venture

●

An exchange of a group of assets that constitutes a business or nonprofit activity for a noncontrolling interest in an entity
(including an equity method investee or joint venture)

The amendments in the ASU also clarify that the decrease in ownership guidance in FASB ASC 810-10 does not apply to: (a) sales of in
substance real estate and (b) conveyances of oil and gas mineral rights, even if these transfers involve businesses.
(continued)
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Yes

No

N/A

the carryover method if the combination is a merger or the acquisition method if the combination is an acquisition. It also requires certain information to be disclosed to enable users of financial statements to evaluate the nature and financial effects of a merger or an
acquisition to make it fully applicable by not-for-profit entities. FASB
ASC 958-805-65 provides effective date and transition information. In
summary, FASB ASC 958-805 is effective as follows:
●

Mergers for which the merger date is on or after the beginning of an initial reporting period beginning on or after December 15, 2009.

●

Acquisitions for which the acquisition date is on or after the
beginning of the first annual reporting period beginning on
or after December 15, 2009.

●

It may not be applied to mergers or acquisitions before those
dates.

For mergers and acquisitions occurring prior to the effective date of
FASB ASC 958-805, not-for-profit entities should continue to follow
the guidance in paragraphs 1.15–.18 of Audit and Accounting Guide
Not-for-Profit Entities and in Accounting Principles Bulletin No. 16,
Business Combinations, as amended by pronouncements prior to the
issuance of FASB Statement No. 141(R), Business Combinations, and
complete questions 1–2.
Questions 3–11 should be completed for mergers occurring after the
effective date of FASB ASC 958-805.
Questions 12–37 should be completed for acquisitions occurring after
the effective date of FASB ASC 958-805.
. 1.

If a combination occurred during the period and met the
specified conditions for a pooling-of-interests, do the statements and notes include the required disclosures? (Note: notfor-profit entities are, under certain circumstances, permitted
to use the pooling-of-interests method, even though they generally do not issue common stock.)
[AAG-NPO 1.15–.20; APB 16 par. 45–48 and 63–65]

The amendments in ASU No. 2010-02 expand the disclosure requirements about deconsolidation of a subsidiary or derecognition of
a group of assets to include all of the the following:
●

The valuation techniques used to measure the fair value of any retained investment

●

The nature of any continuing involvement with the subsidiary or entity acquiring the group of assets

●

Whether the transaction that resulted in the deconsolidation or derecognition was with a related party or whether the former
subsidiary or entity acquiring the assets will become a related party after the transaction

The amendments are effective beginning in the period that an entity adopts FASB Statement No. 160, Noncontrolling Interests in Consolidated Financial Statements—an amendment of ARB 51 (now included in FASB ASC 810-10). If an entity has previously adopted FASB
Statement No. 160, the amendments are effective beginning in the first interim or annual reporting period ending on or after December
15, 2009 (that is, January 1, 2009, for entities with calendar year-ends). The amendments in ASU 2010-02 should be applied retrospectively
to the first period that an entity adopts FASB Statement 160.
This checklist has been updated to include the presentation and disclosure requirements of ASU No. 2010-02.
Readers can refer to the full text of the ASU on the FASB website at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition and open effective date information discussed in FASB ASC 81010-65-3.
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Yes
. 2.

If a business combination does not meet the specified conditions for a pooling-of-interests
a.

is the combination accounted for by the purchase
method?
[APB 16 par. 66–88 and 90–94; SFAS 38; FIN 4 concerns
research and development activities of an acquired subsidiary]

b.

do the statements and notes include the required disclosures?
[APB 16 par. 78 and 95–96]

Mergers
. 3.

If the new entity formed by the merger presents a statement
of financial position as of the beginning of the initial reporting period, does that statement present the combined assets,
liabilities, and net assets of the merging entities as of the
merger date?
[FASB ASC 958-805-45-1]

. 4.

Are assets and liabilities as of the beginning of the initial reporting period measured at the amounts reported in the financial statements prepared in accordance with GAAP of the
merging entities as of that date?
[FASB ASC 958-805-30-1]

. 5.

Are amounts as of the beginning of the initial reporting period adjusted as necessary in accordance with paragraphs 2–4
of FASB ASC 958-805-30?
[FASB ASC 958-805-30-1]

. 6.

Does the statement of activities for the new entity include in
the opening amounts (the reported amounts as of the beginning of the period), the combined amounts of the merging
entities’ net assets, in total and by classes of net assets, as of
the merger date, and are any adjustments in accordance with
FASB ASC 958-805-25-7 and paragraphs 2 and 4 of FASB ASC
958-805-30 reflected in the opening amounts?
[FASB ASC 958-805-45-2]

. 7.

Does the statement of activities reflect only activity from the
merger date to the end of the reporting period?
[FASB ASC 958-805-45-2]

. 8.

Does the statement of cash flows for the new entity include
in the reported amounts as of the beginning of the period (the
opening amounts) of cash and cash equivalents at the beginning of the period as of the merger date and are any adjustments in accordance with FASB ASC 958-805-25-7 and paragraphs 2 and 4 of FASB ASC 958-805-30 reflected in the
opening amounts?
[FASB ASC 958-805-45-2]

. 9.

Does the statement of cash flows reflect only activity from the
merger date to the end of the reporting period?
[FASB ASC 958-805-45-2]
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Yes
. 10.

. 11.

No

N/A

Does the new entity disclose the following information for
the merger that resulted in its formation:
a.

The name and a description of each merging entity?

b.

The merger date?

c.

The primary reasons for the merger?

d.

The nature and amount of any significant adjustments
made to conform the individual accounting policies of
the merging entities?

e.

The nature and amount of any significant adjustments
made to eliminate intraentity balances?
[FASB ASC 958-805-50-2]

Does the new entity disclose the following information about
each of the merging entities:
a.

The amounts recognized as of the merger date for each
major class of assets and liabilities and each class of net
assets?

b.

The nature and amounts, if applicable, of any significant assets (for example, conditional promises receivable or collections) or liabilities (for example, conditional
promises payable) that GAAP does not require to be
recognized?
[FASB ASC 958-805-50-2]

. 12.

If the disclosures made in questions 3–11 are insufficient to
enable users of the financial statements to evaluate the nature
and financial effect of the merger that resulted in the formation of the new entity, did the entity disclose whatever additional information is necessary to meet that objective?
[FASB ASC 958-805-50-6]

. 13.

For public entities: If the new entity is a public entity as defined in FASB ASC 958-805-20, have the additional disclosures in paragraphs 3–5 of FASB ASC 958-805-50 been included with the financial statements?
[FASB ASC 958-805-50-6]

Acquisitions
. 14.

If the operations of the acquiree as part of the combined entity are expected to be predominantly supported by contributions and returns on investments, does the not-for-profit
entity acquirer report a separate charge in its statement of activities as of the acquisition date, measured in accordance
with FASB ASC 958-805-30-6 (rather than goodwill)?
[FASB ASC 958-805-25-29; FASB ASC 958-805-45-4]

. 15.

Does the not-for-profit entity recognize an inherent contribution received, measured in accordance with FASB ASC 958805-30-8, as a separate credit in its statement of activities as
of the acquisition date?
a.

Restrictions imposed on the net assets of the acquiree
by a donor before the acquisition?
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Yes
b.

Restrictions imposed by the donor of the business or
nonprofit activity acquired, if any?

c.

Report the contribution recognized as restricted support if restricted by the donor, even if the restrictions
are met in the same reporting period in which the acquisition occurs? (That is, the acquirer shall not apply
the reporting exception in FASB ASC 958-605-45-4 to
restricted net assets acquired in an acquisition.)
[FASB ASC 958-805-45-6]

. 16.

Do the financial statements of the acquirer (the combined entity) report the acquisition as activity of the period in which
the acquisition occurs?
[FASB ASC 958-805-45-3]

. 17.

If, by transferring consideration in the acquisition, the acquirer satisfied a donor-imposed restriction on its net assets,
is the expiration of those restrictions either reported separately in the statement of activities or aggregated and reported with other similar expirations of donor-imposed restrictions during the period in which the acquisition occurs?
[FASB ASC 958-805-45-9]

. 18.

If other changes to the acquirer’s net asset classifications occur during the period as a result of the acquisition, are those
other changes reported separately from both any other reclassifications or any expiration of those restrictions during the
period in which the acquisition occurs? (For example, an acquirer that transfers as consideration its unrestricted assets
and acquires assets from the acquiree that have permanent or
temporary donor restrictions shall recognize a reclassification
in its statement of activities.)
[FASB ASC 958-805-45-10]

. 19.

Is the entire amount of any net cash flow resulting from the
acquisition (cash paid as consideration, if any, less acquired
cash of the acquiree) reported as an investing activity in the
statement of cash flows?
[FASB ASC 958-805-45-11]

. 20.

Are noncash contributions received and any other noncash
amounts received or transferred related to the acquisition reported as noncash activities in accordance with FASB ASC
230-10-50-3?
[FASB ASC 958-805-50-15]

. 21.

During the measurement period, are adjustments to the provisional amounts (amounts that were initially recognized for
an identifiable asset or liability) recognized either:
a.
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Yes
b.

.l 22.

. 23.

No

N/A

by a direct credit (charge) to the statement of activities
if goodwill was not recognized as an asset? (Per FASB
ASC 958-805-25-29, goodwill is not recognized as an asset if the operations of the acquiree as part of the combined entity are expected to be predominantly supported by contributions and returns on investments.)
[FASB ASC 805-10-25-16]

Do the financial statements disclose the following information for each acquisition that occurs during the reporting period:
a.

The name and a description of the acquiree?

b.

The acquisition date?

c.

The percentage of ownership interests, such as voting
equity instruments, acquired, if applicable?

d.

The primary reasons for the acquisition and a description of how the acquirer obtained control of the acquiree?
[FASB ASC 805-10-50-2]

Do the financial statements disclose the following information for each acquisition that occurs during the reporting period:
a.

A qualitative description of the factors, such as expected synergies from combining operations of the acquiree and the acquirer, intangible assets that do not
qualify for separate recognition, or other factors, such
as the nonrecognition of collections, that make up either the goodwill recognized or the charge recognized
in accordance with FASB ASC 958-805-25-29?

b.

The acquisition-date fair value of the total consideration transferred (or if no consideration was transferred,
that fact?

c.

The acquisition-date fair value of each major class of
consideration?

d.

The amounts recognized as of the acquisition date for
each major class of assets acquired and liabilities assumed?

e.

The total amount of goodwill that is expected to be deductible for tax purposes?

f.

The amount of collection items acquired that are recognized in the statement of activities as a decrease in
the acquirer’s net assets in accordance with FASB ASC
958-805-25-23?

g.

The undiscounted amount of conditional promises to
give acquired or assumed and a description and the
amount of each group of promises with similar characteristics, such as amounts of promises conditioned on
establishing new programs, completing a new building,
or raising matching gifts by a specified date?
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Yes
h.

. 24.

.l 25.

.l 26.

.l 27.
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If the acquisition resulted in an inherent contribution
received, a description of the reasons that the transaction resulted in a contribution received?
[FASB ASC 958-805-50 par. 11–12]

Do the financial statements disclose the following information about contingent consideration arrangements and indemnification assets:
a.

The amount recognized as of the acquisition date?

b.

A description of the arrangement and the basis for determining the amount of the payment?

c.

An estimate of the range of outcomes (undiscounted)
or, if a range cannot be estimated, that fact and the reasons why a range cannot be estimated?

d.

If the maximum amount of the payment is unlimited,
the acquirer shall disclose that fact?
[FASB ASC 958-805-50-11]

Do the financial statements disclose the following information about acquired receivables? (Note: This requirement
does not apply if the disclosures required by FASB ASC 31030 are made.)
a.

The fair value of the receivables by major class of receivable?

b.

The gross contractual amounts receivable by major
class of receivable?

c.

The best estimate at the acquisition date of the contractual cash flows not expected to be collected by major
class of receivable?
[FASB ASC 805-20-50-1]

Does the note that describes the acquisition disclose the following information about assets and liabilities arising from
contingencies recognized at the acquisition date:
a.

The amounts recognized at the acquisition date and the
measurement basis applied (that is, at fair value or at
an amount recognized in accordance with FASB ASC
450)?

b.

The nature of the contingencies?
[FASB ASC 805-20-50-1]

If contingencies have not been recognized at the acquisition
date, are the disclosures required by FASB ASC 450, included
in the note that describes the acquisition? See section I.I,
"Contingencies and Commitments," in FSP section 14,200 of
Checklists and Illustrative Financial Statements for Not-for-Profit
Entities.
[FASB ASC 805-20-50-1]

No

N/A
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Yes
.l 28.

.l 29.

.l 30.

.l 31.

No

N/A

Do the financial statements disclose the following information about transactions that are recognized separately from
the acquisition of assets and assumptions of liabilities in the
acquisition (that is, a transaction entered into by or on behalf
of the acquirer or primarily for the benefit of the acquirer or
the combined entity, rather than primarily for the benefit of
the acquiree [or its former owners] before the combination, as
described in FASB ASC 805-10-25-20):
a.

A description of each transaction?

b.

How the acquirer accounted for each transaction?

c.

The amounts recognized for each transaction and the
line item in the financial statements in which each
amount is recognized?

d.

If the transaction is the effective settlement of a preexisting relationship, the method used to determine the
settlement amount?
[FASB ASC 805-10-50-2]

Does the disclosure required in question 28 include the following information about acquisition-related costs:
a.

The amount of acquisition-related costs?

b.

The amount recognized as an expense?

c.

The line item or items in the statement of activities in
which that expense is recognized?

d.

The amount of any debt issuance costs not recognized
as an expense and how they were recognized?
[FASB ASC 805-10-50-2]

If the acquirer holds less than 100 percent of the equity interests in the acquiree at the acquisition date, do the financial
statements disclose
a.

the fair value of the noncontrolling interest in the acquiree at the acquisition date?

b.

the valuation technique(s) and significant inputs used
to measure the fair value of the noncontrolling interest?
[FASB ASC 805-20-50-1]

For an acquisition achieved in stages
a.

is the gain or loss resulting from the acquirer remeasuring its previously held equity interest in the acquiree at
its acquisition date fair value reported in the statement
of activities?

b.

is the amount of the gain or loss and the line item in
the statement of activities in which that gain or loss is
recognized disclosed?

c.

is the acquisition date fair value of the equity interest
in the acquiree held by the acquirer immediately before
the acquisition date disclosed?
[FASB ASC 805-10-25-10; FASB ASC 805-10-50-2]
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Yes
.l 32.

For individually immaterial acquisitions occurring during the
reporting period that are material collectively, are the disclosures required by questions 23–31 made in the aggregate?
[FASB ASC 805-10-50-3]

.l 33.

If the disclosures made in questions 3–32 are insufficient to
enable users of the financial statements to evaluate the nature
and financial effect of an acquisition, did the entity disclose
whatever additional information is necessary to meet that objective?
[FASB ASC 805-10-50-7]

.l 34.

For public entities: If the acquirer is a public entity as defined
in FASB ASC 958-805-20, have the additional disclosures in
paragraphs 8–10 of FASB ASC 958-805-50 been included with
the financial statements?
[FASB ASC 958-805-50 par. 8–10]

.l 35.

If the initial accounting for an acquisition is incomplete for
particular assets, liabilities, noncontrolling interests, or items
of consideration and the amounts recognized in the financial
statements for the acquisition thus have been determined
only provisionally, are the following disclosures included in
the financial statements:

.l 36.
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a.

The reasons that the initial accounting is incomplete?

b.

The assets, liabilities, equity interests, or items of consideration for which the initial accounting is incomplete?

c.

The nature and amount of any measurement period adjustments recognized during the reporting period in accordance with paragraph 61 of FASB Statement No.
164, Not-for-Profit Entities: Mergers and Acquisitions—Including an amendment of FASB Statement No.
142?
[FASB ASC 805-10-50-6]

If an acquisition included contingent consideration, is the following information disclosed if the not-for-profit entity has
not yet collected, sold, or otherwise lost the right to a contingent consideration asset, or settled or otherwise extinguished
a contingent consideration liability:
a.

Any changes in the recognized amounts, including any
differences arising upon settlement?

b.

Any changes in the range of outcomes (undiscounted)
and the reasons for those changes?

c.

The disclosures required by paragraphs 1–3 of FASB
ASC 820-10-50?
[FASB ASC 958-805-50-16]

No

N/A
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Yes
.l 37.

No

N/A

If the disclosures made in questions 35–36 are insufficient to
enable users of the financial statements to evaluate the financial effects of adjustments recognized in the current reporting
period that relate to acquisitions that occurred in the current
or previous reporting periods, did the not-for-profit entity
disclose whatever additional information is necessary to meet
that objective?
[FASB ASC 805-10-50-7]

Disclosure
Business Combinations Occurring During a Current Reporting Period or After the Reporting Date but Before the Financial Statements
Are Issued
.l 38.

As the acquirer in a business combination, the entity must
properly disclose information that enables users of its financial statements to evaluate the nature and financial effect of a
business combination that occurred either in the current reporting period or after the reporting period but before the financial statements are issued or are available to be issued. To
meet these objectives, has the entity properly disclosed the
following:
a.

The name and a description of the acquiree?

b.

The acquisition date?

c.

The percentage of voting equity interests acquired?

d.

The primary reasons for the business combination and
a description of how the acquirer obtained control of
the acquiree?

e.

For transactions that are recognized separately from the
acquisition of assets and assumptions of liabilities in
the business combination (see FASB ASC 805-10-25-20),
all of the following:

f.

i.

A description of each transaction?

ii.

How the acquirer accounted for each transaction?

iii

The amounts recognized for each transaction and
the line item in the financial statements in which
each amount is recognized?

iv.

If the transaction is the effective settlement of a
preexisting relationship, the method used to determine the settlement amount?

For separately recognized transactions required in item
(e) all of the following:
i.

The amount of acquisition-related costs, the
amount recognized as an expense, and the line
item or items in the income statement in which
those expenses are recognized?

ii.

The amount of any issuance costs not recognized
as an expense and how they were recognized?
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Yes
g.

h.

.l 39.
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In a business combination achieved in stages, both of
the following:
i.

The acquisition-date fair value of the equity interest in the acquiree held by the acquirer immediately before the acquisition date?

ii.

The amount of any gain or loss recognized as a
result of remeasuring to fair value the equity interest in the acquiree held by the acquirer before
the business combination (see FASB ASC 805-1025-10) and the line item in the income statement
in which that gain or loss is recognized?

If the acquirer is a public business entity, are all of the
following disclosed:
i.

The amounts of revenue and earnings of the acquiree since the acquisition date included in the
consolidated income statement for the reporting
period?

ii.

The revenue and earnings of the combined entity
for the current reporting period as though the acquisition date for all business combinations that
occurred during the year had been as of the beginning of the annual reporting period (supplemental pro forma information)?

iii.

If comparative financial statements are presented, the revenue and earnings of the combined entity for the comparable prior reporting
period as though the acquisition date for all business combinations that occurred during the current year had occurred as of the beginning of the
comparable prior annual reporting period (supplemental pro forma information)?
[FASB ASC 805-10-50-1; “Pending Content” in
FASB ASC 805-10-50-2]

Has the entity properly disclosed, for individually immaterial
business combinations occurring during the reporting period
that are material collectively, the information required by
“Pending Content” in FASB ASC 805-10-50-2(e)–(h), in the
aggregate?
[FASB ASC 805-10-50-3]

No

N/A
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Yes
.l 40.

No

N/A

Has the entity properly disclosed, if the acquisition date of a
business combination is after the reporting date but before
the financial statements are issued or available to be issued,
has the entity, as the acquirer, the information required by
FASB ASC 805-10-50-2, unless the initial accounting for the
business combination is incomplete at the time the financial
statements are issued or available to be issued? (Note: If the
initial accounting is incomplete, the entity, as the acquirer,
should describe which disclosures could not be made and the
reasons why they could not be made.)
[FASB ASC 805-10-50-4]

The Financial Effects of Adjustments That Relate to Business Combinations That Occurred in the Current or Previous Reporting Periods28
.l 41.

Has the entity properly disclosed, if the initial accounting for
a business combination is incomplete (see paragraphs 13–14
of FASB ASC 805-10-25) and the amounts recognized in the
financial statements have been determined only provisionally, the following information for each material business
combination (or, in the aggregate for individually immaterial
business combinations that are material collectively):
a.

The reasons why the initial accounting is incomplete?

b.

The assets, liabilities, equity interests, or items of consideration for which the initial accounting is incomplete?

c.

The nature and amount of any measurement period adjustments recognized during the reporting period in accordance with FASB ASC 805-10-25-17?
[FASB ASC 805-10-50-6]

Other Disclosures
.l 42.

B.

Has the entity properly disclosed, if the specific disclosures
required by FASB ASC 805-10-50 (this subtopic) and other
U.S. GAAP do not meet the objectives set out in paragraphs
1 and 5 of FASB ASC 805-10-50, whatever additional information is necessary to meet those objectives?
[FASB ASC 805-10-50-7]

Identifiable Assets and Liabilities, and Any Noncontrolling Interest—Business Combinations (FASB ASC 805-20)
Disclosure
Business Combinations Occurring During a Current Reporting Period or After the Reporting Date but Before the Financial Statements
Are Issued

.l 1.

Has the entity properly disclosed, in order to meet the objective of FASB ASC 805-10-50-1, the following information for
each business combination that occurred during the period:

28

FASB ASC 805-10-50-5 states that an acquirer should disclose information that enables users of its financial statements to evaluate
the financial effects of adjustments recognized in the current reporting period that relate to business combinations that occurred in the
current or previous reporting periods.
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Yes
a.

b.

For indemnification assets, all of the following:
i.

The amount recognized as of the acquisition
date?

ii.

A description of the arrangement and the basis
for determining the amount of the payment?

iii.

An estimate of the range of outcomes (undiscounted) or, if a range cannot be estimated, that
fact and the reasons why a range cannot be estimated? (If the maximum amount of the payment
is unlimited, the entity should disclose that fact.)

For acquired receivables not subject to the requirements
of FASB ASC 310-30, all of the following (by major class
of receivable, such as loans, direct financing leases in
accordance with FASB ASC 840-30, and any other class
of receivables):
i.

The fair value of the receivables?

ii.

The gross contractual amounts receivable?

iii.

The best estimate at the acquisition date of the
contractual cash flows not expected to be collected?

c.

The amounts recognized as of the acquisition date for
each major class of assets acquired and liabilities assumed (see example 5 in FASB ASC 805-10-55-37)?

d.

For contingencies (included in the footnote that describes the business combination),

e.

i.

for assets and liabilities arising from contingencies recognized at the acquisition date (which
may be aggregated for assets or liabilities arising
from contingencies that are similar in nature), (1)
the amounts recognized at the acquisition date
and the measurement basis applied (that is, at
fair value or at an amount recognized in accordance with FASB ASC 450, Contingencies, and
FASB ASC 450-20-25), and (2) the nature of the
contingencies?

ii.

for contingencies that are not recognized at the
acquisition date, the disclosures required by
FASB ASC 450 if the criteria for disclosures
therein are met (which may be aggregated for assets and liabilities arising from contingencies that
are similar in nature)?

For each business combination in which the entity
holds less than 100 percent of the equity interests in the
acquiree at the acquisition date,
i.
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No

N/A
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Yes
ii.

N/A

the valuation technique(s) and significant inputs
used to measure the fair value of the noncontrolling interest?
[FASB ASC 805-20-50-1]

.l 2.

Has the entity properly disclosed, for individually immaterial
business combinations occurring during the reporting period
that are material collectively, the information required FASB
ASC 805-20-50-1, in the aggregate?
[FASB ASC 805-20-50-2]

.l 3.

Has the entity properly disclosed, if the acquisition date of a
business combination is after the reporting date but before
the financial statements are issued or available to be issued,
the information required by FASB ASC 805-20-50-1, unless
the initial accounting for the business combination is incomplete at the time the financial statements are issued or available to be issued? (Note: If the initial accounting is incomplete, the entity, as the acquirer, should describe which
disclosures could not be made and the reasons why they
could not be made.)
[FASB ASC 805-20-50-3]

C.

No

Goodwill or Gain From Bargain Purchase, Including Consideration Transferred (FASB ASC 805-30)
Disclosure
Business Combinations Occurring During a Current Reporting Period or After the Reporting Date but Before the Financial Statements
Are Issued
l 1.

Has the entity properly disclosed, in order to meet the objective of FASB ASC 805-10-50-1, the following information for
each business combination that occurred during the reporting
period:
a.

A qualitative description of the factors that make up
the goodwill recognized, such as expected synergies
from combining operations of the acquiree and the acquirer, intangible assets that do not qualify for separate
recognition, or other factors?

b.

The acquisition-date fair value of the total consideration transferred and the acquisition-date fair value of
each major class of consideration, such as the following:
i.

Cash?

ii.

Other tangible or intangible assets, including a
business or subsidiary of the acquirer?

iii.

Liabilities incurred, for example, a liability for
contingent consideration?

iv.

Equity interests of the acquirer, including the
number of instruments or interests issued or issuable and the method of determining the fair
value of those instruments or interests?
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Yes
c.

For contingent consideration arrangements, all of the
following:
i.

The amount recognized as of the acquisition
date?

ii.

A description of the arrangement and the basis
for determining the amount of the payment?

iii.

An estimate of the range of outcomes (undiscounted) or, if a range cannot be estimated, that
fact and the reasons why a range cannot be estimated? If the maximum amount of the payment
is unlimited, the acquirer should disclose that
fact.

d.

The total amount of goodwill that is expected to be deductible for tax purposes?

e.

If the acquirer is required to disclose segment information in accordance with FASB ASC 280-10, the amount
of goodwill by reportable segment? (If the assignment
of goodwill to reporting units required by paragraphs
41–44 of FASB ASC 350-20-35 has not been completed
as of the date the financial statements are issued or are
available to be issued, the acquirer should disclose that
fact.)

f.

In a bargain purchase (see paragraphs 2–4 of FASB
ASC 805-30-25), both of the following:
i.

The amount of any gain recognized in accordance with FASB ASC 805-30-25-2 and the line
item in the income statement in which the gain is
recognized?

ii.

A description of the reasons why the transaction
resulted in a gain?
[FASB ASC 805-30-50-1]

.l 2.

Has the entity properly disclosed, for individually immaterial
business combinations occurring during the reporting period
that are material collectively, the information required FASB
ASC 805-30-50-1, in the aggregate?
[FASB ASC 805-30-50-2]

.l 3.

Has the entity properly disclosed, if the acquisition date of a
business combination is after the reporting date but before
the financial statements are issued or available to be issued,
the information required by FASB ASC 805-30-50-1, unless
the initial accounting for the business combination is incomplete at the time the financial statements are issued or available to be issued? (Note: If the initial accounting is incomplete, the entity, as the acquirer, should describe which
disclosures could not be made and the reasons why they
could not be made.)
[FASB ASC 805-30-50-3]

FSP §11,100.01

No

N/A

151

Financial Statements and Notes Checklist

Yes

No

N/A

The Financial Effects of Adjustments That Relate to Business Combinations That Occurred in the Current or Previous Reporting Periods
.l 4.

Has the entity properly disclosed, in order to meet the objective of FASB ASC 805-10-50-5, the following information for
each material business combination, or in the aggregate for
individually immaterial business combinations that are material collectively, that occurred during the period:
a.

b.

D.

For each reporting period after the acquisition date until the entity collects, sells, or otherwise loses the right
to a contingent consideration asset, or until the entity
settles a contingent consideration liability or the liability is cancelled or expires, all of the following:
i.

Any changes in the recognized amounts, including any differences arising upon settlement?

ii.

Any changes in the range of outcomes (undiscounted) and the reasons for those changes?

iii.

The fair value disclosures required by paragraphs 1–3 of FASB ASC 820-10-50?

A reconciliation of the carrying amount of goodwill at
the beginning and end of the reporting period as required by FASB ASC 350-20-50-1?
[FASB ASC 805-30-50-4]

Business Combinations—Related Issues (FASB ASC 805-50)
Presentation
Transactions Between Entities Under Common Control—Financial
Statement Presentation in Period of Transfer

.l 1.

For assets and liabilities transferred between entities under
common control, has the receiving entity properly presented
the results of operations for the period in which the transfer
occurs as though the transfer of net assets or exchange of equity interest had occurred at the beginning of the period?
[FASB ASC 805-50-45-2]

.l 2.

Has the receiving entity properly presented the statement of
financial position and other financial information as of the beginning of the period as though the assets and liabilities had
been transferred at that date?
[FASB ASC 805-50-45-4]

Transactions Between Entities Under Common Control—Comparative Financial Statement Presentation in Prior Years
.l 3.

Has the entity properly presented prior years’ financial statements and financial information retrospectively adjusted to
furnish comparative information, only adjusting periods during which the entities were under common control? (Note:
All adjusted financial statements and financial summaries
should clearly indicate that financial data of previously separate entities are combined.)
[FASB ASC 805-50-45-5]

FSP §11,100.01

152

Health Care Entities

Yes

No

N/A

Disclosure
Transactions Between Entities Under Common Control29
.l 4.

Has the entity properly disclosed the nature of and effects on
EPS of nonrecurring intraentity transactions involving longterm assets and liabilities? (Note: Under the guidance of
FASB ASC 805-50-45-3 the effects of these transaction is not
required to be eliminated.)
[FASB ASC 805-50-50-2]

.l 5.

Has the entity properly disclosed, in the notes to the financial
statements, the following, for the period in which the transfer
of assets and liabilities or exchange of equity interests occurred:

E.

a.

The name and brief description of the entity included
in the reporting entity as a result of the net asset transfer or exchange of equity interests?

b.

The method of accounting for the transfer of net assets
or exchange of equity interests?
[FASB ASC 805-50-50-3]

Collaborative Arrangements (FASB ASC 808-10)
Disclosure

.l 1.

Has the entity properly disclosed the following, if a participant in a collaborative arrangement, in the period in which
the collaborative arrangement has been entered into and all
annual periods thereafter: (Note: Information related to individually significant collaborative arrangements should be
disclosed separately.)
a.

Information about the nature and purpose of its collaborative arrangements?

b.

Its rights and obligations under the collaborative arrangements?

c.

The accounting policy for collaborative arrangements
in accordance with FASB ASC 235, Notes to Financial
Statements?

d.

The income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants for each period an income statement is presented?
[FASB ASC 808-10-50-1]

29
Per FASB ASC 805-50-50-4, the entity should also consider whether additional disclosures are required in accordance with FASB
ASC 850-10-50, which provides guidance on related party transactions and certain common control relationships.
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Yes
F.

No

N/A

Consolidation (FASB ASC 810-10)30
Presentation
Procedures

.l 1.

Has the parent properly presented its consolidated financial
statements with intraentity balances and transactions eliminated?
[FASB ASC 810-10-45-1]

.l 2.

Has the parent properly presented its consolidated financial
statements without retained earnings or deficit of a subsidiary
at the date of acquisition included in consolidated retained
earnings?
[FASB ASC 810-10-45-2]

.l 3.

Has the parent properly presented in its consolidated financial statements a subsidiary’s revenues, expenses, gains, and
losses only from the date the subsidiary was initially consolidated?
[FASB ASC 810-10-45-4]

.l 4.

Has the entity properly not presented shares of the parent,
held by the subsidiary as outstanding shares in the consolidated statement of financial position? (These shares are not
considered outstanding shares and should be eliminated and
reflected as treasury shares.)
[FASB ASC 810-10-45-5]

Combined Financial Statements
.l 5.

Has the entity properly presented its combined financial
statements, prepared for a group of related entities, with intraentity transactions and profits or losses eliminated, and
noncontrolling interests, foreign operations, different fiscal
periods, or income taxes treated and presented in the same
manner as in consolidated financial statements?
[FASB ASC 810-10-45-10]

30
In December 2009, FASB issued ASU No. 2009-17, Consolidations (Topic 810): Improvements to Financial Reporting by Enterprises Involved
with Variable Interest Entities. This update is to incorporate FASB Statement No. 167, Amendments to FASB Interpretation No. 46(R), into the
codification. ASU No. 2009-17 represents a revision to former FASB Interpretation No. 46(R), Consolidation of Variable Interest Entities
(revised December 2003)—an interpretation of ARB No. 51, and changes how a reporting entity determines when an entity that is insufficiently capitalized or is not controlled through voting (or similar rights) should be consolidated. The determination of whether a reporting
entity is required to consolidate another entity is based on, among other things, the other entity’s purpose and design and the reporting
entity’s ability to direct the activities of the other entity that most significantly impact the other entity’s economic performance. The
amendments in this ASU will be effective for interim and annual reporting periods beginning after November 15, 2009, and interim
periods within those fiscal years (that is, January 1, 2010, for entities with calendar year-ends). Early adoption is not permitted.

This checklist has been updated to include the presentation and disclosure requirements of ASU No. 2009-17.
Readers can refer to the full text of the ASU on the FASB website at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition and open effective date information discussed in FASB ASC 81010-65-2.
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Yes

No

N/A

Parent-Entity Financial Statements
l 6.

Has the entity properly presented parent-entity financial
statements, in addition to consolidated financial statements,
if necessary, to adequately indicate the position of bondholders and other creditors or preferred shareholders of the parent?
[FASB ASC 810-10-45-11]

Differing Fiscal Year-Ends Between Parent and Subsidiary
.l 7.

Has the entity properly presented information regarding intervening events that materially affect the financial position
or results of operations if the financial reporting periods of
any subsidiaries are different from that of the parent?
[FASB ASC 810-10-45-12]

A Change in the Fiscal Year-End Lag Between Subsidiary and Parent
l 8.

Has the parent or investor properly presented information regarding a change to (or the elimination of) a previously existing difference between the parent’s reporting period and the
reporting period of a consolidated entity or between the reporting period of an investor and the reporting period of an
equity method investee in the parent’s or investor’s consolidated financial statements, in accordance with FASB ASC
250, Accounting Changes and Error Corrections, as described in
FASB ASC 810-10-45-13?
[FASB ASC 810-10-45-13]

Noncontrolling Interest in a Subsidiary—Nature and Classification
of the Noncontrolling Interest in the Consolidated Statement of Financial Position
Presentation
.l 9.

Has the entity properly presented, clearly identified and labeled, a noncontrolling interest in the entity (net assets) section of the consolidated statement of position, separately
from the entity’s equity (net assets)? (Note: An entity with
noncontrolling interests in more than one subsidiary may
present those interests in aggregate.)
[FASB ASC 810-10-45-16]31

Disclosure
. 10.

31

If the not-for-profit entity both (a) controls a related but separate not-for-profit entity through a majority voting interest
in the board of that not-for-profit entity by means other than
majority ownership interest, sole corporate membership, or
majority voting interest and (b) has an economic interest in
that other not-for-profit entity, and consolidated financial
statements are not presented, do disclosures include

The “Pending Content” in FASB ASC 810-10-45-16 includes a parenthetical reference to “net assets” when discussing the entity’s
equity. Entities subject to FASB Statement No. 164, Not-for-Profit Entities: Mergers and Acquisitions—Including an amendment of FASB
Statement No. 142, should refer to the transition and open effective date information in FASB ASC 810-10-65-1 for more information.

FSP §11,100.01

155

Financial Statements and Notes Checklist

Yes
a.

identification of the other not-for-profit entity and the
nature of its relationship with the reporting entity that
results in control?

b.

summarized financial data of the other not-for-profit
entity including: total assets, liabilities, net assets, revenue, and expenses, and resources that are held for the
benefit of the reporting entity or that are under its control?

c.

disclosures required by FASB ASC 850, Related Party
Disclosures, as described in question 4 and in section
I.K, “Related Parties,” of FSP section 14,200 of Checklists
and Illustrative Financial Statements for Not-for-Profit Entities?
[FASB ASC 958-810-50-2]

. 11.

Has the not-for-profit parent entity that has one or more consolidated subsidiaries with a noncontrolling interest properly
provided a schedule of changes in consolidated net assets attributable to the parent and the noncontrolling interest either
in the notes to the consolidated financial statements or on the
face of the financial statements, which reconciles beginning
and ending balances of the parent’s controlling interest and
the noncontrolling interests for each class of net assets for
which a noncontrolling interest exists during the reporting
period?
[FASB ASC 958-810-50-4]

. 12.

Has the schedule referred to in question 10 preceding included a performance indicator, amounts of discontinued operations, amounts of extraordinary items, changes in ownership interests in a subsidiary, and an aggregate amount of all
other changes in unrestricted net assets for the period?
[FASB ASC 958-810-50-5]

No

N/A

Medical Malpractice Trust Funds
Presentation
.l 13.

Is a portion of the medical malpractice trust funds (the
amount of assets expected to be liquidated to pay malpractice
claims classified as current liabilities) classified as a current
asset in a classified balance sheet/statement of financial position?
[FASB ASC 954-810-45-4]

.l 14.

Is the balance of the medical malpractice trust funds, if any,
classified as a noncurrent asset in a classified balance sheet/
statement of financial position?
[FASB ASC 954-810-45-4]

.l 15.

Are medical malpractice trust fund revenue and administrative expenses included in the statement of activities/income
statement?
[FASB ASC 954-810-45-4]
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Yes

No

N/A

Disclosure
.l 16.

Has the existence of medical malpractice trust funds and
whether they are irrevocable been disclosed?
[FASB ASC 954-810-50-1]

Attributing Net Income and Comprehensive Income to the Parent
and the Noncontrolling Interest
Presentation
.l 17.

Has the entity properly presented, in the consolidated financial statements, revenues, expenses, gains, losses, net income
or loss, and OCI at the consolidated amounts, which include
amounts attributable to the owners of the parent and the noncontrolling interest?
[FASB ASC 810-10-45-19]

Disclosure
Additional Disclosure Information
FASB ASC 810-10-50 contains disclosures for both nonpublic and public companies. Further, “Pending Content” related to ASU No. 2009-17, Consolidations (Topic 810): Improvements to Financial Reporting by Enterprises
Involved with Variable Interest Entities, contains guidance that is applicable to all entities. As such, this portion
of the checklist has been divided into three distinct sections.
For entities that have not adopted the guidance of ASU No. 2009-17, the following sections are applicable:
●

Disclosures for all entities, and

●

Disclosures for nonpublic entities, or

●

Disclosures for public entities.

For entities for which the guidance of ASU No. 2009-17 is mandatorily effective (early adoption is not permitted), the following sections are applicable:
●

Disclosures for all entities, and

●

Disclosures for all entities (subject to ASU No. 2009-17)
Disclosure for All Entities
Consolidation Policy
.l 18.

Has the entity properly disclosed the consolidation policy
that is being followed? (Note: In most cases this can be made
apparent by the headings or other information in the financial
statements.)
[FASB ASC 810-10-50-1]

Parent With a Less-Than-Wholly-Owned Subsidiary
.l 19.

Has the parent properly disclosed all the following regarding
one or more less-than-wholly-owned subsidiaries for each reporting period:
a.
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statements, both of the following:
i.

The amounts of consolidated net income and
consolidated comprehensive income?

ii.

The related amounts on each attributable to the
parent and the noncontrolling interest?
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Yes
b.

No

N/A

Either in the notes or on the face of the consolidated
income statement, amounts attributable to the parent
for any of the following, if reported in the consolidated
financial statements:
i.

Income from continuing operations?

ii.

Discontinued operations?

iii.

Extraordinary items?

c.

Either in the consolidated statement of changes in equity, if presented, or in the notes to consolidated financial statements, a reconciliation at the beginning and
the end of the period of the carrying amount of total
equity (net assets), equity (net assets) attributable to the
parent, and equity (net assets) attributable to the noncontrolling interest? (Note: This reconciliation should
separately disclose [i] net income, [ii] transactions with
owners acting in their capacity as owners, showing separately contributions from and distributions to owners,
and [iii] each component of OCI.)

d.

In notes to the consolidated financial statements, a separate schedule that shows the effects of any changes in
a parent’s ownership interest in a subsidiary on the equity attributable to the parent?
[FASB ASC 810-10-50-1A]

. 20.

Are restrictions made by entities outside of the reporting entity on distributions from the controlled not-for-profit organization to the reporting organization and any resulting unavailability of the net assets of the controlled not-for-profit
organization for use by the reporting organization disclosed?
[FASB ASC 958-810-50-1]

. 21.

If, as described in FASB ASC 958-810-25-4, the not-for-profit
entity (the reporting entity) controls a related but separate
not-for-profit through a form other than majority ownership
interest, sole corporate membership, or majority voting interest in the board of the other entity and has an economic interest in that other not-for-profit, has the reporting entity disclosed all of the following information if it does not present
consolidated financial statements:
a.

Identification of the other not-for-profit and the nature
of its relationship with the reporting entity that results
in control?

b.

Summarized financial data of the other not-for-profit,
which shall include the following information:
i.

Total assets, liabilities, net assets, revenue, and
expenses?

ii.

Resources that are held for the benefit of the reporting entity or that are under its control?
[FASB ASC 740-10-50-17; FASB ASC 850-10-50-1]
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Yes
c.

The disclosures required by paragraphs 1–6 of FASB
ASC 850-10-50?
[FASB ASC 958-810-50-2]

Deconsolidation of a Subsidiary
.l 22.

Has the entity properly disclosed the following, as a parent
entity, if a subsidiary has been deconsolidated:
a.

The amount of any gain or loss recognized in accordance with FASB ASC 810-10-40-5?

b.

The portion of any gain or loss related to the remeasurement of any retained investment in the former subsidiary of group of assets to its fair value?

c.

The caption in the income statement in which the gain
or loss is recognized unless separately presented on the
face of the income statement?

d.

A description of the valuation technique(s) used to
measure the fair value of any direct or indirect retained
investment in the former subsidiary or group of assets?

e.

Information that enables users of the parent’s financial
statements to assess the inputs used to develop the fair
value in item (d)?

f.

The nature of continuing involvement with the subsidiary or entity acquiring the group of assets after it has
been deconsolidated or derecognized?

g.

Whether the transaction that resulted in the deconsolidation or derecognition was with a related party?

h.

Whether the former subsidiary or entity acquiring a
group of assets will be a related party after deconsolidation?
[“Pending Content” in FASB ASC 810-10-50-1B]

A Change in the Difference Between Parent and Subsidiary Fiscal
Year-Ends
.l 23.

Has the entity properly disclosed, pursuant to FASB ASC 250,
regarding a change in (or elimination of) a previously existing difference between the fiscal year-ends of a parent entity
and subsidiary or an investor and an equity method investee?
[FASB ASC 810-10-50-2]

Disclosure for Nonpublic Entities
Variable Interest Entities—Nonpublic Entities—Primary Beneficiary
.l 24.
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If the entity is a primary beneficiary of a variable interest entity (VIE), has the entity disclosed all of the following (unless
the primary beneficiary also holds a majority voting interest):
a.

The nature, purpose, size, and activities of the VIE?

b.

The carrying amount and classification of consolidated
assets that are collateral for the VIE’s obligations?

No

N/A
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Yes
c.

No

N/A

Lack of recourse if creditors (or beneficial interest holders) of a consolidated VIE have no recourse to the general credit of the primary beneficiary?
[FASB ASC 810-10-50-3]

Variable Interest Entities—Nonpublic Entities—Holder of Significant Variable Interest in a Variable Interest Entity
.l 25.

Has the entity properly disclosed all of the following, if it
holds a significant interest in a VIE, but is not the VIE’s primary beneficiary:
a.

The nature of its involvement with the VIE and when
that involvement began?

b.

The nature, purpose, size, and activities of the VIE?

c.

The reporting entity’s maximum exposure to loss as a
result of its involvement with the VIE?
[FASB ASC 810-10-50-4]

Variable Interest Entities—Nonpublic Entities—Relation to FASB
ASC 860, Transfers and Servicing, Disclosures
.l 26.

Has the entity properly disclosed information required by
FASB ASC 860 regarding VIEs in the same note as the disclosures required by this subtopic? (Note: Information about
VIEs may be reported in the aggregate for similar entities if
separate reporting would not add material information.)
[FASB ASC 810-10-50-5]

Variable Interest Entities—Nonpublic Entities—Scope–Related, Disclosures
.l 27.

Has the reporting entity properly disclosed the following information if the entity does not apply the guidance in the
“Variable Interest Entities” subsections of FASB ASC 810,
Consolidation, to one or more VIEs or potential VIEs because
of the condition described in FASB ASC 810-10-15-17(c):
a.

The number of legal entities to which this guidance is
not being applied and the reason why the information
required to apply this guidance is not available?

b.

The nature, purpose, size (if available), and activities of
the legal entity or entities and the nature of the reporting entity’s involvement with the legal entity or entities?

c.

The reporting entity’s maximum exposure to loss because of its involvement with the legal entity or entities?

d.

The amount of income, expense, purchases, sales, or
other measure of activity between the reporting entity
and the legal entity or entities for all periods presented?
[FASB ASC 810-10-50-6]
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Disclosure for Public Entities
Aggregation of Certain Disclosures
l 28.

Has the public entity properly disclosed, if providing disclosures about VIEs, and if providing separate reporting would
not provide more useful information to financial statement
users, how similar entities are aggregated? The reporting entity should distinguish between (a) VIEs that are consolidated
and (b) those that are not consolidated because the reporting
entity is not the primary beneficiary, but has a significant variable interest or is the sponsor that holds the variable interest?
(Note: The entity should consider quantitative and qualitative
information about different risk and reward characteristics of
each VIE and the significance of each VIE to the entity. Further, disclosures should be presented in a manner that clearly
and fully explains to the financial statement users the nature
and extent of an entity’s involvement with VIEs.)
[FASB ASC 810-10-50-9]

Aggregation of Certain Disclosures—Public Entity That Is a Primary Beneficiary, Holds a Significant Variable Interest, or Is a Sponsor
l 29.

Has the public entity properly disclosed the following information if the entity is a primary beneficiary of a VIE, holds a
significant variable interest in a VIE, or is a sponsor that
holds a variable interest in a VIE:
a.

Its methodology for determining whether the reporting
entity is (or is not) the primary beneficiary of a VIE,
including, but not limited to, significant judgments and
assumptions made?

b.

If the conclusion to consolidate a VIE has changed in
the most recent financial statements the primary factors
that caused the change and the effect on the entity’s financial statements?

c.

Whether the reporting entity has provided financial or
other support during the periods presented to the VIE
that it was not previously contractually required to
provide, including both of the following:

d.

i.

The type and amount of support?

ii.

The primary reasons for providing the support?

Qualitative and quantitative information about the reporting entity’s involvement with the VIE, including
but not limited to the nature, purpose, size, and activities of the VIE, including how the VIE is financed?
[FASB ASC 810-10-50-12]

Aggregation of Certain Disclosures—The Primary Beneficiary of a
VIE
.l 30.

FSP §11,100.01

Has the entity properly disclosed the following, if the entity
is the primary beneficiary of a VIE:

No

N/A
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Yes
a.

The carrying amount and classification of the VIE’s assets and liabilities in the statement of financial position
that are consolidated in accordance with the guidance
in the “Variable Interest Entities” subsections of FASB
ASC 810-10, including qualitative information about
the relationship(s) between those assets and associated
liabilities?

b.

Lack of recourse if creditors (or beneficial interest holders) of a consolidated VIE have no recourse to the general credit of the primary beneficiary?

c.

Terms of arrangements, giving consideration to both
explicit arrangements and implicit variable interests,
that could require the reporting entity to provide financial support to the VIE, including events or circumstances that could expose the reporting entity to a loss?
[FASB ASC 810-10-50-14]

No

N/A

Aggregation of Certain Disclosures—Public Entity That Holds a
Significant Variable Interest or Is a Sponsor but Is Not the Primary
Beneficiary
l 31.

Has the public entity properly disclosed the following, if it
holds a significant variable interest or is a sponsor that holds
a variable interest in a VIE, but is not the VIE’s primary beneficiary: (Note: A public entity meeting items [a]–[c], which
follow, are encouraged to disclose information about any liquidity arrangements, guarantees, or other commitments by
third parties that may affect the fair value or risk of the reporting entity’s variable interest in the VIE.)
a.

The carrying amount and classification of the assets
and liabilities in the reporting entity’s statement of financial position that relate to the reporting entity’s variable interest in the VIE?

b.

The reporting entity’s maximum exposure to loss as a
result of its involvement with the VIE, including the
following:

c.

i.

How the maximum exposure is determined?

ii.

The significant sources of the reporting entity’s
exposure to the VIE?

iii.

If a maximum exposure cannot be identified, has
that fact been disclosed?

A tabular comparison of the carrying amount of the liability (as required by item [a]) and the reporting entity’s maximum exposure to loss (as required by item
[b]).
[FASB ASC 810-10-50-15]
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Aggregation of Certain Disclosures—Scope-Related Disclosures
.l 32.

Has the entity properly disclosed the following if it has not
applied the guidance in the “Variable Interest Entities” subsections of FASB ASC 810-10-50 to one or more VIEs or potential VIEs because of the condition described in FASB ASC
810-10-15-17(c):
a.

The number of legal entities to which that guidance is
not being applied?

b.

The reason why the information required to apply that
guidance is not available?

c.

The nature, purpose, size (if available), and activities of
the legal entities?

d.

The nature of the reporting entity’s involvement with
the legal entities?

e.

The reporting entity’s maximum exposure to loss because of its involvement with the legal entities?

f.

The amount of income, expense, purchases, sales, or
other measure of activity between the reporting entity
and the legal entities for all periods presented?
[FASB ASC 810-10-50-16]

Aggregation of Certain Disclosures—Nontransferor Sponsor or
Nontransferor Servicer of a Qualifying Special-Purpose Entity
l 33.

Has the public entity properly disclosed the following information that provides financial statement users with an understanding of its involvement with the qualifying special-purpose entity (QSPE) if the public entity is either a
nontransferor sponsor or a nontransferor servicer?
[FASB ASC 810-10-50-17]

l 34.

Has the public entity properly disclosed the following information that provides financial statement users with an understanding of its involvement with the QSPE if the public entity
is either a nontransferor sponsor or a nontransferor servicer?
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a.

The nature, purpose, size, and activities of the QSPE,
including how the entity is financed?

b.

The carrying amount and classification of the assets
and liabilities recognized in the statement of financial
position related to the reporting entity’s involvement
with the QSPE?

c.

Terms of arrangements that could require the reporting
entity to provide financial support to the QSPE, including events or circumstances that could expose the entity
to loss? (All available evidence should be considered.
See FASB ASC 810-10-50-19[c] for specific examples of
evidence to consider).

No

N/A
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Yes
d.

The reporting entity’s maximum exposure to loss as a
result of its involvement with the QSPE, including how
the maximum exposure is determined and the significant sources of the reporting entity’s exposure to the
QSPE? (If the entity’s maximum exposure to loss as a
result of its involvement with the QSPE cannot be
quantified, that fact should be disclosed.)

e.

Whether the entity has provided financial or other support during the periods presented to the QSPE that it
was not previously contractually required to provide,
including both of the following:
i.

The type and amount of support?

ii.

The primary reasons for providing the support?
[FASB ASC 810-10-50-19]

No

N/A

Disclosure for All Entities (subject to the guidance of ASU No. 2009-17)
.l 35.

(Public and nonpublic entities that have applied ASU No.
2009-17) Has the entity properly included disclosures, in order to provide financial statement users with an understanding of the following: (The entity may need to supplement the
disclosures required by this subsection to achieve the objectives that follow. Further, these disclosures may be made in
more than one note, provided there is a cross-reference provided.)
a.

The significant judgments and assumptions made by
the entity in determining whether it must (i) consolidate a VIE, and (ii) disclose information about its involvement in a VIE?

b.

The nature of restrictions on the consolidated VIE’s assets and on the settlement of its liabilities reported by
the entity in its statement of financial position, including the carrying amounts of such assets and liabilities?

c.

The nature of, and changes in, the risks associated with
the reporting entity’s involvement with the VIE?

d.

How the entity’s involvement with the VIE affects the
reporting entity’s financial position, financial performance, and cash flows?
[“Pending Content” in FASB ASC 810-10-50-2AA]

Variable Interest Entities—Primary Beneficiary of a Variable Interest Entity
.l 36.

(Public and nonpublic entities that have applied ASU No.
2009-17) Has the entity properly disclosed, if it is the primary
beneficiary of a VIE, all of the following: (Note: A VIE may
issue voting equity interests, and the entity that holds a majority voting interest may also be the primary beneficiary of
the VIE. If so, and if the VIE meets the definition of a business
and the VIE’s assets can be used for purposes other than the
settlement of the VIE’s obligations, the disclosures that follow
are not required.)
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Yes
a.

The carrying amounts and classification of the VIE’s assets and liabilities in the statement of financial position
that are consolidated in accordance with the “Variable
Interest Entities” subsections of FASB ASC 810-10, including qualitative information about the relationship(s) between those assets and liabilities?

b.

Lack of recourse if creditors (or beneficial interest holders) of a consolidated VIE have no recourse to the general credit of the primary beneficiary?

c.

Terms of arrangements, giving consideration to both
explicit arrangements and implicit variable interests
that could require the reporting entity to provide financial support to the VIE, including events or circumstances that could expose the reporting entity to a loss?
[“Pending Content” in FASB ASC 810-10-50-3]

Variable Interest Entities—Nonprimary Beneficiary of a Variable Interest Entity
.l 37.
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(Public and nonpublic entities that have applied ASU No.
2009-17) Has the entity properly disclosed the following, if it
holds an interest in a VIE, but is not the VIE’s primary beneficiary:
a.

The carrying amounts and classification of the assets
and liabilities in the reporting entity’s statement of financial position that relate to the reporting entity’s variable interest in the VIE?

b.

The reporting entity’s maximum exposure to loss as a
result of its involvement with the VIE, including how
the maximum exposure is determined and the significant sources of the reporting entity’s exposure to the
VIE?

c.

A tabular comparison of the carrying amounts of the
assets and liabilities, as required by item (a), preceding,
and the reporting entity’s maximum exposure to loss,
as required by item (b), preceding? (Note: The reporting
entity should provide qualitative and quantitative information to allow financial statement users to understand the differences between the two amounts. That
discussion should include, but is not limited to, the
terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, that
could require the reporting entity to provide financial
support to the VIE, including events or circumstances
that could expose the reporting entity to a loss.)

d.

Encouraged, although not required, information about
any liquidity arrangements, guarantees, or other commitments by third parties that may affect the fair value
or risk of the reporting entity’s variable interest in
theVIE?

No

N/A
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Yes
e.

No

N/A

If applicable, significant factors considered and judgments made in determining that the power to direct the
activities of a VIE that most significantly impact the
VIE’s economic performance is shared in accordance
with the guidance in FASB ASC 810-10-25-38D?
[“Pending Content” in FASB ASC 810-10-50-4]

Variable Interest Entities—Primary Beneficiaries or Other Holders
of Interests in Variable Interest Entities
.l 38.

(Public and nonpublic entities that have applied ASU No.
2009-17) Has the reporting entity properly disclosed the following, if it is a primary beneficiary of a VIE or if it holds a
variable interest in a VIE but is not the entity’s primary beneficiary: (Note: A VIE may issue voting equity interests, and
the entity that holds a majority voting interest may also be
the primary beneficiary of the VIE. If so, and if the VIE meets
the definition of a business and the VIE’s assets can be used
for purposes other than the settlement of the VIE’s obligation,
the disclosures that follow are not required.)
a.

Its methodology for determining whether the reporting
entity is the primary beneficiary of a VIE, including,
but not limited to, significant judgments and assumptions made. (The entity may meet this disclosure requirement by providing information about the types of
involvements a reporting entity considers significant,
supplemented with information about how the significant involvements were considered in determining
whether the reporting entity is the primary beneficiary.)

b.

If facts and circumstances change such that the conclusion to consolidate a VIE has changed in the most recent financial statements (for example, the VIE was previously consolidated and is not currently consolidated),
the primary factors that caused the change and the effect on the reporting entity’s financial statements?

c.

Whether the reporting entity has provided financial or
other support (explicitly or implicitly) during the periods presented to the VIE that it was not previously
contractually required to provide or whether the reporting entity intends to provide that support, including both of the following:
i.

The type and amount of support, including situations in which the reporting entity assisted the
VIE in obtaining another type of support?

ii.

The primary reason for providing the support?
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Yes
d.

.l 39.

G.

No

N/A

Qualitative and quantitative information about the reporting entity’s involvement (giving consideration to
both explicit arrangements and implicit variable interests) with the VIE, including, but not limited to, the nature, purpose, size, and activities of the VIE, including
how the VIE is financed?
[“Pending Content” in FASB ASC 810-10-50-5A]

(Public and nonpublic entities that have applied ASU No.
2009-17) Has the entity properly disclosed, if providing disclosures about VIEs, and if providing separate reporting
would not provide more useful information to financial statement users, how similar entities are aggregated? The reporting entity should distinguish between (a) VIEs that are consolidated and (b) those that are not consolidated because the
reporting entity is not the primary beneficiary, but has a significant variable interest. (Note: The entity should consider
quantitative and qualitative information about different risk
and reward characteristics of each VIE and the significance of
each VIE to the entity. Further, disclosures should be presented in a manner that clearly explains to the financial statement users the nature and extent of an entity’s involvement
with VIEs.)
[“Pending Content” in FASB ASC 810-10-50-9]

Derivatives and Hedging (FASB ASC 815-10)32
Presentation
Balance Sheet—Netting

.l 1.

Has the entity properly not presented a hedging derivative’s
asset (or liability) position against the hedged liability (or asset) position in the balance sheet?
[FASB ASC 815-10-45-2]

32
In March 2010, FASB issued ASU No. 2010-11, Derivatives and Hedging (Topic 815): Scope Exception Related to Embedded Credit Derivatives. The amendments in this ASU, among others, clarify the scope exception under paragraphs 8–9 of FASB ASC 815-15-25 for embedded
credit derivative features related to the transfer of credit risk in the form of subordination of one financial instrument to another. Further,
the amendments address how to determine which embedded credit derivatives, including those in collateralized debt obligations and
synthetic collateralized debt obligations, are considered to be embedded derivatives that should not be analyzed under FASB ASC 81515-25 for potential bifurcation and separate accounting. The amendments in this ASU are effective at the beginning of the entity’s first
fiscal quarter beginning after June 15, 2010. Early adoption is permitted at the beginning of each entity’s first fiscal quarter beginning
after issuance of this ASU.

This checklist has been updated to include the presentation and disclosure requirements of ASU No. 2010-11.
Readers can refer to the full text of the ASU on the FASB website at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition and open effective date information discussed in FASB ASC 81510-65-5.
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Yes

No

N/A

Income Statement Classification—Derivative Instruments Held for
Trading Purposes
.l 2.

Has the entity properly presented gains and losses (realized
and unrealized) on all derivative instruments within the
scope of FASB ASC 815, Derivatives and Hedging, as net when
recognized in the income statement, whether or not settled
physically, if the derivative instruments are held for trading
purposes?
[FASB ASC 815-10-45-9]

Cash Flow Statement Classification—Derivative Instruments With a
Financing Element
.l 3.

If an other-than-insignificant financing element is present at
inception—other than a financing element inherently included in an at-the-market derivative instrument with no prepayments—has the entity properly presented all cash inflows
and outflows associated with that derivative instrument, in a
manner consistent with financing activities as described in
paragraphs 14–15 of FASB ASC 230-10-45?
[FASB ASC 815-10-45-12]

Disclosure
.l 4.

.l 5.

Has the entity properly disclosed information, in order for
the users of the financial statements to understand the following, if the entity has derivative instruments (or nonderivative
instruments that are designated and qualify as hedging instruments pursuant to FASB ASC 815-20-25-58 and 815-20-2566):
a.

How and why an entity uses derivative instruments (or
such nonderivative instruments)?

b.

How derivative instruments (or such nonderivative instruments) and related hedged items are accounted for
under FASB ASC 815?

c.

How derivative instruments (or such nonderivative instruments) and related hedged items affect the entity’s
financial position, performance and cash flows?
[FASB ASC 815-10-50-1]

Has the entity properly disclosed the following for each annual and interim reporting period for which a statement of
financial position and statement of financial performance are
presented, if the entity has derivative instruments (or nonderivative instruments that are designated and qualify as hedging instruments pursuant to FASB ASC 815-20-25-58 and 81520-25-66):
a.

Its objectives for holding or issuing those instruments?

b.

The context needed to understand those objectives?

c.

Its strategies for achieving those objectives?

FSP §11,100.01

168

Health Care Entities

Yes
d.

Information that would enable users of its financial
statements to understand the volume of its activity in
those instruments? (An entity should select the format
and the specifics of disclosures relating to its volume of
such activity that are most relevant and practicable for
its individual facts and circumstances.)
[FASB ASC 815-10-50-1A]

.l 6.

Has the entity properly disclosed information, regarding the
derivative instruments in question 5(d), in the preceding
question, in such a format and in enough specifics relating to
the volume of such activity such that the disclosures are most
relevant and practicable for the individual facts and circumstances? For items in question 5(a)–(c) in the preceding question, has information been disclosed in the context of each
instrument’s primary underlying risk exposure and have
such items been distinguished between those used for risk
management purposes and those used for other purposes?
[FASB ASC 815-10-50-1B]

.l 7.

Has the entity properly disclosed the following to distinguish
between the instruments with disclosures required by question 5(a)–(c):
a.

b.
.l 8.
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Derivative instruments (and nonderivative instruments) used for risk management purposes, distinguished between each of the following:
i.

Derivative instruments (and nonderivative instruments) designated as hedging instruments,
distinguished between each of the following: (1)
fair value hedging instruments, (2) cash flow
hedging instruments, and (3) hedges of foreign
currency exposure of net investments in foreign
operations?

ii.

Derivative instruments used as economic hedges
and for other purposes related to the entity’s risk
exposure?

Derivative instruments used for other purposes?
[FASB ASC 815-10-50-2]

Has the entity properly disclosed the purpose of any derivative instruments not designated as hedging instruments under FASB ASC 815-20?
[FASB ASC 815-10-50-4]

No

N/A

169

Financial Statements and Notes Checklist

Yes

No

N/A

Overall Quantitative Disclosures
.l 9.

Has the entity properly disclosed in tabular format, for every
annual and interim reporting period for which a statement of
financial position and statement of financial performance are
presented, the location and fair value amounts of derivative
instruments reported in the statement of financial position
and the location and amount of the gains and losses on derivative instruments (or nonderivative instruments it holds or
issues that are designated and qualify as hedging instruments
pursuant to FASB ASC 815-20-25 paragraphs 58 and 66) reported in the statement of financial performance (or when applicable, the statement of financial position) (for example,
gains and losses initially recognized in OCI)?
[FASB ASC 815-10-50-4A]

.l 10.

Has the entity properly formatted the disclosures, with respect to the disclosures required by FASB ASC 815-10-50A(a), to conform to the following: (Note: Amounts to be reported for nonderivative instruments pursuant to paragraphs
58 and 66 of FASB ASC 815-20-25 should be the carrying
value of the nonderivative hedging instrument, rather than
the following.)
a.

The fair value of derivative instruments have been disclosed on a gross basis (even if the derivative instruments are subject to master netting agreements and
qualify for net presentation in the statement of financial
position in accordance with FASB ASC 210-20 [general
hedging activities])?

b.

Cash collateral payables and receivables associated
with those instruments have not been added to or netted against fair value amounts?

c.

Fair value amounts have been presented as separate asset and liability values segregated between each of the
following:

d.

.l 11.

i.

Those instruments designated and qualifying as
hedging instruments under FASB ASC 815-20,
presented separately by type of contract?

ii.

Those instruments not designated as hedging instruments, presented separately by type of contract?

The disclosure has identified the line item(s) in the
statement of financial position in which the fair value
amounts for these categories of derivative instruments
are included?
[FASB ASC 815-10-50-4B]

Has the entity properly disclosed in tabular format (with the
exception of item [a], which follows) the gains and losses disclosed pursuant to FASB ASC 815-10-50-4A(b) separately for
all of the following by type of contract:
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Yes

.l 12.

a.

Derivative instruments designated and qualifying as
hedging instruments in fair value hedges and related
hedged items designated and qualifying in fair value
hedges?

b.

The effective portion of gains and losses on derivative
instruments designated and qualifying in cash flow
hedges and net investment hedges that was recognized
in OCI during the current period?

c.

The effective portion of gains and losses on derivative
instruments designated and qualifying in cash flow
hedges and net investment hedges recorded in accumulated OCI during the term of the hedging relationship and reclassified into earnings during the current
period?

d.

The portion of gains and losses on derivative instruments designated and qualifying in cash flow hedges
and net investment hedges representing (i) the amount
of the hedges’ ineffectiveness and (ii) the amount, if
any, excluded from the assessment of hedge effectiveness?

e.

Derivative instruments not designated or qualifying as
hedging instruments under FASB ASC 815-20?
[FASB ASC 815-10-50-4C]

Has the entity properly disclosed separately, pursuant to
question 11, information by type of derivative contract (for
example, interest rate contracts, foreign exchange contracts,
equity contracts, commodity contracts, credit contracts, and
so forth) as well as identify the line item(s) in the statement
of financial performance in which the gains and losses for the
categories of derivative instruments are included?
[FASB ASC 815-10-50-4D]

Trading Derivatives
.l 13.

If the entity’s policy is to include derivative instruments that
are not designated or qualified as hedging instruments under
FASB ASC 815-20 in its trading activities, and the entity elects
not to separately disclose gain and losses as required by
FASB ASC 815-10-50-4C(e), has the entity properly disclosed
the following: (Note: If the disclosure option in this paragraph is elected, the entity should include a footnote in the
required tables referencing the use of this alternative disclosure for trading activities.)
a.
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The gains and losses on its trading activities (including
both derivative and nonderivative instruments) recognized in the statement of financial performance, separately by major types of items (such as fixed income/
interest rates, foreign exchange, equity, commodity,
and credit)?

No

N/A
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Yes
b.

The line items in the statement of financial performance
in which trading activities gains and losses are included?

c.

A description of the nature of its trading activities and
related risks, and how the entity manages those risks?
[FASB ASC 815-10-50-4F]

No

N/A

Credit-Risk-Related Contingent Features
.l 14.

Has the entity properly disclosed, for every annual and interim reporting period for which a statement of financial position and statement of financial performance are presented,
the following information about derivative instruments it
holds or issues (or nonderivative instruments it holds or issues that are designated and qualify as hedging instruments
pursuant to FASB ASC 815-20-25-58 and FASB ASC 815-2025-66) that have credit-risk-related contingent features and
that are in a net liability position at the end of the reporting
period: (Note: Amounts to be reported for nonderivative instruments pursuant to paragraphs 58 and 66 of FASB ASC
815-20-25 should be the carrying value of the nonderivative
hedging instrument, rather than the following.)
a.

The existence and nature of credit-risk-related contingent features and the circumstances in which the features could be triggered in derivative instruments that
are in a net liability position at the end of the reporting
period?

b.

The aggregate fair value amounts of derivative instruments that contain credit-risk-related contingent features that are in a net liability position at the end of the
reporting period?

c.

The aggregate fair value of assets that are already
posted as collateral at the end of the reporting period
and (i) the aggregate fair value of additional assets that
would be required to be posted as collateral and (ii) the
aggregate fair value of assets needed to settle the instrument immediately, if the credit-risk-related contingent features were triggered at the end of the reporting
period?
[FASB ASC 815-10-50-4H]

Information in More Than One Footnote
.l 15.

Has the entity properly included cross-references to other
notes in which derivative-related information is disclosed, if
the disclosures related to derivative instruments (or nonderivative instruments that are designated and qualify as hedging instruments pursuant to paragraphs 58 and 66 of FASB
ASC 815-20-25) are disclosed in more than a single footnote?
[FASB ASC 815-10-50-4I]
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Credit Derivatives
.l 16A. Has the entity properly disclosed the following, as a seller of
credit derivative (as defined in FASB ASC 815-10-50-4J as a
guarantor in a guarantee type contract or any party that provides the credit protection in an option type contract, a credit
default swap, or any other credit derivative), even if the likelihood of the seller’s having to make any payments under the
credit derivative is remote:
a.
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The nature of the credit derivative, including all of the
following:
i.

The approximate term of the credit derivative?

ii.

The reasons for entering into the credit derivative?

iii.

The events or circumstances that would require
the seller to perform under the credit derivative?

iv.

The current status (that is, as of the date of the
statement of financial position) of the payment/
performance risk of the credit derivative?

v.

If the entity uses internal groupings for the purposes of item (iv), how those groupings are determined and used for managing risk?

b.

The maximum potential amount of future payments
(undiscounted) that the seller could be required to
make under the credit derivative, which should not be
reduced by the effect of any amounts that may possibly
be recovered under recourse or collateralization provisions in the credit derivative?

c.

If the terms of the credit derivative provide for no limitation to the maximum potential future payments under the credit derivative, is that fact disclosed?

d.

If the seller is unable to develop an estimate of the maximum potential amount of future payments under the
credit derivative, the reasons why the maximum potential amount cannot be estimated?

e.

The fair value of the credit derivative as of the date of
the statement of financial position?

f.

The nature of
i.

any recourse provisions that would enable the
seller to recover from third parties any of the
amounts paid under the guarantee?

ii.

any assets held either as collateral or by third
parties that, upon the occurrence of any triggering event or condition under the guarantee, the
guarantor can obtain and liquidate to recover all
or a portion of the amounts paid under the guarantee?

No

N/A
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Yes
g.

No

N/A

If estimable, the approximate extent to which the proceeds from liquidation of those assets would be expected to cover the maximum potential amount of future payments under the guarantee?
[FASB ASC 815-10-50-4K]

Note: For hybrid instruments that have embedded credit derivatives, the seller of the embedded credit derivative should disclose the information required for the entire hybrid instrument,
not just the embedded credit derivatives.
[FASB ASC 815-10-50-4L]
Note (ASU No. 2010-11, Derivatives and Hedging (Topic 815):
Scope Exception Related to Embedded Credit Derivatives ):
ASU No. 2010-11 affects FASB ASC 815-10-50-4K, question 16A,
preceding, in the following manner:
●

The “Pending Content” included in FASB ASC 815-1050-4K includes minor wording changes which do not
significantly impact the disclosure requirements; and

●

The “Pending Content” included in FASB ASC 815-1050-4K includes the following additional passage, “The
disclosures required by this paragraph (FASB ASC 81510-50-4K) do not apply to the embedded derivative feature discussed in FASB ASC 815-15-15-9.”

As such, entities that have adopted the provisions of ASU No.
2010-11 should consider the disclosure requirements contained
in question 16A, preceding, with these changes in mind.
Qualitative Disclosures
.l 17.

Although encouraged, but not required, has the entity properly included additional qualitative disclosures for every annual and interim reporting period for which a statement of
financial position and statement of financial performance are
presented related to qualitative items about the entity’s objectives and strategies for using derivative instruments? (Note:
These disclosures may relate to interest rate risk, foreign currency exchange rate risk, commodity price risk, credit risk,
and equity price risk.)
[FASB ASC 815-10-50-5]

Unconditional Purchase Obligations
.l 18.

Has the entity properly disclosed the information required by
FASB ASC 440, Commitments, and FASB ASC 815 if the entity
has unconditional purchase obligations which are subject to
the requirements of those topics?
[FASB ASC 815-10-50-6]

Balance Sheet Offering
.l 19.

Has the entity properly disclosed its policy for offsetting or
not offsetting in accordance with FASB ASC 815-10-45-6?
[FASB ASC 815-10-50-7]
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.l 20.

Has the entity properly disclosed the amounts recognized at
the end of each reporting period for the right to reclaim cash
collateral or the obligation to return cash collateral as follows:
a.

If the entity has made an accounting policy decision to
offset fair value amounts, has it separately disclosed
amounts recognized for the right to reclaim cash collateral or the obligation to return cash collateral that have
been offset against net derivative positions in accordance with FASB ASC 815-10-45-5?

b.

Has the entity separately disclosed amounts recognized
for the right to reclaim cash collateral or the obligation
to return cash collateral under master netting arrangements that have not been offset against net derivative
instrument positions?

c.

If the entity has made an accounting policy decision to
not offset fair value amounts, has it separately disclosed the amounts recognized for the right to reclaim
cash collateral or the obligation to return cash collateral
under master netting arrangements?
[FASB ASC 815-10-50-8]

Certain Contracts on Debt and Equity Securities
.l 21.

H.

Has the entity properly disclosed its accounting policy for the
premium paid (time value) to acquire an option that is classified as held to maturity or available for sale, if applicable?
[FASB ASC 815-10-50-9]

Embedded Derivatives (FASB ASC 815-15)
Presentation

.l 1.

Has the entity properly presented hybrid financial instruments measured at fair value under the election and practicability exception in FASB ASC 815-15-30-1 by either (a) displaying separate line items for the fair value and
non-fair-value carrying amounts or (b) presenting the aggregate of the fair value and non-fair-value amounts and parenthetically disclosing the amount of fair value included in the
aggregate amount?
[FASB ASC 815-15-45-1]

Disclosure
Hybrid Instruments That Are Not Separated
.l 2.
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Has the entity properly disclosed, for those hybrid financial
instruments measured at fair value under the election and
under the practicability exception in FASB ASC 815-15-30-1
on earnings (or other performance indicators for entities that
do not report earnings), the information in paragraphs 28–32
of FASB ASC 825-10-50?
[FASB ASC 815-15-50-1]

No

N/A
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.l 3.

No

N/A

Has the entity properly disclosed information that will allow
users to understand the effect of changes in the fair value of
hybrid financial instruments measured at fair value under the
election and under the practicability exception in FASB ASC
815-15-30-1 on earnings (or other performance indicators for
entities that do not report earnings)?
[FASB ASC 815-15-50-2]

Embedded Conversion Option That Is No Longer Bifurcated
.l 4.

I.

Has the entity properly disclosed, for those embedded conversion options previously accounted for as a derivative instrument under FASB ASC 815-15 (embedded derivatives)
that no longer meet the separation criteria, a description of
the principal changes causing the embedded conversion option to no longer require bifurcation and the amount of the
liability for the conversion option which has been reclassified
to stockholders’ equity?
[FASB ASC 815-15-50-3]

Fair Value Hedging (FASB ASC 815-25)
Disclosure

.l 1.

J.

Has the entity properly disclosed, for every annual and interim reporting period for which a statement of financial position and statement of financial performance are presented,
the following for derivative instruments, as well as nonderivative instruments that may give rise to foreign currency
transaction gains or losses under FASB ASC 830-20, that have
been designated and have qualified as fair value hedging instruments and for the related hedged items:
a.

The net gain or loss recognized in earnings during the
reporting period representing (i) the amount of the
hedges’ ineffectiveness and (ii) the component of the
derivative instruments’ gain or loss, if any, excluded
from the assessment of hedge effectiveness?

b.

The amount of net gain or loss recognized in earnings
when a hedged firm commitment no longer qualifies as
a fair value hedge?
[FASB ASC 815-25-50-1]

Cash Flow Hedges (FASB ASC 815-30)
Presentation
Other Comprehensive Income

.l 1.

Has the entity properly presented, as a separate classification
within OCI, the net gain or loss on any derivative instruments designated and qualifying as cash flow hedging instruments that are reported in comprehensive income pursuant
to FASB ASC 815-20-25-65 and FASB ASC 815-30-35-3?
[FASB ASC 815-30-45-1]
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Disclosure
.l 2.

.l 3.

K.

Has the entity properly disclosed, for every annual and interim reporting period for which a statement of financial position and statement of financial performance are presented,
the following for derivative instruments that have been designated and have qualified as cash flow hedging instruments
and for the related hedged transactions:
a.

A description of the transactions or other events that
will result in the reclassification into earnings of gains
and losses that are reported in accumulated OCI, and
the estimated net amount of the existing gains or losses
at the reporting date that is expected to be reclassified
into earnings within the next 12 months?

b.

The estimated net amount of the existing gains or losses
that are reported in accumulated OCI at the reporting
date that is expected to be reclassified into earnings in
the next 12 months?

c.

The maximum length of time over which the entity is
hedging its exposure to the variability in future cash
flows for forecasted transactions excluding those forecasted transactions related to the payment of variable
interest on existing financial instruments?

d.

The amount of gains and losses reclassified into earnings as a result of the discontinuance of cash flow
hedges because it is probable that the original forecasted transactions will not occur by the end of the
originally specified time period or within the additional period of time discussed in paragraphs 4–5 of
FASB ASC 815-30-40?
[FASB ASC 815-30-50-1]

Has the entity properly disclosed, as a separate component of
OCI, the beginning and ending accumulated derivative instrument gain or loss, the related net change associated with
current period hedging transactions, and the net amount of
any reclassification into earnings?
[FASB ASC 815-30-50-2]

Net Investment Hedges (FASB ASC 815-35)
Disclosure

.l 1.
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Although encouraged, but not required, has the entity properly included additional qualitative disclosures to present a
more complete picture of its activities about derivative instruments by presenting information that may be more useful,
and less likely to be perceived to be out of context or otherwise misunderstood, if similar information is disclosed about
other financial instruments or nonfinancial assets and liabilities to which the derivative instruments are related by activity?
[FASB ASC 815-35-50-2]

No

N/A
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Yes
L.

No

N/A

Contracts in Entity’s Own Equity (FASB ASC 815-40)
Disclosure
l 1.

Has the entity properly disclosed, in the financial statements,
changes in fair value for all contracts within the scope of
FASB 815-40 classified as assets or liabilities as long as the
contracts remain classified as assets or liabilities?
[FASB ASC 815-40-50-1]

l 2.

Has the entity properly disclosed the related disclosures required by FASB ASC 815-10-50; FASB ASC 815-25-50; FASB
ASC 815-30-50; and FASB ASC 815-35-50, if a contract within
the scope of FASB ASC 815-40 meets the definition of a derivative instrument?
[FASB ASC 815-40-50-2]

Reclassifications and Related Accounting Policy Disclosures
l 3.

Has the entity properly disclosed the contract reclassification,
the reason for the reclassification and the effect on the entity’s
financial statements, if contracts within the scope of FASB
ASC 815-40 are reclassified into (or out of) equity during the
life of the instrument (in whole or in part) pursuant to the
provisions of paragraphs 8–13 of FASB ASC 815-40-35?
[FASB ASC 815-40-50-3]

l 4.

Has the entity properly disclosed the accounting policy decision pursuant to FASB ASC 235, if the entity partially reclassifies a contract(s) subject to FASB ASC 815-40?
[FASB ASC 815-40-50-4]

Interaction With Disclosures About Capital Structure
l 5.

Has the entity properly disclosed the following, pursuant to
FASB ASC 505-10-50, if the entity has contracts related to
their capital structure of the following nature:
a.

If the entity has an option or forward contract, has relevant information including (i) the forward rate, (ii) the
option strike price, (iii) the number of shares to which
the contract is indexed, (iv) the settlement date(s), and
(v) the issuers accounting for the contract (asset, liability, or equity) been disclosed?

b.

If the entity’s contract(s) provide settlement alternatives, has the relevant information including (i) who
controls the settlement alternatives and (ii) the maximum number of shares that could be required to be issued to net share settle the contract been disclosed?

c.

If the entity’s contract(s) does not have a fixed or determinable maximum number of shares that may be required to be issued, is the fact that an infinite number
may be required to settle the contract(s) disclosed?
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Yes

M.

d.

For each of the entity’s contract(s) has disclosure been
made of the current fair value for each settlement alternative and how changes in the price of the issuer’s equity instruments affect those settlement amounts? (For
some issuers, a tabular format may provide the most
concise and informative presentation of these data.)

e.

If the entity has temporary equity (for example redeemable stock issued by nonpublic entities) have the disclosures required by FASB ASC 505-10-50-11 been made?
[FASB ASC 815-40-50-5]

No

N/A

Weather Derivatives (FASB ASC 815-40)
Disclosure

.l 1.

N.

Has the entity properly disclosed information for financial instruments, such as those required in FASB ASC 825-10-50, for
weather derivative contracts, which are financial instruments
within the scope of FASB ASC 815-45?
[FASB ASC 815-45-50-1]

Fair Value Measurements and Disclosures (FASB ASC 820-10)33
Disclosure
Additional Disclosure Information

The quantitative disclosures required by FASB ASC 820-10-50 should be presented using a tabular format.
[FASB ASC 820-10-50-8]
.l 1A.

Has the entity properly disclosed information that enables users of its financial statements to assess both of the following:

33
In January 2010, FASB issued ASU No. 2010-06. This ASU requires some new disclosures and clarifies some existing disclosure
requirements about fair value measurement in FASB ASC 820-10. FASB’s objective is to improve these disclosures and, thus, increase the
transparency in financial reporting. Specifically, ASU No. 2010-06 amends FASB ASC 820-10 to now require the following:

●

A reporting entity should disclose separately the amounts of significant transfers in and out of level 1 and level 2 fair value
measurements and describe the reasons for the transfers; and

●

In the reconciliation for fair value measurements using significant unobservable inputs, a reporting entity should present
separately information about purchases, sales, issuances, and settlements.

In addition, ASU No. 2010-06 clarifies the requirements of the following existing disclosures:
●

For purposes of reporting fair value measurement for each class of assets and liabilities, a reporting entity needs to use
judgment in determining the appropriate classes of assets and liabilities; and

●

A reporting entity should provide disclosures about the valuation techniques and inputs used to measure fair value for both
recurring and nonrecurring fair value measurements.

The amendments in this ASU are effective for interim and annual reporting periods beginning after December 15, 2009 (that is, January
1, 2010, for entities with calendar year-ends), except for the disclosures about purchases, sales, issuances, and settlements in the roll
forward of activity in level 3 fair value measurements, see FASB ASC 820-10-50-2(c)(2). Those disclosures are effective for fiscal years
beginning after December 15, 2010 (that is, January 1, 2011, for entities with calendar year-ends), and for interim periods within those
fiscal years. Early adoption is permitted.
This checklist has been updated to include the presentation and disclosure requirements of ASU No. 2010-06.
Readers can refer to the full text of the ASU on the FASB website at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition and open effective date information discussed in FASB ASC 82010-65-7.
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Yes

.l 1B.

.l 2A.

a.

For assets and liabilities that are measured at fair value
on a recurring basis in the periods subsequent to initial
recognition, the inputs used to develop those measurements?

b.

For recurring fair value measurements using significant
unobservable inputs (level 3), the effect of the measurements on earnings (or changes in net assets) for the period?
[FASB ASC 820-10-50-1]

No

N/A

(ASU No. 2010-06) Has the entity properly disclosed information that enables users of its financial statements to assess
both of the following:
a.

For assets and liabilities that are measured at fair value
on a recurring basis in the periods subsequent to initial
recognition, the valuation techniques and inputs used
to develop those measurements?

b.

For recurring fair value measurements using significant
unobservable inputs (level 3), the effect of the measurements on earnings (or changes in net assets) for the period?
[“Pending Content” in FASB ASC 820-10-50-1]

Has the entity properly disclosed the following information,
for each interim and annual period separately for each major
category of assets and liabilities: (Note: For equity and debt
securities, major category should be defined as major security
type as described in FASB ASC 320-10-50-1B, even if the equity or debt securities are not within the scope of FASB ASC
320-10.)
a.

The fair value measurements at the reporting date?

b.

The level within the fair value hierarchy in which the
fair value measurements in their entirety fall, segregating (i) fair value measurements using quoted prices in
active markets for identical assets or liabilities (level 1),
(ii) significant other observable inputs (level 2), and (iii)
significant unobservable inputs (level 3)?

c.

For fair value measurements using significant unobservable inputs (level 3), a reconciliation of the beginning and ending balances, separately presenting
changes during the period attributable to any of the following (may be presented net):
i.

Total gains or losses for the period (realized and
unrealized), segregating those gains or losses included in earnings (or changes in net assets), and
a description of where those gains or losses included in earnings (or changes in net assets) are
reported in the statement of income (or activities)?

ii.

Purchases, sales, issuances, and settlements (net)?
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Yes
iii.

.l 2B.
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Transfers in and out, or both, of level 3 (for example, transfers due to changes in the observability of significant inputs)?

d.

The amount of the total gains or losses for the period
in FASB ASC 820-10-50-1(c)(1) included in earnings (or
changes in net assets) that are attributable to the change
in unrealized gains or losses relating to those assets and
liabilities still held at the reporting date and a description of where those unrealized gains or losses are reported in the statement of income?

e.

The inputs and valuation technique(s) used to measure
fair value and a discussion of changes in valuation
techniques and related inputs, if any, during the period?
[FASB ASC 820-10-50-2]

(ASU No. 2010-06) Has the entity properly disclosed the following information, to meet the objectives of FASB ASC 82010-50-1, for each interim and annual period separately for
each class of assets and liabilities: (Note: The reporting entity
should determine appropriate classes of assets and liabilities
on the basis of guidance in “Pending Content” in FASB ASC
820-10-50-2. It should provide sufficient information to permit reconciliation of the fair value measurement disclosures
for the various classes of assets and liabilities to the line items
in the statement of financial position.)
a.

The fair value measurement at the reporting date?

b.

The level within the fair value hierarchy in which the
fair value measurements in their entirety fall, segregating (i) fair value measurements using quoted prices in
active markets for identical assets or liabilities (level 1),
(ii) significant other observable inputs (level 2), and (iii)
significant unobservable inputs (level 3)?

c.

The amounts of significant transfers between level 1
and level 2 of the fair value hierarchy and the reasons
for the transfers? (Significant transfers into each level
should be disclosed separately from transfers out of
each level. The reporting entity should disclose and
consistently follow its policy for determining when
transfers between levels are recognized. The policy
about the timing of recognizing transfers should be the
same for transfers into the levels as that for transfers
out of the levels. Examples of policies for when to recognize the transfer include [i] the actual date of the
event or change in circumstances that caused the transfer, [ii] the beginning of the reporting period, and [iii]
the end of the reporting period.)

No

N/A
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Yes
d.

.l 3B.

No

N/A

For fair value measurements using significant unobservable inputs (level 3), a reconciliation of the beginning and ending balances, separately presenting
changes during the period attributable to any of the following:
i.

Total gains or losses for the period (realized and
unrealized), separately presenting gains or losses
included in earnings (or changes in net assets),
and gains or losses recognized in OCI, and a description of where those gains or losses included
in earnings (or changes in net assets) are reported
in the statement of income (or activities) or in
OCI?

ii.

Purchases, sales, issuances, and settlements (each
type disclosed separately)?

iii.

Transfers in and out, or both, of level 3 and the
reasons for those transfers? (Significant transfers
into level 3 should be disclosed separately from
significant transfers out of level 3. Examples include [1] the actual date of the event or change in
circumstances that caused the transfer and [2] the
beginning and [3] the end of the reporting period.)

e.

The amount of the total gains or losses for the period
in FASB ASC 820-10-50-1(c)(1) included in earnings (or
changes in net assets) that are attributable to the change
in unrealized gains or losses relating to those assets and
liabilities still held at the reporting date and a description of where those unrealized gains or losses are reported in the statement of income (or activities)?

f.

For fair value measurements using significant other observable inputs (level 2) and significant unobservable
inputs (level 3), a description of the valuation technique
(or multiple valuation techniques) used, such as the
market approach, income approach, or the cost approach, and the inputs used in determining the fair values of each class of assets or liabilities? (Note: If there
has been a change in the valuation technique[s], the reporting entity should disclose that change and the reason for making it.)
[“Pending Content” in FASB ASC 820-10-50-2]

(ASU No. 2010-06) Has the entity properly disclosed both of
the following:
a.

The fair value disclosures required by FASB ASC 82010-50-2(a) on a gross basis?

b.

The reconciliation disclosure required by FASB ASC
820-10-50-2(c)–(d) either gross or net?
[“Pending Content” in FASB ASC 820-10-50-3]
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Liability Issued With an Inseparable Third-Party Credit Enhancement
.l 4.

Has the entity properly disclosed, for a liability issued with
an inseparable third-party credit enhancement that is measured or disclosed at fair value on a recurring basis (and is not
subject to the listed exceptions in FASB ASC 820-10-50-4A),
the existence of a third-party credit enhancement on its issued liability, if such an enhancement exists?
[FASB ASC 820-10-50-4A]

Nonrecurring Measurements
.l 5A.

.l 5B.

Has the entity properly disclosed the following information
regarding assets and liabilities that are measured at fair value
on a nonrecurring basis in periods subsequent to initial recognition, for each interim and annual period separately for
each major category of assets and liabilities: (Note: For equity
and debt securities, major category should be defined as major security type as described in FASB ASC 320-10-50-1B,
even if the equity or debt securities are not within the scope
of FASB ASC 320-10.)
a.

The fair value measurements recorded during the period and the reasons for the measurements?

b.

The level within the fair value hierarchy in which the
fair value measurements in their entirety fall, segregating (i) fair value measurements using quoted prices in
active markets for identical assets or liabilities (level 1),
(ii) significant other observable inputs (level 2), and (iii)
significant unobservable inputs (level 3)?

c.

For fair value measurements using significant unobservable inputs (level 3), a description of the inputs and
the information used to develop the inputs?

d.

The inputs and valuation technique(s) used to measure
fair value and a discussion of changes, if any, in the
valuation technique(s) used to measure similar assets
or liabilities or both in prior periods?
[FASB ASC 820-10-50-5]

(ASU No. 2010-06) Has the entity properly disclosed the following information regarding assets and liabilities that are
measured at fair value on a nonrecurring basis in periods
subsequent to initial recognition, for each interim and annual
period separately for each class of assets and liabilities: (Note:
The reporting entity should determine appropriate classes of
assets and liabilities on the basis of guidance in “Pending
Content” in FASB ASC 820-10-50-2A.)
a.
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The fair value measurement recorded during the period and the reasons for the measurement?

No

N/A
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Yes
b.

The level within the fair value hierarchy in which the
fair value measurement in its entirety fall, segregating
the fair value measurement using quoted prices in active markets for identical assets or liabilities (level 1),
significant other observable inputs (level 2), and significant unobservable inputs (level 3)?

c.

For fair value measurements using significant other observable inputs (level 2) and significant unobservable
inputs (level 3), the disclosure required by FASB ASC
820-10-50-2(e)?
[“Pending Content” in FASB ASC 820-10-50-5]

No

N/A

Fair Value Measurements of Investments in Certain Entities That
Calculate Net Asset Value Per Share (or Its Equivalent)
.l 6A.

Has the entity properly disclosed the following information,
for each interim and annual period, separately, regarding
each major category of investment that are within the scope
of FASB ASC 820-10-15-4 and FASB ASC 820-10-15-5 and that
are measured at fair value on a recurring or nonrecurring basis during the period, information that enables users of its financial statements to understand the nature and risks of the
investment and whether the investment are probably of being
sold at amounts different from net asset value per share (or
its equivalent):
a.

The fair value of the investments in the major category,
and a description of the significant investment strategies of the investee(s) in the major category?

b.

For each major category of investment that includes investments that can never be redeemed with the investees, but the reporting entity receives distributions
through the liquidation of the underlying assets of the
investees, the reporting entity’s estimate of the period
of time over which the underlying assets are expected
to be liquidated by the investees?

c.

The amount of the reporting entity’s unfunded commitments related to investments in the major category?

d.

A general description of the terms and conditions upon
which the investor may redeem investments in the major category?

e.

The circumstances in which an otherwise redeemable
investment in the major category (or a portion thereof)
might not be redeemable. (Note: For those otherwise redeemable investments that are restricted from redemption as of the reporting entity’s measurement date, the
reporting entity should disclose its estimate of when
the restriction from redemption might lapse. If an estimate cannot be made, the reporting entity should disclose that fact and how long the restriction has been in
effect.)
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.l 6B.
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f.

Any other significant restriction on the ability to sell investments in the major category at the measurement
date?

g.

If the reporting entity determines that it is probable
that it will sell an investment(s) for an amount different
from net asset value per share (or its equivalent) as described in FASB ASC 820-10-35-62, the reporting entity
should disclose the total fair value of all investments
that meet those criteria and any remaining actions required to complete the sale?

h.

If a group of investments would otherwise meet the criteria in FASB ASC 820-10-35-62 but the individual investments to be sold have not been identified, so the
investments continue to qualify for the practical expedient in FASB ASC 820-10-35-59, the reporting entity
should disclose its plans to sell and any remaining actions required to complete the sale(s)?
[FASB ASC 820-10-50-6A]

(ASU No. 2010-06) Has the entity properly disclosed the following information, for each interim and annual period, separately, regarding each class of investment that are within the
scope of paragraphs 4–5 of FASB ASC 820-10-15 and that are
measured at fair value, information that enables users of its
financial statements to understand the nature and risks of the
investment and whether the investment are probably of being
sold at amounts different from net asset value per share (or
its equivalent):
a.

The fair value of the investments in the class, and a description of the significant investment strategies of the
investee(s) in the class?

b.

For each class of investment that includes investments
that can never be redeemed with the investees, but the
reporting entity receives distributions through the liquidation of the underlying assets of the investees, the
reporting entity’s estimate of the period of time over
which the underlying assets are expected to be liquidated by the investees?

c.

The amount of the reporting entity’s unfunded commitments related to investments in the class?

d.

A general description of the terms and conditions upon
which the investor may redeem investments in the
class?

No

N/A
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e.

The circumstances in which an otherwise redeemable
investment in the class (or a portion thereof) might not
be redeemable? (Note: For those otherwise redeemable
investments that are restricted from redemption as of
the reporting entity’s measurement date, the reporting
entity should disclose its estimate of when the restriction from redemption might lapse. If an estimate cannot be made, the reporting entity should disclose that
fact and how long the restriction has been in effect.)

f.

Any other significant restriction on the ability to sell investments in the class at the measurement date?

g.

If the reporting entity determines that it is probable
that it will sell an investment(s) for an amount different
from net asset value per share (or its equivalent) as described in FASB ASC 820-10-35-62, the reporting entity
should disclose the total fair value of all investments
that meet those criteria and any remaining actions required to complete the sale?

h.

If a group of investments would otherwise meet the criteria in FASB ASC 820-10-35-62 but the individual investments to be sold have not been identified, so the
investments continue to qualify for the practical expedient in FASB ASC 820-10-35-59, the reporting entity
should disclose its plans to sell and any remaining actions required to complete the sale(s)?
[“Pending Content” in FASB ASC 820-10-50-6A]

No

N/A

Relation to Other Disclosure Requirements
.l 7.

O.

Although encouraged but not required, has the entity
a.

combined the fair value information disclosed under
FASB ASC 820-10-50 with the fair value information
disclosed under other FASB ASC subtopics (for example, FASB ASC 825-10-50) in the periods in which those
disclosures are required, if practicable?

b.

disclosed information about other similar measurements (for example, inventories measured at market
value under FASB ASC 330, Inventory), if practicable?
[FASB ASC 820-10-50-9]

Financial Instruments (FASB ASC 825-10)
Presentation
Fair Value Option—Statement of Financial Position

.l 1.

Has the entity properly presented information that separates
the reported assets and liabilities that are measured at fair
value, pursuant to the fair value option in FASB ASC 825,
from the carrying amounts of similar assets measured using
another measurement attribute by either
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a.

presenting the aggregate of fair value and non-fairvalue amounts in the same line item in the statement of
financial position and parenthetically disclosing the
amount measured at fair value included in the aggregate amount, or

b.

presenting two separate line items to display the fair
value and non-fair-value carrying amounts?
[FASB ASC 825-10-45 par. 1–2]

No

N/A

Fair Value Option—Statement of Cash Flows
.l 2.

Has the entity properly presented cash receipts and cash payments related to items measured at fair value according to
their nature and purpose as required by FASB ASC 230?
[FASB ASC 825-10-45-3]

Disclosure
Applicability of This Subsection—Entities
Additional Disclosure Information
The disclosure about fair values of financial instruments is optional (for annual reporting periods) for reporting entities that meet all of the following criteria:
●

Are nonpublic entities as defined in the FASB ASC glossary,

●

Have total assets of less than $100 million on the date of the financial statements, and

●

Have no instrument that, in whole or in part, is accounted for as a derivative instrument under
FASB ASC 815, other than commitments related to the origination of mortgage loans to be held for
sale during the reporting period.

This criterion should be applied to the most recent year presented in comparative financial statements to
determine the applicability of FASB ASC 825-10-50.
The following table clarifies the requirements for disclosures if prior periods are presented in comparative
financial statements.
If Disclosures for the Current
Period Are:

And Disclosures for Prior
Periods Were:

Then Disclosures for Prior
Periods Presented in
Comparative Statements Are:

Optional
Optional
Required
Required

Optional
Required
Optional
Required

Optional
Optional
Optional
Required

[FASB ASC 825-10-50 par. 3–7]
Transactions
.l 3.

Has the entity properly not made disclosure if the requirements of FASB ASC 825-10-50 paragraphs 10–16 for the following items:
a.

FSP §11,100.01

Employers’ and plans’ obligations for pension benefits,
other postretirement benefits including health care and
life insurance benefits, postemployment benefits, employee stock option and stock purchase plans, and
other forms of deferred compensation agreements?
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Yes
b.

Substantively extinguished debt subject to the disclosure requirements of FASB ASC 405-20?

c.

Insurance contracts, other than financial guarantees
and investment contracts, as discussed in FASB ASC
944-20?

d.

Lease contracts as defined in FASB ASC 840, Leases?

e.

Warranty obligations?

f.

Unconditional purchase obligations as defined in FASB
ASC 440-10-50-2?

g.

Investments accounted for under the equity method in
accordance with the requirements of FASB ASC 323, Investments—Equity Method and Joint Ventures?

h.

Noncontrolling interests and equity investments in consolidated subsidiaries?

i.

Equity instruments issued by the entity and classified
in stockholders’ equity in the statement of financial position?
[FASB ASC 825-10-50-8]

No

N/A

Fair Value of Financial Instruments
.l 4.

Has the entity properly made the following disclosures:
a.

Either in the body of the financial statements or in the
accompanying notes, the fair value of financial instruments for which it is practicable to estimate the value?

b.

The method or methods and significant assumptions
used to estimate the fair value of financial instruments?

c.

A description of the changes in the method or methods
and significant assumptions used to estimate the fair
value of financial instruments, if any, during the period?
[FASB ASC 825-10-50-10]

.l 5.

Has the entity properly disclosed fair value in the notes together with the related carrying amount in a form that clarifies both (a) whether the fair value and carrying amount represent assets or liabilities and (b) how the carrying amounts
relate to what is reported in the statement of financial position?
[FASB ASC 825-10-50-11]

.l 6.

Has the entity properly disclosed, if fair value information is
disclosed in more than a single note, a summary table of the
fair value and related carrying amounts in one note, and does
the note cross-reference to the location(s) of the remaining required disclosures?
[FASB ASC 825-10-50-12]
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Yes
.l 7.

Has the entity properly not disclosed a net presentation of the
fair value of financial instruments with the fair value of other
financial instruments, even if those financial instruments are
of the same class or are otherwise considered to be related,
except to the extent that the offsetting of carrying amounts in
the statement of financial position is permitted under the general principle in FASB ASC 210-20-45-1, or the exceptions for
master netting arrangements in FASB ASC 815-10-45-5 and
for amounts related to certain repurchase and reverse repurchase agreements in paragraphs 11–17 of FASB ASC 210-2045?
[FASB ASC 825-10-50-15]

.l 8.

Has the entity properly made both of the following disclosures if it is not practicable (see FASB ASC 825-10-50 paragraphs 17–19 for a definition of practicable in this context) to
estimate the fair value of a financial instrument or a class of
financial instruments:
a.

Information pertinent to estimating the fair value of
that financial instrument or class of financial instruments, such as the carrying amount, effective interest
rate, and maturity?

b.

The reasons why it is not practicable to estimate fair
value?
[FASB ASC 825-10-50-16]

Concentration of Credit Risk
.l 9.

Has the entity properly disclosed, except as indicated in
FASB ASC 825-10-50-22, all significant concentrations of
credit risk arising from all financial instruments, whether
from an individual counterparty or groups of counterparties?
(Note: Group concentrations of credit risk exist if a number
of counterparties are engaged in similar activities and have
similar economic characteristics that would cause their ability
to meet contractual obligations to be similarly affected by
changes in economic or other conditions.) (Note: This disclosure includes derivatives.)
[FASB ASC 825-10-50-20]

.l 10.

Has the entity properly disclosed the following about each
significant concentration: (Note: These disclosure requirements do not apply to financial instruments described in
FASB ASC 825-10-50-8[a], [c], [e], or [f], except for reinsurance
receivables and prepaid reinsurance premiums or financial
instruments of a pension plan, including plan assets, if subject
to the accounting and reporting requirements of FASB ASC
715, Compensation—Retirement Benefits.) See the preceding,
with regard to derivatives.
a.
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Information about the (shared) activity, region, or economic characteristic that identifies the concentration?

No

N/A
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Yes
b.

The maximum amount of loss due to credit risk that,
based on the gross fair value of the financial instrument, the entity would incur if parties to the financial
instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the
amount due proved to be of no value to the entity?

c.

The entity’s policy of requiring collateral or other security to support financial instruments subject to credit
risk, information about the entity’s access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting
those financial instruments?

d.

The entity’s policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for
which the entity is a party, and a brief description of
the terms of those arrangements, including the extent
to which they would reduce the entity’s maximum
amount of loss due to credit risk?
[FASB ASC 825-10-50-21]

No

N/A

Market Risk of All Financial Instruments
.l 11.

Although encouraged but not required, has the entity properly disclosed quantitative information about the market risks
of financial instruments that is consistent with the way it
manages or adjusts those risks? Although appropriate ways
of reporting that quantitative information will differ, possibilities include the following: (Note: The following is not an exhaustive list and the entity is encouraged to develop other
ways of reporting quantitative information.)
a.

More details about current positions and perhaps activity during the period?

b.

The hypothetical effects on comprehensive income (or
net assets), or annual income, of several possible
changes in market prices?

c.

A gap analysis of interest rate repricing or maturity
dates?

d.

The duration of the financial instruments?

e.

The entity’s value at risk from derivatives and from
other positions at the end of the reporting period and
the average value at risk during the year?
[FASB ASC 825-10-50-23]

Fair Value Option—Required Disclosures as of Each Date for Which
an Interim or Annual Statement of Financial Position Is Presented
.l 12.

Has the entity properly disclosed, as of each date for which a
statement of financial position is presented, the following information about items measured at fair value under the option in FASB ASC 825:

FSP §11,100.01
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Yes
a.

Management’s reasons for electing a fair value option
for each eligible item or group of similar eligible items?

b.

The following information of the fair value option is
elected for some but not all eligible items within a
group of similar eligible items:

c.

d.

e.

FSP §11,100.01

i.

A description of those similar items and the reasons for partial election?

ii.

Information to enable users to understand how
the group of similar items relates to individual
line items on the statement of financial position?

The following information for each line item in the
statement of financial position that includes an item or
items for which the fair value option has been elected:
i.

Information to enable users to understand how
each line item in the statement of financial position relates to major categories of assets and liabilities presented in accordance with the fair
value disclosure requirements in FASB ASC 820,
Fair Value Measurements and Disclosures?

ii.

The aggregate carrying amount of items included
in each line item in the statement of financial position that are not eligible for the fair value option, if any?

The difference between the aggregate fair value and the
aggregate unpaid principal balance of the following:
i.

Loans and long term receivables (other than securities subject to FASB ASC 320, Investments—Debt and Equity Securities) that have contractual principal amounts and for which the fair
value option has been elected?

ii.

Long term debt instruments that have contractual principal amounts and for which the fair
value option has been elected?

For loans held as assets for which the fair value option
has been elected,
i.

the aggregate fair value of loans that are 90 days
or more past due?

ii.

if the entity’s policy is to recognize interest income separately from other changes in fair value,
the aggregate fair value of loans in nonaccrual
status?

iii.

the difference between the aggregate fair value
and the aggregate unpaid principal balance for
loans that are 90 days or more past due, in nonaccrual status, or both?

No

N/A
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Yes
f.

No

N/A

The information required by FASB ASC 323-10-50-3
(equity method and joint venture investments) for investments that would have been accounted for under
the equity method if the entity had not chosen to apply
the fair value option? (Note: This disclosure applies to
investments in common stock, in-substance common
stock, and other investments that both [i] would otherwise be required to be accounted for under the equity
method and [ii] would be required to satisfy the requirements of FASB ASC 323-10-50-3. When applying
this item, the entity should apply the guidance of FASB
ASC 323-10-50-2 and FASB ASC 323-10-50-3[a] and [c].)
[FASB ASC 825-10-50-28]

Fair Value Option—Required Disclosures for Each Period for
Which an Interim or Annual Income Statement Is Presented
.l 13.

Has the entity properly disclosed, for each period for which
an interim or annual income statement is presented, the following information about items measured at fair value under
the option in FASB ASC 825:
a.

For each line item in the statement of financial position,
the amounts of gains and losses from fair value
changes included in earnings during the period and in
which line in the income statement those gains and
losses are reported? (An entity may meet this requirement by disclosing amounts of gains and losses that include amounts of gains and losses for other items measured at fair value, such as items required to be
measured at fair value.)

b.

A description of how interest and dividends are measured and where they are reported in the income statement?

c.

For loans and other receivables held as assets, (i) the
estimated amount of gains or losses included in earnings during the period attributable to changes in instrument-specific credit risk and (ii) how the gains or losses
attributable to changes in instrument-specific credit risk
were determined?

d.

For liabilities with fair values that have been significantly affected during the reporting period by changes
in the instrument-specific credit risk, (i) the estimated
amount of gains and losses from fair value changes included in earnings that are attributable to changes in
the instrument-specific credit risk, (ii) qualitative information about the reasons for those changes, and (iii)
how the gains and losses attributable to changes in instrument-specific credit risk were determined?
[FASB ASC 825-10-50-30]

FSP §11,100.01
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Yes
Fair Value Option—Other Required Disclosures
.l 14.

Has the entity properly disclosed, for its annual period only,
the methods and significant assumptions used to estimate the
fair value of items for which the fair value option has been
elected?
[FASB ASC 825-10-50-31]

.l 15.

Has the entity properly disclosed the following information
in the financial statements for the period of the election, if it
had elected the fair value option at the time one of the events
in FASB ASC 825-10-25-4(d)–(e) occurred:

P.

a.

Qualitative information about the nature of the event?

b.

Quantitative information by line item in the statement
of financial position indicating which line items in the
income statement include the effect of initially electing
the fair value option for an item?
[FASB ASC 825-10-50-32]

Financial Instruments—Registration Payment Arrangements
(FASB ASC 825-20)
Disclosure

.l 1.

Has the entity properly disclosed the following information,
if it is the issuer of a registration payment arrangement, about
each registration payment arrangement or each group of similar arrangements: (Note: These disclosures are incremental to
the disclosures that may be required under other applicable
GAAP and are required even if the likelihood of the issuer
having to make any payments under the arrangement is remote.)
a.
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The nature of the registration payment, including all of
the following:
i.

The approximate term of the arrangement?

ii.

The financial instrument(s) subject to the arrangement?

iii.

The events or circumstances that would require
the issuer to transfer consideration under the arrangement?

b.

Any settlement alternatives contained in the terms of
the registration payment arrangement, including the
party that controls the settlement alternatives?

c.

The maximum potential amount of consideration, undiscounted, that the issuer could be required to transfer
under the registration payment arrangement (including
the maximum number of shares that may be required
to be issued)?

d.

If the terms of the arrangement provide for no limitation to the maximum potential consideration (including
shares) to be transferred, that fact should be disclosed?

No

N/A
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Yes

Q.

e.

The current carrying amount of the liability representing the issuer’s obligations under the registration payment arrangement?

f.

The income statement classification of any gains or
losses resulting from changes in the carrying amount of
the liability representing the issuer’s obligations under
the registration payment arrangement?
[FASB ASC 825-20-50 par. 1–2]

No

N/A

Foreign Currency Transactions (FASB ASC 830-20)
Presentation

.l 1.

Has the entity properly presented the aggregate transaction
gain or loss included in determining net income for the period in the financial statement or the notes thereto?
[FASB ASC 830-20-45-1]

Disclosure
.l 2.

Has the entity properly disclosed, in the notes to the financial
statements (if not disclosed in the financial statements, as discussed in FASB ASC 830-20-45-2), the aggregate transaction
gain or loss included in determining net income for the period?
[FASB ASC 830-20-50-1]

Subsequent Rate Changes
.l 3.

Has the entity properly disclosed significant rate changes that
have occurred after the date of the financial statements and
the effects on unsettled balances related to foreign currency
transactions? (Note: The disclosure should include consideration of changes in unsettled transactions from the date of the
financial statements to the date that the rate changed. Further, in some cases it is not practicable to determine these
changes, if so, the entity should disclose that fact.)
[FASB ASC 830-20-50-2]

Effects of Rate Changes on Results of Operations
.l 4.

Although encouraged but not required, has the entity supplemented the disclosures required by FASB ASC 830-20-50 with
an analysis and discussion of the effects of rate changes on
the reported results of operations? (Note: This type of disclosure might include the mathematical effects of translating
revenue and expenses at rates that are different from those
used in a preceding period as well as the economic effects of
rate changes, such as the effects on selling prices, sales volume, and cost structures. The purpose is to assist financial
report users in understanding the broader economic implications of rate changes and to compare recent results with those
of prior periods.)
[FASB ASC 830-20-50-3]
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Yes
R.

Foreign Currency Matters—Translation of Financial Statements
(FASB ASC 830-30)
Disclosure
Analysis of Changes in Cumulative Translation Adjustment

.l 1.

Has the entity properly disclosed an analysis of the changes
during the period in the accumulated amount of translation
adjustments reported in equity, either in a separate financial
statement, as a part of the statement of changes in equity or
in the notes to the financial statements? (See FASB ASC 83030-45-20 for minimum disclosure requirements.)
[FASB ASC 830-30-50-1]

Subsequent Rate Change
.l 2.

S.

Has the entity properly disclosed, if significant rate changes
have occurred after the date of the financial statements, the
rate change and its effects on unsettled balances related to
foreign currency transactions, if significant?
[FASB ASC 830-30-50-2]

Capitalization of Interest (FASB ASC 835-20)
Disclosure

.l 1.

T.

Has the entity properly disclosed the following information
regarding interest cost, in the financial statement or related
notes:
a.

For accounting periods in which no interest is capitalized, the amount of interest cost incurred and charged
to expense during the period?

b.

For an accounting period in which some interest cost is
capitalized, the total amount of interest cost incurred
during the period and the amount thereof that has been
capitalized?
[FASB ASC 835-20-50-1]

Imputation of Interest (FASB ASC 835-30)
Disclosure

.l 1.
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If a note is noninterest bearing or has an inappropriate stated
interest rate
a.

is the discount or premium presented as a deduction
from or addition to the face amount of the note?

b.

does the disclosure include the effective interest rate
and face amount of the note?

c.

is amortization of discount or premium reported as interest in the income statement? (Note: See FASB ASC
835-30-55-8 for an illustration of balance sheet presentation of a discount on a note.)

d.

are issue costs reported on the balance sheet as deferred
charges?
[FASB ASC 835-30-45 par. 1–4]

No

N/A
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Yes

No

N/A

Note: The requirements of FASB ASC 835-30 do not apply to the amortization of premium and discount and the debt issuance costs of liabilities that are reported at fair value.
U.

Leases—Overall (Lessees) (FASB ASC 840-10)
Presentation

.l 1.

Has the entity properly presented the accounts of any subsidiaries whose principal business activity is leasing property or
facilities to the parent or other affiliated entities on a consolidated basis? (Note: The equity method is not adequate for fair
presentation of those subsidiaries.)
[FASB ASC 840-10-45-1]

Disclosure
.l 2.

Has the entity properly disclosed the nature and extent of
leasing transactions with related parties?
[FASB ASC 840-10-50-1]

.l 3.

Has the entity, as a lessee, properly disclosed, in its financial
statements or notes thereto, a general description of its leasing arrangements, including, but not limited to:

V.

a.

The basis on which contingent rental payments are determined?

b.

The existence and terms of renewal or purchase options
and escalation clauses?

c.

Restrictions imposed by lease agreements, such as
those concerning dividends, additional debt, and further leasing?
[FASB ASC 840-10-50-2]

Operating Leases (Lessees) (FASB ASC 840-20)
Presentation

.l 1.

Has the entity properly presented rental costs in the lessee’s
income from continuing operations?
[FASB ASC 840-20-45-1]

Disclosure
.l 2.

Has the entity properly disclosed, for all operating leases, the
rental expense for each period for which an income statement
is presented, with separate amounts for minimum rentals,
contingent rentals, and sublease rentals? (Note: Rental payments under leases with terms of a month or less that were
not renewed need not be included.)
[FASB ASC 840-20-50-1]
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Yes
.l 3.

Has the entity properly disclosed, for all operating leases
having initial or remaining noncancelable lease terms in excess of one year (a) the future minimum rental payments required as of the date of the latest balance sheet presented, in
aggregate and for each of the five succeeding fiscal years, and
(b) the total of minimal rentals to be received in the future
under noncancelable subleases as of the date of the latest balance sheet presented?
[FASB ASC 840-20-50-2]

.l 4.

If there is a modification of lease terms and the increase in
lease payments is a termination penalty, is the accounting
policy disclosed in accordance with FASB ASC 235, Notes to
Financial Statements?
[FASB ASC 840-20-55-6]

W.

Capital Leases (Lessees) (FASB ASC 840-30)
Presentation

.l 1.

Has the entity properly presented assets recorded under capital leases and the accumulated amortization thereon separately in the lessee’s balance sheet or notes thereto?
[FASB ASC 840-30-45-1]

.l 2.

Has the entity properly presented obligations under capital
leases and separately identified them as such in the lessee’s
balance sheet and have they been properly classified using
the same consideration as other obligations in classifying
them with current and noncurrent liabilities in classified balance sheets?
[FASB ASC 840-30-45-2]

.l 3.

Has the entity properly presented interest expense or amortization of leased assets with depreciation expense and properly disclosed that fact, or properly presented the amortization charge as a separate disclosure in the financial
statements or notes thereto?
[FASB ASC 840-30-45-3]

Disclosure
.l 4.

Has the entity properly disclosed the following information,
in the financial statements or notes thereto, about capital
leases:
a.
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The gross amounts of assets recorded under capital
leases as of each balance-sheet date presented by major
classes according to nature or function? (Note: This information may be combined with comparable information for owned assets.)

No

N/A
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Yes

X.

b.

The future minimum lease payments as of the latest
balance sheet presented in the aggregate and for each
of the five succeeding fiscal years with separate deductions from the total for the amount representing executory costs, including any profit thereon, included in the
minimum lease payments and for the amount of imputed interest necessary to reduce net minimum lease
payments to present value?

c.

The total of future minimum sublease rentals to be received in the future under noncancelable subleases as
of the latest balance-sheet date?

d.

The total contingent rentals actually incurred for each
period for which an income statement is presented?
[FASB ASC 840-30-50-1]

No

N/A

Sale-Leaseback Transactions (Lessees) (FASB ASC 840-40)
Disclosure

.l 1.

Has the entity properly disclosed in the financial statements,
as a seller-lessee, a description of the terms of the sale-leaseback transaction including future commitments, obligations,
provisions, or circumstances that require or result in the
seller-lessee’s continuing involvement?
[FASB ASC 840-40-50-1]

Real Estate—Transactions That Do Not Qualify for Sale-Leaseback
Accounting
.l 2.

Y.

Has the entity properly disclosed in the financial statements,
as a seller-lessee that has accounted for a sale-leaseback transaction by the deposit method or as a financing according to
the guidance of FASB ASC 840-40, both of the following:
a.

The obligation for future minimum lease payments as
of the date of the latest balance sheet presented in the
aggregate and for each of the five succeeding fiscal
years?

b.

The total of minimum sublease rentals, if any, to be received in the future under noncancelable subleases in
the aggregate and for each of the five succeeding fiscal
years?
[FASB ASC 840-40-50-2]

Leases—Overall (Lessors) (FASB ASC 840-10)
Disclosure

.l 1.

Has the entity properly disclosed the nature and extent of
leasing transactions with related parties?
[FASB ASC 840-10-50-1]

.l 2.

Has the entity properly disclosed, in the financial statements
or footnotes thereto, a general description of the leasing arrangements if a significant part of the entity’s business activities is leasing activity?
[FASB ASC 840-10-50-4]
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Yes
.l 3.

Z.

Has the entity properly disclosed (a) its accounting policy for
contingent rental income, and (b) if a lessor accrues contingent rental income before the lessee’s achievement of the
specified target (provided the achievement of that target is
considered probable), disclosure of the impact on rental income presented as if the lessor’s accounting policy was to
defer contingent rental income until the specified target is
met?
[FASB ASC 840-10-50-5]

Operating Leases (Lessors) (FASB ASC 840-20)
Presentation

.l 1.

Has the entity properly presented leased property with or
near property, plant, and equipment in the balance sheet?
[FASB ASC 840-20-45-2]

.l 2.

Has the entity properly presented accumulated depreciation
as a deduction in the investment in the leased property in the
balance sheet?
[FASB ASC 840-20-45-3]

Disclosure
.l 3.

Has the entity properly disclosed, in the financial statements
or footnotes thereto, the following, if a significant part of the
entity’s business activities are the result of leasing activity:
a.

The cost and carrying amount (if different) of property
on lease or held for leasing by major classes of property
according to nature and function, and the amount of
accumulated depreciation in total as of the latest balance-sheet date?

b.

The minimum future rentals on noncancelable leases as
of the latest balance-sheet date presented, in the aggregate and for each of the five succeeding fiscal years?

c.

The total contingent rentals included in income for each
period for which an income statement is presented?
[FASB ASC 840-20-50-4]

AA. Capital Leases (Lessors) (FASB ASC 840-30)
Presentation
Sales-Type Leases and Direct Financing Leases
.l 1.
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Has the entity properly presented the net investment in a
sales-type or direct financing lease(s) using the same considerations as other assets in classification as current or noncurrent assets in a classified balance sheet?
[FASB ASC 840-30-45-4]

No

N/A
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Yes

No

N/A

Leveraged Leases
.l 2.

Has the entity properly presented, for the purposes of presenting the investment in a leveraged lease, the amount of
related deferred taxes separately from the remainder of the
net investment, in the balance sheet, and the amount of pretax income, the tax effect of pretax income, and the amount
of investment tax credit recognized, separately, in the income
statement or notes thereto?
[FASB ASC 840-30-45-5]

Disclosure
Sales-Type Leases and Direct Financing Leases
.l 3.

Has the entity properly disclosed, in the financial statements
or footnotes thereto, the following, if a significant part of the
entity’s business activities are the result of sales-type and direct financing leasing activity:
a.

The components of the net investment in sales-type and
direct financing leases as of each balance-sheet date:
i.

Future minimum lease payments to be received,
with separate deductions for (1) amounts representing executory costs, including any profit
thereon, included in minimum lease payments
and (2) the accumulated allowances for uncollectible minimum lease payments receivable?

ii.

The unguaranteed residual values accruing to the
benefit of the lessor?

iii.

For direct financing leases only, initial direct
costs?

iv.

Unearned income?

b.

The future minimum lease payments to be received for
each of the five succeeding fiscal years as of the latest
balance sheet presented?

c.

The total contingent rentals included in income for each
period for which an income statement is presented?
[FASB ASC 840-30-50-4]

Leveraged Leases
.l 4.

Has the entity properly disclosed, in the notes to the financial
statements, the following, as set forth in FASB ASC 840-3025-8, if a significant part of the entity’s business activities are
the result of leveraged leasing activity:
a.

Rentals receivable?

b.

Investment-tax-credit receivable?

c.

Estimated residual value of the leased asset?

d.

Unearned and deferred income?
[FASB ASC 840-30-50-5]

FSP §11,100.01

200

Health Care Entities

Yes
.l 5.

BB.

Has the entity properly disclosed, if accounting for the effect
on leveraged leases of the change in tax rates results in a significant variation from the customary relationship between
income tax expense and pretax accounting income and the
reason for that variation is not otherwise apparent, the reason
for that variation?
[FASB ASC 840-30-50-6]

Nonmonetary Transactions (FASB ASC 845-10)
Disclosure

.l 1.

.l 2.

Has the entity properly disclosed the following, related to
nonmonetary transactions during the period:
a.

The nature of the transactions?

b.

The basis of accounting for the assets transferred?

c.

Any gains or losses recognized on the transfers?
[FASB ASC 845-10-50-1]

Has the entity properly disclosed, in each period’s financial
statements, the amount of gross operating revenue recognized as a result of nonmonetary transactions (see FASB ASC
505-50)?
[FASB ASC 845-10-50-2]

Purchase and Sale of Inventory
.l 3.

CC.

Has the entity properly disclosed the amount of revenue and
costs (or gains and losses) associated with inventory exchanges recognized at fair value?
[FASB ASC 845-10-50-3]

Related Party Disclosures (FASB ASC 850-10)
Disclosure

.l 1.
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Has the entity properly disclosed the following for material
related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business (excluding any that are eliminated
in the preparation of consolidated or combined financial
statements):
a.

The nature of the relationship(s) involved?

b.

A description of the transactions, including transactions to which no amounts or nominal amounts were
ascribed, for each of the periods for which income
statements are presented, and such other information
deemed necessary to an understanding of the effects of
the transactions on the financial statements?

c.

The dollar amounts of transactions for each of the periods for which income statements are presented and the
effect of any change in the method of establishing the
terms from that used in the preceding period?

d.

Amounts due from or to related parties as of the date
of each balance sheet presented and, if not otherwise
apparent, the terms and manner of settlement?

No

N/A
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Yes
e.

No

N/A

If the entity issues separate financial statements and is
a member of a group that files a consolidate tax return,
i.

the aggregate amount of current and deferred tax
expense for each statement of earnings presented
and the amount of any tax-related balances due
to or from affiliates as of the date of each statement of financial position presented?

ii.

the principal provisions of the method by which
the consolidated amount of current and deferred
tax expense is allocated to members of the group
and the nature and effect of any changes in that
method (and in determining related balances to
or from affiliates) during the years for which the
preceding disclosures are presented?
[FASB ASC 850-10-50-1]

.l 2.

Has the entity shown separately notes or accounts receivable
from officers, employees, or affiliated entities and not included them under a general heading (such as notes receivable or accounts receivable)?
[FASB ASC 850-10-50-2]

.l 3.

Has the entity properly disclosed, if necessary to understand
the relationship, the name of the related party?
[FASB ASC 850-10-50-3]

.l 4.

Has the entity properly not disclosed duplicate disclosures in
a separate set of financial statements that are presented in the
financial report of another entity (the primary entity) if those
separate financial statements are also consolidated or combined in a complete set of financial statements and both sets
of financial statements are presented in the same financial report?
[FASB ASC 850-10-50-4]

Purchase and Sales of Inventory
.l 5.

Has the entity properly disclosed representations about transactions with related parties in such a manner that they avoid
the implication that the related party transactions were consummated at arm’s length, or if such implications are made,
can they be substantiated?
[FASB ASC 850-10-50-5]

Control Relationships
.l 6.

If the reporting entity and one or more other entities are under common ownership or common control and the existence
of that control could result in operating results or financial
position of the reporting entity being significantly different
from those that would have been obtained if the entities were
autonomous, has the entity properly disclosed the nature of a
control relationship, even if there are no transactions between
the entities?
[FASB ASC 850-10-50-6]
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Yes

No

N/A

DD. Reorganizations (FASB ASC 852-10 and FASB ASC 852-20)
Additional Presentation and Disclosure Information
For entities involved in reorganizations, see FASB ASC 852-10 for presentation and disclosure information.
For entities involved in quasi-reorganizations, see FASB ASC 852-20 for presentation and disclosure information.
EE.

Subsequent Events (FASB ASC 855-10)34
Disclosure
Dates Through Which Subsequent Events Have Been Evaluated

.l 1.

Has the entity properly disclosed the following regarding
subsequent events:
a.

The date through which subsequent events have been
evaluated?

b.

Whether the date disclosed in item (a) is the date the
financial statements were issued, or the date the financial statements were available to be issued?
[FASB ASC 855-10-50-1]

Nonrecognized Subsequent Events
.l 2.

.l 3.

Has the entity properly disclosed the following regarding
nonrecognized subsequent events such that the financial
statements are kept from being misleading:
a.

The nature of the event?

b.

An estimate of its financial effect, or a statement that
such an estimate cannot be made?
[FASB ASC 855-10-50-2]

Has the entity considered disclosing, regarding significant
nonrecognized subsequent events, historical financial statements with pro forma financial data, including the presentation of pro forma statements (usually a balance sheet only, in
columnar form on the face of the historical statements)?
[FASB ASC 855-10-50-3]

34
In February 2010, FASB issued ASU No. 2010-09, Subsequent Events (Topic 855): Amendments to Certain Recognition and Disclosure
Requirements. This ASU amends the guidance to require entities (except Securities and Exchange Commission [SEC] filers and conduit
debt obligors [CDOs]) to evaluate subsequent events through the date that the financial statements are available to be issued. SEC filers
and CDOs should evaluate subsequent events through the date the financial statements are issued. Entities other than SEC filers should
disclose both the date through which subsequent events have been evaluated and whether that date is the "issued" date or "available to
be issued" date.

The amendments in this ASU were effective immediately upon issuance, except for CDOs. The amendments in this ASU are effective
for CDOs for interim and annual periods ending after June 15, 2010 (that is, December 31, 2010, for entities with calendar year-ends).
This checklist has been updated to include the presentation and disclosure requirements of ASU No. 2010-09.
Readers can refer to the full text of the ASU on the FASB website at www.fasb.org.
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Yes

No

N/A

Reissuance of Financial Statements
.l 4.

FF.

Has the entity properly disclosed in revised financial statements the dates through which subsequent events have been
evaluated in both the issued or available to be issued financial statements and in the revised financial statements?
[FASB ASC 855-10-50-4]

Transfers and Servicing (FASB ASC 860-10)35
Disclosure
Additional Disclosure Information

FASB ASC 860-10-50 contains disclosures for both nonpublic and public companies. See the following section, “Public Entity Disclosures,” for required disclosures specific to public entities.
.l 1A.

If it is not practicable to estimate the fair value of certain assets obtained or liabilities incurred in transfers of financial assets during the period, has the entity disclosed a description
of those items and the reasons why it is not practicable to
estimate their fair value?
[FASB ASC 860-10-50-1]
Note (ASU No. 2009-16): This paragraph has been superseded
by ASU No. 2009-16.
[“Pending Content” in FASB ASC 860-10-50-1]

Public Entity Disclosures
Public Entities—Disclosure Objectives
l 2A.

35

Has the public entity properly disclosed the following:
a.

A transferor’s continuing involvement with financial
assets that it has transferred in a securitization or assetbacked financing arrangement?

b.

The nature of any restrictions on assets reported by an
entity in its statement of financial position that related
to a transferred financial asset, including the carrying
amounts of such assets?

c.

How servicing assets and servicing liabilities are reported under FASB ASC 860-50?

d.

For securitization or asset-backed financing arrangements accounted for as sales if a transferor has continuing involvement with the transferred financial assets
and transfers of financial assets accounted for as secured borrowings, how the transfer of financial assets
affects an entity’s financial position, financial performance, and cash flows?
[FASB ASC 860-10-50-3]

See footnote 4.
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Yes
l 2B.

(ASU No. 2009-16) Has the public entity properly disclosed,
in order to meet the objectives of the public entity disclosure
requirements of FASB ASC 860, the following in order to provide the financial statement users an understanding of the
following:
a.

A transferor’s continuing involvement, if any, with
transferred financial assets?

b.

The nature of any restrictions on assets reported by an
entity in its statement of financial position that related
to a transferred financial asset, including the carrying
amounts of such assets?

c.

How servicing assets and servicing liabilities are reported under FASB ASC 860-50?

d.

For both of the following, how the transfer of financial
assets affects an entity’s financial position, financial
performance, and cash flows:
i.

Transfers accounted for as sales, if a transferor
has continuing involvement with the transferred
financial assets?

ii.

Transfers of financial assets accounted for as secured borrowing?
[“Pending Content” in FASB ASC 860-10-50-3]

l 3A.

Has the public entity properly disclosed the items in FASB
ASC 860-10-50-3 in a manner that clearly and fully explains
to the financial statements users the risks related to the transferred financial assets and any restrictions on the assets of the
entity? (Note: The entity may need to supplement the required public-entity disclosures of FASB ASC 860 depending
on the facts and circumstances of a transfer and the entity’s
continuing involvement with the transferred financial assets.)
[FASB ASC 860-10-50-4]

l 3B.

(ASU No. 2009-16) Has the public entity achieved the objectives in FASB ASC 860-10-50-3 through their disclosures, regardless of whether any of the specific disclosures of FASB
ASC 860, including any possible supplemental disclosures
depending on the following apply (disclosures required for a
particular form of continuing involvement should be considered when determining whether the disclosure objectives of
FASB ASC 860 have been met):
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a.

The facts and circumstances of the transfer?

b.

The nature of an entity’s continuing involvement with
the transferred financial assets?

c.

The effect of an entity’s continuing involvement on the
transferor’s financial position, financial performance,
and cash flows?
[“Pending Content” in FASB ASC 860-10-50-4]

No

N/A
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Yes

No

N/A

Public Entities—Aggregation of Certain Disclosures
l 4B.

l 5A.

(ASU No. 2009-16) Has the public entity properly disclosed
the following, if it aggregates disclosures for similar transfers
(and separate reporting would not provide more information):
a.

How similar transfers are aggregated?

b.

A distinguishment between transfers that are accounted for as secured borrowings and transfers that
are accounted for as sales?
[“Pending Content” in FASB ASC 860-10-50-4A]

Has the public entity properly disclosed the following, if it
aggregates disclosures for similar transfers (and separate reporting would not provide more information): (Note: Quantitative and qualitative information about the characteristics
of the transferred financial assets should be considered when
determining whether to aggregate disclosures for multiple
transfers. Consideration should be given to, at a minimum,
[a] the nature of the transferor’s continuing involvement, [b]
the types of financial assets transferred, [c] risks related to the
transferred financial assets to which the transferor continues
to be exposed after the transfer and the change in the transferor’s risk profile as a result of the transfer, and [d] the guidance of FASB ASC 310-10-50-25 and FASB ASC 825-10-55 paragraphs 1–2.)
a.

A distinguishment between transfers that are accounted for as secured borrowings and transfers that
are accounted for as sales?

b.

A distinguishment between transfers to qualifying special-purpose entities accounted for as sales and all other
transactions accounted for as sales?
[FASB ASC 860-10-50-5]36

GG. Sales of Financial Assets (FASB ASC 860-20)37
Disclosure
Additional Disclosure Information
FASB ASC 860-20-50 contains disclosures for both nonpublic and public companies. See the following section, “Public Entity Disclosures,” for required disclosures specific to public entities.

36
“Pending Content” in FASB ASC 860-10-50-5 removes the requirements from FASB ASC 860-10-50-5 regarding a distinguishment
between transfers that are accounted for as secured borrowings and transfers that are accounted for as sales and a distinguishment
between transfers to qualifying special-purpose entities accounted for as sales and all other transactions accounted for as sales. Entities
subject to ASU No. 2009-16 should refer to “Pending Content” in FASB ASC 860-10-50-5 for more information.
37

See footnote 4.
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Yes

No

N/A

Nonpublic Entities—Financial Assets Securitized38
.l 1A.

.l 1B.

Has the entity properly disclosed the following, for each major asset type, if it has securitized financial assets during any
period presented and accounts for that transfer as a sale:
a.

Its accounting policies for initially measuring the interests that continue to be held by the transferor, if any,
and servicing assets or servicing liabilities, if any, including the methodology (whether quoted market
price, prices based on sales of similar assets and liabilities, or prices based on valuation techniques) used in
determining their fair value?

b.

The characteristics of securitizations (a description of
the transferor’s continuing involvement with the transferred assets, including, but not limited to, servicing,
recourse, and restrictions on interests that continue to
be held by the transferor) and the gain or loss from sale
of financial assets in securitizations?

c.

The key assumptions used in measuring the fair value
of interests that continue to be held by the transferor
and servicing assets or servicing liabilities, if any, at the
time of securitization (including, at a minimum, quantitative information about discount rates, expected prepayments including the expected weighted-average life
of prepayable financial assets, and anticipated credit
losses, if applicable)? (If any entity has made multiple
securitizations of the same major asset type during a
period, it may disclose the range of assumptions.)

d.

Cash flows between the securitization special purpose
entity and the transferor, unless reported separately
elsewhere in the financial statements or notes (including proceeds from new securitizations, proceeds from
collections reinvested in revolving-period securitizations, purchases of delinquent or foreclosed loans, servicing fees, and cash flows received on interests that continue to be held by the transferor)?
[FASB ASC 860-20-50-3]

(ASU No. 2009-16) Has the entity properly disclosed the following, for each income statement period presented, the following:
a.

The characteristics of the transfer, including (i) a description of the transferor’s continuing involvement
with the transferred financial assets, (ii) the nature and
fair value of the assets obtained as proceeds and the
liabilities incurred in the transfer, and (iii) the gain or
loss from the sale of transferred financial assets?

38
At the effective date of ASU No. 2009-16, the title of this section will change to “Nonpublic Entities—Disclosures for Each Income
Statement Presented.”
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Yes
b.

For the initial fair value measurements in item (a), the
level within the fair value hierarchy, as described in
FASB ASC 820, in which fair value measurements fall,
segregating fair value measurements into each “level?”

c.

For the initial fair value measurements in item (a), the
key inputs and assumptions used in measuring the fair
value of assets obtained and liabilities incurred as a result of the sale that relate to the transferor’s continuing
involvement, including quantitative information about
all of the following:
i.

Discount rates?

ii.

Expected prepayments including the expected
weighted-average life of prepayable financial assets?

iii.

Anticipated credit losses, including expected
static pool losses?

d.

For the initial fair value measurements in item (a), the
valuation technique(s) used to measure fair value?

e.

Cash flows between a transferor and transferee, including (i) proceeds from new transfers, (ii) proceeds from
collections reinvested in revolving-period transfers, (iii)
purchases of previously transferred financial assets, (iv)
servicing fees, and (v) cash flows received from a transferor’s interests?
[“Pending Content” in FASB ASC 860-20-50-3]

No

N/A

Nonpublic Entities—Interests That Continue to Be Held39
.l 2A.

Has the entity properly disclosed the following, if the entity
has interests that continue to be held by a transferor in financial assets that is has securitized or servicing assets or servicing liabilities relating to assets that it has securitized, at the
date of the latest statement of financial position presented, for
each major asset type:
a.

Its accounting policies for subsequently measuring
those interest, including the methodology used in determining their fair value?

b.

The key assumptions used in subsequently measuring
the fair value of those interests including, at a minimum, quantitative information about (i) discount rates,
(ii) expected prepayments including the expected
weighted-average life of prepayable financial assets,
and (iii) anticipated credit losses, if applicable?

39
At the effective date of ASU No. 2009-16 the title of this section will change to "Nonpublic Entities—Disclosures for Each Statement
of Financial Position Presented."
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Yes

.l 2B.

c.

A sensitivity analysis or stress test showing the hypothetical effect on the fair value of those interests (including any servicing assets or servicing liabilities) of
two or more unfavorable variations from the expected
levels for each key assumption that is reported under
item (b) independently from any change in another key
assumption?

d.

A description of the objectives, methodology, and limitations of the sensitivity analysis or stress test?

e.

For the securitized assets and any other financial assets
that it manages together with them,
the total principal amount outstanding, the portion that has been derecognized, and the portion
that continues to be recognized in each category
reported in the statement of financial position, at
the end of the period?

ii.

delinquencies at the end of the period?

iii.

credit losses, net of recoveries, during the period?
[FASB ASC 860-20-50-4]

(ASU No. 2009-16) Has the entity properly disclosed the following, for each statement of financial presented, regardless
of when the transfer occurred, the following:
a.
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i.

Qualitative and quantitative information about the
transferor’s continuing involvement with transferred financial assets that provides financial statement users
with sufficient information to assess the reasons for the
continuing involvement and the risks related to the
transferred financial assets to which the transferor continues to be exposed after the transfer and the extent
that the transferor’s risk profile has changed as a result
of the transfer, including the following:
i.

The total principal amount outstanding?

ii.

The amount that has been derecognized?

iii.

The amount that continues to be recognized in
the statement of financial position?

iv.

The terms of any arrangements that could require the transferor to provide financial support
to the transferee or its beneficial interest holders,
including (1) a description of any events or circumstances that could expose the transferor to
loss and (2) the amount of the maximum exposure to loss?

No

N/A
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Yes
v.

Whether the transformer has provided financial
or other support during the periods presented
that it was not previously contractually required
to provide to the transferee or its beneficial interest holders, including (1) the type and amount of
support and (2) the primary reason for providing
the support?

vi.

Although encouraged, but not required, information about any liquidity arrangements, guarantees, or other commitments by third parties related to the transferred financial assets that may
affect the fair value or risk of the related transferor’s interest?

b.

The entity’s accounting policies for subsequently measuring assets or liabilities that relate to the continuing
involvement with the transferred financial assets?

c.

The key inputs and assumptions used in measuring the
fair value of those interests including, at a minimum,
quantitative information about (i) discount rates, (ii) expected prepayments including the expected weightedaverage life of prepayable financial assets, and (iii) anticipated credit losses, if applicable? (Note: If the entity
has aggregated transfers during a period in accordance
with FASB ASC 860-10-50-5, it may disclose the range
of assumptions.)

d.

A sensitivity analysis or stress test showing the hypothetical effect on the fair value of those interests (including any servicing assets or servicing liabilities) of
two or more unfavorable variations from the expected
levels for each key assumption that is reported under
item (b) independently from any change in another key
assumption?

e.

A description of the objectives, methodology, and limitations of the sensitivity analysis or stress test?

f.

Information about the asset quality of transferred financial assets and any other financial assets that it
manages together with them? (Note: This information
should be separated between assets that have been derecognized and assets that continue to be recognized in
the statement of financial position. This information is
intended to provide financial statement users with an
understanding of the risks inherent in the transferred
financial assets as well as in other financial assets and
liabilities that it manages together with transferred financial assets.)
[“Pending Content” in FASB ASC 860-20-50-4]

No

N/A
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Yes

No

N/A

All Entities Within the Scope of Subtopic—Sales of Loans and Trade
Receivables
.l 3.

Has the entity properly disclosed the aggregate amount of
gains or losses on sales of loans or trade receivables (including adjustments to record loans held for sale at the lower of
cost or fair value) separately in the financial statements or in
the notes to the financial statements?
[FASB ASC 860-20-50-5]40

Public Entity Disclosures
Public Entities
l 4A.

If specific disclosures are required elsewhere in FASB ASC for
a particular form of the transferor’s continuing involvement,
has the public entity properly disclosed the information required in paragraphs 8(b) and 9(a) of FASB ASC 860-20-50
with a cross reference between the separate notes to the financial statements so that a user can understand the risks retained in the transfer, if, other specific disclosures required by
FASB ASC are made elsewhere? (Note: The entity is not required to provide each specific disclosure in FASB ASC 86020-50-8(a), 860-20-50-8(c), 860-20-50-9(a)(1)–(4), and 860-2050-9(b)–(e) if the disclosure is not required by other U.S.
GAAP and if it is not meaningful to financial statement users.)
[FASB ASC 860-20-50-7]
Note (ASU No. 2009-16): This paragraph has been superseded
by ASU No. 2009-16.
[“Pending Content” in FASB ASC 860-20-50-7]

Public Entities—Disclosures for Each Income Statement Presented
Presentation
l 5A.

Has the public entity properly disclosed, for each income
statement presented, the following related to securitization or
asset-backed financing arrangements accounted for as sales if
the transferor has continuing involvement:
a.

Its accounting policies for initially measuring the interests that continue to be held by the transferor, if any,
and servicing assets or servicing liabilities, if any?

b.

The characteristics of the transfer including a description of the transferor’s continuing involvement with the
transferred financial assets and the gain or loss from
the sale of transferred assets?

40
“Pending Content” in FASB ASC 860-20-50-5 will not change the disclosure requirements on FASB ASC 860-20-50-5 and has not
been included in this checklist.
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Yes
c.

No

N/A

Cash flows between a transferee and the transferor, including proceeds from new transfers, proceeds from
collections reinvested in revolving-period transfers,
purchases of previously transferred financial assets (or
its underlying collateral), servicing fees, and cash flows
received on the interests that continue to be held by the
transferor?
[FASB ASC 860-20-50-8]

Note (ASU No. 2009-16): This paragraph has been superseded
by ASU No. 2009-16.
[“Pending Content” in FASB ASC 860-20-50-8]
Public Entities—Disclosures for Each Statement of Financial
Position Presented
l 6A. Has the public entity properly disclosed, for each statement
of financial position presented, the following related to securitization or asset-backed financing arrangements accounted
for as sales if the transferor has continuing involvement:
a.
Qualitative and quantitative information about the
transferor’s continuing involvement with transferred financial assets that provides financial statement users
with sufficient information to assess the reasons for the
continuing involvement and the risks related to the
transferred financial assets to which the transferor continues to be exposed after the transfer and the extent
that the transferor’s risk profile has changed as a result
of the transfer (including, but not limited to, credit risk,
interest rate risk, and other risks), including all of the
following:
i.
The nature, purpose, size, and activities of special-purpose entities used to facilitate a transfer
of financial assets, if applicable, including how
the special-purpose entities are financed?
ii.
The total principal amount outstanding, the portion that has been derecognized, and the amount
that continues to be recognized in each category
reported in the statement of financial position?
iii.
The terms of any arrangements that could require the transferor to provide financial support
(for example, liquidity arrangements and obligations to purchase assets) to the transferee or its
beneficial interest holders, including a description of any events or circumstances that could expose the transferor to loss. All available evidence
should be considered, including, but not limited
to all of the following: (1) explicit written arrangements, (2) communications between the
transferor and the transferee or its beneficial interest holders, and (3) unwritten arrangements
customary to similar transfers?
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Yes
iv.

b.

c.

d.

e.

Whether the transferor has provided financial or
other support during the periods presented that
it was not previously contractually required to
provide to the transferee or its beneficial interest
holders, including—when the transferor assisted
the transferee or its beneficial interest holders in
obtaining support—both the type and amount of
support and the primary reasons for the support?
v.
Although encouraged, but not required, information about any liquidity arrangements, guarantees, or other commitments by third parties related to the transferred financial assets that may
affect the fair value or risk of the interest that
continues to be held by the transferor?
The accounting policies for subsequently measuring assets or liabilities that relate to the continuing involvement with the transferred financial assets?
The key inputs and assumptions used in measuring the
fair value of assets or liabilities that relate to the transferor’s continuing involvement including, at a minimum, quantitative information about (i) discount rates,
(ii) expected prepayments, including the expected
weighted-average life of prepayable financial assets,
and (iii) anticipated credit losses, including expected
static pool losses?
For interests that continue to be held by the transferor
in financial assets, both of the following:
i.
A sensitivity analysis or stress test showing the
hypothetical effect on the fair value of those interests, including any servicing assets or servicing liabilities, of two or more unfavorable variations from the expected levels for each key
assumption that is reported under item (c), independently from any change in another key assumption?
ii.
A description of the objectives, methodology,
and limitations of the sensitivity analysis or
stress test?
Information about the asset quality of transferred financial assets and any other financial assets that it
manages together with them?
[FASB ASC 860-20-50-9]

Note (ASU No. 2009-16): This paragraph has been superseded
by ASU No. 2009-16.
[“Pending Content” in FASB ASC 860-20-50-9]

FSP §11,100.01

No

N/A

213

Financial Statements and Notes Checklist

Yes

No

N/A

HH. Secured Borrowing and Collateral (FASB ASC 860-30)41
Presentation
.l 1.
Has the entity properly presented a collateral asset, which the
secured party has the right by contract or custom to sell or
repledge, separately from other assets not so encumbered, in
its statement of financial position?
[FASB ASC 860-30-45-1]
.l 2.
Has the entity properly presented liabilities incurred by either the secured party or the obligor in securities borrowing
or resale transactions separately?
[FASB ASC 860-30-45-2]
Disclosure
Additional Disclosure Information
FASB ASC 860-30-50 contains disclosures for both nonpublic and public companies. See the following section, “Public Entity Disclosures,” for required disclosures specific to public entities.
Nonpublic Entities—Collateral
.l 3A. Has the entity properly disclosed the following, regarding
collateral:
a.
If the entity has entered into repurchase agreements or
securities lending transactions, its policy for requiring
collateral or other security?
b.
If the entity has pledged any of its assets as collateral
that are not reclassified and separately reported in the
statement of financial position pursuant to FASB ASC
860-30-25-5(a), the carrying amount and classification
of those assets as of the date of the latest statement of
financial position presented?
c.
If the entity has accepted collateral that it is permitted
by contract or custom to sell or repledge, the fair value
(as of the date of each statement of financial position
presented) of that collateral and of the portion of that
collateral that it has sold or repledged, and information
about the sources and uses of that collateral?
[FASB ASC 860-30-50-1A]
.l 3B. (ASU No. 2009-16) Has the entity properly disclosed the following, regarding collateral:
a.
If the entity has entered into repurchase agreements or
securities lending transactions, its policy for requiring
collateral or other security?

41

See footnote 4.
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Yes
b.

As of the date of the latest statement of financial position presented, the carrying amount and classifications
of any assets pledged as collateral that are not reclassified and separately reported in the statement of financial position in accordance with FASB ASC 860-30-255(a) and associated liabilities, and qualitative
information about the relationship(s) between those assets and associated liabilities?
c.
If the entity has accepted collateral that it is permitted
by contract or custom to sell or repledge, the fair value
(as of the date of each statement of financial position
presented) of that collateral and of the portion of that
collateral that it has sold or repledged, and information
about the sources and uses of that collateral?
[“Pending Content” in FASB ASC 860-30-50-1A]
Nonpublic Entities—Restricted Assets
.l 4A. Has the entity properly disclosed the description of the nature of restrictions placed on any assets set aside solely for
the purpose of satisfying scheduled payments of a specific
obligation?
[FASB ASC 860-30-50-2]
Note (ASU No. 2009-16): This paragraph has been superseded
by ASU No. 2009-16.
[“Pending Content” in FASB ASC 860-30-50-2]
Public Entity Disclosure
Public Entities—Collateral
l 5A. Has the public entity properly disclosed the following, regarding collateral:
a.
The policy for requiring collateral or other security disclosed if the reporting entity has entered into repurchase agreements or securities lending transactions?
b.
If the entity has pledged any assets as collateral, the
carrying amount, and classification of those assets and
associated liabilities as of the date of the latest statement of financial position presented, including qualitative information about the relationship(s) between
those assets and associated liabilities?
c.
If the entity has accepted collateral that is permitted by
contract or custom to sell or repledge, the following:
i.
The fair value, as of the date of each statement of
financial position presented of that collateral?
ii.
The fair value, as of the date of each statement of
financial position presented of the portion of that
collateral that it has sold or repledged?
iii.
Information about the sources and uses of that
collateral?
[FASB ASC 860-30-50-4]
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Yes

No

N/A

Note (ASU No. 2009-16): This paragraph has been superseded
by ASU No. 2009-16.
[“Pending Content” in FASB ASC 860-30-50-4]
Public Entities—Secured Borrowings
l 6A. Has the public entity properly disclosed, regarding a transfer
of financial assets accounted for as a secured borrowing, the
carrying amount and classification of assets and associated liabilities recognized in the transferor’s statement of financial
position at the end of each period presented, including qualitative information about the relationship(s) between those
assets and associated liabilities?
[FASB ASC 860-30-50-5]
Note (ASU No. 2009-16): This paragraph has been superseded
by ASU No. 2009-16.
[“Pending Content” in FASB ASC 860-30-50-5]
II.
Servicing Assets and Liabilities (FASB ASC 860-50)42
Presentation
.l 1.
Has the entity properly presented recognized servicing assets
and servicing liabilities that are subsequently measured using
the fair value measurement method in a manner that separates those carrying amounts on the face of the statement of
financial position from the carrying amounts for separately
recognized servicing assets and servicing liabilities that are
subsequently measured using the amortization method?
[FASB ASC 860-50-45-1]
.l 2.
Has the entity properly presented the information, in order to
accomplish the separate reporting in FASB ASC 860-40-45-1,
either by (a) displaying separate line items for the amounts
that are subsequently measured using the fair value measurement method and amounts that are subsequently measured
using the amortization method, or (b) presenting the aggregate of those amounts that are subsequently measured at fair
value and those amounts that are subsequently measured using the amortization method and by disclosing parenthetically the amount that is subsequently measured at fair value
is included in the aggregate amount?
[FASB ASC 860-50-45-2]

42

See footnote 4.
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Yes

No

N/A

Disclosure
Additional Disclosure Information
FASB ASC 860-50-50 contains disclosures for both nonpublic and public companies. See the following section, “Public Entity Disclosures,” for required disclosures specific to public entities.
Nonpublic Entities—All Servicing Assets and Servicing Liabilities
.l 3A. Has the public entity properly disclosed the following regarding all servicing assets and servicing liabilities:
a.
Management’s basis for determining its classes of servicing assets and servicing liabilities?
b.
A description of the risks inherent in servicing assets
and servicing liabilities and, if applicable, the instruments used to mitigate the income statement effect of
changes in fair value of the servicing assets and servicing liabilities? (Disclosure of quantitative information
about the instruments used to manage the risks inherent in servicing assets and servicing liabilities, including the fair value of those instruments at the beginning
and end of the period, is encouraged but not required.)
c.
The amount of contractually specified servicing fees (as defined in the FASB ASC glossary), late fees, and ancillary
fees earned for each period for which results of operations are presented, including a description of where
each amount is reported in the statement of income?
[FASB ASC 860-50-50-2]
.l 3B. (ASU No. 2009-16) Has the entity properly disclosed the following regarding all servicing assets and servicing liabilities:
a.
Management’s basis for determining its classes of servicing assets and servicing liabilities?
b.
A description of the risks inherent in servicing assets
and servicing liabilities and, if applicable, the instruments used to mitigate the income statement effect of
changes in fair value of the servicing assets and servicing liabilities?
c.
The amount of contractually specified servicing fees (as defined in the FASB ASC glossary), late fees, and ancillary
fees earned for each period for which results of operations are presented, including a description of where
each amount is reported in the statement of income?
d.
Quantitative and qualitative information about the assumptions used to estimate fair value?
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Yes

No

N/A

e.

Although not required, the entity is encouraged to disclose quantitative information about the instruments
used to manage the risks inherent in servicing assets
and servicing liabilities, including the fair value of
those instruments at the beginning and the end of the
period, and quantitative and qualitative information
about the assumptions used to estimate the fair value
of those instruments?
[“Pending Content” in FASB ASC 860-50-50-2]
Nonpublic Entities—Servicing Assets and Servicing Liabilities Subsequently Measured at Fair Value
.l 4A. Has the entity properly disclosed the following regarding all
servicing assets and servicing liabilities subsequently measured at fair value:
a.
For each class of servicing assets and servicing liabilities, the activity in the balance of servicing assets and
the activity in the balance of servicing liabilities (including a description of where changes in fair value are
reported in the statement of income for each period for
which results of operations are presented), including,
but not limited to, the following:
i.
The beginning and ending balances?
ii.
Additions (through purchases of servicing assets,
assumptions of servicing obligations, and servicing obligations that result from transfers of financial assets)?
iii.
Disposals?
iv.
Changes in the fair value during the period resulting from changes in valuation inputs or assumptions used in the valuation model?
v.
Changes in the fair value during the period resulting from other changes in fair value and a description of those changes?
vi.
Other changes that affect the balance and a description of those changes?
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Yes
b.

A description of the valuation techniques or other
methods used to estimate the fair value of servicing assets and servicing liabilities? If a valuation model is
used, the description should include the methodology
and model validation procedures, as well as quantitative and qualitative information about the assumptions
used in the valuation model (for example, discount
rates and prepayment speeds). (An entity that provides
quantitative information about the instruments used to
manage the risks inherent in the servicing assets and
servicing liabilities, is also encouraged, but not required, to disclose a description of the valuation techniques, as well as quantitative and qualitative information about the assumptions used to estimate the fair
value of those instruments.)
[FASB ASC 860-50-50-3]
.l 4B. (ASU No. 2009-16) Has the entity properly disclosed the following regarding all servicing assets and servicing liabilities
subsequently measured at fair value:
a.
For each class of servicing assets and servicing liabilities, the activity in the balance of servicing assets and
the activity in the balance of servicing liabilities (including a description of where changes in fair value are
reported in the statement of income for each period for
which results of operations are presented), including,
but not limited to, the following:
i.
The beginning and ending balances?
ii.
Additions (through purchases of servicing assets,
assumptions of servicing obligations, and recognition of servicing obligations that result from
transfers of financial assets)?
iii.
Disposals?
iv.
Changes in the fair value during the period resulting from changes in valuation inputs or assumptions used in the valuation model?
v.
Changes in the fair value during the period resulting from other changes in fair value and a description of those changes?
vi.
Other changes that affect the balance and a description of those changes?
[“Pending Content” in FASB ASC 860-50-50-3]
Nonpublic Entities—Servicing Assets and Servicing Liabilities Subsequently Amortized
.l 5A. Has the entity properly disclosed the following regarding all
servicing assets and servicing liabilities measured subsequently under the amortization method:
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Yes
a.

b.

c.

d.

e.

No

N/A

For each class of servicing assets and servicing liabilities, the activity in the balance of servicing assets and
the activity in the balance of servicing liabilities (including a description of where changes in the carrying
amount are reported in the statement of income for
each period for which results of operations are presented), including, but not limited to, the following:
i.
The beginning and ending balances?
ii.
Additions (through purchases of servicing assets,
assumption of servicing obligations, and servicing obligations that result from transfers of financial assets)?
iii.
Disposals?
iv.
Amortization?
v.
Application of valuation allowance to adjust carrying value of servicing assets?
vi.
Other-than-temporary impairments?
vii. Other changes that affect the balance and a description of those changes?
For each class of servicing assets and servicing liabilities, the fair value of recognized servicing assets and
servicing liabilities at the beginning and end of the period if it is practicable to estimate the value?
A description of the valuation techniques or other
methods used to estimate fair value of the servicing assets and servicing liabilities? If a valuation model is
used, the description should include the methodology
and model validation procedures, as well as quantitative and qualitative information about the assumptions
used in the valuation model (for example, discount
rates and prepayment speeds). (An entity that provides
quantitative information about the instrument used to
manage the risks inherent in the servicing assets and
servicing liabilities, is also encouraged, but not required, to disclose a description of the valuation techniques as well as quantitative and qualitative information about the assumptions used to estimate the fair
value of those instruments.)
The risk characteristics of the underlying financial assets used to stratify recognized servicing assets for purposes of measuring impairment in accordance with
FASB ASC 860-50-35-9?
The activity by class in any valuation allowance for impairment of recognized servicing assets—including beginning and ending balances, aggregate additions
charged and recoveries credited to operations, and aggregate write-downs charged against the allowance—for each period for which results of operations
are presented?
[FASB ASC 860-50-50-4]
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Yes
.l 5B.
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Has the entity properly disclosed the following regarding all
servicing assets and servicing liabilities subsequently measured under the amortization method:
a.
For each class of servicing assets and servicing liabilities, the activity in the balance of servicing assets and
the activity in the balance of servicing liabilities (including a description of where changes in the carrying
amount are reported in the statement of income for
each period for which results of operations are presented), including, but not limited to, the following:
i.
The beginning and ending balances?
ii.
Additions (through purchases of servicing assets,
assumption of servicing obligations, and recognition of servicing obligations that result from
transfers of financial assets)?
iii.
Disposals?
iv.
Amortization?
v.
Application of valuation allowance to adjust carrying value of servicing assets?
vi.
Other-than-temporary impairments?
vii. Other changes that affect the balance and a description of those changes?
b.
For each class of servicing assets and servicing liabilities, the fair value of recognized servicing assets and
servicing liabilities at the beginning and end of the period?
c.
The risk characteristics of the underlying financial assets used to stratify recognized servicing assets for purposes of measuring impairment in accordance with
FASB ASC 860-50-35-9? (Note: If the predominant risk
characteristics and resulting stratums are changes, that
fact and the reasons for those changes should be included in the disclosures about the risk characteristics
of the underlying financial assets used to stratify the
recognized servicing assets in accordance with “Pending Content” in FASB ASC 860-50-50-4.)
d.
The activity by class in any valuation allowance for impairment of recognized servicing assets—including beginning and ending balances, aggregate additions
charged and recoveries credited to operations, and aggregate write-downs charged against the allowance—for each period for which results of operations
are presented?
[“Pending Content” in FASB ASC 860-50-50-4]

No

N/A
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Yes

No

N/A

All Entities Within the Scope of Subtopic—Servicing Assets and
Servicing Liabilities Which Subsequently Measurement at Fair
Value Is Elected as of the Beginning of the Fiscal Year
.l 6.
Has the entity properly disclosed separately, if it elected under FASB ASC 860-50-35-3(d) to subsequently measure a class
of servicing assets and servicing liabilities at fair value at the
beginning of the fiscal year, the amount of the cumulativeeffect adjustment to retained earnings?
[FASB ASC 860-50-50-5]43
Public Entity Disclosures
Public Entities—All Servicing Assets and Servicing Liabilities
l 7A. Has the public entity properly disclosed the following for all
servicing assets and servicing liabilities:44
a.
Management’s basis for determining its classes of servicing assets and servicing liabilities?
b.
A description of the risks inherent in servicing assets
and servicing liabilities?
c.
If applicable, a description of the instruments used to
mitigate the income statement effect of changes in fair
value of the servicing assets and servicing liabilities?
d.
The amount of contractually specified servicing fees,
late fees, and ancillary fees earned for each period for
which results of operations are presented, including a
description of where each amount is reported in the
statement of income?
e.
Quantitative and qualitative information about the assumptions used to estimate the fair value?
[FASB ASC 860-50-50-7]
Note (ASU No. 2009-16): This paragraph has been superseded
by ASU No. 2009-16.
l 8A.

[“Pending Content” in FASB ASC 860-50-50-7]
Has the public entity properly disclosed the following for all
servicing assets and servicing liabilities subsequently measured at fair value:
a.
For each class of servicing assets and servicing liabilities, the activity in the balance of servicing assets and
the activity in the balance of servicing liabilities (including a description of where changes in fair value are
reported in the statement of income for each period for
which results of operations are presented), including,
but not limited to, all of the following:
i.
The beginning and ending balances?

43
Upon the effective date of ASU No. 2009-16, the requirements of FASB ASC 860-50-50-5 will not change; however, the heading will
be modified.
44
Per FASB ASC 860-50-50-7, disclosure of quantitative information about the instruments used to manage the risks inherent in
servicing assets and servicing liabilities, including the fair value of those instruments at the beginning and end of the period, is encouraged but not required. An entity that provides such quantitative information is also encouraged, but not required, to disclose quantitative
and qualitative information about the assumptions used to estimate the fair value of those instruments.
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Yes
ii.

iii.
iv.

v.

Additions (through purchases of servicing assets,
assumption of servicing obligations, and recognition of servicing obligations that result from
transfers of financial assets)?
Disposals?
Changes in fair value during the period resulting
from (1) changes in valuation inputs or assumptions used in the valuation model and (2) other
changes in fair value and a description of those
changes?
Other changes that affect the balance and a description of those changes?
[FASB ASC 860-50-50-8]

Note (ASU No. 2009-16): This paragraph has been superseded
by ASU No. 2009-16.
l 9A.
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[“Pending Content” in FASB ASC 860-50-50-8]
Has the public entity properly disclosed the following for all
servicing assets and servicing liabilities subsequently amortized in proportion to and over the period of estimated net
servicing income or loss and assessed for impairment or increased obligation:
a.
For each class of servicing assets and servicing liabilities, the activity in the balance of servicing assets and
the activity in the balance of servicing liabilities (including a description of where changes in the carrying
amount are reported in the statement of income for
each period for which results of operations are presented), including, but not limited to, the following:
i.
The beginning and ending balances?
ii.
Additions (through purchases of servicing assets,
assumption of servicing obligations, and servicing obligations that result from transfers of financial assets)?
iii.
Disposals?
iv.
Amortization?
v.
Application of valuation allowance to adjust carrying value of servicing assets?
vi.
Other-than-temporary impairments?
vii. Other changes that affect the balance and a description of those changes?
b.
For each class of servicing assets and servicing liabilities, the fair value of recognized servicing assets and
servicing liabilities at the beginning and end of the period if it is practicable to estimate the value?
c.
The risk characteristics of the underlying financial assets used to stratify recognized servicing assets for purposes of measuring impairment in accordance with the
guidance in paragraphs 9–14 of FASB ASC 860-50-35?

No

N/A
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Yes
d.

No

N/A

For each period for which results of operations are presented, the activity by class in any valuation allowance
for impairment of recognized servicing assets, including (i) beginning and ending balances, (ii) aggregate
additions charged and recoveries credited to operations, and (iii) aggregate write-downs charged against
the allowance?
[FASB ASC 860-50-50-9]

Note (ASU No. 2009-16): This paragraph has been superseded
by ASU No. 2009-16.
[“Pending Content” in FASB ASC 860-50-50-9]

VIII. Continuing Care Retirement Communities
Presentation
Practice Tip
Health care entities, including not-for-profit, business-oriented health care entities, should classify assets and
liabilities as current and noncurrent as discussed in FASB ASC 210-10-45. However, rather than presenting
a classified balance sheet, a continuing care retirement community instead may sequence assets according
to their nearness of conversion to cash and may sequence liabilities according to the nearness of the maturity
and resulting use of cash.
[FASB ASC 954-210-45-1]
Disclosure
Refundable Advance Fees
.l1.

Have the method of accounting for advance fees, the method
of calculating the obligation to provide future services and
use of facilities, and the refund policy for refundable fees
been disclosed?
[FASB ASC 954-430-50-1]

.l2.

Has the gross amount of contractual refund obligations under
existing contracts and the continuing care retirement community’s refund policy been disclosed in the notes to the financial statements?
[FASB ASC 954-430-50-2]
Practice Tip

With regards to the preceding question, those amounts refunded should be disclosed in the statement of
cash flows as a financing transaction.
[FASB ASC 954-430-50-2]
.l3.

If any portion of an advance fee is refundable, is the method
of amortization of that liability disclosed in the noted to the
financial statements?
[FASB ASC 954-430-50-3]

.l4.

Is the amortization method for deferred revenue disclosed?
[FASB ASC 954-430-50-4]
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Yes
Obligations to Provide Future Services and Use of Facilities to Current
Residents
.l5.

Do the notes to the financial statements of the continuing care
retirement community include the carrying amount of the liability to provide future services and the use of facilities related to continuing-care contracts presented at present value
(if not separately disclosed in the balance sheet/statement of
financial position) and the interest rate used to discount that
liability?
[FASB ASC 954-440-50-1]

Other
.l6.

Do the notes to the financial statements of the continuing care
retirement community include a description of the continuing
care retirement community and the nature of the related continuing-care contracts entered into by the continuing care retirement community?
[FASB ASC 954-440-50-1]

.l7.

Do the notes to the financial statements of the continuing care
retirement community include the statutory escrow or similar
requirements?
[FASB ASC 954-440-50-1]

.l8.

Do the notes to the financial statements of the continuing care
retirement community include the refund policy of the continuing care retirement community and the general amount
of refund obligation under existing contracts?
[FASB ASC 954-440-50-1]

IX. OMB Circular A-133 Presentation Requirements
Presentation
1.

Does the schedule of expenditures of federal awards disclose the basis of
accounting and the significant accounting policies used in preparing the
schedule?
[AAG-SLA 7.09]

2.

Did the auditee prepare a schedule of expenditures of federal awards for
the period covered by the auditee’s financial statements that, at a minimum
a.

lists individual federal programs by federal agency?

b.

includes, for federal awards received as a subrecipient, the name of
the pass-through entity and the identifying number assigned by the
pass-through entity?

c.

provides the total federal awards expended for each individual federal program and the Catalog of Federal Domestic Assistance
(CFDA) number or other identifying number when the CFDA information is not available?

d.

includes notes that describe the significant accounting policies used
in preparing the schedule?
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Yes

3.

4.

e.

for federal awards received as a pass-through entity, identifies, to
the extent practical, the total amount provided to subrecipients
from each federal program?

f.

includes, in either the schedule or a note to the schedule, the value
of federal awards expended in the form of noncash assistance, the
amount of insurance in effect during the year, and loans or loan
guarantees outstanding at year end?
[AAG-SLA 7.10]

No

N/A

If nonfederal data are presented in the schedule of expenditures of federal
awards
a.

are the nonfederal data segregated and clearly designated as nonfederal?

b.

is the title of the schedule modified to indicate that nonfederal
awards are included?
[AAG-SLA 7.14]

If the auditee is unable to obtain the CFDA number, does the schedule
include
a.

a statement that the CFDA number is not available?

b.

if available, other identifying numbers?
[AAG-SLA 7.15]
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FSP Section 11,200
Auditors’ Reports Checklist
.01 This section of the checklist has been developed primarily to address the requirements most likely
to be encountered when reporting on financial statements of health care entities in accordance with generally
accepted auditing standards (GAAS) as issued by the Auditing Standards Board (ASB), a senior technical
committee of the AICPA. Certain key differences in reporting requirements between audits conducted in
accordance with GAAS and audits conducted in accordance with the rules and standards of the Public
Company Accounting Oversight Board (PCAOB) are identified in bold text throughout this section of the
checklist. However, the differences identified are not intended to be all inclusive, and readers should seek
appropriate guidance for a comprehensive source of reporting requirements associated with audits conducted in accordance with the rules and standards of the PCAOB.
.02 This section does not contain all requirements for reports required to be issued in audits in accordance with Government Auditing Standards (Yellow Book), with the audit requirements of Office of Management and Budget Circular A-133, Audits of States, Local Governments, and Non-Profit Organizations (Single
Audits), or PCAOB professional standards.
Yes
1.

Is each financial statement audited specifically identified in the introductory paragraph of the auditor’s report?
[AU 508.06]

2.

Do the titles of the financial statements referred to in the introductory paragraph of the auditor’s report match the titles of the financial statements presented?
[Common Practice]

3.

Do the dates of the financial statements referred to in the introductory paragraph of the auditor’s report match the dates of the financial statements presented?
[Common Practice]

4.

Is the report appropriately addressed?
[AU 508.09]

No

N/A

Practice Tip
Interpretation No. 17, “Clarification in the Audit Report of the Extent of Testing of Internal Control Over
Financial Reporting in Accordance With Generally Accepted Auditing Standards,” of AU section 508, Reports on Audited Financial Statements (AICPA, Professional Standards, vol. 1, AU sec. 9508 par. .85–.88), provides language that may be added to the auditor’s standard report on the financial statements of a nonissuer
to clarify differences between a GAAS audit and an audit conducted in accordance with the standards of
the PCAOB. Interpretation No. 18, “References to PCAOB Standards in an Audit Report on a Nonissuer,”
of AU section 508 (AICPA, Professional Standards, vol. 1, AU sec. 9508 par. .89–.92) explains how the auditor
should report if engaged to also follow PCAOB auditing standards in the audit of a nonissuer.
5.

Does the independent auditor’s report include the following elements:
a.

A title that includes the word independent?
[AU 508.08a]
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Yes
b.

The titles of each financial statement in the introductory paragraph of the report?
[AU 508.06]

c.

If the financial statements include a separate statement of
changes in stockholders’ equity accounts, it is identified in the
introductory paragraph of the report?
[AU 508.06]

d.

A statement that the financial statements are the responsibility of management and that the auditor’s responsibility is to
express an opinion on the financial statements based on his
or her audit?
[AU 508.08c]

e.

For audits conducted in accordance with GAAS in the United
States, a statement that the audit was conducted in accordance with GAAS and an identification of the country of origin of those standards (for example, auditing standards generally accepted in the United States of America or U.S.
GAAS)?
[AU 508.08d]

f.

(Audits of Issuers Only) A statement that the audit was conducted in accordance with the standards of the PCAOB
(United States)?
[PCAOB Auditing Standard No. 1 par. 3 (AU-P app. A par.
3)]

g.

A statement that those standards require that the auditor plan
and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material misstatement?
[AU 508.08e]

h.

A statement that an audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements; assessing the accounting principles used
and significant estimates made by management; and evaluating the overall financial statement presentation?
[AU 508.08f]

i.

A statement that the auditor believes that his or her audit
provides a reasonable basis for his or her opinion?
[AU 508.08g]

j.

When the auditor reports on financial statements presented
in conformity with U.S. generally accepted accounting principles (GAAP), an opinion concerning whether the financial
statements present fairly, in all material respects, the financial
position of the reporting entity as of the balance sheet date
and the results of its operations and its cash flows for the period then ended in conformity with GAAP? The opinion
should include an identification of the United States of America as the country of origin of those accounting principles.
[AU 508.08h]
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Yes

No

N/A

Notes: Interpretation No. 19, “Financial Statements Prepared in Conformity
With International Financial Reporting Standards as Issued by the International Accounting Standards Board,” of AU section 508 (AICPA, Professional Standards, vol. 1, AU sec. 9508 par. .93–.97) provides that, when the
auditor of a nonissuer reports on financial statements prepared in conformity with International Financial Reporting Standards (IFRSs), the auditor
would refer, in the auditor’s report, to the IFRSs rather than U.S. GAAP.
When an auditor of a nonissuer reports on financial statements presented
in conformity with both the IFRSs as issued by the International Accounting Standards Board (IASB) and a jurisdictional variation of the IFRSs, the
auditor would refer, in the auditor’s report, to both the IFRSs and the IFRSs
as endorsed by [insert name of endorsing country or economic union].
When an auditor of a nonissuer reports on financial statements presented
in conformity with a jurisdictional variation of the IFRSs such that the entity’s financial statements do not contain an explicit and unreserved statement of compliance with the IFRSs as issued by the IASB, paragraphs
.14–.15 of AU section 534, Reporting on Financial Statements Prepared for Use
in Other Countries (AICPA, Professional Standards, vol. 1), and paragraphs
.35–.60 of AU section 508 (AICPA, Professional Standards, vol. 1) apply to
financial statements prepared for more than limited distribution in the
United States.
k.

When the auditor reports on financial statements presented
in conformity with the IFRSs, an opinion concerning whether
the financial statements present fairly, in all material respects,
the financial position of the reporting entity as of the balance
sheet date and the results of its operations and its cash flows
for the period then ended in conformity with the IFRSs as
issued by the IASB?
[AU 9508.93–.97]

l.

When the auditor reports on financial statements presented
both in conformity with the IFRSs and a jurisdictional variant
of the IFRSs, an opinion concerning whether the financial
statements present fairly, in all material respects, the financial
position of the reporting entity as of the balance sheet date
and the results of its operations and its cash flows for the period then ended in conformity with the IFRSs as issued by the
IASB and with the IFRSs as endorsed by [insert name of endorsing country or economic union]?
[AU 9508.93–.97]

m.

When the auditor reports on financial statements presented
in conformity with a jurisdictional variation of the IFRSs such
that the entity’s financial statements do not contain an explicit
and unreserved statement of compliance with the IFRSs as
issued by the IASB, a variation of the standard report that
reflects the guidance in paragraphs .14–.15 of AU section 534
and paragraphs .35–.60 of AU section 508 (AICPA, Professional Standards, vol. 1) for financial statements prepared for
more than limited distribution in the United States?
[AU 9508.93–.97]
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Yes
n.

The manual or printed signature of the auditor’s firm?
[AU 508.08i]

o.

The date of the audit report?
[AU 508.08j; AU 530.05]

No

N/A

Practice Tip
The independent auditor has 2 methods available for dating the report when a subsequent event disclosed
in the financial statements occurs after the original date of the auditor’s report but before the issuance of the
related financial statements. The auditor may use "dual dating" (for example, "February 16, 20pp, except for
Note pp, for which the date is March 1, 20pp,") or may date the report as of the later date. In the former
instance, the responsibility for events occurring subsequent to the original report date is limited to the specific event referred to in the note (or otherwise disclosed). In the latter instance, the independent auditor’s
responsibility for subsequent events extends to the date of the report, and, accordingly, the procedures outlined in paragraph .12 of AU section 560, Subsequent Events (AICPA, Professional Standards, vol. 1), generally
should be extended to that date.
6.

7.

Does the reporting language conform with the auditor’s standard
report on
a.

financial statements of a single year or period?

b.

comparative financial statements?
[AU 508.08]

Does the report include appropriate language for the following situations:
a.

Only one basic financial statement is presented and there are
no scope limitations?
[AU 508.33–.34]

b.

Audited and unaudited financial statements are presented in
comparative form?
[AU 504.15–.17]

c.

Different opinions are expressed on comparative financial
statements?
[AU 508.05]

Note: Interpretation No. 14, “Reporting on Audits Conducted in Accordance With Auditing Standards Generally Accepted in the United States of
America and in Accordance With International Standards on Auditing,” of
AU section 508 (AICPA, Professional Standards, vol. 1, AU sec. 9508 par.
.56–.59) provides that, when the audit of a nonissuer is conducted both in
accordance with standards generally accepted in the United States of
America and in accordance with the International Standards on Auditing
(ISAs), the auditor may so indicate in the auditor’s report. To determine
whether an audit was conducted in accordance with the ISAs, it is necessary to consider the text of the ISAs in their entirety, including the basic
principles and essential procedures together with the related guidance included in the ISAs.
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Practice Tip
If the audit of financial statements to be used in the United States was conducted in accordance with auditing standards generally accepted in the United States of America and ISAs as issued by the International
Auditing and Assurance Standards Board, in their entirety, although not required, has the auditor considered indicating in the auditor‘s report that the audit was also conducted in accordance with ISA as allowed.
[AU 9508.57–.59]
8.

Is the reporting form, content, and timing of paragraphs .20–.30 of
AU section 325, Communicating Internal Control Related Matters Identified in an Audit (AICPA, Professional Standards, vol. 1), followed
when communicating matters related to an organization’s internal
control over financial reporting identified in an audit of financial
statements?
[AU 325.20–.30]

Note: Auditors are required to communicate control deficiencies identified
during an audit that are significant deficiencies or material weaknesses as
defined by AU section 325, including significant deficiencies or material
weaknesses that were communicated in previous audits and have not yet
been remediated. Those control deficiencies must be communicated in
writing to management and those charged with governance.
9.

10.

If a subsequent event disclosed in the financial statements occurs
after the original date of the independent auditor’s report but before the issuance of the related financial statements, has the auditor
followed one of the following two methods available for dating the
report:
a.

Dual dating, in which the independent auditor’s responsibility for events occurring subsequent to the original report date
is limited to the specific event referred to in an explanatory
note in the report (or otherwise disclosed)?

b.

Dating the report as of the later date, in which the independent auditor’s responsibility for subsequent events extends to
the date of the report?
[AU 530.03–.05]

(Audits of Issuers Only) If the auditor obtains knowledge about a
subsequent event that
a.

materially and adversely affects the effectiveness of the entity’s internal control over financial reporting as of the date
specified in the assessment, has the auditor either
i.

issued an adverse opinion on internal control over financial reporting (and followed the direction in paragraph .C2 of appendix C of PCAOB Auditing Standard
No. 5 (AU-P sec. 320) if management’s assessment
states that internal control over financial reporting is effective)?
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b.

11.

disclaimed an opinion if the auditor is unable to determine the effect of the subsequent event on the effectiveness of the entity’s internal control over financial reporting?

relates to conditions that did not exist at the date specified in
the assessment but arose subsequent to that date and before
issuance of the auditor’s report, and the subsequent event has
a material effect on the entity’s internal control over financial
reporting, has the auditor included in his or her report an
explanatory paragraph describing the event and its effects or
directed the reader’s attention to the event and its effects as
disclosed in management’s report?
[PCAOB Auditing Standard No. 5 par. .96–.97 (AU-P
320.96–.97)]

If the accountant is not independent, has he or she followed one of
the two reporting alternatives available:
a.

Disclaiming the opinion with respect to the financial statements and specifically stating that he or she is not independent?

b.

Issuing a compilation report in accordance with Statements
on Standards for Accounting and Review Services (SSARSs)
indicating the lack of independence (nonpublic entities only)?
[AU 504.05 and .09–.10; AR 100.21 and .48]

Note: The Accounting and Review Services Committee issued SSARS
No. 19, Compilation and Review Engagements (AICPA, Professional Standards, vol. 2), that revises the standards for compilation and review
engagements, including the following:

12.

●

The introduction of new terms, such as review evidence and
review risk, to the review literature to harmonize with international review standards.

●

A discussion of materiality in the context of a review engagement.

●

A requirement that an accountant document the establishment of an understanding with management through a written communication (that is, an engagement letter) regarding
the services to be performed.

●

The establishment of enhanced documentation requirements
for compilation and review engagements.

●

The ability for an accountant to include a general description
in the accountant’s compilation report regarding the reason(s)
for an independence impairment.

If the opinion is based in part on the report of another auditor,
a.
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does the opinion paragraph include a reference to the report
of the other auditor?
[AU 508.11a, .12, and .13]

13.

If, to prevent the financial statements from being misleading because of unusual circumstances, the financial statements contain a
departure from an accounting principle promulgated by a body
designated by the AICPA Council to establish such principles, does
the report include, in a separate paragraph or paragraphs, the information required by the rule?
[AU 508.11b and .15]

14.

If the auditor uses the work of a specialist in performing an audit,
have they added an optional explanatory paragraph?
[AU 336.16]
Note: Reference to and identification of the specialist may be added if
the auditor believes such a reference will facilitate an understanding
of the reason for the explanatory paragraph.
[AU 336.16]

15.

If there is substantial doubt about the entity’s ability to continue as
a going concern for a reasonable period of time, not to exceed one
year beyond the date of the financial statements being audited,
a.

does the report include an explanatory paragraph, following
the opinion paragraph, to reflect that conclusion?

b.

is that conclusion expressed through the use of the phrase
“substantial doubt about its (the entity’s) ability to continue
as a going concern” or similar wording that includes the
terms substantial doubt and going concern?
[AU 508.11c; AU 341.12]
Practice Tip

In evaluating whether there is substantial doubt about the entity’s ability to continue as a going concern, the
auditor’s evaluation is based on his or her knowledge of relevant conditions that exist at or have occurred
prior to the date of the auditor’s report. If, after considering identified conditions and events and management’s
plans, the auditor concludes that substantial doubt about the entity’s ability to continue as a going concern
for a reasonable period of time remains, the audit report should include an explanatory paragraph to reflect
that conclusion.
In a going concern paragraph, the auditor should not use conditional language in expressing a conclusion
concerning the existence of substantial doubt about the entity’s ability to continue as a going concern. See
paragraph .13 of AU section 341, The Auditor’s Consideration of an Entity’s Ability to Continue as a Going Concern (AICPA, Professional Standards, vol. 1), for an example.
16.

Is the report dated no earlier than the date on which the auditor has
obtained sufficient appropriate audit evidence to support the auditor’s opinion on the financial statements?
[AU 530.01]
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17.

(Audits of Issuers Only) Is the report dated no earlier than the date
on which the auditor has obtained sufficient competent evidence to
support the auditor‘s opinion on the financial statements?
[PCAOB Auditing Standard No. 5 par. .89 (AU-P 320.89)]

18.

(Audits of Issuers Only) When performing an integrated audit of
financial statements and internal control over financial reporting,
are the auditor’s reports on the entity’s financial statements and on
internal control over financial reporting dated the same?
[PCAOB Auditing Standard No. 5 par. .89 (AU-P 320.89)]

19.

(Audits of Issuers Only) Prior to the report release date, among
other matters, has the auditor obtained sufficient evidence to support the representations in the auditor’s reports?
[PCAOB Auditing Standard No. 3 par. .15 (AU-P 339.15)]

No

N/A

Practice Tip
Changes in Accounting Estimates
Paragraph .15 of AU section 420, Consistency of Application of Generally Accepted Accounting Principles (AICPA,
Professional Standards, vol. 1), clarifies that the change in an accounting estimate that does not include a
change in accounting principle does not require an explanatory paragraph in the auditor’s report. However,
an accounting change of this type having a material effect on the financial statements may require disclosure
in a note to the financial statements.
Changes in Classification
Paragraph .17 of AU section 420 clarifies that changes in classification from the prior year’s financial statements are usually not of sufficient importance to necessitate disclosure; however, material changes in classification should be indicated and explained in the financial statements or notes.
Error Corrections
Paragraph .16 of AU section 420 states that the correction of an error in previously issued financial statements resulting from mathematical mistakes, oversight, or misuse of facts that existed at the time the financial statements were originally prepared does not involve the consistency standard if no element of accounting principles or their application is included. Accordingly, the independent auditor need not recognize the
correction in his report. However, if the independent auditor had previously reported on the financial statements containing the error, the auditor has concluded, based on the considerations in paragraph .05 of AU
section 561, Subsequent Discovery of Facts Existing at the Date of the Auditor’s Report (AICPA, Professional Standards, vol. 1), that action should be taken to prevent future reliance on his report, and the issuance of financial statements accompanied by the auditor’s report for a subsequent period is imminent, the auditor should
disclose the revision in such statements instead of reissuing the earlier statements.

Notes: For audits of issuers, certain circumstances, although not affecting
the auditor’s unqualified opinion, may require that the auditor add explanatory language to the standard report as described in paragraphs .11–.19 of
AU-P section 508, Reports on Audited Financial Statements (AICPA, PCAOB
Standards and Related Rules, Standards).
Other circumstances may require a departure from an unqualified opinion,
either in the form of a qualified opinion, an adverse opinion, or a disclaimed opinion as described in paragraphs .20–.63 of AU-P section 508.
For special reporting situations relating to the auditor’s report on internal
control over financial reporting, refer to appendix C, Special Reporting Situations, of Auditing Standard No. 5 (AU-P sec. 320).
(continued)

FSP §11,200.02

235

Auditors’ Reports Checklist

Yes

No

N/A

******
PCAOB Auditing Standard No. 6, Evaluating Consistency of Financial Statements (AICPA, PCAOB Standards and Related Rules, Standards, AU-P sec.
420), updated the auditor’s responsibilities to evaluate and report on the
consistency of an entity’s financial statements and align the auditor’s responsibilities with Financial Accounting Standards Board (FASB) Statement No. 154, Accounting Changes and Error Corrections.
One significant difference in terminology between FASB Statement No. 154
(which is codified in FASB Accounting Standards Codification (ASC) 250, Accounting Changes and Error Corrections) and Auditing Standard No. 6 (AU-P
sec. 420) is the use of the term error in the FASB standard whereas the
PCAOB standard uses the term misstatement and specifically states that the
meaning is the same for purposes of the PCAOB Auditing Standards. Auditing Standard No. 6 (AU-P sec. 420) also establishes that the auditor’s
report should indicate whether an adjustment to previously issued financial statements results from a change in accounting principle or the correction of a misstatement.
Auditing Standard No. 6 (AU-P sec. 420) contains numerous amendments
to AU-P section 508 and other interim PCAOB Auditing Standards. If Auditing Standard No. 6 (AU-P sec. 420) is applicable to issuers’ financial
statements, answer questions 21–22; otherwise, skip questions 21–22. For
more information and for the full text of the auditing standard, refer to the
PCAOB website at www.pcaob.org. Also refer to the Securities and
Exchange Commission (SEC) website at www.sec.gov.
20.

If there has been a material change between periods in accounting
principles or in the method of their application, including a change
from an accounting principle that is not generally accepted to one
that is generally accepted and a change in accounting principle that
is inseparable from the effect of a change in estimate, that has a
material effect on the comparability of the reporting entity’s financial statements,
a.

does the report include an explanatory paragraph, following
the opinion paragraph that refers to the change?

b.

does the explanatory paragraph identify the nature of the
change and refer the reader to the note to the financial statements that discusses the change in detail?
[AU 508.05–.06 and .12–.13]

c.

if the change in the accounting principle is a change in reporting entity that did not result from a transaction or an
event, is an explanatory paragraph included in the auditor’s
report? (Note: A change in the reporting entity resulting from
a transaction or event, such the creation, cessation, or complete or partial purchase or disposition of a subsidiary or
other business unit, does not require that an explanatory paragraph about consistency be included in the auditor’s report.)
[AU 420.08]
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21.

22.

23.

(Audits of Issuers Only) If there has been a change in accounting
principle that has a material effect on the financial statements, including a change in the method of applying an accounting principle, a change in estimate effected by a change in accounting principle, and a change in classification that represents a change in
accounting principle, and meets the four criteria established in paragraph 7 of PCAOB Auditing Standard No. 6 (AU-P sec. 420 par.
.07),
a.

does the report include an explanatory paragraph, following
the opinion paragraph, in the year of the change and in subsequent years until the new accounting principle is applied in
all periods presented?

b.

does the explanatory paragraph identify the nature of the
change and include a reference to the note disclosure describing the change?

c.

if the change in the accounting principle is a change in reporting entity that did not result from a transaction or an
event, is an explanatory paragraph included in the auditor’s
report? (Note: A change in the reporting entity resulting from
a transaction or event, such the creation, cessation, or complete or partial purchase or disposition of a subsidiary or
other business unit, does not require recognition in the auditor’s report.)
[PCAOB Auditing Standard No. 6 par. 4–8 and 11 (AU-P
420.04–.08 and .11)]

(Audits of Issuers Only) If there has been a correction of a material
misstatement in previously issued financial statements, including a
change from an accounting principle that is not generally accepted
to one that is generally accepted and a change in classification that
represents the correction of a material misstatement, does the auditor’s report contain an explanatory paragraph, following the
opinion paragraph, that includes
a.

a statement that the previously issued financial statements
have been restated for the correction of a misstatement in the
respective period?

b.

a reference to the entity’s disclosure of the correction of the
misstatement?
[PCAOB Auditing Standard No. 6 par. 5 and 9–11 (AU-P
420.05 and .09–.11)]

In an updated report on the individual financial statements of one
or more prior periods presented on a comparative basis with those
of the current period, if the opinion is different from the opinion
previously expressed on the financial statements of a prior period,
a.

does the report include an explanatory paragraph, preceding
the opinion paragraph that discloses all of the substantive
reasons for the different opinion?

b.

does the explanatory paragraph disclose
i.
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24.

b.

26.

the type of opinion previously expressed?

iii.

the circumstances or events that caused the auditor to
express a different opinion?

iv.

that the auditor’s updated opinion on the financial
statements of the prior period is different from his or
her previous opinion on those statements?
[AU 508.11e and .69]

N/A

If financial statements of a prior period (presented for comparative
purposes) have been audited by a predecessor auditor whose report
is not presented,
a.

25.

ii.

No

does the introductory paragraph of the report indicate
i.

that the financial statements of the prior period were
audited by another auditor?

ii.

the date of the predecessor auditor’s report?

iii.

the type of report issued by the predecessor auditor?

iv.

if the report was other than a standard report, the substantive reasons therefore, including a description of
the nature of and reasons for the explanatory paragraph added to the predecessor’s report or his or her
opinion qualification?

if the financial statements have been restated, does the introductory paragraph indicate that the predecessor auditor reported on the financial statements of the prior period before
restatement?
[AU 508.11e and .74]

Is an explanatory paragraph (or other explanatory language) added
to the standard auditor’s report if
a.

the auditor wishes to clarify that an audit performed in accordance with GAAS does not require the same level of testing
and reporting on internal control over financial reporting as
an audit of an issuer when Section 404(b) of the SarbanesOxley Act is applicable? (Note: Not required—Interpretation
No. 17 of AU section 508 [AICPA, Professional Standards, vol.
1] provides an example report.)
[AU 9508.85–.88]

b.

the audit is conducted in accordance with both GAAS and the
PCAOB’s Auditing Standards as allowed by Interpretation
No. 18 of AU section 508 (AICPA, Professional Standards, vol.
1)? (Note: Not required—Interpretation No. 18 of AU section
508 [AICPA, Professional Standards, vol. 1] provides an example report.)
[AU 9508.89–.92]

Is an explanatory paragraph (or other explanatory language) added
to the standard auditor’s report if the prior period’s financial statements are audited by a predecessor auditor who has ceased operations?
[AU 9508.60–.75]
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27.

If selected quarterly financial data required by SEC Regulation S-K
has been omitted or has not been reviewed, does the report include
an additional paragraph stating that fact?
[AU 508.11f; AU 722.50]

Note: Statement on Auditing Standards (SAS) No. 116, Interim Financial Information (AICPA, Professional Standards, vol. 1, AU sec. 722), amends AU
section 722 to accommodate reviews of interim financial information of
nonissuers, including companies offering securities pursuant to SEC Rule
144A or participating in private equity exchanges.
28.

If other information in a document containing audited financial
statements is materially inconsistent with information appearing in
the financial statements, has it been determined whether the financial statements, the auditor’s report, or both require revision?
[AU 508.11h; AU 550A.04]

Note: In February 2010, the ASB issued SAS No. 118, Other Information in
Documents Containing Audited Financial Statements (AICPA, Professional Standards, vol. 1, AU sec. 550); SAS No. 119, Supplementary Information in Relation to the Financial Statements as a Whole (AICPA, Professional Standards, vol.
1, AU sec. 551); and SAS No. 120, Required Supplementary Information (AICPA, Professional Standards, vol. 1, AU sec. 558). These standards amend or
supersede AU section 550A, Other Information in Documents Containing Audited Financial Statements; AU section 551A, Reporting on Information Accompanying the Basic Financial Statements in Auditor-Submitted Documents; and
AU section 558A, Required Supplementary Information (AICPA Professional
Standards, vol. 1), respectively. Collectively, these statements address the
auditor’s responsibilities with respect to information that is required by a
designated standard setter (for example, FASB, the Governmental Accounting Standards Board, the Federal Accounting Standards Advisory Board,
and the IASB) to accompany an entity’s basic financial statements and supplementary information that is presented outside the basic financial statements. The effective date of the SASs is for audits of financial statements
for periods beginning on or after December 15, 2010, and early application
is permitted.
29.

If the auditor decides to emphasize a matter regarding the financial
statements in the report, is the matter being emphasized disclosed
in the financial statements’ and is the explanatory information presented in a separate paragraph that avoids use of phrases such as
“with the foregoing (following) explanation”?
[AU 508.11 and .19; AU 9410.18; AU 9342.03]

30.

If it has not been possible to conduct the audit in accordance with
GAAS or to apply all of the procedures considered necessary in the
circumstances, has consideration been given to the need to issue a
qualified opinion or to disclaim an opinion?
[AU 508.22]
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If a qualified opinion is to be expressed because of a scope limitation,
a.

are all of the substantive reasons for the qualification disclosed in one or more explanatory paragraphs preceding the
opinion paragraph?

b.

does the qualified opinion include the word except or exception in a phrase such as except for or with the exception of?

c.

is the situation described and referred to in both the scope
and opinion paragraphs?

d.

does the wording in the opinion paragraph indicate that the
qualification pertains to the possible effects on the financial
statements and not to the scope limitation itself?
[AU 508.22–.32; AU 318.76]
Practice Tip

Scope limitations can be imposed by the client or by circumstances such as the timing of the auditor’s work,
the inability to obtain sufficient appropriate audit evidence, or an inadequacy in the accounting records.
Sufficient appropriate audit evidence includes, among other things, management having asserted responsibility for the final financial statements. As provided in Technical Questions and Answers (TIS) section
9100.06, “The Effect of Obtaining the Management Representation Letter on Dating the Auditor’s Report”
(AICPA, Technical Practice Aids), the auditor will need to have the signed management representation letter
in hand prior to releasing the auditor’s report because management’s refusal to furnish written representations constitutes a limitation on the scope of the audit sufficient to preclude an unqualified opinion.
In circumstances in which the auditor is unable to obtain sufficient appropriate audit evidence to support
management’s assertions about the nature of a matter involving an uncertainty and its presentation or disclosure in the financial statements, the auditor should consider the need to express a qualified opinion or to
disclaim an opinion because of a scope limitation.
It also includes situations in which the auditor’s only evidence of the existence, valuation, or both, of (a)
investments without readily determinable fair value, or (b) interests held in trust by a third-party trustee, is
receiving confirmation from a third party for those assets.
In circumstances in which the auditor is unable to audit the existence or measurement of interests in investments in securities and interests in trusts, the auditor should consider whether that scope limitation requires
the auditor to either qualify his or her opinion or to disclaim an opinion, as discussed in paragraphs .22–.26
of AU section 508 (AICPA, Professional Standards, vol. 1); Interpretation No. 1, “Auditing Interests in Trusts
Held by a Third-Party Trustee and Reported at Fair Value,” of AU section 328, Auditing Fair Value Measurements and Disclosures (AICPA, Professional Standards, vol. 1, AU sec. 9328 par. .01–.04); and Interpretation No.
1, “Auditing Investments in Securities Where a Readily Determinable Fair Value Does Not Exist,” of AU
section 332, Auditing Derivative Instruments, Hedging Activities, and Investments in Securities (AICPA, Professional Standards, vol. 1, AU sec. 9332 par. .01–.04).
32.

Is a qualified opinion or disclaimer of opinion expressed if the auditor’s understanding of internal control raises doubts about the auditability of an entity’s financial statements, such as
a.

concerns about the integrity of an entity’s management cause
the auditor to conclude that the risk of management misrepresentation in the financial statements is such that an audit
cannot be conducted?
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b.

33.

concerns about the condition and reliability of an entity’s records cause the auditor to conclude that it is unlikely that sufficient appropriate audit evidence will be available to support
an unqualified opinion on the financial statements?
[AU 314.109]

If, in the auditor’s judgment, the two-way communication between
the auditor and those charged with governance as described in AU
section 380 is not adequate and the situation cannot be resolved,
thereby prohibiting the auditor from obtaining all the audit evidence required to form an opinion on the financial statements, has
the auditor considered the following:
a.

Modifying the audit opinion on the basis of a scope limitation?

b.

Obtaining legal advice about the consequences of different
courses of action?

c.

Communicating with an appropriate third party (for example, a regulator)?

d.

Withdrawing from the engagement?
[AU 380.63]

34.

If, in the auditor’s judgment, significant difficulties in dealing with
management such as those described in AU section 380 have been
encountered, has the auditor considered modifying the audit opinion on the basis of a scope limitation?
[AU 380.39]

35.

If an opinion is disclaimed because of a scope limitation,
a.

are all of the substantive reasons for the disclaimer stated in
a separate paragraph or paragraphs?

b.

does the report state that the scope of the audit was not sufficient to warrant the expression of an opinion?

c.

does the report avoid identifying procedures that were performed?

d.

is the scope paragraph omitted?

e.

if there are reservations about fair presentation of the financial statements in conformity with GAAP, are they described
in the report?
[AU 508.62–.63]

Note: Consult the Topical Index to AICPA Professional Standards under
“Scope of Audit—Limitations” for additional references to specific types of
scope limitations that could result in either a qualified or disclaimer of
opinion.
36.

If the financial statements are materially affected by a departure
from GAAP (including, for example, inadequate disclosure, inappropriate accounting principles, and unreasonable accounting estimates), has the auditor issued a qualified opinion or an adverse
opinion?
[AU 508.35]
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37.

38.

No

N/A

If a qualified opinion is to be expressed because of a GAAP departure,
a.

are all of the substantive reasons that have led to the conclusion that there is a departure from GAAP disclosed in one or
more separate explanatory paragraphs preceding the opinion
paragraph?

b.

does the qualified opinion include the word except or exception in a phrase such as except for or with the exception of and a
reference to the explanatory paragraph?

c.

does the explanatory paragraph disclose the principle effects
of the departure on financial position, results of operations,
and cash flows, if practicable, or state that the effects are not
reasonably determinable?
[AU 508.21 and AU 508.37–.39]

If an adverse opinion is to be expressed because of a GAAP departure,
a.

are all of the substantive reasons for the adverse opinion disclosed in one or more separate explanatory paragraphs preceding the opinion paragraph?

b.

does the explanatory paragraph disclose the principle effects
of the departure on financial position, results of operations,
and cash flows, if practicable, or state that the effects are not
reasonably determinable?

c.

state that the financial statements do not present fairly the
financial position, or results of operations or cash flows in
conformity with GAAP?
[AU 508.58–.59]

39.

If essential data concerning an impending change in GAAP and the
future resulting restatement are not disclosed, has the auditor issued a qualified or adverse opinion?
[AU 9410.15]

40.

If the auditor concludes that an illegal act has a material effect on
the financial statements and the act has not been properly accounted for or disclosed, has the auditor issued a qualified or adverse opinion (depending on the materiality effect on the financial
statements taken as a whole)?
[AU 317.18]

Note: Consult the Topical Index to AICPA Professional Standards under “Departures From Standard Report” for additional information.
Readers may also wish to refer to TIS section 1400.31, “GAAP Departure
for FASB ASC 810” (AICPA, Technical Practice Aids), for assistance in determining the implications on the auditors report if the reporting entity does
not consolidate a variable interest entity.
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Practice Tip
Reporting on financial statements prepared in conformity with an other comprehensive basis of accounting
is addressed in AU section 623, Special Reports (AICPA, Professional Standards, vol. 1). For purposes of that
section, a comprehensive basis of accounting other than GAAP is one of the following:
a.

A basis of accounting that the reporting entity uses to comply with the requirements or financial
reporting provisions of a governmental regulatory agency to whose jurisdiction the entity is subject.
An example is a basis of accounting insurance companies use pursuant to the rules of a state insurance commission.

b.

A basis of accounting that the reporting entity uses or expects to use to file its income tax return for
the period covered by the financial statements.

c.

The cash receipts and disbursements basis of accounting, and modifications of the cash basis having
substantial support, such as recording depreciation on fixed assets or accruing income taxes.

d.

A definite set of criteria having substantial support that is applied to all material items appearing in
financial statements, such as the price-level basis of accounting.

In considering whether the financial statements (including the accompanying notes) include all informative
disclosures that are appropriate for the basis of accounting used, paragraph .09 of AU section 623 states that
the auditor should apply essentially the same criteria to financial statements prepared on an other comprehensive basis of accounting as he or she does to financial statements prepared in conformity with GAAP.
41.

When reporting on financial statements prepared in conformity
with a comprehensive basis of accounting other than GAAP, as defined in paragraph .04 of AU section 623, does the independent auditor’s report include the following elements (for audits prepared
in conformity with GAAS):
a.

A title that includes the word independent?
[AU 623.05a]

b.

A paragraph that states that

c.
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the financial statements identified in the report were
audited?

ii.

the financial statements are the responsibility of the entity’s management and that the auditor is responsible
for expressing an opinion on the financial statements
based on the audit?
[AU 623.05b]

A paragraph that states that
i.

the audit was conducted in accordance with GAAS
with specific identification of the United States of
America as the country of origin of those standards?

ii.

those standards require that the auditor plan and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material
misstatement?
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Yes

d.

42.

iii.

an audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial
statements; assessing the accounting principles used
and significant estimates made by management; and
evaluating the overall financial statement presentation?

iv.

the auditor believes that his or her audit provides a reasonable basis for the opinion?
[AU 623.05c]

No

N/A

A paragraph that states
i.

the basis of presentation and refers to the note to the
financial statements that describes the basis?

ii.

that the basis of presentation is a comprehensive basis
of accounting other than GAAP?
[AU 623.05d]

e.

A paragraph that expresses the auditor’s opinion (or disclaims an opinion) on whether the financial statements are
presented fairly, in all material respects, in conformity with
the basis of accounting described?
[AU 623.05e]

f.

If the financial statements are prepared in conformity with
the requirements or financial reporting provisions of a governmental regulatory agency, a separate paragraph at the end
of the report stating that the report is intended solely for the
information and use of those within the entity and the regulatory agencies to whose jurisdiction the entity is subject, and
is not intended to be and should not be used by anyone other
than these specified parties?
[AU 623.05f]

g.

The manual or printed signature of the auditor’s firm?
[AU 623.05g]

h.

The date of the audit report?
[AU 623.05h]

When the financial statements are prepared in conformity with the
requirements or financial reporting provisions of a governmental
regulatory agency and the financial statements and reports will be
used by parties or distributed by the entity to parties other than the
regulatory agencies to whose jurisdiction the entity is subject, has
the standard form of report been modified as appropriate because
of the departures from GAAP and has an additional paragraph
been added to express an opinion on whether the financial statements are presented in conformity with the regulatory basis of accounting? (Note: Interpretation 15, “Auditor Reports on Regulatory
Accounting or Presentation When the Regulated Entity Distributes
the Financial Statements to Parties Other Than the Regulatory
Agency Either Voluntarily or Upon Specific Request,” of AU section
623 [AICPA, Professional Standards, vol. 1, AU sec. 9623 par. .96–.98]
provides an example report.)
[AU 544.04; AU 9623.96–.98]
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Yes
43.

If certain other information, including supplementary information
required by GAAP, contained in annual reports and other clientprepared documents described in paragraph .02 of AU section
550A, Other Information in Documents Containing Audited Financial
Statements (AICPA, Professional Standards, vol. 1), that contain audited financial statements has been subjected to auditing procedures applied in the audit of the basic financial statements, does the
auditor express an opinion on whether the information is fairly
stated in all material respects in relation to those financial statements taken as a whole in the auditor’s report and does the report
describe clearly the character of the auditor’s work and the degree
of responsibility the auditor is taking?
[AU 550A.07; AU 558A.09]

44.

If other information contained in annual reports and other clientprepared documents described in AU section 550A paragraph .02
that contain audited financial statements is materially inconsistent
with information appearing in the financial statements, has it been
determined whether the financial statements, the auditor’s report,
or both require revision?
[AU 508.11h; AU 550A.04]

45.

If other information contained in annual reports and other clientprepared documents described in AU section 550A paragraph .02
that contain audited financial statements is materially inconsistent
with information appearing in the financial statements, and the auditor has determined that neither the financial statements nor the
auditor’s report require revision, has the auditor either

46.

a.

requested that the client revise the other information to eliminate the material consistency?

b.

considered other actions such as revising the audit report to
include an explanatory paragraph describing the material inconsistency, withholding the use of the audit report in the
document, and withdrawing from the engagement?
[AU 550A.04]

If information accompanies the basic financial statements and auditor’s report in an auditor-submitted document, is it accompanied
by a report that
a.

states that the audit was performed for the purpose of forming an opinion on the basic financial statements taken as a
whole?

b.

specifically identifies the accompanying information?

c.

states that the accompanying information is presented for
purposes of additional analysis and is not a required part of
the basic financial statements?
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Yes
d.

47.

No

N/A

includes either an opinion on whether the accompanying information is fairly stated in all material respects in relation to
the basic financial statements taken as a whole or a disclaimer
of opinion (depending on whether the information was subjected to the auditing procedures applied in the audit of the
basic financial statements)?
[AU 551A.05–.06]

If information accompanying the basic financial statements and auditor’s report in an auditor-submitted document is materially misstated in relation to the basic financial statements taken as a whole,
has the auditor either
a.

requested that the client revise the accompanying information to eliminate the material misstatement?

b.

considered other actions such as modifying the audit report
to describe the misstatement or refusing to include the accompanying information in the auditor-submitted document?
[AU 551A.09]

48.

When the basic financial statements are accompanied by supplementary information required by GAAP and such supplementary
information has not been audited as part of the basic financial statements, does the auditor’s report exclude any language that refers to
the supplementary information or the limited procedures applied
(except in the circumstances described in AU section 558A paragraph .08)?
[AU 558A.08]

49.

When the basic financial statements are accompanied by supplementary information required by GAAP and such supplementary
information has been audited as part of the basic financial statements, has the audit report been expanded in accordance with AU
section 550A paragraph .07?
[AU 558A.09]

50.

If supplementary information required by GAAP has been omitted,
the presentation of such information departs materially from prescribed guidelines, the auditor is unable to complete prescribed
procedures with respect to such information, or the auditor is unable to remove substantial doubt about whether the supplementary
information conforms to prescribed guidelines, does the report include an additional paragraph stating that fact?
[AU 558A.08]
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FSP Section 11,300
Auditors’ Reports Checklist for Audits
Performed in Accordance With
Government Auditing Standards and
OMB Circular A-133
.01 Government Auditing Standards (also referred to as the Yellow Book), issued by the Comptroller General of the United States of the U.S. Government Accountability Office (GAO; formerly U.S. General Accounting Office), applies to the audits of governmental entities, programs, activities, and functions, and of
governmental assistance administered by contractors, not-for-profit organizations, and other nongovernmental entities, when required by statute or other mandates or when auditors hold themselves out as following those standards.1 The Single Audit Act Amendments of 1996 (the Single Audit Act) and Office of Management and Budget (OMB) Circular A-133, Audits of States, Local Governments, and Non-Profit Organizations,
require a single or program-specific audit for entities that expend $500,000 or more of federal awards in a
fiscal year. The Single Audit Act Amendments of 1996 requires single audits and program-specific audits of
federal awards to be performed in accordance with Government Auditing Standards. Similarly, Government
Auditing Standards requires the use of its standards when auditing compliance with regulations relating to
federal award expenditures and other governmental financial assistance in conjunction with or as a byproduct of a financial statement audit.
.02 This checklist has two parts. Part I is for auditor’s reports on financial statement audits performed
in accordance with Government Auditing Standards. (This checklist does not address the performance auditing
or attestation standards of Government Auditing Standards. It also does not address types of financial audits
other than financial statement audits, except for Circular A-133 audits.) Part II contains the additional requirements for auditor’s reports on audits performed in accordance with the Single Audit Act Amendments
of 1996 and Circular A-133. For audits performed in accordance with Circular A-133, both parts I and II of
this checklist must be completed. Illustrative auditor’s reports on financial statement audits performed in
accordance with Government Auditing Standards and illustrative auditor’s reports and an illustrative schedule
of findings and questioned costs for Circular A-133 audits are in the AICPA Audit Guide Government Auditing Standards and Circular A-133 Audits.
.03 The OMB issues an annual Circular A-133 compliance supplement for conducting single audits. That
supplement is available from the Government Printing Office by calling (202) 512-1800 and on the OMB’s
website at www.whitehouse.gov/omb/grants/grantspcirculars.html. The AICPA issues the annual Audit
Risk Alert Government Auditing Standards and Circular A-133 Developments, as a complement to the Audit
Guide Government Auditing Standards and Circular A-133 Audits. The AICPA has also issued the related
practice aid Auditing Recipients of Federal Awards: Practical Guidance for Applying OMB Circular A-133, Audits
of States, Local Governments, and Non-Profit Organizations (product no. 006621).

1
As discussed in paragraph 4.26 of the AICPA Audit Guide Government Auditing Standards and Circular A-133 Audits (the guide),
paragraph 5.06 of Government Auditing Standards (GAS) acknowledges that an auditee may need a financial statement audit for purposes
other than to comply with a requirement calling for an audit in accordance with GAS. For example, the auditee may need a financial
statement audit to issue bonds. In that case, GAS permits auditors to issue a separate report on the financial statements conforming only
to the requirements of generally accepted auditing standards (GAAS). The information contained in this checklist is based on the GAS
July 2007 revision, which is effective for audits of periods beginning on or after January 1, 2008.
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.04 The Public Company Accounting Oversight Board (PCAOB) establishes standards for audits of issuers, as that term is defined by the Sarbanes-Oxley Act of 2002, or whose audit is prescribed by the rules of
the Securities and Exchange Commission. Other entities are referred to as nonissuers. Because not-for-profit
organizations are nonissuers, this checklist does not address PCAOB standards. However, although not
common, the auditor may be engaged to audit and report on the effectiveness of an not-for-profit organization’s internal control over financial reporting in accordance with PCAOB auditing standards. In those
cases, the auditor should modify this checklist considering the guidance in PCAOB standards, the GAO
Internet Notice at www.gao.gov/govaud/ybk01.htm titled Guidance on Complying with Government Auditing
Standards Reporting Requirements for the Report on Internal Control for Audits of Certain Entities Subject to the
Requirements of the Sarbanes-Oxley Act of 2002 and Government Auditing Standards, and Interpretation No.
18, “Reference to PCAOB Standards in an Audit Report on a Nonissuer,” of AU section 508, Reports on
Audited Financial Statements (AICPA, Professional Standards, vol. 1, AU sec. 9508 par. .89–.92), as well as the
discussion in the preface and appendix A to chapter 4 of the AICPA Audit Guide Government Auditing
Standards and Circular A-133 Audits.
.05 This checklist has been updated for the revisions to OMB Circular A-133 published in the Federal
Register on June 26, 2007, that changes the reporting requirements on internal control deficiencies over compliance to be consistent with the control deficiency definitions of AU section 325, Communicating Internal
Control Related Matters Identified in an Audit (AICPA, Professional Standards, vol. 1). Interpretation No. 1,
“Communicating Deficiencies in Internal Control Over Compliance in an Office of Management and Budget
Circular A-133 Audit,” of AU section 325, Communicating Internal Control Related Matters Identified in an Audit
(AICPA, Professional Standards, vol. 1, AU sec. 9325 par. .01–.03), provides guidance on implementing these
reporting requirements.
.06 Explanation of References:
A-133 5 OMB Circular A-133, Audits of States, Local Governments, and Non-Profit Organizations
(June 2007 Revision)
GAS 5 GAO 2007 revision to Government Auditing Standards, as amended through Amendment
No. 3, Independence
AU 5
Reference to section number in AICPA Professional Standards (vol. 1)
AAG 5 AICPA Audit Guide Government Auditing Standards and Circular A-133 Audits (with
conforming changes as of May 1, 2010)
.07 Checklist Questionnaire:

Part I—Reports on Audits Performed in Accordance With Government Auditing
Standards
Yes
1.

No

N/A

In a financial statement audit performed in accordance with Government
Auditing Standards, has the auditor issued the following reports:2
a.

A report on the entity’s financial statements that provides an opinion or disclaimer of opinion on the financial statements?
[GAS 5.03; AAG 4.04 and .22]

2

There is no provision in GAS that requires the auditee to prepare financial statements in accordance with accounting principles
generally accepted in the United States of America (GAAP). If an auditee prepares financial statements in conformity with comprehensive
bases of accounting other than GAAP, known as other comprehensive bases of accounting, or OCBOA, the auditor still is required to
express or disclaim an opinion and should follow the reporting guidance in AU section 623, Special Reports (AICPA, Professional Standards,
vol. 1) (GAS paragraph 5.03 footnote 62 and paragraph 4.22h of the guide).
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Yes
b.

No
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N/A

A report on internal control over financial reporting and on compliance with laws, regulations, and provisions of contracts or grant
agreements based on an audit of financial statements performed in
accordance with Government Auditing Standards?
[GAS 5.07; AAG 4.04, .08, and .27]

Report on the Financial Statements
2.

3.

In addition to the elements listed in the checklist for the auditor’s report
on the financial statements in FSP section 11,200, does the auditor’s report
on the financial statements contain
a.

a statement that the audit was conducted in accordance with the
standards applicable to financial audits contained in Government
Auditing Standards, issued by the Comptroller General of the United
States?3
[GAS 5.05; AAG 4.05a, .22d, and .24]

b.

a statement or a reference to a separate report on internal control
over financial reporting and on compliance with certain provisions
of laws, regulations, contracts, and grant agreements and other
matters prepared in accordance with Government Auditing Standards,4 which includes
i.

a description of the scope of testing of internal control over
financial reporting and compliance with laws, regulations,
and provisions of contracts or grant agreements and the results of that testing, and a statement as to whether the tests
performed provided sufficient appropriate evidence to support an opinion on the internal control over financial reporting or on compliance with laws, regulations, and provisions
of contracts or grant agreements?5

ii.

if a separate report is issued, a reference to the separate report
is included in the report on the financial statements and a
statement that the separate report is an integral part of an
audit performed in accordance with Government Auditing
Standards and should be considered in assessing the results of
the audit?
[GAS 5.08–.09; AAG 4.05b and .22i]

If the auditor does not follow an applicable standard of Government Auditing Standards, does the scope section of the report disclose the standard
that was not followed, the reasons therefore, and how not following the
standard affected, or could have affected, the results of the audit?
[GAS 1.12b; AAG 4.25]

3
When personal, external, and organizational impairments to independence exist, a government auditor who cannot decline to perform the work because of a legislative requirement or for other reasons should report the impairment in the scope section of the auditor’s
report (GAS paragraph 3.05 and paragraph 4.22d of the guide).
4
If the reporting on internal control over financial reporting and on compliance and other matters is included in the report on the
financial statements, the reference to the separate report is not required. The guide recommends separate reporting (paragraphs 4.05b
and 4.21i of the guide).
5

Paragraph 5.08 of the guide permits, but does not require, an opinion on internal control over financial reporting or on compliance if
sufficient work was performed. This statement should be modified if the auditor is providing an opinion on internal control over financial
reporting or on compliance in the GAS report (paragraphs 4.05b and 4.22i of the guide).
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Yes
4.

No

N/A

If a material organizational unit is not required to have an audit in accordance with Government Auditing Standards, has the scope paragraph of the
report on the financial statements been modified to indicate the portion
of the entity that was not audited in accordance with Government Auditing
Standards?
[AAG 4.39–.40]

Report on Internal Control Over Financial Reporting and on Compliance and
Other Matters Based on an Audit Performed in Accordance With Government
Auditing Standards
5.

Does the auditor’s report on internal control over financial reporting and
on compliance and other matters conform to the standard report language
illustrated in the guide?
[AAG examples 4-3 and 4-5]

6.

Does the auditor’s report on internal control over financial reporting and
on compliance and other matters contain

6

a.

a statement that the auditor has audited the financial statements of
the auditee and a reference to the auditor’s report on the financial
statements, including a description of any departure from the standard report (for example, a qualified opinion, a modification as to
consistency because of a change in accounting principle, or a reference to the report of other auditors)?
[AAG 4.28a and examples 4-3 and 4–5]

b.

a statement that the audit was conducted in accordance with GAAS
(with an identification of the United States of America as the country of origin of those standards) and with the standards applicable
to financial audits contained in Government Auditing Standards, issued by the Comptroller General of the United States?6

c.

a statement that in planning and performing the audit, the auditor
considered the auditee’s internal control over financial reporting in
order to determine the auditing procedures for the purpose of expressing an opinion on the financial statements and not to provide
an opinion on the internal control over financial reporting; and accordingly, do not express an opinion on the effectiveness of the entity’s internal control over financial reporting?7

d.

the definition of control deficiency and significant deficiency? If applicable, a statement that deficiencies were identified that are considered to be significant deficiencies in internal control over financial
reporting?

e.

a statement that the auditor’s consideration of internal control over
financial reporting would not necessarily identify all deficiencies in
internal control that might be significant deficiencies or material
weaknesses. If significant deficiencies are identified, a statement
that certain deficiencies in internal control over financial reporting
were identified that the auditor considers to be significant deficiencies?

See footnote 3 (GAS paragraph 3.06 and paragraph 4.28b of the guide).

7

Paragraph 5.08 of the guide permits, but does not require, an opinion on internal control over financial reporting or on compliance if
sufficient work was performed. This statement should be modified if the auditor is providing an opinion on internal control over financial
reporting (paragraph 4.28c of the guide).
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Yes
f.

if applicable, a description of the significant deficiencies identified
(including the views of responsible officials and their planned corrective action) or a reference to a separate schedule in which the
significant deficiencies, views of responsible officials, and their
planned corrective action are described?8

g.

the definition of a material weakness?

h.

if no significant deficiencies are identified, a statement that no material weaknesses were identified. If significant deficiencies are
identified, a statement that the auditor’s consideration of internal
control over financial reporting would not necessarily identify all
deficiencies in the internal control that might be significant deficiencies and a statement about whether the auditor believes any of the
significant deficiencies identified are material weaknesses and, if
they are, that identifies which significant deficiencies are considered material weaknesses?9(If there are no reportable conditions
noted, a statement is made that no material weaknesses were
noted.)

i.

a statement that as part of obtaining reasonable assurance about
whether the auditee’s financial statements are free of material misstatement, the auditor performed tests of the auditee’s compliance
with certain provisions of laws, regulations, contracts, and grant
agreements, noncompliance with which could have a direct and
material effect on the determination of financial statement
amounts?

j.

a statement that providing an opinion on compliance with those
provisions was not an objective of the audit and that, accordingly,
the auditor does not express such an opinion?10

k.

a statement that notes whether the results of tests disclosed instances of noncompliance or other matters (certain fraud and abuse)
that are required to be reported under Government Auditing Standards and, if they are, describes the instances of noncompliance and
other matters (including the views of responsible officials and their
planned corrective action) or refers to the separate schedule in
which the noncompliance and other matters, views of responsible
officials, and their planned corrective action are described?11
[AAG 4.26]

l.

if applicable, a statement that the auditor did not audit the auditee’s
response and, accordingly, expresses no opinion on it?
[AAG 4.28]

No

251
N/A

8
For an audit in accordance with Circular A-133, all findings, including those required to be reported under GAS, should be included
in the schedule of findings and questioned costs. Therefore, for such audits, this report should refer to the schedule of findings and
questioned costs. See the questions about that schedule in part II of this checklist (paragraphs 4.28f and 13.17 of the guide).
9

In reporting significant deficiencies, the auditor should identify those that are individually or in the aggregate material weaknesses
(GAS paragraph 5.13 and paragraph 4.09 of the guide).
10
Paragraph 5.08 of the guide permits, but does not require, an opinion on internal control over financial reporting or on compliance
if sufficient work was performed. This statement should be modified if the auditor is providing an opinion on compliance (paragraph
4.28 of the guide).
11

See footnote 27 in chapter 4 of the guide.

FSP §11,300.07

252

Health Care Entities

Yes
m.

if applicable, a statement that additional matters were communicated to the auditee in a management letter?
[AAG 4.28l, .37, table 1, and examples 4-3 and 4-5]

n.

a separate paragraph at the end of the report stating that the report
is intended solely for the information and use of the management,
[identify the body or individuals charged with governance], others within
the entity, and [identify any specified legislative or regulatory body]12
and is not intended to be and should not be used by anyone other
than these specified parties?13

o.

the manual or printed signature of the auditor’s firm?

p.

the date of the auditor’s report?
[AAG 4.28]

7.

Does the report carry the same date as the report on the financial statements?
[AAG 4.28r]

8.

If a material operating unit or organizational component is not required
to have an audit in accordance with Government Auditing Standards, has
the scope paragraph of the report been modified to indicate the portion
of the entity that was not audited in accordance with Government Auditing
Standards?
[AAG 4.39–.40 ]

9.

If certain pertinent information is prohibited from public disclosure or is
excluded from a report due to the confidential or sensitive nature of the
information (as it may be by federal, state, or local laws or regulations),
does the auditor’s report state that certain information has been omitted
and the reason or other circumstance that makes the omission necessary?
[GAS 5.39; AAG 4.05g]

10.

Does the language in the compliance and other matters section of the report refer to findings that do or may include fraud and abuse? (That language should appear in all reports, even if the report does not describe or
refer to findings of fraud or abuse or even if the only findings of fraud or
abuse are described in or referred to from the section on internal control
over financial reporting.)
[AAG 4.31]

11.

Are findings that relate to both internal control over financial reporting
and to compliance reported in or referred to from both the section of the
report concerning internal control over financial reporting and in the section of the report concerning compliance and other matters? (The reporting in one section of the report or schedule may be in summary form with
a reference to a detailed reporting in the other section.)
[AAG 4.30]

No

N/A

12
For an audit in accordance with A-133, this reference should include federal awarding agencies and, if applicable, pass-through
entities (paragraphs 4.28m and 13.17 of the guide).
13
This paragraph conforms to AU section 532, Restricting the Use of an Auditor’s Report (AICPA, Professional Standards, vol. 1). See AU
section 532 for additional guidance on restricted-use reports (paragraph 4.28m of the guide).
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Yes
12.

Are findings of fraud and abuse reported in or referred to from the compliance and other matters section of the report, unless the primary nature
of the finding is a significant deficiency in internal control? (Auditors
should present or refer to findings of fraud and abuse that represent significant deficiencies in internal control in the internal control section.)
[AAG 4.31]

13.

Do the reported findings include all identified deficiencies in internal control over financial reporting considered to be significant deficiencies
(identifying those considered to be material weaknesses) and all fraud
and illegal acts (unless inconsequential),14 and material violations of provisions of contracts or grant agreements and material abuse that has occurred or is likely to have occurred?15
[GAS 5.10; AAG 4.05c, .09, .16–.17 and .29 and 13.35]

14.

Does each finding include a reference number? (For example, findings
identified and reported in the audit of fiscal year 20X1 could be assigned
reference numbers 20X1-1, 20X1-2, and so forth.)
[AAG 4.34]

15.

Do the reported findings place the findings in proper perspective (or context) by describing the nature and extent of the issues reported and the
work performed that resulted in the finding? (The identified instances
should be related to the population or the number of cases examined and
be quantified in terms of dollar value or other measures, if appropriate.)
[GAS 5.22; AAG 4.32]
a.

No

253
N/A

When reporting instances of fraud, illegal acts, violations of provisions of contracts or grant agreements, or abuse, are the results projected? (If the results cannot be projected, auditors should limit
their conclusions appropriately.)
[GAS 5.22; AAG 4.32]

16.

To the extent possible and to achieve audit objectives, do the reported
findings present criteria, condition, cause, effect or potential effect, and
recommendation?
[GAS 4.14–.18 and 5.21; AAG 4.33]

17.

Does the auditor’s report include the views of responsible officials concerning the findings, conclusions, and recommendations, as well as
planned corrective actions?16, 17
[GAS 5.32; AAG 4.05f and .35]

14
In an audit conducted in accordance with A-133, the auditor should apply a financial statement materiality consideration in reporting
in the GAS report fraud and illegal acts involving federal awards that are subject to A-133 reporting. That is because those findings
already are reported in the A-133 report and reporting findings that are not material to the financial statements again in the GAS report
would be unnecessarily duplicative (paragraphs 4.16 and 13.15 and 13.35 of the guide).
15
GAS requires this reporting even if the auditor disclaims an opinion on the financial statements. GAS also provides reporting
requirements for other findings of internal control deficiencies, fraud, illegal acts, violations of provisions of contracts or grants agreements, and abuse; see questions 18–19.
16
In an audit in accordance with A-133, the auditee is required to submit a corrective action plan. For those audits, depending on the
status of the development of the corrective action plan at the time the auditor’s reports are released, the auditor may be able to refer to
the corrective action plan to satisfy as the required presentation of the auditee’s views and planned corrective actions. See the questions
about the reporting of auditee views and the corrective action plan in part II of this checklist (paragraph 4.35 of the guide).
17
The auditor is required to extend a reasonable effort to obtain and report auditee views and planned corrective actions. GAS does
not require the auditor to delay or withhold the release of the report if the auditee does not provide the necessary information on a timely
basis. If, however, the auditee does not provide the necessary information by the time the report is released, the report should indicate
that the audited entity did not provide comments (paragraph 4.36 of the guide).
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Yes
a.

If the auditor receives, in writing, the views of responsible officials,
is a copy of the officials’ written comments or a summary of the
comments received included in the auditor’s report?18

b.

Does the auditor’s report include an evaluation of the comments, as
appropriate?

c.

If the entity’s views oppose the report’s findings, conclusions, or
recommendations, and are not, in the auditor’s opinion, valid—or
if the planned corrective actions do not adequately address the auditor’s recommendations—does the report state reasons for disagreeing with the comments or planned corrective actions?

d.

If the audited entity refused to provide comments or is unable to
provide comments within a reasonable period of time, does the auditor’s report state that the audited entity did not provide comments?
[GAS 5.34–.38; AAG 4.35]

No

N/A

Other Reporting and Communication Considerations
18.

19.

Does the management letter communicate the following unless clearly inconsequential—deficiencies in internal control that are not significant deficiencies, immaterial violations of provisions of contracts or grant agreements, and immaterial abuse?19
[GAS 5.16; AAG 4.19 and .37]
a.

Are the management letter discussions worded so that readers can
distinguish those matters that are required to be included by GAAS
or Government Auditing Standards from matters that are recommendations for improvements or information about “best practices”?
[AAG 4.38]

b.

Does the management letter not include personal identification or
other potentially sensitive matters?
[AAG 4.49]

Has the auditor used professional judgment to determine whether and
how to communicate to auditee officials deficiencies in internal control,
fraud, illegal acts, violations of provisions of contracts or grant agreements, and abuse that are less than material but more than inconsequential?20
[GAS 5.16; AAG 4.37]

18
When the responsible officials provide oral comments only, auditors should prepare a summary of the oral comments and provide
a copy of the summary to the responsible officials to verify that the comments are accurately stated.
19
Generally, GAS requires the auditor to evaluate findings for the purpose of communication in the management letter based on their
consequence to the financial statements or other financial data significant to the audit objectives. In an audit in accordance with A-133,
however, the auditor should evaluate findings involving federal awards for the purpose of that communication based only on their
consequence to the financial statements. Further, the auditor should not communicate such findings in the management letter if they are
otherwise reported as audit findings in accordance with A-133 (paragraphs 4.37 and 13.25 of the guide).
20
GAAS require that whenever the auditor has determined that there is evidence that fraud may exist, the auditor should bring that
matter to the attention of an appropriate level of management, even if the matter might be considered inconsequential (paragraph .79 of
AU section 316, Consideration of Fraud in a Financial Statement Audit [AICPA, Professional Standards, vol. 1], and paragraphs 4.12 and 4.37
of the guide).
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Yes
20.

Has the auditor reported known or likely fraud, illegal acts, violations of
provisions of contracts or grant agreements, and abuse directly to parties
outside of the auditee in the situations required by Government Auditing
Standards, even if the auditor has resigned or been dismissed from the
audit?
[GAS 5.18–.20; AAG 4.20]

21.

In addition to the communications required by GAAS, has the auditor
communicated the following information regarding his or her planned
work and reporting related to testing internal control over financial reporting and compliance with laws, regulations, and provisions of contracts or grant agreements, preferably in a writing such as the engagement letter, to those charged with governance of the audited entity and
to the individuals contracting for or requesting the audit during the planning stages of the audit:
a.

The auditor’s responsibilities for testing and reporting on internal
control over financial reporting and on compliance with laws, regulations, and provisions of contracts or grant agreements?

b.

The nature of any additional testing of internal control and compliance required by laws, regulations, and provisions of contracts or
grant agreements or otherwise requested, and whether the auditor
is planning on providing an opinion on internal control over financial reporting or on compliance with laws, regulations, and provisions of contracts or grant agreements?

c.

A contrasting of the responsibilities in questions 21 a–b with other
audits of internal control and compliance?

d.

Potential restrictions on the auditor’s reports?

e.

Additional relevant topics, such as the auditor’s fieldwork and reporting responsibilities for fraud and abuse?
[GAS 4.06–.07]

22.

If an audit is terminated before it is complete, is the reason for terminating the audit communicated to auditee management, the entity requesting
the audit, and other appropriate officials, preferably in writing?
[GAS 4.08; AAG 2.30]

23.

If the auditor is
a.

a government auditor, does the auditor submit the auditor’s reports
to the appropriate officials of the audited entity, appropriate officials of the organizations requiring or arranging for the audits (unless legal restrictions prevent it), and other officials who have legal
oversight authority or who may be responsible for acting on audit
findings and recommendations and to others authorized to receive
such reports?

b.

a nongovernment auditor, does the auditor clarify report distribution responsibilities with the party contracting for the audit and follow the agreements reached?
[GAS 5.44; AAG 4.05h]

No

255
N/A
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24.

Unless the report is restricted by law or regulation, or contains privileged
and confidential information, does the auditor clarify that copies are
made available for public inspection? (That clarification should be made
in the engagement letter and may also be made in correspondence that
transmits the reports to the auditee and other recipients.)
[GAS 5.44; AAG 4.05h]

25.

If the auditor is reporting on restated financial statements, did the auditor’s report include an explanatory paragraph in the reissued or updated
auditor’s report that included
a.

a statement disclosing that the previously-issued financial statements have been restated?

b.

a statement that the previously-issued report (referred to by report
date) is not to be relied upon (because previously issued financial
statements were materially misstated) and is being replaced by the
auditor’s report on the restated financial statements?

c.

a reference to the notes to the restated financial statements that discusses the restatement?

d.

if applicable, a reference to the report on internal control containing
a discussion of any significant deficiency identified related to the
failure to prevent or detect the misstatement and any management
corrective action taken?
[GAS 5.29]

26.

If the auditor is reporting on restated financial statements and if management fails to include the appropriate disclosures related to the restatement, are the omitted disclosures included in the auditor’s report?
[GAS 5.28c and .30]

27.

Has the auditor notified those charged with governance if the entity’s
management (a) does not act in an appropriate time frame after new information was available to determine the financial statement effects of the
new information and take the necessary steps to timely inform those who
are likely to rely on the financial statements and the related auditor’s reports of the situation or (b) does not restate with reasonable timeliness the
financial statements under circumstances in which auditors believe they
need to be restated?
[GAS 5.31]

No

N/A

Part II—Reports on Audits Performed in Accordance With A-133
1.

In an audit performed in accordance with A-133, has the auditor issued
the following reports in addition to those in part I of this checklist:21
a.

A report on the supplementary schedule of expenditures of federal
awards that provides an opinion (or disclaimer of opinion) as to
whether the schedule is presented fairly in all material respects in
relation to the financial statements taken as a whole?

21
Because of the requirements of GAS, the auditor also has other reporting and communication responsibilities in an A-133 audit. See
the questions in the section titled “Other Reporting and Communication Considerations” in part I of this checklist.
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Yes
b.

A report on compliance with requirements applicable to each major
program and on internal control over compliance in accordance
with A-133 that provides an opinion (or disclaimer of opinion) as
to whether the audited entity complied with laws, regulations, and
the provisions of contracts or grant agreements which could have a
direct and material effect on each major program, and, where applicable, a reference to the separate schedule of findings and questioned costs?

c.

A schedule of findings and questioned costs?
[A-133 sec. 505; AAG 13.06]

No

257
N/A

Report on the Supplementary Schedule of Expenditures of Federal Awards
2.

Is the report on the schedule (a) included in the auditor’s report on the
financial statements, (b) included in the report on compliance with requirements applicable to each major program and on internal control over
compliance in accordance with A-133, or (c) issued as a stand-alone report?
[AAG 13.11, .14, .24, and .28]

3.

If the report on the financial statements refers to the work of other auditors, has the auditor considered the need to refer to the major federal programs audited by other auditors in the report on the schedule?
[AAG 13.31]

4.

If the report on the schedule is included in the auditor’s report on the
financial statements or in the A-133 report on compliance and on internal
control over compliance, does it

5.

a.

conform to the standard report language illustrated in the guide?
[AAG 13.13 and example 13-1]

b.

identify the schedule of expenditures of federal awards as accompanying supplementary information by descriptive title or by page
number of the document?

c.

contain a statement that the audit was conducted for the purpose
of forming an opinion on the basic financial statements taken as a
whole and that the schedule is presented for purposes of additional
analysis and is not a required part of the financial statements?
[AAG 13.11 and example 13-1]

d.

contain an opinion or a disclaimer of opinion as to whether the
Schedule is fairly stated, in all material respects, in relation to the
financial statements taken as a whole?
[AAG 13.09, .11, and example 13-1]

e.

carry the same date as the report on the financial statements, even
if that requires a dual date on the A-133 report on compliance and
on internal control over compliance?
[AAG 13.26–.28]

f.

consider the effect of any modifications to this report?
[AAG 13.12]

If the report on the schedule is issued as a stand-alone report, is the guidance AU section 508 followed in issuing that report?
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Yes
a.

Does the report carry the same date as the A-133 report on compliance and on internal control over compliance?
[AAG 13.28]

Report on Compliance With Requirements Applicable to Each Major Program and on Internal Control Over Compliance in Accordance With A-133
6.

Does the report conform to the standard report language illustrated in the
guide?
[AAG examples 13-1–13-5]

7.

Does the report contain the following elements:
a.

A statement that the auditor has audited the compliance of the auditee with the types of compliance requirements described in the
OMB Circular A-133 Compliance Supplement that are applicable to
each of its major programs?

b.

A statement that the auditee’s major programs are identified in the
summary of the auditor’s results section of the accompanying
schedule of findings and questioned costs?

c.

A statement that compliance with the requirements of laws, regulations, contracts, and grants applicable to each of the auditee’s major federal programs is the responsibility of the auditee’s management, and that the auditor’s responsibility is to express an opinion
on the auditee’s compliance based on the audit?

d.

A statement that the audit of compliance was conducted in accordance with GAAS (with an identification of the United States of
America as the country of origin of those standards), the standards
applicable to financial audits contained in Government Auditing
Standards issued by the Comptroller General of the United States,
and A-133?

e.

A statement that those standards and A-133 require that the auditor
plan and perform the audit to obtain reasonable assurance about
whether noncompliance with the types of compliance requirements
that could have a direct and material effect on a major federal program occurred?

f.

A statement that an audit includes examining, on a test basis, evidence about the auditee’s compliance with those requirements and
performing such other procedures as the auditor considered necessary in the circumstances?

g.

A statement that the auditor believes that the audit provides a reasonable basis for the auditor’s opinion?

h.

A statement that the audit does not provide a legal determination
of the auditee’s compliance with those requirements?

i.

If instances of noncompliance are noted that result in an opinion
modification, a reference to a description in the accompanying
schedule of findings and questioned costs, including
i.

the reference number(s) of the finding(s)?

ii.

an identification of the type(s) of compliance requirements
and related major program(s)?
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iii.

No
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N/A

a statement that compliance with such requirements is necessary, in the auditor’s opinion, for the auditee to comply
with the requirements applicable to the program(s)?

j.

An opinion on whether the auditee complied, in all material respects, with the types of compliance requirements that are applicable to each of its major federal programs?

k.

If applicable, a statement that the results of the auditing procedures
disclosed instances of noncompliance that are required to be reported in accordance with A-133 and a reference to the schedule of
findings and questioned costs in which they are described?

l.

A statement that the auditee’s management is responsible for establishing and maintaining effective internal control over compliance
with the requirements of laws, regulations, contracts, and grants
applicable to federal programs?

m.

A statement that in planning and performing the audit, the auditor
considered the auditee’s internal control over compliance with requirements that could have a direct and material effect on a major
federal program, to determine the auditing procedures for the purpose of expressing an opinion on compliance but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance?

n.

The definition of control deficiency and significant deficiency. If applicable, a statement that deficiencies were identified that are considered to be significant deficiencies in internal control over compliance?

o.

If applicable, a reference to a description of the significant deficiencies identified in the accompanying schedule of findings and questioned costs, including the reference number of the finding(s)?

p.

If no significant deficiencies are identified, a statement that the auditor’s consideration of internal control over compliance would not
necessarily disclose all matters in internal control that might be significant deficiencies or material weaknesses; if significant deficiencies are identified, a statement that the auditor’s consideration of
internal control over compliance would not necessarily disclose all
matters in the internal control that might be significant deficiencies
or material weaknesses and a statement that certain deficiencies
were identified that are considered to be significant deficiencies
(and, if applicable, material weaknesses)?

q.

The definition of a material weakness?

r.

If applicable, a statement about whether the auditor believes any of
the significant deficiencies identified are material weaknesses and,
if they are, a reference to a description of the material weaknesses
in the schedule of findings and questioned costs, including the reference number of the finding(s)? (If there are no significant deficiencies identified, a statement should be made that no material weaknesses were identified.)
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s.

If applicable, a statement that the auditee’s response to findings
identified in the audit are described in the accompanying schedule
of findings and questioned costs, and that the auditor did not audit
the auditee’s response and, accordingly, expresses no opinion on it?

t.

A separate paragraph at the end of the report stating that the report
is intended solely for the information and use of [identify the body or
individuals charged with governance], others within the entity, [identify
the specified legislative or regulatory body], federal awarding agencies,
and (if applicable) pass-through entities and is not intended to be
and should not be used by anyone other than these specified parties?22

u.

The manual or printed signature of the auditor’s firm?

v.

The date of the auditor’s report?
[AAG 13.23]

8.

If the audit of the auditee’s compliance with requirements applicable to a
major program detects material instances of noncompliance with those
requirements, does the auditor’s report express a qualified or adverse
opinion?
[AAG 13.19]

9.

Have scope limitations on the auditor’s testing of the auditee’s compliance with laws, regulations, and the provisions of contracts or grant
agreements been considered in the opinion on compliance with requirements applicable to each major program?
[AAG 13.20–.22]

10.

Have the cumulative effects of all instances of noncompliance with federal programs and scope limitations been considered in the opinion on
the financial statements?
[AAG 13.19–.20 ]

11.

If there are abuse findings reported in the federal awards section of the
schedule of findings and questioned costs that do not otherwise meet the
A-133 requirements for reporting as findings, has the auditor considered
the need to modify the report on compliance and on internal control over
compliance?
[AAG 13.38]

12.

Is the report dated the same as or later than the date of the auditor’s report on the financial statements?
a.

13.

22

If the report is dated later than the date of the auditor’s report on
the financial statements, have appropriate subsequent events procedures been performed?
[AAG 13.27]

If the audit of federal awards does not encompass the entirety of the auditee’s operations expending federal awards, are the operations that are
not included identified in a separate paragraph following the first paragraph of the report?
[AAG 13.30]

See footnote 20 in paragraph 13.23v of the guide.
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If the report on the financial statements refers to the work of other auditors, has the auditor considered the need to refer to the major federal programs audited by other auditors in the report on compliance and on internal control over compliance?
[AAG 13.29]

Schedule of Findings and Questioned Costs
15.

Does the report conform to the standard report language illustrated in the
guide?
[AAG example 13-6]

16.

Is the report presented even if there are no findings to report? (In a situation in which there are no findings or questioned costs, the auditor
should prepare the summary of auditor’s results section of the schedule
and either omit the other sections or include them, indicating that no matters were reported.)
[AAG 13.42]

17.

Does the report contain the following three sections:

18.

a.

A summary of the auditor’s results?

b.

Findings related to the financial statements that are required to be
reported in accordance with Government Auditing Standards? (See
the questions about those findings in part I of this checklist.)

c.

Findings and questioned costs for federal awards?
[AAG 13.33]

Does the summary of auditor’s results include
a.

the type of report the auditor issued on the financial statements of
the auditee (that is, unqualified opinion, qualified opinion, adverse
opinion, or disclaimer of opinion)?

b.

where applicable, a statement that significant deficiencies in internal control were disclosed by the audit of the financial statements
and whether any such deficiencies were material weaknesses?

c.

a statement on whether the audit disclosed any noncompliance that
is material to the financial statements?

d.

where applicable, a statement that significant deficiencies in the internal control over major programs were disclosed by the audit and
whether any such deficiencies were material weaknesses?

e.

the type of report the auditor issued on compliance for major programs (that is, unqualified opinion, qualified opinion, adverse opinion, or disclaimer of opinion)? (If the audit report for one or more
major programs is other than unqualified, indicate the type of report issued for each program.)

f.

a statement on whether the audit disclosed any audit findings that
the auditor is required to report under A-133? (See the following
question 20.)

g.

an identification of major programs?

h.

the dollar threshold used to distinguish between type A and type B
programs?
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i.

N/A

a statement on whether the auditee qualified as a low-risk auditee?
[AAG 13.34a]

19.

If there are abuse findings reported in the federal awards section of the
schedule of findings and questioned costs that do not otherwise meet the
A-133 requirements for reporting as findings, has the auditor considered
the need to modify the summary of the auditor’s results?
[AAG 13.38]

20.

Are the following reported as audit findings related to federal awards:

21.

No

a.

Significant deficiencies and material weaknesses in internal control
over major programs? (The auditor should identify significant deficiencies that are individually or cumulatively material weaknesses.)

b.

Material noncompliance with the provisions of laws, regulations,
contracts, or grant agreements related to a major program?

c.

Known questioned costs that are greater than $10,000 for a type of
compliance requirement for a major program?

d.

Known questioned costs when likely questioned costs are greater
than $10,000 for a type of compliance requirement for a major program?

e.

Known questioned costs that are greater than $10,000 for programs
that are not audited as major?

f.

The circumstances concerning why the auditor’s report on compliance for major programs is other than an unqualified opinion, if not
otherwise reported as an audit finding?

g.

Known fraud affecting a federal award, if not otherwise reported as
an audit finding? (An audit finding is not required if the fraud was
reported outside the entity as required by GAS.)
[A-133 sec. 510(a); AAG 13.37]

h.

Instances of material misrepresentation by the auditee of the status
of any prior audit findings?
[A-133 sec. 510(a); AAG 13.37 and .44]

i.

Abuse involving federal awards that is material to a major program?
[AAG 13.38]

Does the audit finding detail include
a.

a reference number? (For example, findings identified and reported
in the audit of fiscal year 20X1 would be assigned reference numbers 20X1-1, 20X1-2, and so forth.)
[A-133 sec. 510(c); AAG 13.41]

b.

identification of the federal program and specific federal award, including the Catalog of Federal Domestic Assistance title and number, federal award number and year, name of the federal agency,
and name of the applicable pass-through entity?23

23

When information such as the Catalog of Federal Domestic Assistance (CFDA) title and number or the federal award number is not
available, the auditor should provide the best information available to describe the federal award (chapter 7 of the guide discusses an
alternative for presentation if a CFDA number is not available) (A-133 section 510(b)(1) and paragraph 13.39a of the guide).
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Yes
c.

the criteria or specific requirement upon which the audit finding is
based, including the statutory, regulatory, or other citation?

d.

the condition found, including facts that support the deficiency
identified in the audit finding?

e.

identification of questioned costs and how they were computed?

f.

information to provide a proper perspective for judging the prevalence and consequences of the audit findings?24

g.

the possible asserted effect to provide sufficient information to the
auditee and federal agency, or pass-through entity in the case of a
subrecipient, to permit them to determine the cause and effect to
facilitate prompt and proper corrective action?

h.

recommendations to prevent future occurrences of the deficiency?
[A-133 sec. 510(b); AAG 13.39]

22.

Do the audit findings related to federal awards also meet the presentation
requirements of Government Auditing Standards? (See the questions about
those presentation requirements in part I of this checklist.)
[AAG 13.40]

23.

Are audit findings that relate to federal awards
a.

and that relate to the same issue presented as one finding?

b.

organized by federal agency or pass-through entity, where practical?
[A-133 sec. 505(d)(3)(i); AAG 13.34c]

24.

Are audit findings that relate to both the financial statements and the federal awards reported in both sections of the schedule? (An alternative is
to report the finding in one section of the schedule in summary form, with
a reference to a detailed reporting in the other section of the schedule.)
[A-133 sec. 505(d)(3)(ii); AAG 13.34c]

25.

Are findings of abuse involving federal awards presented in the compliance section of the schedule, unless the primary nature of the finding is a
significant deficiency in internal control? (Auditors should present findings of abuse that represent significant deficiencies in internal control in
the internal control section.)
[AAG 13.38]

26.

Do the findings report the views of responsible officials concerning the
findings, conclusions, and recommendations, as well as planned corrective actions, as required by Government Auditing Standards, or refer to the
corrective action plan, depending on the status of the development of the
corrective action plan at the time the auditor’s reports are released?25
[AAG 13.36 and .40]

No

263
N/A

24
Where appropriate, the instances identified should be related to the universe and the number of cases examined and be quantified
in terms of the dollar value (A-133 section 510(b)(5) and paragraph 13.39e of the guide).
25

See footnote 17.

FSP §11,300.07

264

Health Care Entities

Yes
a.

27.

No

N/A

If the auditee’s comments oppose the report’s findings, conclusions,
or recommendations, and are not, in the auditors’ opinion,
valid—or if the planned corrective actions do not adequately address the auditors’ recommendations—does the federal awards section of the schedule of findings and questioned costs state the auditor’s reasons for disagreeing with the comments or planned
corrective actions?
[A-133 sec. 510(b)(8); AAG 13.40]

Do the audit report and any attached or referenced schedules not include
names, Social Security numbers, other personal identification, or other potentially sensitive matters?
[AAG 13.53]

Data Collection Form26
28.

Has the auditor completed the appropriate parts of the data collection
form?

29.

Has the auditor signed the form and dated it as of the date on which the
auditor completes and signs the form?
[AAG 13.47]

30.

Does the information on the data collection form agree to the information
in the auditor’s reports and the summary of auditor’s results in the schedule of findings and questioned costs?
[Federal Audit Clearinghouse, Data Collection Form, No. SF-SAC]
Practice Tip

When an auditee expends federal awards under only one federal program (excluding research and development) and the federal program’s laws, regulations, or grant agreements do not require a financial statement audit of the auditee, the auditee may elect to have a program-specific audit. A program-specific audit
may not be elected for research and development unless all federal awards expended were received from
the same federal agency (or the same federal agency and the same pass-through entity) and that federal
agency (or pass-through entity, in the case of a subrecipient) approves a program-specific audit in advance.
[A-133 sec. 200(c); AAG 14.02]
Program-Specific Audits
31.

If a program-specific audit guide is available and current with regard to
the program’s compliance requirements, has the auditor issued the reports required by the guide?
[A-133 sec. 235(a); AAG 14.04]

26

The data collection form and related instructions are available from the Federal Audit Clearinghouse’s (FAC’s) home page at
http://harvester.census.gov/sac. The form number is SF-SAC. The FAC requires electronic submission of the data collection form via an
online Internet Data Entry System. The Office of Management and Budget periodically revises the data collection form and its accompanying instructions. Auditors should exercise caution to make sure they complete the version of the form and instructions that applies to
the fiscal year audited (paragraph 13.48 of the guide).
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32.

33.

No

265
N/A

If a program-specific audit guide is not available or not current with regard to the program’s compliance requirements, has the auditor issued
the following reports:27, 28
a.

A report on the federal program’s financial statements that provides an opinion or disclaimer of opinion on the financial statements?

b.

A report on compliance with requirements applicable to the federal
program and on the internal control over compliance in accordance
with the program-specific audit option under A-133?

c.

A schedule of findings and questioned costs for the program?
[A-133 sec. 235(b)(4); AAG 14.07–.09]

Do the reports conform to the standard report language illustrated in the
guide?
[AAG examples 13-1–13-6 and 14-1–14-2]

27
If the financial statement(s) of the program present only the activity of the federal program, the auditor is not required to issue a
separate report to meet the reporting requirements of GAS. However, if the financial statement(s) of the federal program present more
than the program’s activity the auditor should issue a separate GAS report and modify it so that it refers only to the financial statement(s)
of the federal program (paragraph 14.10 of the guide).
28

See footnote 21.
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Illustrative Financial Statements
.01 The following illustrative auditor’s reports and financial statements demonstrate one form of currently acceptable practice. The illustrative financial statements in this section are reproduced from the AICPA Audit and Accounting Guide Health Care Entities, with conforming changes as of June 1, 2010. The
illustrative financial statements are intended to provide sample financial statement formats and disclosures,
and are not intended to provide all financial statement formats and disclosures, or all of the disclosures
covered in the financial statement checklist. Other forms of financial statements are acceptable. More or less
detail should appear either in the financial statements or in the notes, depending on the circumstances.
.02 Governmental health care entities are required to follow the accounting and reporting requirements
of the Governmental Accounting Standards Board (GASB). GASB pronouncements may require governmental health care entities to present information beyond or different from that presented by not-for-profit
and investor-owned entities.
.03 Certain disclosures required by Securities and Exchange Commission (SEC) rules and regulations
are not presented in the illustrative financial statements. Furthermore, the illustrative financial statements
do not include all disclosures and presentation items promulgated.
Note: The illustrative financial statements and notes included in this checklist have been updated to reflect Financial Accounting Standards Board (FASB) Accounting Standards Codificatione (ASC). However,
in FASB’s notice to constituents, it suggests the use of plain English in financial statement footnotes to
describe broad FASB ASC topic references. FASB suggests a reference similar to “as required by the Derivatives and Hedging topic of the FASB Accounting Standards Codification.” Entities might consider revising
their financial statement references to reflect this plain English referencing, rather than the use of specific
FASB ASC references. We have provided these detailed references in the 2010 editions as a learning tool
to familiarize constituents with FASB ASC.
.04 This section contains illustrative financial statements, prepared using the illustrative financial statements in the AICPA Audit and Accounting Guide Health Care Entities (with conforming changes as of June
1, 2010), for the following types of health care organizations:
a.

Not-for-profit hospital

b.

Governmental hospital authority

c.

Nursing home

d.

Continuing care retirement community

e.

Home health agency

f.

Health maintenance organization

g.

Ambulatory care organization
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.05
Sample Not-for-Profit Hospital
Balance Sheets*
December 31, 20X7 and 20X6
(in thousands)
20X7
Assets
Current assets:
Cash and cash equivalents
Short-term investments
Assets limited as to use
Patient accounts receivable, net of allowance for doubtful accounts of
$2,500 in 20X7 and $2,400 in 20X6
Other current assets
Total current assets

20X6

$4,758
15,836
970

$5,877
10,740
1,300

15,100
2,670

14,194
2,856

39,334

34,967
(continued)

*
The fair value option subsections of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 825-10
permit all entities, including not-for-profit organizations, to choose to measure eligible items at fair value at specified election dates.
Notable eligible items include recognized financial assets and financial liabilities (except for those specifically prohibited), written loan
commitments, and rights and obligations under a warranty that is not a financial instrument (because it requires or permits the insurer
to provide goods or services rather than a cash payment) but whose terms permit the insurer to settle by paying a third party to provide
those goods or services. Prohibited recognized financial assets and liabilities include

a.

an investment in a subsidiary that the entity is required to consolidate.

b.

an interest in a variable interest entity that the entity is required to consolidate.

c.

employers and plans’ obligations (or assets representing net overfunded positions) for pension benefits, other postretirement
benefits (including health care and life insurance benefits), postemployment benefits, employee stock option and stock purchase plans, and certain other forms of deferred compensation arrangements, as defined by the applicable FASB pronouncements.

d.

financial assets and financial liabilities recognized under leases as defined in FASB ASC 840, Leases, excluding guarantees of a
third-party lease obligation or a contingent obligation arising from a cancelled lease.

e.

deposit liabilities, withdrawable on demand, of banks, savings and loan associations, credit unions, and other similar depository institutions.

f.

financial instruments that are, in whole or in part, classified by the issuer as a component of shareholder’s equity (including
temporary equity). An example is a convertible debt security with a noncontingent beneficial conversion feature.

Entities shall report assets and liabilities that are measured at fair value pursuant to the fair value option in this statement in a manner
that separates those reported fair values from the carrying amounts of similar assets and liabilities measured using another measurement
attribute. To accomplish that, an entity shall either
a.

present the aggregate of fair value and non-fair-value amounts in the same line item in the statement of financial position and
parenthetically disclose the amount measured at fair value included in the aggregate amount, or

b.

present two separate line items to display the fair value and non-fair-value carrying amounts.
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20X7
Interest in net assets of Sample Hospital Foundation1
Assets limited as to use:
Internally designated for capital acquisition
Held by trustee

20X6

510

462

12,000
6,949

12,500
7,341

18,949
(970)

19,841
(1,300)

17,979

18,541

4,680
320
51,038
1,185

4,680
520
50,492
908

$115,046

$110,570

$1,470
5,818
2,143
1,969

$1,750
5,382
1,942
2,114

11,400

11,188

23,144
3,953

24,014
3,166

Total liabilities

38,497

38,368

Net assets:
Unrestricted
Temporarily restricted
Permanently restricted

70,846
2,115
3,588

66,199
2,470
3,533

Total net assets

76,549

72,202

$115,046

$110,570

Less amount required to meet current obligations
Long-term investments
Long-term investments restricted for capital acquisition
Property and equipment, net
Other assets
Total assets
Liabilities and Net Assets
Current liabilities:
Current portion of long-term debt
Accounts payable and accrued expenses
Estimated third-party payor settlements
Other current liabilities
Total current liabilities
Long-term debt, net of current portion
Other liabilities

Total liabilities and net assets
See accompanying notes to financial statements.

1
These illustrative financial statements include a presentation of an interest in the net assets of a financially interrelated foundation
that is based on the particular fact pattern described in note 11 to the illustrative financial statements and the following additional facts:

●

Sample Not-for-Profit Hospital can influence the financial decisions of Sample Hospital Foundation to such an extent that it
can determine the timing and amount of distributions from the Foundation. Thus, it is inappropriate for the hospital to imply
a time restriction on amounts held by the Foundation.

●

Contributions to Foundation are restricted by donors for property acquisitions. Those restrictions have been met by the hospital
even though the net assets remain at the Foundation. Thus, the net assets related to the interest in the Foundation are classified
as unrestricted in the hospital’s financial statements.

●

The hospital’s policy is to report restricted revenues as unrestricted if the restriction is met in the same period as the revenues
are recognized.

Because the change in the interest in net assets of the foundation results from contributions restricted to property acquisitions, this
presentation shows the change in that interest reported separately from the performance indicator, in the spirit of the guidance in
paragraph 10.32 of Audit and Accounting Guide Health Care Entities for contributions restricted to property acquisitions. The AICPA has
released Technical Question and Answer (TIS) sections 6400.36–.42 (AICPA, Technical Practice Aids), that address recognition of the
interests in the net assets of financially interrelated organizations and the classification of the changes in those interests.
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.06
FORMAT A
Sample Not-for-Profit Hospital
Statements of Operations
Years Ended December 31, 20X7 and 20X6
(in thousands)
20X7
Unrestricted revenues, gains and other support:
Net patient service revenue
Premium revenue
Other revenue
Net assets released from restrictions used for operations

20X6

$85,156
11,150
2,601
300

$78,942
10,950
5,212

99,207

95,104

88,521
4,782
1,752
1,000
2,000

80,585
4,280
1,825
1,300
1,300

Total expenses

98,055

89,290

Operating income
Other income:
Investment income

1,152

5,814

3,900

3,025

(500)
4,552

8,839

Total revenues, gains and other support
Expenses:
Operating expenses
Depreciation and amortization
Interest
Provision for bad debts
Other

Other expense:
Loss from extinguishment of debt
Excess of revenues over expenses
Change in net unrealized gains and losses on other than trading
securities
Net assets released from restrictions used for purchase of property and
equipment
Change in interest in net assets of Sample Hospital Foundation2
Transfers to parent
Increase in unrestricted net assets
See accompanying notes to financial statements.

2

See footnote 1.
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200
283
(688)
$4,647

375

536
(3,051)
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.07
FORMAT B
Sample Not-for-Profit Hospital
Statements of Operations
Years Ended December 31, 20X7 and 20X6
(in thousands)

Unrestricted revenues, gains and other support:
Net patient service revenue
Premium revenue
Other, primarily investment income
Net assets released from restrictions used for
operations
Total revenues, gains and other support
Expenses:
Salaries and benefits
Medical supplies and drugs
Insurance
Depreciation and amortization
Interest
Allowance for bad debts
Loss from extinguishment of debt
Other
Total expenses
Excess of revenues, gains, and other support over
expenses
Change in net unrealized gains and losses on other than
trading securities
Net assets released from restrictions used for purchase
of property and equipment
Change in interest in net assets of Sample Hospital
Foundation3
Transfers to parent
Increase in unrestricted net assets

20X7

20X6

$85,156
11,150
6,501

$78,942
10,950
8,237

300
103,107

98,129

53,900
26,532
8,089
4,782
1,752
1,000
500
2,000

49,938
22,121
8,526
4,280
1,825
1,300

98,555

89,290

4,552

8,839

300

375

200

—

283
(688)
$4,647

1,300

536
(3,051)
$6,699

See accompanying notes to financial statements.

3

See footnote 1.
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.08
Sample Not-for-Profit Hospital
Statements of Changes in Net Assets
Years Ended December 31, 20X7 and 20X6
(in thousands)
20X6

20X7
Unrestricted net assets:
Excess of revenues over expenses
Net unrealized gains on investments, other than
trading securities
Change in interest in net assets of Sample Hospital
Foundation4
Transfer to parent
Net assets released from restrictions used for purchase
of property and equipment
Increase in unrestricted net assets
Temporarily restricted net assets:
Contributions for charity care
Net realized and unrealized gains on investments
Net assets released from restrictions
Increase (decrease) in temporarily restricted net assets
Permanently restricted net assets:
Contributions for endowment funds
Net realized and unrealized gains on investments
Increase in permanently restricted net assets
Increase in net assets
Net assets, beginning of year
Net assets, end of year
See accompanying notes to financial statements.

4

See footnote 1.
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$4,552

$8,839

300

375

283
(688)

536
(3,051)

200
4,647

6,699

140
5
(500)

996
8

(355)

1,004

50
5

411
2

55

413

4,347
72,202

8,116
64,086

$76,549

$72,202
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Sample Not-for-Profit Hospital
Statements of Cash Flows (Indirect Method)
Years Ended December 31, 20X7 and 20X6
(in thousands)
20X7
Cash flows from operating activities:
Change in net assets
Adjustments to reconcile change in net assets to net
cash provided by operating activities:
Loss from extinguishment of debt
Depreciation and amortization
Net realized and unrealized gains on investments,
other than trading
Undistributed portion of change in interest in net assets
of Sample Hospital Foundation
Transfers to parent
Allowance for bad debts
Restricted contributions and investment income
received
(Increase) decrease in:
Patient accounts receivable
Trading securities
Other current assets
Other assets
Increase (decrease) in:
Accounts payable and accrued expenses
Estimated third-party payor settlements
Other current liabilities
Other liabilities
Net cash provided by operating activities
Cash flows from investing activities:
Proceeds from sale of investments
Purchase of investments
Capital expenditures
Net cash used in investing activities

20X6

$4,347

$8,116

500
4,782

4,280

(450)

(575)

(48)
688
1,000

(51)
3,051
1,300

(290)

(413)

(1,906)
215
186
(277)

(2,036)

436
201
(145)
787

679
305
(257)
(128)

(2,481)
(190)

10,026

11,600

45,100
(48,869)
(4,728)

50,650
(52,800)
(5,860)

(8,497)

(8,010)
(continued)
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20X7
Cash flows from financing activities:
Transfer to parent
Proceeds from restricted contributions and restricted
investment income
Payments on long-term debt
Payments on capital lease obligations
Proceeds from issuance of long-term debt

20X6

(688)

(3,051)

290
(24,700)
(150)
22,600

413
(804)
(100)
500

(2,648)

(3,042)

Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents, beginning of year

(1,119)
5,877

548
5,329

Cash and cash equivalents, end of year

$4,758

$5,877

Net cash used in financing activities

Supplemental Disclosures of Cash Flow Information:
The hospital entered into capital lease obligations in the amount of $600,000 for new
equipment in 20X7.
Cash paid for interest (net of amount capitalized) in 20X7 and 20X6 was $1,780,000
and $1,856,000, respectively.
See accompanying notes to financial statements.
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.10

Sample Not-For-Profit Hospital
Notes to Financial Statements†
December 31, 20X7 and 20X6
1.

Description of Organization and Summary of Significant Accounting Policies5

Organization. The Sample Not-for-Profit Hospital (the hospital), located in Tulsa, Oklahoma, is a not-forprofit acute care hospital. The hospital provides inpatient, outpatient and emergency care services for residents of northeastern Oklahoma. Admitting physicians are primarily practitioners in the local area. The
hospital was incorporated in Oklahoma in 20X1 and is affiliated with the Sample Health System.
Use of estimates. The preparation of financial statements in conformity with generally accepted accounting
principles (GAAP) requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results
could differ from those estimates.
Cash and cash equivalents. Cash and cash equivalents include certain investments in highly liquid debt instruments with original maturities of three months or less.
The hospital routinely invests its surplus operating funds in money market mutual funds. These funds generally invest in highly liquid U.S. government and agency obligations.
Investments. Investments in equity securities with readily determinable fair values and all investments in
debt securities are measured at fair value in the balance sheet. Investment income or loss (including realized
gains and losses on investments, interest and dividends) is included in the excess of revenues over expenses
unless the income or loss is restricted by donor or law. Unrealized gains and losses on investments are
excluded from the excess of revenues over expenses unless the investments are trading securities.
Assets limited as to use. Assets limited as to use primarily include assets held by trustees under indenture
agreements and designated assets set aside by the Board of Trustees for future capital improvements, over
which the Board retains control and may at its discretion subsequently use for other purposes. Amounts
required to meet current liabilities of the hospital have been reclassified in the balance sheet at December
31, 20X7 and 20X6.
†
FASB ASC 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value in generally
accepted accounting principles (GAAP), and expands disclosures about fair value measurements. This guidance applies under other
accounting pronouncements that require or permit fair value measurements, the FASB having previously concluded in those accounting
pronouncements that fair value is the relevant measurement attribute. Accordingly, FASB ASC 820 does not require any new fair value
measurements but the application of it will change current practice.

FASB ASC 820 retains the exchange price notion already established within GAAP but clarifies, among other matters, that fair value
is the price that would be received to sell the asset or paid to transfer the liability (for example, an exit price) and not the price that would
be paid to acquire the asset or paid to transfer the liability (for example, an entry price). Additionally, FASB ASC 820 establishes a fair
value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. Level 1 inputs are
quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the
measurement date and shall be used to measure fair value when available, with limited exceptions. Level 2 inputs are inputs other than
quoted prices included within level 1 that are observable for the asset or liability, either directly or indirectly, and may include, for
example, quoted prices for similar assets or liabilities in active markets. Level 3 inputs are unobservable inputs for the asset or liability.
Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for
situations in which there is little, if any, market activity. Unobservable inputs shall be developed based on the best information available
in the circumstances, which might include the reporting entity’s own data.
FASB ASC 820-10-50 expands disclosures about the use of fair value to measure assets and liabilities in interim and annual periods
subsequent to initial recognition. The disclosures focus on the fair value hierarchy and the effect of the measurements on earnings (or
changes in net assets) for the period. Entities are encouraged to combine the fair value information disclosed under this statement with
other required fair value information, including that required by FASB ASC 825-10-50 about financial instruments.
5
FASB ASC 310-10-50 provides guidance on accounting policy disclosures for loans, trade receivables, and doubtful accounts that
should be included in the summary of significant accounting policies.
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Property and equipment. Property and equipment acquisitions are recorded at cost. Depreciation is provided
over the estimated useful life of each class of depreciable asset and is computed using the straight-line
method. Equipment under capital lease obligations is amortized on the straight-line method over the shorter
period of the lease term or the estimated useful life of the equipment. Such amortization is included in
depreciation and amortization in the financial statements. Interest cost incurred on borrowed funds during
the period of construction of capital assets is capitalized as a component of the cost of acquiring those assets.
Gifts of long-lived assets such as land, buildings, or equipment are reported as unrestricted support, and
are excluded from the excess of revenues over expenses, unless explicit donor stipulations specify how the
donated assets must be used. Gifts of long-lived assets with explicit restrictions that specify how the assets
are to be used and gifts of cash or other assets that must be used to acquire long-lived assets are reported
as restricted support. Absent explicit donor stipulations about how long those long-lived assets must be
maintained, expirations of donor restrictions are reported when the donated or acquired long-lived assets
are placed in service.
Temporarily and permanently restricted net assets.‡ Temporarily restricted net assets are those whose use by the
hospital has been limited by donors to a specific time period or purpose. Permanently restricted net assets
have been restricted by donors to be maintained by the hospital in perpetuity.
Excess of revenues over expenses. The statement of operations includes excess of revenues over expenses. Changes
in unrestricted net assets which are excluded from excess of revenues over expenses, consistent with industry practice, include unrealized gains and losses on investments other than trading securities, permanent
transfers of assets to and from affiliates for other than goods and services, and contributions of long-lived
assets (including assets acquired using contributions which by donor restriction were to be used for the
purposes of acquiring such assets).
Net patient service revenue. The hospital has agreements with third-party payors that provide for payments
to the hospital at amounts different from its established rates. Payment arrangements include prospectively
determined rates per discharge, reimbursed costs, discounted charges, and per diem payments. Net patient
service revenue is reported at the estimated net realizable amounts from patients, third-party payors, and
others for services rendered, including estimated retroactive adjustments under reimbursement agreements
with third-party payors. Retroactive adjustments are accrued on an estimated basis in the period the related
services are rendered and adjusted in future periods as final settlements are determined.
Premium revenue. The hospital has agreements with various health maintenance organizations (HMOs) to
provide medical services to subscribing participants. Under these agreements, the hospital receives monthly
capitation payments based on the number of each HMO’s participants, regardless of services actually performed by the hospital. In addition, the HMOs make fee-for-service payments to the hospital for certain
covered services based upon discounted fee schedules.
Charity care. The hospital provides care to patients who meet certain criteria under its charity care policy
without charge or at amounts less than its established rates. Because the hospital does not pursue collection
of amounts determined to qualify as charity care, they are not reported as revenue.
Donor-restricted gifts. Unconditional promises to give cash and other assets to the hospital are reported at fair
value at the date the promise is received. Conditional promises to give and indications of intentions to give
are reported at fair value at the date the gift is received. The gifts are reported as either temporarily or
permanently restricted support if they are received with donor stipulations that limit the use of the donated
‡
In August 2008, FASB issued FASB Staff Position (FSP) FAS 117-1, Endowments of Not-for-Profit Organizations: Net Asset Classification of
Funds Subject to an Enacted Version of the Uniform Prudent Management of Institutional Funds Act, and Enhanced Disclosures for All Endowment
Funds, and has codified the FSP primarily in FASB ASC 958-205. FSP FAS 117-1 is effective for fiscal years ending after December 15,
2008. Earlier application is permitted provided that annual financial statements for that fiscal year have not been previously issued. FSP
FAS 117-1 provides guidance on the net asset classification of donor-restricted endowment funds for a not-for-profit entity that is subject
to an enacted version of the Uniform Prudent Management of Institutional Funds Act of 2006 (UPMIFA). The FSP also improves
disclosures about a not-for-profit entity’s endowment funds (both donor-restricted endowment funds and board-designated endowment
funds), whether or not the not-for-profit entity is subject to an enacted version of the UPMIFA. Paragraphs 16–17 of the FSP discuss the
display of the reclassification upon implementation of the guidance and the reinstatement of purpose restrictions on unappropriated net
appreciation if the not-for-profit entity is subject to an enacted version of the UPMIFA.
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assets. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, temporarily restricted net assets are reclassified as unrestricted net assets and reported
in the statement of operations as net assets released from restrictions. Donor-restricted contributions whose
restrictions are met within the same year as received are reported as unrestricted contributions in the accompanying financial statements.
Estimated malpractice costs. The provision for estimated medical malpractice claims includes estimates of the
ultimate costs for both reported claims and claims incurred but not reported.
Income taxes. The hospital is a not-for-profit corporation and has been recognized as tax-exempt pursuant to
Section 501(c)(3) of the Internal Revenue Code.
2.

Net Patient Service Revenue

The hospital has agreements with third-party payors that provide for payments to the hospital at amounts
different from its established rates. A summary of the payment arrangements with major third-party payors
follows:
●

Medicare. Inpatient acute care services and outpatient services rendered to Medicare program beneficiaries are paid at prospectively determined rates. These rates vary according to a patient classification system that is based on clinical, diagnostic, and other factors. Inpatient nonacute services and
defined capital and medical education costs related to Medicare beneficiaries are paid based on a
cost reimbursement methodology. The hospital is reimbursed for cost reimbursable items at a tentative rate with final settlement determined after submission of annual cost reports by the hospital
and audits thereof by the Medicare fiscal intermediary. Beginning in 20X3, the hospital claimed
Medicare payments based on an interpretation of certain "disproportionate share" rules. The intermediary disagreed and declined to pay the excess reimbursement claimed under that interpretation.
Through 20X6, the hospital has not included the claimed excess in net patient revenues pending
resolution of the matter. In 20X7, the intermediary accepted the claims and paid the outstanding
claims, including $950,000 applicable to 20X6 and $300,000 applicable to 20X5 and prior, which has
been included in 20X7 net revenues.

●

Medicaid. Inpatient and outpatient services rendered to Medicaid program beneficiaries are reimbursed under a cost reimbursement methodology. The hospital is reimbursed at a tentative rate with
final settlement determined after submission of annual cost reports by the hospital and audits
thereof by the Medicaid fiscal intermediary.

Revenue from the Medicare and Medicaid programs accounted for approximately XX percent and XX percent, respectively, of the hospital’s net patient revenue for the year ended 20X7, and XX percent and XX
percent, respectively, of the hospital’s net patient revenue, for the year ended 20X6. Laws and regulations
governing the Medicare and Medicaid programs are extremely complex and subject to interpretation. As a
result, there is at least a reasonable possibility that recorded estimates will change by a material amount in
the near term. The 20X6 net patient service revenue increased approximately $XXX due to removal of allowances previously estimated that are no longer necessary as a result of final settlements and years that are no
longer subject to audits, reviews, and investigations. The 20X7 net patient service revenue decreased approximately $XXX due to prior-year retroactive adjustments in excess of amounts previously estimated.
The hospital also has entered into payment agreements with certain commercial insurance carriers, health
maintenance organizations, and preferred provider organizations. The basis for payment to the hospital
under these agreements includes prospectively determined rates per discharge, discounts from established
charges, and prospectively determined daily rates.
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Investments

Assets Limited as to Use
The composition of assets limited as to use at December 31, 20X7 and 20X6, is set forth in the following
table. Investments are stated at fair value.
20X7
Internally designated for capital acquisition:
Cash
U.S. Treasury obligations
Interest receivable
Held by trustee under indenture agreement:
Cash and short-term investments
U.S. Treasury obligation
Interest receivable

20X6

$545,000
11,435,000
20,000

$350,000
12,115,000
35,000

12,000,000

12,500,000

352,000
6,505,000
92,000

260,000
7,007,000
74,000

6,949,000

7,341,000

$18,949,000

$19,841,000

Other Investments
Other investments, stated at fair value, at December 31, 20X7 and 20X6, include:
Trading:
U.S. Corporate Bonds
Other
U.S. Treasury obligations
Interest receivable
Less:
Long-term investments
Long-term investments restricted for capital
acquisitions
Short-term investments

20X7

20X6

$1,260,000

$1,475,000

$19,266,000
310,000

$14,233,000
232,000

20,836,000

15,940,000

4,680,000

4,680,000

320,000

520,000

$15,836,000

$10,740,000

Investment income and gains for assets limited as to use, cash equivalents, and other investments are comprised of the following for the years ending December 31, 20X7 and 20X6:
Income:
Interest income
Realized gains on sales of securities
Unrealized gains on trading securities
Other Changes in Unrestricted Net Assets:
Unrealized gains on other than trading securities
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20X7

20X6

$3,585,000
150,000
165,000

$2,725,000
200,000
100,000

$3,900,000

$3,025,000

$300,000

$375,000
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4.

Property and Equipment

A summary of property and equipment at December 31, 20X7 and 20X6, follows:
20X7

20X6

Land
Land improvements
Buildings and improvements
Equipment
Equipment under capital lease obligations

$3,000,000
472,000
46,852,000
29,190,000
2,851,000

$3,000,000
472,000
46,636,000
26,260,000
2,752,000

Less accumulated depreciation and amortization

82,365,000
34,928,000

79,120,000
30,661,000

Construction in progress

47,437,000
3,601,000

48,459,000
2,033,000

$51,038,000

$50,492,000

Property and equipment, net

Depreciation expense for the years ended December 31, 20X7 and 20X6 amounted to approximately
$4,782,000 and $4,280,000. Accumulated amortization for equipment under capital lease obligations was
$689,000 and $453,000 at December 31, 20X7 and 20X6, respectively. Construction contracts of approximately
$7,885,000 exist for the remodeling of Hospital facilities. At December 31, 20X7, the remaining commitment
on these contracts approximated $4,625,000.
5.

Long-Term Debt

A summary of long-term debt and capital lease obligations at December 31, 20X7 and 20X6, follows:
20X7
7.25 percent 20X7 Tax-Exempt Revenue Bonds, principal
maturing in varying annual amounts, due November
1, 20XX, collateralized by a pledge of the hospital’s
gross receipts
8.50 percent 20X2 Tax-Exempt Revenue Bonds, principal
maturing in varying annual amounts, due June 1,
20XX
7.75 percent mortgage loan, principal maturing in
varying annual amounts, due January 20XX,
collateralized by a mortgage on certain property and
equipment
7.75 percent note payable, payable in monthly
installments of $12,000, including interest, due March
20XX, unsecured
Capital lease obligations, at varying rates of imputed
interest from 6.8 percent to 9.3 percent collateralized
by leased equipment
Less current portion

20X6

$21,479,000

$22,016,000

2,010,000

2,127,000

125,000

671,000

1,000,000

950,000

24,614,000
1,470,000

25,764,000
1,750,000

$23,144,000

$24,014,000

Under the terms of the 20X7 and 20X2 revenue bond indentures, the hospital is required to maintain certain
deposits with a trustee. Such deposits are included with assets limited as to use. The revenue note indenture
also places limits on the incurrence of additional borrowings and requires that the hospital satisfy certain
measures of financial performance as long as the notes are outstanding.
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Scheduled principal repayments on long-term debt and payments on capital lease obligations are as follows:
Year Ending
December 31,
20X8
20X9
20Y0
20Y1
20Y2
Thereafter

Long-Term Debt

Capital Leases
Obligations

$970,000
912,000
983,000
1,060,000
1,143,000
18,546,000

$550,000
260,000
260,000
45,000
—
—

$23,614,000

1,115,000

Less amount representing interest under capital
leases obligations

115,000
$1,000,000

A summary of interest cost and investment income on borrowed funds held by the trustee under the 20X7
and 20X2 revenue bond indentures during the years ended December 31, 20X7 and 20X6, follows:
20X7
Interest cost:
Capitalized
Charged to operations
Total
Investment income:
Capitalized
Credited to other revenue
Total
6.

20X6

$740,000
1,752,000

$700,000
1,825,000

$2,492,000

$2,525,000

$505,000
330,000

$663,000
386,000

$835,000

$1,049,000

Temporarily and Permanently Restricted Net Assets

Temporarily restricted net assets are available for the following purposes or periods at December 31, 20X7
and 20X6:
20X7
Health care services
Purchase of equipment
Indigent care
Health education
For periods after December 31, 20X9

20X6

$320,000
840,000
350,000
605,000

$520,000
950,000
400,000
600,000

$2,115,000

$2,470,000

Permanently restricted net assets at December 31, 20X7 and 20X6, are restricted to:
20X7
Investments to be held in perpetuity, the income from
which is expendable to support health care services
(reported as operating income)
Endowment requiring income to be added to original
gift until fund value is $1,500,000
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20X6

$2,973,000

$2,923,000

615,000

610,000

$3,588,000

$3,533,000
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During 20X7, net assets were released from donor restrictions by incurring expenses satisfying the restricted
purposes of indigent care and health care education in the amounts of $250,000 and $50,000, respectively.
7.

Medical Malpractice Claims

The hospital purchases professional and general liability insurance to cover medical malpractice claims.
There are known claims and incidents that may result in the assertion of additional claims, as well as claims
from unknown incidents that may be asserted arising from services provided to patients. The hospital has
employed independent actuaries to estimate the ultimate costs, if any, of the settlement of such claims.
Accrued malpractice losses have been discounted at 7 percent and in management’s opinion provide an
adequate reserve for loss contingencies.
On March 15, 20X7, a patient filed a suit against the hospital for malpractice during care received as an
inpatient. The hospital believes it has meritorious defenses against the suit; however, the ultimate resolution
of the matter could result in a loss. The patient has claimed $16 million in actual damages. Under state law,
punitive damages are determined at trial. The hospital maintains insurance coverage for malpractice claims.
The coverage does not include punitive damages awards. Trial is scheduled to occur within the next year.
8.

Pension Plan and Other Postretirement Benefit Plans6, 7

[The following two paragraphs are encouraged but not required.]
The hospital has a defined benefit pension plan covering substantially all of its employees. The plan benefits
are based on years of service and the employees’ compensation during the last five years of covered employment. Contributions are intended to provide not only for benefits attributed to service to date but also
for those expected to be earned in the future.
The hospital also sponsors two defined benefit postretirement plans that cover both salaried and nonsalaried
employees. One plan provides medical and dental benefits, and the other provides for the payment of life
insurance premiums. The postretirement health care plan is contributory, with retiree contributions adjusted
annually; the life insurance plan is noncontributory. The accounting for the health care plan anticipates
future cost-sharing changes to the written plan that are consistent with the hospital’s expressed intent to
increase retiree contributions each year to 50 percent of the excess of the expected general inflation rate over
6 percent. Beginning in 20X7, the hospital adopted a funding policy for its postretirement health care plan
similar to its funding policy for its life insurance plan—an amount equal to a level percentage of the employees’ salaries is contributed to the plan annually. For 20X7, that percentage was 4.25, and the aggregate
contribution for both plans was $34,000. The hospital uses a December 31 measurement date for its plans.

6

This note to the financial statements illustrates the financial statement disclosures about pension and postretirement benefit plans for
a public entity. Readers should refer to FASB ASC 715-20-50 when considering disclosure requirements for nonpublic entities.
FASB Statement No. 158, Employers’ Accounting for Defined Benefit Pension and Other Postretirement Plans—an amendment of FASB
Statements No. 87, 88, 106, and 132(R), as amended, is incorporated in FASB ASC 715, Compensation—Retirement Benefits, subject to the
effective date and transition guidance in FASB ASC 715-20-65-1. An employer with publicly traded equity securities shall initially apply
the requirement to recognize the funded status of a benefit plan and the disclosure requirements as of the end of the fiscal year ending
after December 15, 2006. An employer without publicly traded equity securities shall initially apply the requirement to recognize the
funded status of a benefit plan and the disclosure requirements as of the end of the fiscal year ending after June 15, 2007. An employer
without publicly traded equity securities shall provide the disclosures in paragraph 14 in the notes to the financial statements for a fiscal
year ending after December 15, 2006, but before June 16, 2007 unless it has applied the recognition provisions of this statement in
preparing those financial statements; the requirement to measure plan assets and benefit obligations as of the date of the employer’s fiscal
year-end statement of financial position shall be effective for fiscal years ending after December 15, 2008.
7
Readers may also need to consider the accounting and disclosure requirements of the “Medicare Prescription Drug, Improvement
and Modernization Act” subsections of FASB ASC 715-60 when an employer provides postretirement prescription drug coverage.

FSP §11,400.10

282

Health Care Entities

The following table sets forth the changes in benefit obligations, changes in plan assets and components of
net periodic benefit cost for both the pension plan and the other postretirement benefit plans:
Other Benefits

Pension Benefits
20X7
Change in benefit obligation:
Benefit obligation at beginning of year
Service cost
Interest cost
Plan participants’ contributions
Actuarial gain
Benefits paid
Benefit obligation at end of year
Change in plan assets:
Fair value of plan assets at beginning of year
Actual return on plan assets
Employer contribution
Plan participants’ contributions
Benefits paid
Fair value of plan assets at end of year
Funded status
Unrecognized net actuarial gain
Unrecognized prior service cost
Unrecognized transition obligation
Unrecognized transition asset
Prepaid (accrued) benefit cost

20X6

$9,710
905
700

20X7

$500
15
44
34

(1,410)

$585
14
50
34
(7)
(66)

10,920

9,710

610

585

9,800
759
866

9,610
810
790
(1,410)

89
4
39
34
(66)

40
4
19
34
(8)

9,800

100

89
(496)
(40)
19
470
—
($47)

(20)
(375)

(375)
11,050

$9,700
770
650

20X6

130
(30)
50

90
(40)
55

(15)

(20)

(510)
(30)
16
445
—

$85

($79)

$135

(8)

The accumulated benefit obligation for the defined benefit pension plan was $XXX and $XXX at December
31, 20X7, and 20X6, respectively.
Other Benefits

Pension Benefits
20X7
Components of net periodic benefit cost:
Service cost
Interest cost
Expected return on plan assets
Amortization of prior service cost
Recognized net actuarial (gain)
Amortization of transition obligation
Amortization of transition asset

20X6

20X7

$905
700
(784)
5
(5)

$770
650
(769)
7
(2)

(5)

(1)

20X6

$14
50
(6)
3
(15)
25
—

$15
44
(3)
2
(1)
25
—

Net periodic benefit cost

$816

$655

$71

$82

Additional Information
Assumptions
Weighted-average assumptions used to
determine benefit obligations at December 31
Discount rate
Rate of compensation increase

7.00%
6.00%

7.00%
6.00%

7.00%

7.00%
(continued)
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Pension Benefits
20X7
Weighted-average assumptions used to
determine net periodic benefit cost for years
ended December 31
Discount rate
Expected long-term return on plan assets
Rate of compensation increase

Other Benefits

20X6

7.00%
8.00%
6.00%

20X7

7.00%
8.00%
6.00%

20X6

7.00%
6.60%

7.00%
6.60%

(Entity specific narrative description of the basis used to determine the overall expected long-term rate of
return on assets, as described in FASB ASC 715-20-50-1(d)(3) would be included here.)
Assumed health care cost trend rates at December 31
Health care cost trend rate assumed for next year
Rate to which the cost trend rate is assumed to decline (the
ultimate trend rate)
Year that the rate reaches the ultimate trend rate

7%

7%

5%
20Y2

5%
20Y2

Assumed health care cost trend rates have a significant effect on the amounts reported for the health care
plans. A one-percentage-point change in assumed health care cost trend rates would have the following
effects:
1-PercentagePoint Increase
Effect on total of service and interest cost
Effect on postretirement benefit obligation

1-PercentagePoint Decrease

$13
73

($11)
(67)

Plan Assets
The composition of plan assets at December 31, 20X7, and 20X6, is as follows:
Pension Benefits
20X7

Other Benefits
20X6

20X7

20X6

Asset Category

XX%

XX%

XX%

XX%

Equity securities
Debt securities
Real estate
Other
Total

XX
XX
XX
XX
100%

XX
XX
XX
XX
100%

XX
XX
XX
XX
100%

XX
XX
XX
XX
100%

(Entity specific narrative description of investment policies and strategies for plan assets, including
weighted-average target asset allocations [if used as part of those policies and strategies] as described in
FASB ASC 715-20-50-1(d)(2), would be included here.)
Cash Flows
Contributions
The hospital expects to contribute $XXX to its pension plan and $XXX to its other postretirement benefit
plan in 20X8.
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Estimated Future Benefit Payments
The following benefit payments, which reflect expected future service, as appropriate, are expected to be
paid:
Other Benefits

Pension Benefits
20X8
20X9
20Y0
20Y1
20Y2
Years 20Y3–20Y7
9.

$XXX
XXX
XXX
XXX
XXX
XXX

$XXX
XXX
XXX
XXX
XXX
XXX

Concentrations of Credit Risk

The hospital grants credit without collateral to its patients, most of whom are local residents and are insured
under third-party payor agreements. The mix of receivables from patients and third-party payors at December 31, 20X7 and 20X6, was as follows:
20X6

20X7
Medicare
Medicaid
Blue Cross
Other third-party payors
Patients

10.

51%
17
18
7
7

53%
14
17
9
7

100%

100%

Commitments and Contingencies

Operating leases. The hospital leases various equipment and facilities under operating leases expiring at various dates through April 20Y2. Total rental expense in 20X7 and 20X6 for all operating leases was approximately $859,000 and $770,000, respectively.
The following is a schedule by year of future minimum lease payments under operating leases as of December 31, 20X7, that have initial or remaining lease terms in excess of one year.
Year Ending
December 31,
20X8
20X9
20Y0
20Y1
20Y2

Amount
$517,000
506,000
459,000
375,000
343,000

Litigation. The hospital is involved in litigation and regulatory investigations arising in the course of business. After consultation with legal counsel, management estimates that these matters will be resolved without material adverse effect on the hospital’s future financial position or results from operations.
Allowance for doubtful accounts. Beginning in 20X5, the hospital has provided care under an agreement with
Associated HMO. The HMO currently owes the hospital $950,000, substantially all of which is overdue. The
hospital has notified the HMO that further services under the contract cannot be provided without payment
on the outstanding balance. The HMO has assured the hospital that additional funds are being obtained in
order to pay the overdue balance and continue service under the agreement, however, if the HMO is unable
to make payments, additional allowances for bad debts would need to be accrued.
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11.

Related Party Transactions

During the years ended December 31, 20X7 and 20X6, the hospital contributed capital to Sample Health
System, an affiliate with some board members in common with the hospital, in the amounts of $688,000 and
$3,051,000, respectively.
The Sample Hospital Foundation (the Foundation), which is controlled by Sample Health System, was established to solicit contributions from the general public solely for the funding of capital acquisitions by the
hospital. Funds are distributed to the hospital as determined by the Foundation’s Board of Directors. A
summary of the foundation’s assets, liabilities, net assets, results of operations, and changes in net assets
follows. The hospital’s interest in the net assets of the Foundation is reported as a noncurrent asset in the
balance sheets.
At December 31,
20X7

20X6

$521,000

$472,000

11,000
510,000

10,000
462,000

Total liabilities and net assets

$521,000

$472,000

Support and revenue

$269,000

$535,000

235,000
13,000

485,000
16,000

248,000

501,000

21,000
27,000
462,000

34,000
17,000
411,000

$510,000

$462,000

Assets principally cash and cash equivalents
Liabilities
Unrestricted net assets

Expenses
Distributions to Sample Hospital for property
acquisitions
Other
Total expenses
Excess of support and revenue over expenses
Other changes in net assets
Unrestricted net assets, beginning of year
Unrestricted net assets, end of year

Liabilities include $10,000 payable at the end of each year to Sample Hospital. These amounts were paid
after the end of each year.
12.

Functional Expenses

The hospital provides general health care services to residents within its geographic location. Expenses related to providing these services are as follows (in thousands):
At December 31,
20X7
Health care services
General and administrative

13.

20X6

$86,000
12,055

$78,647
10,643

$98,055

$89,290

Fair Value of Financial Instruments

The following methods and assumptions were used by the hospital in estimating the fair value of its financial instruments:
Cash and cash equivalents: The carrying amount reported in the balance sheet for cash and cash equivalents approximates its fair value.
Investments: Fair values, which are the amounts reported in the balance sheet, are based on quoted market prices, if available, or estimated using quoted market prices for similar securities.
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Assets limited as to use: These assets consist primarily of cash and short-term investments and interest
receivable. The carrying amount reported in the balance sheet is fair value.
Accounts payable and accrued expenses: The carrying amount reported in the balance sheet for accounts
payable and accrued expenses approximates its fair value.
Estimated third-party payor settlements: The carrying amount reported in the balance sheet for estimated
third-party payor settlements approximates its fair value.
Long-term debt: Fair values of the hospital’s revenue notes are based on current traded value. The fair
value of the hospital’s remaining long-term debt is estimated using discounted cash flow analyses, based
on the hospital’s current incremental borrowing rates for similar types of borrowing arrangements.
The carrying amounts and fair values of the hospital’s financial instruments at December 31, 20X7 and
20X6, are as follows (In thousands):
20X7
Carrying
Amount
Cash and cash equivalents
Short-term investments
Assets limited as to use
Long-term investments
Long-term investments restricted for capital acquisition
Accounts payable and accrued expenses
Estimated third-party payor settlements
Long-term debt
14.

$4,758
15,836
18,949
4,680
320
5,818
2,143
24,614

20X6
Fair
Value
$4,758
15,836
18,949
4,680
320
5,818
2,143
23,980

Carrying
Amount
$5,877
10,740
19,841
4,680
520
5,382
1,942
25,764

Fair
Value
$5,877
10,740
19,841
4,680
520
5,382
1,942
24,918

Promises to Contribute

At December 31, 20X7, the hospital had received $1,500,000 of conditional promises to contribute to the
building of a new facility for outpatient services. These contributions will be recorded as temporarily restricted support when received. The hospital had no material outstanding unconditional promises of support at December 31, 20X7.
15.

Charity Care

The amount of charges foregone for services and supplies furnished under the hospital’s charity care policy
aggregated approximately $4,500,000 and $4,100,000 in 20X7 and 20X6, respectively.
Subsequent Event\

16.

On February 9, 20X8, the hospital signed a contract in the amount of $1,050,000 for the purchase of certain
real estate.
\

In May 2009, FASB issued Statement No. 165, Subsequent Events, which establishes general standards of accounting for and disclosure
of events that occur after the balance sheet date but before financial statements are issued or are available to be issued. This statement
sets forth
a.

the period after the balance sheet date during which management of a reporting entity should evaluate events or transactions
that may occur for potential recognition or disclosure in the financial statements.

b.

the circumstances under which an entity should recognize events or transactions occurring after the balance sheet date in its
financial statements.

c.

the disclosures that an entity should make about events or transactions that occurred after the balance sheet date.

FASB Statement No. 165 introduces the concept of financial statements being available to be issued. It also requires disclosure of the date
through which an entity has evaluated subsequent events and the basis for that date (that is, whether that date represents the date the
financial statements were issued or were available for issue).
FASB Statement No. 165 is effective for interim or annual financial periods ending after June 15, 2009. For additional information
please visit the FASB website at www.fasb.org.
FASB Statement No. 165 has been codified in FASB ASC 855, Subsequent Events.

FSP §11,400.10

287

Illustrative Financial Statements

ILLUSTRATIVE FINANCIAL STATEMENTS FOR A GOVERNMENTAL HOSPITAL
AUTHORITY
.11
Sample Governmental Hospital Authority
A Component Unit of Feeling County, State of Union
Balance Sheets8
December 31, 20X7 and 20X6
(in thousands)
20X7
Assets
Current assets:
Cash and cash equivalents
Short term investments
Patient accounts receivable, net of estimated
uncollectibles of $2,125 (20X7) and $2,040 (20X6)
Supplies and other current assets

20X6

$7,136
3,142

$7,557
3,423

19,834
2,270

16,727
2,428

Total current assets
Noncurrent cash and investments:
Internally designated for capital acquisitions
Other long term investments
Held by trustee for debt service
Restricted by contributors and grantors for capital
acquisitions and research
Principal of permanent endowments
Delinquent property taxes
Capital Assets:
Land
Depreciable capital assets, net of accumulated
depreciation

32,382

30,135

15,000
2,605
1,945

15,000
1,327
2,005

1,124
3,003
385

1,078
2,919
229

3,590

3,590

39,792

39,328

Total capital assets, net of accumulated depreciation
Other assets

43,382
1,056

42,918
936

$100,882

$96,547

$1,250
4,945
1,822
1,673

$1,488
4,575
1,651
1,797

9,690

9,511
(continued)

Total assets
Liabilities and Net Assets
Current liabilities:
Current maturities of long term debt
Accounts payable and accrued expenses
Estimated third-party payor settlements
Other current liabilities
Total current liabilities

8

GASB Statement No. 34, Basic Financial Statements—and Management’s Discussion and Analysis—for State and Local Governments, paragraphs 97–99 provide guidance on the statement of net assets or balance sheet. Governmental health care entities that are special-purpose
governments engaged only in business-type activities may use either a balance sheet format—assets equal liabilities plus net assets/
equity—or a net assets format—assets less liabilities equal net assets/equity. Assets and liabilities are required to be presented in a
classified format.
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20X7
Long term debt, net of current maturities
Other long term liabilities
Total liabilities
Net Assets:
Invested in capital assets net of related debt
Restricted:
For debt service
Expendable for capital acquisitions
Expendable for research
Expendable for specific operating activities
Nonexpendable permanent endowments
Unrestricted

20X6

19,672
3,361

20,412
2,690

32,723

32,613

22,460

21,018

1,945
733
781
331
3,003
38,906

2,005
628
899
573
2,919
35,892

68,159

63,934

$100,882

$96,547

9

Total net assets
Total liabilities and net assets
See accompanying notes to financial statements.

9
Either the term net assets or equity may be used to refer to the difference between assets and liabilities. Regardless of the label, net
assets/equity is required to be reported in three broad components: (a) invested in capital assets, net of related debt; (b) restricted, and (c)
unrestricted. When permanent endowments are reported in restricted net assets, two additional components—expendable and nonexpendable—are required, as discussed in paragraph 35 of GASB Statement No. 34.
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.12
Sample Governmental Hospital Authority
A Component Unit of Feeling County, State of Union
Statements of Revenues, Expenses, and Changes in Net Assets10
Years Ended December 31, 20X7 and 20X6
(in thousands)
20X7
Operating revenues:
Net patient service revenue (net of provision for bad debts of
$859 in 20X7 and $938 in 20X6)
Premium revenue
Other
Total operating revenues
Operating expenses:
Salaries and benefits
Medical supplies and drugs
Insurance
Other supplies
Depreciation and amortization
Total operating expenses
Operating loss
Nonoperating revenues (expenses):
Property taxes
Investment income
Interest expense
Noncapital grants and contributions
Other
Total nonoperating revenues (expenses)
Excess of revenues over expenses before
capital grants, contributions, and additions
to permanent endowments
Capital grants and contributions
Additions to permanent endowments
Increase in net assets
Net assets beginning of the year
Net assets end of the year

20X6

$43,305
9,876
3,416

$43,736
13,058
3,248

56,597

60,042

46,845
12,746
7,030
10,314
4,065

43,235
7,986
7,382
11,166
3,638

81,000

74,407

(24,403)

(13,365)

23,895
5,653
(1,489)
170
(425)

15,309
5,304
(1,552)
853
—

27,804

19,914

3,401

6,549

824
—

2,560
351

$4,225
63,934

$9,460
54,474

$68,159

$63,934

See accompanying notes to financial statements.

10

GASB Statement No. 34 paragraph 101 requires proprietary funds and special purpose governments engaged only in business-type
activities to present an operating statement that uses an “all-inclusive” format, presenting all changes in both restricted and unrestricted
net assets and presenting a final total, “Increase (decrease) in net assets/equity.” Either the term net assets or equity may be used to refer
to the difference between assets and liabilities. Regardless of the label, net assets/equity is required to be reported in three broad
components: (a) invested in capital assets, net of related debt; (b) restricted, and (c) unrestricted. When permanent endowments are
reported in restricted net assets, two additional components—expendable and nonexpendable—are required, as discussed in paragraph
35 of GASB Statement No. 34.
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.13
Sample Governmental Hospital Authority
A Component Unit of Feeling County, State of Union
Statements of Cash Flows
Years Ended December 31, 20X7 and 20X6
(in thousands)
20X7

20X6

Cash flows from operating activities:
Receipts from and on behalf of patients
Payments to suppliers and contractors
Payments to employees
Other receipts and payments, net

$50,074
(30,029)
(46,955)
4,591

$54,680
(26,634)
(43,460)
3,597

Net cash provided by operating activities

(22,319)

(11,817)

Cash flows from noncapital financing activities:
Property taxes
Noncapital grants and contributions
Contributions to permanent endowments
Other

20,739
170
—
(425)

12,224
853
351
—

Net cash provided by noncapital financing activities

20,484

13,428

Cash flows from capital and related financing activities:
Capital grants and contributions
Property taxes restricted to capital acquisitions
Principal paid on long term debt
Interest paid on long term debt
Purchase of capital assets

824
3,000
(1,488)
(1,489)
(4,019)

2,560
3,000
(1,896)
(1,552)
(4,111)

Net cash used by capital and related financing activities

(3,172)

(1,999)

Cash flows from investing activities:
Interest and dividends on investments
Purchases of investments
Proceeds from sale of investments

2,737
(1,045)
2,327

2,124
(289)
683

4,019

2,518

Net cash provided by investing activities
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of year
Reconciliation of cash and cash equivalents to the statement
of net assets:
Cash and cash equivalents in current assets
Restricted cash and cash equivalents
Total cash and cash equivalents
Reconciliation of operating income (loss) to net cash provided (used)
by operating activities:
Operating loss
Adjustments to reconcile operating income to net cash flows used in
operating activities:
Depreciation and amortization
Provision for bad debts

FSP §11,400.13

(988)

2,130

9,101
$8,113

6,971
$9,101

7,136
977

7,557
1,544

$8,113

$9,101

($24,403)

($13,365)

4,065
859

3,638
938
(continued)
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20X7
Changes in:
Patient accounts receivable
Supplies and other current assets
Other assets
Accounts payable, accrued expenses, and other current liabilities
Estimated third-party payor settlements
Other liabilities related to operating activities
Net cash used in operating activities

20X6

(3,966)
158
(120)
246
171
671

(2,909)
100
—
(225)
(235)
241

($22,319)

($11,817)

Noncash Investing, Capital, and Financing Activities:
The authority entered into capital lease obligations of $510,000 for new equipment in
20X7.
The authority held investments at December 31, 20X7, with a fair value of $XXX.
During 20X7, the net increase in the fair value of these investments was $XXX.
See accompanying notes to financial statements.
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.14

Sample Governmental Hospital Authority
A Component Unit of Feeling County, State of Union
Notes to Financial Statements11
December 31, 20X7 and 20X6 (in thousands)
1.

Description of Reporting Entity and Summary of Significant Accounting Policies

Reporting entity. The Sample Hospital Authority (the authority) is a public corporation. It was created on
January 1, 19XX, by the board of county commissioners of Feeling County, State of Union, to operate, control, and manage all matters concerning the county’s health care functions. The board of county commissioners appoints the board of trustee members of the authority, and the authority may not issue debt or levy
taxes without the county’s approval. For this reason, the authority is considered to be a component unit of
Feeling County and is included as a discretely presented component unit in the basic financial statements of
the county.
Use of estimates. The preparation of financial statements in conformity with GAAP requires management to
make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues
and expenses during the reporting period. Actual results could differ from those estimates.
Enterprise fund accounting. The authority uses enterprise fund accounting. Revenues and expenses are recognized on the accrual basis using the economic resources measurement focus. Based on GASB Statement
No. 20, as amended, the authority has elected to apply the provisions of all relevant pronouncements of the
FASB, including those issued after November 30, 1989, that do not conflict with or contradict GASB pronouncements.
Cash and cash equivalents. Cash and cash equivalents include investments in highly liquid debt instruments
with an original maturity of three months or less.
Capital assets. The authority’s capital assets are reported at historical cost. Contributed capital assets are
reported at their estimated fair value at the time of their donation. All capital assets other than land are
depreciated or amortized (in the case of capital leases) using the straight-line method of depreciation using
these asset lives:
Land improvements
Buildings and building improvements
Equipment, computers, and furniture

15–20 years
20–40 years
3–7 years

Costs of borrowing. Except for capital assets acquired through gifts, contributions, or capital grants, interest
cost on borrowed funds during the period of construction of capital assets is capitalized as a component of
the cost of acquiring those assets. None of the authority’s interest cost was capitalized in either 20X7 or
20X6.

11
The notes to the financial statements in these illustrative financial statements generally include only disclosures unique to a governmental hospital. The disclosures regarding the accounting policies for the use of estimates and cost of borrowing in note 1 and charity
care in note 5 are not unique to a governmental hospital. Also, the notes to the financial statements include disclosures that are not
required.
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Property taxes. The authority received approximately 29 percent in 20X7 and 19 percent in 20X6 of its financial support from property taxes. These funds were used as follows:
20X7
Used to support
operations
Levied for debt service

$20,895
3,000

20X6
$12,309
3,000

Property taxes are levied by the county on the authority’s behalf on January 1 and are intended to finance
the authority’s activities of the same calendar year. Amounts levied are based on assessed property values
as of the preceding July 1.
Property taxes are considered delinquent on the day following each payment due date.
Grants and contributions. From time to time, the authority receives grants from Feeling County and the State
of Union as well as contributions from individuals and private organizations. Revenues from grants and
contributions (including contributions of capital assets) are recognized when all eligibility requirements,
including time requirements are met. Grants and contributions may be restricted for either specific operating
purposes or for capital purposes. Amounts that are unrestricted or that are restricted to a specific operating
purpose are reported as nonoperating revenues. Amounts restricted to capital acquisitions are reported after
nonoperating revenues and expenses.
Endowments. Endowments are provided to the authority on a voluntary basis by individuals and private
organizations. Permanent endowments require that the principal or corpus of the endowment be retained in
perpetuity. If a donor has not provided specific instructions, Union state law permits the authority’s board
of trustees to authorize for expenditure the net appreciation of the investments of endowment funds, as
discussed in note 2.
Restricted resources. When the authority has both restricted and unrestricted resources available to finance a
particular program, it is the authority’s policy to use restricted resources before unrestricted resources.
Net assets. Net assets of the authority are classified in four components. Net assets invested in capital assets net
of related debt consist of capital assets net of accumulated depreciation and reduced by the current balances
of any outstanding borrowings used to finance the purchase or construction of those assets. Restricted expendable net assets are noncapital net assets that must be used for a particular purpose, as specified by creditors, grantors, or contributors external to the authority, including amounts deposited with trustees as required by revenue bond indentures, discussed in note 8. Restricted nonexpendable net assets equal the principal
portion of permanent endowments. Unrestricted net assets are remaining net assets that do not meet the
definition of invested in capital assets net of related debt or restricted.
Operating revenues and expenses. The authority’s statement of revenues, expenses and changes in net assets
distinguishes between operating and nonoperating revenues and expenses. Operating revenues result from
exchange transactions associated with providing health care services—the authority’s principal activity. Nonexchange revenues, including taxes, grants, and contributions received for purposes other than capital asset
acquisition, are reported as nonoperating revenues. Operating expenses are all expenses incurred to provide
health care services, other than financing costs.
Compensated absences. The authority’s employees earn vacation days at varying rates depending on years of
service. Vacation time does not accumulate. Generally, any days not used at year-end expire. Employees
also earn sick leave benefits based on varying rates depending on years of service. Employees may accumulate sick leave up to a specified maximum. Employees are not paid for accumulated sick leave if they
leave before retirement. However, employees who retire from the authority may convert accumulated sick
leave to termination payments at varying rates, depending on the employee’s contract. The estimated
amount of sick leave payable as termination payments is reported as a noncurrent liability in both 20X7 and
20X6.
Risk management. The authority is exposed to various risks of loss from torts; theft of, damage to, and destruction of assets; business interruption; errors and omissions; employee injuries and illnesses; natural disasters; medical malpractice; and employee health, dental, and accident benefits. Commercial insurance cov-
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erage is purchased for claims arising from such matters. Settled claims have not exceeded this commercial
coverage in any of the three preceding years.
Investments in debt and equity securities. Investments in debt and equity securities are reported at fair value
except for short term highly liquid investments that have a remaining maturity at the time they are purchased of one year or less. These investments are carried at amortized cost. Interest, dividends, and gains
and losses, both realized and unrealized, on investments in debt and equity securities are included in nonoperating revenue when earned.
2.

Endowments and Restricted Net Assets

Restricted, expendable net assets are available for the following purposes:
20X7
Program A activities:
Purchase of equipment
Research
General
Program B activities:
Purchase of equipment
Research
General
Program C activities:
General
Buildings and equipment
Research
Total expendable, restricted net assets

20X6

$404
553
46

$321
683
63

235
184
79

235
151
110

206
94
44

400
72
65

$1,845

$2,100

Unless the contributor provides specific instructions, Union state law permits the authority’s board of trustees to authorize for expenditure the net appreciation (realized and unrealized) of the investments in its
endowments. When administering its power to spend net appreciation, the board of trustees is required to
consider the authority’s “long- and short-term needs, present and anticipated financial requirements, expected total return on its investments, price-level trends, and general economic conditions.” Any net appreciation that is spent is required to be spent for the purposes designated by the contributor.
The board of trustees chooses to spend only a portion of the investment income (including changes in the
value of investments) each year. Under the policy established by the board, 5 percent of the average market
value of endowment investments at the end of the previous 3 years has been authorized for expenditure.
The authority retains the remaining amount, if any, to be used in future years when the amount computed
using the spending policy exceeds investment income. At December 31, 20X7 and 20X6, net appreciation of
$864 and $953, respectively, is available to be spent, of which $402 and $682, respectively, is reported as
restricted expendable net assets, and the balance is in unrestricted net assets.
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Restricted nonexpendable net assets as of December 31, 20X7 and 20X6, represent the principal amounts of
permanent endowments, restricted to investment in perpetuity. Investment earnings from the authority’s
permanent endowments are expendable to support these programs as established by the contributor:
20X6

20X7
Program A activities
Program B activities
Program C activities
Any activities of the authority

3.

$158
176
423
854
1,611

$158
176
423
854
1,611

Endowment requiring income to be added to
original gift until the fund’s value is $2,125

1,392

1,308

Total restricted nonexpendable net assets

3,003

2,919

Designated Net Assets

Of the $40,851 and $37,897 of unrestricted net assets reported in 20X7 and 20X6, respectively, $15,000 has
been designated by the authority’s board of trustees for capital acquisitions. Designated funds remain under
the control of the board of trustees, which may at its discretion later use the funds for other purposes.
4.

Deposits and Investments

State law requires collateralization of all deposits with federal depository insurance and other acceptable
collateral in specific amounts. The authority’s bylaws require that all bank balances be insured or collateralized by U.S. government securities held by the pledging financial institution’s trust department in the
name of the authority.
The authority’s investments generally are reported at fair value, as discussed in note 1. At December 31,
20X7 and 20X6, the authority had the following investments and maturities, all of which were held in the
authority’s name by a custodial bank that is an agent of the authority:12
December 31, 20X7
Investment Type
U.S. Treasuries
Federal National Mortgage Association
Government National Mortgage Association
Total

Investment Maturities (in Years)
Carrying
Amount
$21,749
3,580
3,5806
$28,934

December 31, 20X6
Investment Type
U.S. Treasuries
Federal National Mortgage Association
Government National Mortgage Association
Total

Less
Than 1
$XXX
XXX
XXX
$XXX

1–5
$XXX
XXX
XXX
$XXX

6–10

More
Than 10

$XXX
XXX
XXX
$XXX

$XXX
XXX
XXX
$XXX

Investment Maturities (in Years)
Carrying
Amount
$20,039
3,365
3,366
$26,770

Less
Than 1
$XXX
XXX
XXX
$XXX

1–5
$XXX
XXX
XXX
$XXX

6–10
$XXX
XXX
XXX
$XXX

More
Than 10
$XXX
XXX
XXX
$XXX

Interest Rate Risk. The authority does not have a formal investment policy that limits investment maturities
as a means of managing its exposure to fair value losses arising from changing interest rates.
Credit Risk. Statutes authorize the authority to invest in obligations of the U.S. Treasury, agencies, and instrumentalities, commercial paper rated A-1 by Standard & Poor’s Corporation or P-1 by Moody’s Commercial Paper Record, and bankers’ acceptances. However, the authority’s bylaws require that investments be
12
This illustrative note presents interest rate information using the segmented time distribution method. Other methods for illustrating
interest rate information are described in paragraph 15 of GASB Statement No. 40, Deposit and Investment Risk Disclosures.
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made only in U.S. government obligations held by the authority’s third-party agent. As of December 31,
20X7 and 20X6, the authority’s investments in Federal National Mortgage Association were rated AAA by
Standard and Poor’s and Fitch Ratings and Aaa by Moody’s Investor Services.
Concentration of Credit Risk. The authority places no limit on the amount it may invest in any 1 issuer. More
than 5 percent of the authority’s investments at December 31, 20X7 and 20X6 are invested in the Federal
National Mortgage Association. These investments are 12.37 percent and 12.57 percent, respectively, of the
authority’s total investments at December 31, 20X7 and 20X6.
The carrying amounts of deposits and investments are included in the authority’s balance sheets as follows:
20X6

20X7
Carrying amount
Deposits
Investments
Included in the following balance sheet captions
Cash and cash equivalents
Short term investments
Noncurrent cash and investments:
Other long term investments
Restricted by contributors and grantors for
capital acquisitions and research
Internally designated for capital acquisitions
Held by trustee for debt service
Principal of permanent endowments

5.

$5,021
28,934

$6,539
26,770

$33,955

$33,309

$7,136
3,142

$7,557
3,423

2,605

1,327

1,124
15,000
1,945
3,003

1,078
15,000
2,005
2,919

$33,955

$33,309

Charity Care

Charges excluded from revenue under the authority’s charity care policy were $7,100 and $6,845 for 20X7
and 20X6, respectively.
6.

Accounts Receivable and Payable

Patient accounts receivable and accounts payable (including accrued expenses) reported as current assets
and liabilities by the authority at December 31, 20X7 and 20X6 consisted of these amounts:
Patient Accounts Receivable
20X7
Receivable from patients and their insurance carriers
Receivable from Medicare
Receivable from Medicaid
Total patient accounts receivable
Less allowance for uncollectibles amounts
Patient accounts receivable, net
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$13,976
4,286
3,697
21,959

$11,868
3,002
3,897
18,767

2,125

2,040

$19,834

$16,727
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Accounts Payable and Accrued Expenses
20X7

7.

20X6

Payable to employees (including payroll taxes)
Payable to suppliers
Other

$2,437
2,481
27

$1,970
2,591
14

Total accounts payable and accrued expenses

$4,945

$4,575

Capital Assets

Capital asset additions, retirements, and balances for the years ended December 31, 20X7 and 20X6 were as
follows:
Balance
December 31,
20X6

Additions

Retirements

Balance
December 31,
20X7

$3,590
645
29,265
30,375

—
17
965
3,547

—
—
(810)
(1,860)

$3,590
662
29,420
32,062

Totals at historical cost
Less accumulated depreciation for:
Land improvements
Buildings and improvements
Equipment

$63,875

$4,529

($2,670)

$65,734

(291)
(5,352)
(15,314)

(65)
(582)
(3,418)

—
810
1,860

(356)
(5,124)
(16,872)

Total accumulated depreciation

(20,957)

(4,065)

2,670

(22,352)

Capital assets, net

$42,918

$464

Land
Land improvements
Buildings and improvements
Equipment
13

$0

$43,382

Balance
December 31,
20X5

Additions

Retirements

Balance
December 31,
20X6

$3,590
608
29,187
26,710

—
112
78
3,921

—
(75)
—
(256)

$3,590
645
29,265
30,375

Totals at historical cost
Less accumulated depreciation for:
Land improvements
Buildings and improvements
Equipment

$60,095

$4,111

($331)

$63,875

(309)
(4,826)
(12,515)

(57)
(526)
(3,055)

75
—
256

(291)
(5,352)
(15,314)

Total accumulated depreciation

(17,650)

(3,638)

331

(20,957)

Capital assets, net

$42,445

$473

$0

$42,918

Land
Land improvements
Buildings and improvements
Equipment

13

When present, construction-in-progress should be reported in a separate line in this schedule. (See the GASB staff document
Comprehensive Implementation Guide—2005, item 7.353). Also, GASB Statement No. 34 paragraph 20 requires nondepreciable capital assets
to be shown separately on the face of the balance sheet when these balances are significant.
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Long Term Debt and Other Noncurrent Liabilities

A schedule of changes in the authority’s noncurrent liabilities for 20X7 and 20X6 follows:
Balance
December
31, 20X6
Bonds and Notes Payable:
Revenue notes
Mortgage loan
Note payable
Total long term debt
Capital lease obligations
Other Liabilities:
Compensated absences
Net pension obligation
Total other liabilities
Total noncurrent liabilities

Reductions

Amounts Due
Within One Year

$18,714
1,808
570
21,092
808

—
—
—
—
510

($457)
(99)
(464)
(1,020)
(468)

$18,257
1,709
106
20,072
850

$620
99
106
825
425

2,625
65
2,690
$24,590

662
15
677
$1,187

(6)
—
(6)
($1,494)

3,281
80
3,361
$24,283

—
See note 9
—
$1,250

Reductions

Balance
December
31, 20X6

Balance
December
31, 20X5
Bonds and Notes Payable:
Revenue notes
Mortgage loan
Note payable
Total long term debt
Capital lease obligations
Other Liabilities:
Compensated absences
Net pension obligation
Total other liabilities
Total noncurrent liabilities

Additions

Balance
December
31, 20X7

Additions

Amounts Due
Within 1 Year

19,568
1,907
1,045
22,520
1,276

—
—
—
—
—

(854)
(99)
(475)
(1,428)
(468)

18,714
1,808
570
21,092
808

457
99
464
1,020
468

2,400
49
2,449
$26,245

236
16
252
$252

(11)
—
(11)
($1,907)

2,625
65
2,690
$24,590

—
See note 9
—
$1,488

Long term debt. The terms and due dates of the authority’s long term debt, including capital lease obligations,
at December 31, 20X7 and 20X6, follow:
●

7.25 percent revenue notes, due November 1, 20Z7, collateralized by a pledge of the authority’s
gross receipts. Thus all operating and nonoperating revenues of the authority are similarly pledged.

●

9.25 percent mortgage loan, due January 20Y4, collateralized by a mortgage on property and equipment with a depreciated cost of $1,530 at December 31, 20X7

●

9.75 percent note payable, due March 20X8, unsecured

●

Capital lease obligations, at varying rates of imputed interest from 9.8 percent to 12.3 percent collateralized by leased equipment with cost of $1,275 at December 31, 20X7

Under the terms of the revenue note indenture, the authority is required to maintain certain deposits with a
trustee. Such deposits are included with restricted cash and investments in the balance sheet. The revenue
note indenture also places limits on the incurrence of additional borrowings and requires that the authority
satisfy certain measures of financial performance as long as the notes are outstanding.

FSP §11,400.14

299

Illustrative Financial Statements

Scheduled principal and interest repayments on long term debt and payments on capital lease obligations
are as follows:
Capital Lease Obligations

Long Term Debt
Year Ending December 31:
20X8
20X9
20Y0
20Y1
20Y2
20Y3–20Y7
20Y8–20Z2
20Z3–20Z7
Total
9.

Principal

Interest

Principal

Interest

$825
775
836
900
972
5,764
4,824
5,176

$53
487
465
448
432
1,769
1,492
1,116

$425
213
212

$58
27
13

$20,072

$6,762

$850

$98

Commitments Under Noncancelable Operating Leases

The authority is committed under various noncancelable operating leases, all of which are for equipment
and computers. These expire in various years through 20Y9. Future minimum operating lease payments are
as follows:
Year ending December 31:

10.

20X8
20X9
20Y0
20Y1
20Y2
20Y3–20Y7
20Y8–20Y9

$3,109
2,898
2,795
2,780
2,575
4,215
1,065

Total

$19,437

Pension Plan14

Plan description. Sample Hospital Pension Plan (SHPP) provides retirement and disability benefits, annual
cost-of-living adjustments, and death benefits to plan members and beneficiaries. SHPP is affiliated with
County Employees Pension Plan (CEPP), an agent multiple-employer pension plan administered by the
Union Retirement System. Article 39 of the Regulations of the State of Union assigns the authority to establish and amend the benefit provisions of the plans that participate in CEPP to the respective employer entities; for CEPP, that authority rests with the County of Feeling, Union. The Union Retirement System issues
a publicly available financial report that includes financial statements and required supplementary information for SHPP. That report may be obtained by writing to Union Retirement System, State Government
Lane, Anytown, Union 01000 or by calling 1-800-555-PLAN.
Funding policy. The contribution requirements of plan members and the authority are established and may
be amended by the CEPP board of trustees. Plan members are required to contribute 7.8 percent of their
annual covered salary. The authority is required to contribute at an actuarially determined rate; the current
rate for both 20X7 and 20X6 is 11.9 percent of annual covered payroll.

14
The preparer of the financial statements should consider the need for required supplementary information as required by GASB
Statement No. 27, Accounting for Pensions by State and Local Governmental Employers, paragraph 22.
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Annual pension cost and net pension obligation. The authority’s annual pension cost and net pension obligation
to SHPP for 20X7 and 20X6 were as follows:
20X7

20X6

Annual required contribution
Interest on net pension obligation
Adjustment to annual required contribution

$26
3
(3)

$23
2
(2)

Annual pension cost
Contributions made

26
(11)

23
(7)

Increase (decrease) in net pension obligation
Net pension obligation beginning of year
Net pension obligation, end of year

15
65
$80

16
49
$65

The annual required contribution for the current year was determined as part of the December 31, 20X6,
actuarial valuation using the entry age actuarial cost method. The actuarial assumptions included (a) 7.5
percent investment rate of return (net of administrative expenses) and (b) projected salary increases ranging
from 5.5 percent to 9.5 percent per year. Both (a) and (b) included an inflation component of 5.5 percent. The
actuarial assumptions also include a 2 percent per year cost-of-living adjustment. The actuarial value of
assets was determined using techniques that smooth the effects of short term volatility in the market value
of investments over a 4 year period. The same actuarial assumptions were used to determine the actuarial
required contributions for 20X6. The unfunded actuarial accrued liability is being amortized as a level percentage of projected payroll on an open basis. The remaining amortization period at December 31, 20X6,
was 23 years.
Three-Year Trend Information

11.

Fiscal Year Ending

Annual Pension
Cost (APC)

Percentage of
APC Contributed

Net Pension
Obligation

12/31/X5
12/31/X6
12/31/X7

$20
23
26

94%
30
42

$49
65
80

Postretirement Plan#

In addition to the pension benefits previously described, the authority provides postretirement health care
benefits, in accordance with the authority’s bylaws, to all employees who retire from the authority on or
after attaining age 60 with at least 15 years of service. Currently 250 retirees (245 in 20X6) meet these eligibility requirements. The authority reimburses 75 percent of the amount of validated claims for medical,
dental, and hospitalization costs incurred by pre-Medicare retirees and their dependents. The authority also
reimburses a fixed amount of $25 per month for a Medicare supplement for each retiree eligible for Medicare. Expenses for postretirement health care benefits are recognized as retirees report claims and include a
provision for estimated claims incurred but not yet reported to the authority. Expenses of $764 were recog#
In 2004, the GASB issued GASB Statement No. 45 that would supersede or amend previous authoritative guidance on accounting
and financial reporting for an employer’s OPEB expense and related information, including GASB Statement No. 12. GASB Statement
No. 45 requires reporting of the annual cost of OPEB, and the outstanding obligations and commitments related to OPEB in essentially
the same manner as required for pensions in GASB Statement No. 27. Paragraphs 24–25 of GASB Statement No. 45 require disclosures in
the notes to the financial statements for OPEB plans. Conforming changes to modify these illustrative financial statements to reflect the
issuance of GASB Statement No. 45 will be made in a future edition of this checklist.

GASB issued Technical Bulletin 2006-1, Accounting and Financial Reporting by Employers and OPEB Plans for Payments from the Federal
Government Pursuant to the Retiree Drug Subsidy Provisions of Medicare Part D, in June 2006. This Technical Bulletin is effective immediately,
except for portions of answers pertaining specifically to measurement, recognition, or required supplementary information requirements
of GASB Statement Nos. 43, Financial Reporting for Postemployment Benefit Plans Other Than Pension Plans, or 45. Those provisions should
be applied simultaneously with the implementation of GASB Statement Nos. 43 or 45. This Technical Bulletin clarifies the application of
existing standards of accounting and financial reporting to payments that an employer or a defined benefit OPEB plan receives from the
federal government pursuant to the retiree drug subsidy provisions of Medicare Part D, as established in the Medicare Prescription Drug,
Improvement, and Modernization Act of 2003.
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nized for postretirement health care in 20X7; expenses recognized in 20X6 were $636. Approximately $64 of
the $128 increase in expenses over the previous year was caused by the addition of dental benefits, effective
July 1, 20X7.
Note: Although not presented in these sample illustrative financial statements, other disclosures required by
GASB pronouncements may be applicable, including the following:
●

Short term debt (GASB Statement No. 38, Recipient Reporting for Certain Shared Nonexchange Revenues—an amendment of GASB Statement No. 33, paragraph 12)

●

Interfund balances and transfers (GASB Statement No. 38 paragraph 14 when a governmental health
care entity reports multiple enterprise funds or is reported as an enterprise fund of a general purpose government.)

●

Segment information (GASB Statement No. 34, as amended, paragraphs 122–123)

●

Violations of finance-related legal or contractual provisions (GASB Statement No. 38 paragraph 9)

●

Risk financing (Requirements for disclosures about claims and judgments and risk financing by
governmental health care entities that retain a portion of risk for claims and judgments (including
malpractice claims and judgments) are provided in GASB Statement No. 10, as amended). Additionally, GASB Statement No. 34 paragraph 119 requires disclosure of certain information about the long
term portion of accrued claims and judgments, if applicable.

Other required disclosures, which may be applicable and would be similar to the disclosures contained in
the notes to the sample illustrative financial statements for a not-for-profit hospital, are not repeated here.
They include the following:
●

Off-Balance Sheet Risk and Concentration of Credit Risk

●

Fair Value of Financial Instruments

●

Commitments and Contingencies

●

Subsequent Events\

●

Net patient service revenue

●

Related party transactions

●

Description of Reporting Entity and Summary of Significant Accounting Policies—Supplies, Net Patient Service Revenue, Charity Care, Premium Revenue

\

In May 2009, FASB issued Statement No. 165, Subsequent Events, which establishes general standards of accounting for and disclosure
of events that occur after the balance sheet date but before financial statements are issued or are available to be issued. This statement
sets forth
a.

the period after the balance sheet date during which management of a reporting entity should evaluate events or transactions
that may occur for potential recognition or disclosure in the financial statements.

b.

the circumstances under which an entity should recognize events or transactions occurring after the balance sheet date in its
financial statements.

c.

the disclosures that an entity should make about events or transactions that occurred after the balance sheet date.

FASB Statement No. 165 introduces the concept of financial statements being available to be issued. It also requires disclosure of the date
through which an entity has evaluated subsequent events and the basis for that date (that is, whether that date represents the date the
financial statements were issued or were available for issue).
FASB Statement No. 165 is effective for interim or annual financial periods ending after June 15, 2009. For additional information
please visit the FASB website at www.fasb.org.
FASB Statement No. 165 has been codified in FASB ASC 855, Subsequent Events.
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ILLUSTRATIVE FINANCIAL STATEMENTS FOR A NURSING HOME
.15
Sample For-Profit Nursing Home, Inc.
Balance Sheets*
December 31, 20X7 and 20X6
20X7
Assets
Current assets:
Cash and cash equivalents
Investments
Assets limited as to use
Patient accounts receivable, net of allowance for
doubtful accounts of $6,700 in 20X7 and $5,300 in
20X6
Estimated third-party payor settlements
Interest receivable
Supplies
Prepaid expenses
Deferred tax asset
Total current assets
Assets limited as to use, net of amount required for
current liabilities
Property and equipment:
Land
Land improvements
Buildings

20X6

$95,000
150,000
50,000

$129,000

162,000
71,000
7,000
47,000
3,000
12,000

152,000
62,000

597,000

452,000

173,000

150,000

205,000
37,000
1,399,000

205,000
32,000
1,399,000
(continued)

50,000

43,000
2,000
14,000

*
The fair value option subsections of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 825-10
permit all entities, including not-for-profit organizations, to choose to measure eligible items at fair value at specified election dates.
Notable eligible items include recognized financial assets and financial liabilities (except for those specifically prohibited), written loan
commitments, and rights and obligations under a warranty that is not a financial instrument (because it requires or permits the insurer
to provide goods or services rather than a cash payment) but whose terms permit the insurer to settle by paying a third party to provide
those goods or services. Prohibited recognized financial assets and liabilities include

a.

an investment in a subsidiary that the entity is required to consolidate.

b.

an interest in a variable interest entity that the entity is required to consolidate.

c.

employers and plans’ obligations (or assets representing net overfunded positions) for pension benefits, other postretirement
benefits (including health care and life insurance benefits), postemployment benefits, employee stock option and stock purchase plans, and certain other forms of deferred compensation arrangements, as defined by the applicable FASB pronouncements.

d.

financial assets and financial liabilities recognized under leases as defined in FASB ASC 840, Leases, excluding guarantees of a
third-party lease obligation or a contingent obligation arising from a cancelled lease.

e.

deposit liabilities, withdrawable on demand, of banks, savings and loan associations, credit unions, and other similar depository institutions.

f.

financial instruments that are, in whole or in part, classified by the issuer as a component of shareholder’s equity (including
temporary equity). An example is a convertible debt security with a noncontingent beneficial conversion feature.

Entities shall report assets and liabilities that are measured at fair value pursuant to the fair value option in this statement in a manner
that separates those reported fair values from the carrying amounts of similar assets and liabilities measured using another measurement
attribute. To accomplish that, an entity shall either
a.

present the aggregate of fair value and non-fair-value amounts in the same line item in the statement of financial position and
parenthetically disclose the amount measured at fair value included in the aggregate amount, or

b.

present two separate line items to display the fair value and non-fair-value carrying amounts.

FSP §11,400.15

303

Illustrative Financial Statements

20X7
Furniture, fixtures, and equipment

20X6

228,000

189,000

Less accumulated depreciation

1,869,000
210,000

1,825,000
141,000

Property and equipment, net

1,659,000

1,684,000

150,000

127,000

$2,579,000

$2,413,000

$50,000
78,000
175,000
50,000
74,000

$50,000
52,000
188,000
45,000
15,000

427,000

350,000

6,000

14,000

1,700,000

1,750,000

70,000
376,000

70,000
229,000

446,000

299,000

$2,579,000

$2,413,000

Other assets
Total assets
Liabilities and Shareholders’ Equity
Current liabilities:
Current maturities of long-term debt
Accounts payable
Accrued expenses
Deposits from patients
Other current liabilities
Total current liabilities
Deferred tax liability
Long-term debt, net of current maturities
Shareholders’ equity:
Common stock $20 par value; authorized 5,000 shares;
issued and outstanding 3,500 shares
Retained earnings
Total shareholders’ equity
Total liabilities and shareholders’ equity
See accompanying notes to financial statements.
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.16
Sample For-Profit Nursing Home, Inc.
Statements of Income and Retained Earnings
Years Ended December 31, 20X7 and 20X6
20X7

20X6

$2,163,000
67,000
13,000

$1,949,000
22,000
7,000

2,243,000

1,978,000

969,000
511,000
216,000
92,000
69,000
164,000

919,000
499,000
176,000
83,000
57,000
172,000

2,021,000

1,906,000

Operating income
Nonoperating income:
Other interest income

222,000

72,000

Income before provision for income taxes
Provision for income taxes

227,000
80,000

72,000
29,000

Net income
Retained earnings, beginning of year

147,000
229,000

43,000
186,000

$376,000

$229,000

Revenue:
Net patient service revenue
Other revenue
Interest on investments held by trustee
Total revenue
Expenses:
Salaries and benefits
Medical supplies and drugs
Insurance and other
Provision for bad debts
Depreciation
Interest
Total expenses

Retained earnings, end of year
See accompanying notes to financial statements.
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.17
Sample For-Profit Nursing Home, Inc.
Statements of Cash Flows
Years Ended December 31, 20X7 and 20X6

Cash flows from operating activities:
Cash received from residents and third party payors
Cash received from others
Cash paid to employees and suppliers
Interest and dividends received, 10,000
Interest paid
Taxes paid
Deposits received from patients
Deposits refunded to patients
Net cash provided by operating activities

20X7

20X6

$2,019,000
67,000
(1,679,000)
10,000
(160,000)
(29,000)
35,000
(30,000)

$1,796,000
22,000
(1,495,000)
10,000
(170,000)
(30,000)
15,000
(20,000)

233,000

128,000

Cash flows from investing activities:
Purchase of investments
Proceeds from sale of property
Capital expenditures
Purchase of assets limited as to use
Net cash used in investing activities

(217,000)

(77,000)

Cash flows from financing activities:
Repayment of long-term debt

(50,000)

(50,000)

(50,000)

(50,000)

Net cash used in financing activities
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of year
Reconciliation of net income to net cash provided by
operating activities:
Net income
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation
Provision for bad debts
Loss on sale of property
Change in deferred income taxes
(Increase) decrease in:
Patient accounts receivable
Other current assets
Estimated third-party payor settlements
Interest receivable
Other assets
Increase (decrease) in:
Accounts payable and accrued expenses
Deposits from patients
Other current liabilities
Net cash provided by operating activities

(150,000)
(44,000)
(23,000)

(34,000)
129,000
$95,000

$147,000

2,000
(79,000)

1,000
128,000
$129,000

$43,000

69,000
92,000
—
(6,000)

57,000
83,000
11,000
(14,000)

(102,000)
(21,000)
(9,000)
(7,000)
(7,000)

(41,000)
(15,000)
(10,000)
(3,000)
(10,000)

13,000
5,000
59,000
$233,000

43,000
(5,000)
(11,000)
$128,000

See accompanying notes to financial statements.
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Sample For-Profit Nursing Home, Inc.
Notes to Financial Statements†
December 31, 20X7 and 20X6
1.

Description of Organization and Summary of Significant Accounting Policies15

Organization. The Sample Nursing Home, Inc. (the Company) was incorporated in New State in 20X1 and
operates a 128-bed nursing home in Abacus, New State. A summary of the Company’s significant accounting policies follows:
Use of estimates. The preparation of financial statements in conformity with GAAP requires management to
make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues
and expenses during the reporting period. Actual results could differ from those estimates.
Cash and cash equivalents. Cash and cash equivalents include investments in highly liquid debt instruments
with an original maturity of three months or less, excluding amounts whose use is limited by note indenture.
Investments. Investments in debt instruments, including assets limited as to use, are classified as held-tomaturity because the Company has the positive intent and ability to hold the securities until maturity. Heldto-maturity securities are carried at cost adjusted for amortization of premiums and accretion of discounts.
Assets limited as to use. Assets deposited with a trustee under terms of the note indenture and assets set aside
by the Board of Directors for capital improvements are classified as assets limited as to use. Amounts required to meet current liabilities have been reclassified in the balance sheet.
Property and equipment. Property and equipment are recorded at cost. Depreciation is calculated on the
straight-line method over the estimated useful lives of depreciable assets.
Bond issuance costs. Costs incurred in issuing the Series 20X1 bonds are being amortized based on the effective interest method.
Net patient service revenue. Net patient service revenue is reported at the estimated net realizable amounts
from residents, third-party payors, and others for service rendered.
Revenue under third-party payor agreements is subject to audit and retroactive adjustment. Provisions for
estimated third-party payor settlements are provided in the period the related services are rendered. Differ†
FASB ASC 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value in generally
accepted accounting principles (GAAP), and expands disclosures about fair value measurements. This guidance applies under other
accounting pronouncements that require or permit fair value measurements, the FASB having previously concluded in those accounting
pronouncements that fair value is the relevant measurement attribute. Accordingly, FASB ASC 820 does not require any new fair value
measurements but the application of it will change current practice.

FASB ASC 820 retains the exchange price notion already established within GAAP but clarifies, among other matters, that fair value
is the price that would be received to sell the asset or paid to transfer the liability (for example, an exit price) and not the price that would
be paid to acquire the asset or paid to transfer the liability (for example, an entry price). Additionally, FASB ASC 820 establishes a fair
value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. Level 1 inputs are
quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the
measurement date and shall be used to measure fair value when available, with limited exceptions. Level 2 inputs are inputs other than
quoted prices included within level 1 that are observable for the asset or liability, either directly or indirectly, and may include, for
example, quoted prices for similar assets or liabilities in active markets. Level 3 inputs are unobservable inputs for the asset or liability.
Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for
situations in which there is little, if any, market activity. Unobservable inputs shall be developed based on the best information available
in the circumstances, which might include the reporting entity’s own data.
FASB ASC 820-10-50 expands disclosures about the use of fair value to measure assets and liabilities in interim and annual periods
subsequent to initial recognition. The disclosures focus on the fair value hierarchy and the effect of the measurements on earnings (or
changes in net assets) for the period. Entities are encouraged to combine the fair value information disclosed under this statement with
other required fair value information, including that required by FASB ASC 825-10-50 about financial instruments.
15

See footnote 5.
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ences between the estimated amounts accrued and interim and final settlements are reported in operations
in the year of settlement.
Income taxes. The provisions for income taxes are based on amounts estimated to be currently payable and
those deferred because of temporary differences between the financial statement and tax bases of assets and
liabilities. These differences consist principally of bad debts and depreciation.
2.

Assets Limited as to Use

Assets limited as to use include:
Assets held by trustee under the Series 20X1 note indenture agreement at December 31, 20X7 and 20X6.
20X7
U.S. Government obligations
Cash
Accrued interest income
Internally designated by the Board of Directors for
capital improvements
Certificate of deposit
Accrued interest

3.

Investments**

4.

Long-Term Debt

20X6

$150,000
24,000
2,000

$130,000
21,000
2,000

176,000

153,000

$45,000
2,000

$45,000
2,000

47,000

47,000

$223,000

$200,000

Long-term debt at December 31, 20X7 and 20X6, was as follows:
9.5 percent bonds payable to the City of
Abacus, maturing $50,000 annually through
November 1, 20YY, with a final maturity of $1
million on November 1, 20YY
Less current maturities

20X7

20X6

$1,750,000
50,000

$1,800,000
50,000

$1,700,000

$1,750,000

The notes are collateralized by a first mortgage lien on all property and equipment of the Company and a
security interest in all of its receipts. The note indenture requires the maintenance of certain deposits with a
trustee, which are included in assets limited as to use.

**
In reporting disclosures about investments in securities, entities should comply primarily with the requirements of FASB ASC 32010-50. Other disclosure requirements may also be applicable.
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Future maturities of long-term debt as of December 31, 20X7, follow:
Amount

Year Ending December 31,
20X8
20X9
20Y0
20Y1
20Y2
Thereafter

$50,000
50,000
50,000
50,000
50,000
1,500,000

Total
5.

$1,750,000

Income Taxes

The provisions for income taxes are as follows:††
20X7
Current:
Federal
State
Total current
Deferred:
Federal

20X6

$72,000
2,000

$15,000

74,000

15,000

6,000

13,000

State
Total deferred
Total provision for income taxes

1,000
6,000
$80,000

14,000
$29,000

Deferred income taxes are provided for the temporary differences between the financial reporting basis and
the tax basis of the Company’s assets and liabilities.
For the years ended December 31, 20X7 and 20X6, the effective tax rate approximated the statutory rate of
34 percent and 40 percent, respectively.
The net current and noncurrent components of deferred income taxes recognized in the balance sheet at
December 31, 20X7 and 20X6, follows:
20X7
Net current assets
Net noncurrent liabilities

20X6

$12,000
6,000

$14,000
14,000

$6,000

$0

††
FASB ASC 740-10 includes guidance from FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes—an interpretation of
FASB Statement No. 109. This interpretation is effective for fiscal years beginning after December 15, 2006. The interpretation clarifies the
accounting for uncertainty in income taxes recognized in an organization’s financial statements in accordance with FASB Statement No.
109, Accounting for Income Taxes. This interpretation prescribes a recognition threshold and measurement attribute for the financial
statement recognition, measurement and disclosures of a tax position taken or expected to be taken in a tax return. This interpretation
also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.

However, FSP FIN 48-3, Effective Date of FASB Interpretation No. 48 for Certain Nonpublic Enterprises, defers the effective date of that
interpretation to fiscal years beginning after December 15, 2008, for certain nonpublic enterprises as defined by the glossary of FASB ASC
740-10, including nonpublic not-for-profit health care entities. If a nonpublic health care entity decides to defer in accordance with the
FSP, it should disclose that fact and its accounting policy for evaluating uncertain tax positions. Earlier application of FASB Interpretation
No. 48 is permitted. Health care entities that have already adopted the provisions of FASB Interpretation No. 48 are not eligible for the
deferral. This guidance is located in FASB ASC 740-10-15 and 740–10-65. The AICPA has prepared a practice guide to help in understanding the interpretation. The practice guide is available by following the link “Professional Standards and Ethics” at http://tax.aicpa.org/
Resources.
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Management has determined that no valuation allowance related to deferred tax assets is necessary at December 31, 20X7 and 20X6, respectively.
6.

Concentration in State Medicaid Program

The Company has 100 of its 128 beds designated for care of patients under the state’s Medicaid program.
The current funding of that program is 90 days behind filed claims. The current state budget has no provision for reducing that lag and, while the proposed budget for 20X8 includes additional funding, there is no
assurance that the final budget will include the needed additional funds.
7.

Third Party Rate Adjustments and Revenue

Revenue from the Medicaid program accounted for approximately XX percent for the year ended 20X7, and
XX percent for the year ended 20X6, of the Company’s net patient revenue. Laws and regulations governing
the Medicaid program are extremely complex and subject to interpretation. As a result, there is at least a
reasonable possibility that recorded estimates will change by a material amount in the near term. The 20X7
net patient service revenue increased approximately $XXX due to removal of allowances previously estimated that are no longer necessary as a result of final settlements and years that are no longer subject to
audits, reviews, and investigations. The 20X6 net patient service revenue decreased approximately $XXX
due to prior-year retroactive adjustments in excess of amounts previously estimated.
8.

Risks and Uncertainties Disclosures‡‡

9.

Pension Plan‡‡

10.

Postretirement Benefits‡‡

11.

Fair Values of Financial Instruments‡‡

12.

Concentrations of Credit Risk‡‡

‡‡

The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for the
not-for-profit hospital and, therefore, are not repeated here.
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ILLUSTRATIVE FINANCIAL STATEMENTS FOR A CONTINUING CARE
RETIREMENT COMMUNITY
.19
Sample Not-for-Profit Continuing Care Retirement Community
Balance Sheets*
December 31, 20X7 and 20X6
20X7
Assets
Current assets:
Cash
Assets limited as to use
Accounts receivable, net of allowance for doubtful
accounts of $4,000 in 20X7 and $5,000 in 20X6
Supplies
Prepaid expenses
Total current assets
Assets limited as to use, net of amount required for
current liabilities
Property and equipment, net
Deferred financing costs, net of accumulated
amortization of $28,000 in 20X7 and $21,000 in 20X6
Total assets

20X6

$375,000
265,000

$330,000
170,000

187,000
40,000
115,000

197,000
21,000
73,000

982,000

791,000

1,865,000
14,893,000

1,583,000
15,280,000

83,000

90,000

$17,823,000

$17,744,000
(continued)

*
The fair value option subsections of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 825-10
permit all entities, including not-for-profit organizations, to choose to measure eligible items at fair value at specified election dates.
Notable eligible items include recognized financial assets and financial liabilities (except for those specifically prohibited), written loan
commitments, and rights and obligations under a warranty that is not a financial instrument (because it requires or permits the insurer
to provide goods or services rather than a cash payment) but whose terms permit the insurer to settle by paying a third party to provide
those goods or services. Prohibited recognized financial assets and liabilities include

a.

an investment in a subsidiary that the entity is required to consolidate.

b.

an interest in a variable interest entity that the entity is required to consolidate.

c.

employers and plans’ obligations (or assets representing net overfunded positions) for pension benefits, other postretirement
benefits (including health care and life insurance benefits), postemployment benefits, employee stock option and stock purchase plans, and certain other forms of deferred compensation arrangements, as defined by the applicable FASB pronouncements.

d.

financial assets and financial liabilities recognized under leases as defined in FASB ASC 840, Leases, excluding guarantees of a
third-party lease obligation or a contingent obligation arising from a cancelled lease.

e.

deposit liabilities, withdrawable on demand, of banks, savings and loan associations, credit unions, and other similar depository institutions.

f.

financial instruments that are, in whole or in part, classified by the issuer as a component of shareholder’s equity (including
temporary equity). An example is a convertible debt security with a noncontingent beneficial conversion feature.

Entities shall report assets and liabilities that are measured at fair value pursuant to the fair value option in this statement in a manner
that separates those reported fair values from the carrying amounts of similar assets and liabilities measured using another measurement
attribute. To accomplish that, an entity shall either
a.

present the aggregate of fair value and non-fair-value amounts in the same line item in the statement of financial position and
parenthetically disclose the amount measured at fair value included in the aggregate amount, or

b.

present two separate line items to display the fair value and non-fair-value carrying amounts.
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20X7
Liabilities and Net Assets
Liabilities:
Current maturities of long-term debt
Accounts payable
Accrued expenses
Deposits on unoccupied units
Total current liabilities
Long-term debt, less current maturities
Refundable fees
Estimated obligation to provide future services, in
excess of amounts received or to be received
Deferred revenue from advance fees
Total liabilities
Net assets:
Unrestricted
Temporarily restricted
Permanently restricted
Total net assets
Total liabilities and net assets

20X6

$90,000
180,000
161,000
22,000

$77,000
174,000
178,000
40,000

453,000

469,000

8,871,000
59,000

8,935,000
144,000

88,000
6,304,000

100,000
6,585,000

15,775,000

16,233,000

1,286,000
311,000
451,000

833,000
294,000
384,000

2,048,000

1,511,000

$17,823,000

$17,744,000

See accompanying notes to financial statements.
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.20
Sample Not-for-Profit Continuing Care Retirement Community
Statements of Operations
Years Ended December 31, 20X7 and 20X6

Revenue, gains, and other support:
Resident services, including amortization of advance
fees of $935,000 in 20X7 and $915,000 in 20X6
Patient revenue from nonresidents
Change in obligation to provide future services
Contributions
Net assets released from restrictions used for
operations
Investment income
Other
Total revenue, gains, and other support
Expenses:
Salaries and benefits
Medical supplies and drugs
Insurance
Depreciation
Interest
Total expenses

20X7

20X6

$3,946,000
249,000
12,000
54,000

$3,152,000
275,000
(82,000)
39,000

24,000
29,000
75,000

50,000
30,000
68,000

4,389,000

3,532,000

1,708,000
543,000
291,000
452,000
967,000

1,250,000
742,000
311,000
447,000
955,000

3,961,000

3,705,000

Operating income (loss)
Net assets released from restriction—purchase of
equipment

428,000

(173,000)

25,000

45,000

Increase (decrease) in unrestricted net assets

$453,000

See accompanying notes to financial statements.
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.21
Sample Not-for-Profit Continuing Care Retirement Community
Statements of Changes in Net Assets
Years Ended December 31, 20X7 and 20X6
20X7
Unrestricted net assets:
Operating income (loss)
Net assets released from restriction—purchase of
equipment
Increase (decrease) in unrestricted net assets
Temporarily restricted net assets:
Contributions
Net assets released from restrictions used for
operations
Net assets released from restriction—purchase of
equipment
Investment income
Increase (decrease) in temporarily restricted net assets
Permanently restricted net assets:
Contributions
Increase in permanently restricted net assets
Increase (decrease) in net assets
Net assets, beginning of year
Net assets, end of year

$428,000

20X6
$(173,000)

25,000

45,000

453,000

(128,000)

40,000

15,000

(24,000)

(50,000)

(25,000)
26,000

(45,000)
15,000

17,000

(65,000)

67,000

52,000

67,000

52,000

537,000
1,511,000
$2,048,000

(141,000)
1,652,000
$1,511,000

See accompanying notes to financial statements.
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Sample Not-for-Profit Continuing Care Retirement Community
Statements of Cash Flows
Years Ended December 31, 20X7 and 20X6

Cash flows from operating activities:
Cash received from residents and third party payors
Advance fees received
Other receipts from operations
Investment income received
Contributions received
Cash paid to employees and suppliers
Interest paid
Net cash provided by operating activities

20X7

20X6

$3,252,000
654,000
75,000
68,000
51,000
(2,576,000)
(950,000)

$2,341,000
857,000
68,000
53,000
44,000
(2,040,000)
(945,000)

574,000

378,000

Cash flows from investing activities:
Purchase of property and equipment

(65,000)

(250,000)

Purchase of assets limited as to use

(377,000)

229,000

(442,000)

(21,000)

67,000
(103,000)
26,000
(77,000)

52,000
(52,000)
(307,000)

(87,000)

(307,000)

45,000
330,000

50,000
280,000

$375,000

$330,000

$537,000

$(141,000)

654,000
(67,000)
(935,000)
(12,000)
452,000
7,000
3,000

857,000
(52,000)
(915,000)
82,000
447,000
34,000
3,000

7,000
(61,000)

(33,000)
(4,000)

(11,000)

100,000

Net cash used in investing activities
Cash flows from financing activities:
Permanently restricted funds received
Refunds of deposits and refundable fees
Proceeds from issuance of long-term debt
Principal payments of long-term debt
Net cash used in financing activities
Net increase in cash
Cash, beginning of year
Cash, end of year
Reconciliation of change in net assets to net cash
provided by operating activities:
Change in net assets
Adjustments to reconcile change in net assets to net
cash provided by operating activities:
Advance fees received
Restricted net assets received
Amortization of advance fees
Loss (gain) on obligation to provide future services
Depreciation
Amortization of deferred financing costs
Provision for bad debts
(Increase) decrease in:
Accounts receivable
Other assets
Increase (decrease) in:
Accounts payable and accrued expenses
Net cash provided by operating activities
See accompanying notes to financial statements.
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Sample Not-for-Profit Continuing Care Retirement Community
Notes to Financial Statements16, †
December 31, 20X7 and 20X6
1.

Description of Organization and Summary of Significant Accounting Policies\ \, 17

Organization. The Sample Continuing Care Retirement Community (the CCRC) is a nonprofit organization
that principally provides housing, health care, and other related services to residents through the operation
of a retirement facility containing 249 apartments and a 78-bed health care facility located in Evergreen Park,
Illinois. The CCRC was incorporated in Illinois in 20X1. A summary of significant accounting policies follows.
Use of estimates. The preparation of financial statements in conformity with GAAP requires management to
make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues
and expenses during the reporting period. Actual results could differ from those estimates.
Investments. Investments, which consist of U.S. Treasury obligations, are measured at fair value in the balance sheet. Investment income (including realized gains and losses on investments, interest, and dividends)
is included in operating income (loss) unless restricted by donor or law. Unrealized gains and losses on
investments, if any, are excluded from operating income (loss).
Deferred financing costs. Deferred financing costs are amortized using the effective interest method over the
term of the related financing agreement.
Advance fees. Fees paid by a resident upon entering into a continuing care contract, net of the portion thereof
that is refundable to the resident, are recorded as deferred revenue and are amortized to income using the
straight-line method over the estimated remaining life expectancy of the resident.
Obligation to provide future services. The CCRC annually calculates the present value of the net cost of future
services and the use of facilities to be provided to current residents and compares that amount with the
16

Statement of Position (SOP) 00-1, Auditing Health Care Third-Party Revenues and Related Receivables (AICPA, Technical Practice Aids,
AUD sec. 14,360), provides auditors with guidance regarding uncertainties in health care revenue recognition and includes a sample
disclosure in paragraph 37 of the SOP for material differences between an original estimate and subsequent revisions regarding thirdparty payments.
†
FASB ASC 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value in generally
accepted accounting principles (GAAP), and expands disclosures about fair value measurements. This guidance applies under other
accounting pronouncements that require or permit fair value measurements, the FASB having previously concluded in those accounting
pronouncements that fair value is the relevant measurement attribute. Accordingly, FASB ASC 820 does not require any new fair value
measurements but the application of it will change current practice.

FASB ASC 820 retains the exchange price notion already established within GAAP but clarifies, among other matters, that fair value
is the price that would be received to sell the asset or paid to transfer the liability (for example, an exit price) and not the price that would
be paid to acquire the asset or paid to transfer the liability (for example, an entry price). Additionally, FASB ASC 820 establishes a fair
value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. Level 1 inputs are
quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the
measurement date and shall be used to measure fair value when available, with limited exceptions. Level 2 inputs are inputs other than
quoted prices included within level 1 that are observable for the asset or liability, either directly or indirectly, and may include, for
example, quoted prices for similar assets or liabilities in active markets. Level 3 inputs are unobservable inputs for the asset or liability.
Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for
situations in which there is little, if any, market activity. Unobservable inputs shall be developed based on the best information available
in the circumstances, which might include the reporting entity’s own data.
FASB ASC 820-10-50 expands disclosures about the use of fair value to measure assets and liabilities in interim and annual periods
subsequent to initial recognition. The disclosures focus on the fair value hierarchy and the effect of the measurements on earnings (or
changes in net assets) for the period. Entities are encouraged to combine the fair value information disclosed under this statement with
other required fair value information, including that required by FASB ASC 825-10-50 about financial instruments.
\\

Does not include all disclosures common to all health care entities.

17

See footnote 5.
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balance of deferred revenue from advance fees. If the present value of the net cost of future services and the
use of facilities exceeds the deferred revenue from advance fees, a liability is recorded (obligation to provide
future services and use of facilities) with the corresponding charge to income. The obligation is discounted
at 9 percent, based on the expected long-term rate of return on government obligations.
Donor restrictions. The CCRC reports gifts of cash and other assets as restricted support if they are received
with donor stipulations that limit the use of the donated assets. When a donor restriction expires (that is,
when a stipulated time restriction ends or a purpose restriction is accomplished), temporarily restricted net
assets are reclassified as unrestricted net assets and reported in the statement of operations as net assets
released from restrictions. Donor-restricted contributions whose restrictions are met within the same year as
received are reflected as unrestricted contributions in the accompanying financial statements.
The CCRC reports gifts of property and equipment (or other long-lived assets) as unrestricted support unless explicit donor stipulations specify how the donated assets must be used. Gifts of long-lived assets with
explicit restrictions that specify how the assets are to be used and gifts of cash or other assets that must be
used to acquire long-lived assets are reported as restricted support. Absent explicit donor stipulations about
how long those long-lived assets must be maintained, the CCRC reports expirations of donor restrictions
when the donated or acquired long-lived assets are placed in service.
Income taxes. The CCRC has been recognized by the IRS as a not-for-profit corporation as described in Section 501(c)(3) of the Internal Revenue Code (IRC) and is exempt from federal income taxes pursuant to
Section 501(a) of the IRC.
Property and equipment. Property and equipment are stated at cost. Donated property is recorded at its estimated fair value at the date of receipt. Depreciation is computed on the straight-line method based on the
following estimated useful lives:
Land improvements
Buildings and improvements
Furniture and equipment

20 years
40 years
5–15 years

Operating income (loss). The statement of operations includes operating income (loss). Changes in unrestricted
net assets which are excluded from operating income (loss), consistent with industry practice, include unrealized gains and losses on investments other than trading securities, permanent transfers of assets to and
from affiliates for other than goods and services, and contributions of long-lived assets (including assets
acquired using contributions which by donor restriction were to be used for the purposes of acquiring such
assets).
2.

Property and Equipment

A summary of property and equipment at December 31, 20X7 and 20X6, follows:
20X7

20X6

Land
Land improvements
Buildings and improvements
Furniture and equipment

$557,000
205,000
14,573,000
752,000

$557,000
203,000
14,564,000
698,000

Less accumulated depreciation

16,087,000
(1,194,000)

16,022,000
(742,000)

$14,893,000
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3.

Temporarily Restricted Net Assets

Temporarily restricted net assets are available for the following purposes:
20X6

20X7
Purchase of equipment
Charity care

$169,000
142,000

$152,000
142,000

$311,000

$294,000

Net assets were released from donor restrictions by incurring expenses satisfying the restricted purposes or
by occurrence of other events specified by donors:
20X6

20X7

4.

Charity care

$24,000

$50,000

Purchase of equipment

$25,000

$45,000

Permanently Restricted Net Assets

Permanently restricted net assets are restricted to investment in perpetuity, the income from which is expendable to support:
20X7
Charity care
Community activities

5.

20X6

$168,000
283,000

$168,000
216,000

$451,000

$384,000

20X7

20X6

Long-Term Debt

Long-term debt at December 31, 20X7 and 20X6, is as follows:
10.75 percent mortgage note payable
Notes payable to bank—unsecured
Other
Less current maturities

$8,901,000
34,000
26,000

$8,965,000
14,000
33,000

8,961,000
90,000

9,012,000
77,000

$8,871,000

$8,935,000

The mortgage note is payable in consecutive monthly installments of principal and interest of $85,425 to
May 20XX. The note is collateralized by a first mortgage on property and equipment with a depreciated cost
at December 31, 20X7, of $14,893,000 and by a pledge of all operating revenue.
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As required by the mortgage note agreement, the CCRC established an initial debt service reserve fund of
$1,000,000 at April 15, 20X5. All resident fees received thereafter, net of resident fee refunds and debt service
payments not to exceed $300,000 annually in the first four years and $200,000 annually thereafter, are to be
added to the debt service reserve fund until the total sum of $2,050,000 is accumulated. Since June 1, 20X6,
the CCRC has been required to deliver to the trustee $5,500 per month to establish maintenance reserves
until the aggregate of such payments equals a residential unit reserve and a health care center reserve of
$240,000 and $90,000, respectively. At December 31, 20X7 and 20X6, the trustee held investments aggregating $2,130,000 and $1,753,000, respectively. Such amount has been classified as assets limited as to use.
Scheduled annual principal maturities of long-term debt for the next five years are as follows:
Year Ending
December 31,
20X8
20X9
20Y0
20Y1
20Y2
6.

Amount
$90,000
90,000
95,000
105,000
105,000

Classification of Expenses
20X7
Program activities
General and administrative

7.

Assets Limited as to Use‡‡

8.

Risks and Uncertainties Disclosures‡‡

9.

Pension Plan‡‡

10.

Postretirement Benefits‡‡

11.

Fair Values of Financial Instruments‡‡

12.

Concentrations of Credit Risk‡‡

13.

Investments‡‡

‡‡

20X6

3,368,000
593,000

3,135,000
570,000

$3,961,000

$3,705,000

The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for the
not-for-profit hospital and, therefore, are not repeated here.
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ILLUSTRATIVE FINANCIAL STATEMENTS FOR A HOME HEALTH AGENCY
.24
Sample Not-for-Profit Home Health Agency
Balance Sheets*
December 31, 20X7 and 20X6
20X7
Assets
Current assets:
Cash and cash equivalents
Investments
Accounts receivable, net of allowance for doubtful
accounts of $61,000 in 20X7 and $30,000 in 20X6
Other receivables
Total current assets
Investments
Equipment:
Medical and office equipment
Vehicles
Less accumulated depreciation
Equipment, net
Deferred finance charges, net of accumulated
amortization of $15,000 in 20X7 and $10,000 in 20X6
Total assets

20X6

$74,000
147,000

$41,000
137,000

752,000
27,000

476,000
22,000

1,000,000

676,000

100,000

100,000

56,000
50,000

39,000
37,000

106,000
(45,000)

76,000
(24,000)

61,000

52,000

20,000

25,000

$1,181,000

$853,000
(continued)

*
The fair value option subsections of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 825-10
permit all entities, including not-for-profit organizations, to choose to measure eligible items at fair value at specified election dates.
Notable eligible items include recognized financial assets and financial liabilities (except for those specifically prohibited), written loan
commitments, and rights and obligations under a warranty that is not a financial instrument (because it requires or permits the insurer
to provide goods or services rather than a cash payment) but whose terms permit the insurer to settle by paying a third party to provide
those goods or services. Prohibited recognized financial assets and liabilities include

a.

an investment in a subsidiary that the entity is required to consolidate.

b.

an interest in a variable interest entity that the entity is required to consolidate.

c.

employers and plans’ obligations (or assets representing net overfunded positions) for pension benefits, other postretirement
benefits (including health care and life insurance benefits), postemployment benefits, employee stock option and stock purchase plans, and certain other forms of deferred compensation arrangements, as defined by the applicable FASB pronouncements.

d.

financial assets and financial liabilities recognized under leases as defined in FASB ASC 840, Leases, excluding guarantees of a
third-party lease obligation or a contingent obligation arising from a cancelled lease.

e.

deposit liabilities, withdrawable on demand, of banks, savings and loan associations, credit unions, and other similar depository institutions.

f.

financial instruments that are, in whole or in part, classified by the issuer as a component of shareholder’s equity (including
temporary equity). An example is a convertible debt security with a noncontingent beneficial conversion feature.

Entities shall report assets and liabilities that are measured at fair value pursuant to the fair value option in this statement in a manner
that separates those reported fair values from the carrying amounts of similar assets and liabilities measured using another measurement
attribute. To accomplish that, an entity shall either
a.

present the aggregate of fair value and non-fair-value amounts in the same line item in the statement of financial position and
parenthetically disclose the amount measured at fair value included in the aggregate amount, or

b.

present two separate line items to display the fair value and non-fair-value carrying amounts.
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20X7
Liabilities and Net Assets
Current liabilities:
Current maturities of long-term debt
Accounts payable
Accrued payroll and vacation costs
Estimated third-party payor settlements
Advances from third-party payors
Total current liabilities
Long-term debt, less current maturities
Total liabilities
Net assets:
Unrestricted
Temporarily restricted
Permanently restricted
Total net assets
Total liabilities and net assets
See accompanying notes to financial statements.
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20X6

$13,000
40,000
496,000
28,000
70,000

$13,000
21,000
352,000
31,000
66,000

647,000

483,000

105,000

118,000

752,000

601,000

330,000
9,000
90,000

167,000
5,000
80,000

429,000

252,000

$1,181,000

$853,000
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.25
FORMAT A
Sample Not-for-Profit Home Health Agency
Statements of Operations
Years Ended December 31, 20X7 and 20X6

Revenue, gains, and other support:
Net patient service revenue
Contributions
Net assets released from restrictions
Investment income
Other revenue
Total revenue, gains, and other support
Expenses:
Salaries and benefits
Medical supplies and drugs
Insurance and other
Provision for bad debts
Depreciation
Interest
Total expenses
Excess of revenue over expenses and change in
unrestricted net assets

20X7

20X6

$4,042,000
5,000
5,000
13,000
27,000

$2,687,000
22,000
—
6,000
32,000

4,092,000

2,747,000

2,714,000
1,042,000
90,000
46,000
21,000
16,000

1,835,000
675,000
83,000
21,000
15,000
19,000

3,929,000

2,648,000

$163,000

$99,000

See accompanying notes to financial statements.
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.26
FORMAT B
Sample Not-for-Profit Home Health Agency
Statements of Operations
Years Ended December 31, 20X7 and 20X6

Revenue, gains, and other support:
Net patient service revenue
Contributions
Net assets released from restrictions
Other revenue
Total revenue, gains, and other support
Expenses:
Salaries and benefits
Medical supplies and drugs
Insurance and other
Provision for bad debts
Depreciation
Interest
Total expenses
Operating income
Other income:
Investment income
Excess of revenue over expenses and change in
unrestricted net assets
See accompanying notes to financial statements.

FSP §11,400.26

20X7

20X6

$4,042,000
5,000
5,000
27,000

$2,687,000
22,000
—
32,000

4,079,000

2,741,000

2,714,000
1,042,000
90,000
46,000
21,000
16,000

1,835,000
675,000
83,000
21,000
15,000
19,000

3,929,000

2,648,000

150,000

93,000

13,000

6,000

$163,000

$99,000
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.27
Sample Not-for-Profit Home Health Agency
Statements of Changes in Net Assets
Years Ended December 31, 20X7 and 20X6
20X7
Unrestricted net assets:
Excess of revenue over expenses
Increase in unrestricted net assets
Temporarily restricted net assets:
Contributions
Net assets released from restrictions
Increase in temporarily restricted net assets
Permanently restricted net assets:
Contributions
Increase in permanently restricted net assets
Increase in net assets
Net assets, beginning of year
Net assets, end of year

20X6

$163,000

$99,000

163,000

99,000

9,000
(5,000)

5,000
—

4,000

5,000

10,000

6,000

10,000

6,000

177,000
252,000

110,000
142,000

$429,000

$252,000

See accompanying notes to financial statements.
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.28
Sample Not-for-Profit Home Health Agency
Statements of Cash Flows
Years Ended December 31, 20X7 and 20X6

Cash flows from operating activities:
Cash received from patients and third party payors
Other receipts from operations
Cash paid to employees and suppliers
Interest paid
Nonoperating revenue
Net cash provided by operating activities
Cash flows from investing activities:
Purchase of equipment
Purchase of investments
Net cash used in investing activities
Cash flows from financing activities:
Proceeds from contributions restricted for:
Endowment
Other financing activities:
Payment of long-term debt
Net cash provided by (used in) financing activities
Net increase in cash and cash equivalents
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of year
Reconciliation of change in net assets to net cash
provided by operating activities:
Change in net assets
Adjustments to reconcile change in net assets to net
cash provided by operating activities:
Increase in permanently restricted net assets
Provision for bad debts
Depreciation
Amortization of deferred financing charges
(Increase) decrease in:
Accounts receivable
Other receivables
Increase (decrease) in:
Accounts payable, accrued payroll, and vacation costs
Estimated third-party payor settlements
Net cash provided by operating activities
See accompanying notes to financial statements.
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20X7

20X6

$3,721,000
22,000
(3,679,000)
(11,000)
23,000

$2,542,000
32,000
(2,541,000)
(14,000)
22,000

76,000

41,000

(30,000)
(10,000)

(19,000)
(15,000)

(40,000)

(34,000)

10,000

6,000

(13,000)

—

(3,000)

6,000

33,000
41,000

13,000
28,000

$74,000

$41,000

$177,000

$110,000

(10,000)
46,000
21,000
5,000

(6,000)
21,000
15,000
5,000

(322,000)
(5,000)

(150,000)
4,000

163,000
1,000

38,000
4,000

$76,000

$41,000
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.29

Sample Not-for-Profit Home Health Agency
Notes to Financial Statements†
Years Ended December 31, 20X7 and 20X6
1.

Description of Organization and Summary of Significant Accounting Policies18

Organization. The Sample Home Health Agency (the Agency) was incorporated in 20X0 in New State as a
not-for-profit corporation. The Agency provides health and supportive services to individuals at their
homes, primarily in the New State area.
Use of estimates. The preparation of financial statements in conformity with GAAP requires management to
make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues
and expenses during the reporting period. Actual results could differ from those estimates.
Cash and cash equivalents. Cash and cash equivalents include investments in highly liquid debt instruments
with an original maturity of three months or less.
Investments. Investments, which consist of U.S. Treasury obligations, are measured at fair value in the balance sheet. Investment income (including realized gains and losses on investments, interest and dividends)
is included in excess of revenues over expenses unless restricted by donor or law. Unrealized gains and
losses on investments, if any, are excluded from excess of revenues over expenses.
Equipment. Equipment is recorded at cost. Depreciation is computed using the straight-line method over the
estimated useful lives of the assets.
Deferred financing costs. Deferred financing costs are being amortized using the effective interest method over
the term of the related financing agreement.
Donor restrictions. The Agency reports gifts of cash and other assets as restricted support if they are received
with donor stipulations that limit the use of the donated assets. When a donor restriction expires, that is,
when a stipulated time restriction ends or purpose restriction is accomplished, temporarily restricted net
assets are reclassified as unrestricted net assets and reported in the statement of operations as net assets
released from restrictions. When long-lived assets are placed in service, thus satisfying purpose restrictions,
the amount is included as a change in net assets, restricted and unrestricted. Donor-restricted contributions
†
FASB ASC 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value in generally
accepted accounting principles (GAAP), and expands disclosures about fair value measurements. This guidance applies under other
accounting pronouncements that require or permit fair value measurements, the FASB having previously concluded in those accounting
pronouncements that fair value is the relevant measurement attribute. Accordingly, FASB ASC 820 does not require any new fair value
measurements but the application of it will change current practice.

FASB ASC 820 retains the exchange price notion already established within GAAP but clarifies, among other matters, that fair value
is the price that would be received to sell the asset or paid to transfer the liability (for example, an exit price) and not the price that would
be paid to acquire the asset or paid to transfer the liability (for example, an entry price). Additionally, FASB ASC 820 establishes a fair
value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. Level 1 inputs are
quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the
measurement date and shall be used to measure fair value when available, with limited exceptions. Level 2 inputs are inputs other than
quoted prices included within level 1 that are observable for the asset or liability, either directly or indirectly, and may include, for
example, quoted prices for similar assets or liabilities in active markets. Level 3 inputs are unobservable inputs for the asset or liability.
Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for
situations in which there is little, if any, market activity. Unobservable inputs shall be developed based on the best information available
in the circumstances, which might include the reporting entity’s own data.
FASB ASC 820-10-50 expands disclosures about the use of fair value to measure assets and liabilities in interim and annual periods
subsequent to initial recognition. The disclosures focus on the fair value hierarchy and the effect of the measurements on earnings (or
changes in net assets) for the period. Entities are encouraged to combine the fair value information disclosed under this statement with
other required fair value information, including that required by FASB ASC 825-10-50 about financial instruments.
18

See footnote 5.
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whose restrictions are met within the same year as received are reflected as unrestricted contributions in the
accompanying financial statements.
The Agency reports gifts of equipment (or other long-lived assets) as unrestricted support unless explicit
donor stipulations specify how the donated assets must be used. Gifts of long-lived assets with explicit
restrictions that specify how the assets are to be used and gifts of cash or other assets that must be used to
acquire long-lived assets are reported as restricted support. Absent explicit donor stipulations about how
long those long-lived assets must be maintained, the Agency reports expirations of donor restrictions when
the donated or acquired long-lived assets are placed in service.
Net patient service revenue. Net patient service revenue represents the estimated net realizable amounts from
patients, third-party payors, and others for services rendered.
Charity care. The Agency has a policy of providing charity care to patients who are unable to pay. Such
patients are identified based on financial information obtained from the patient and subsequent analysis.
Since the Agency does not expect payment, estimated charges for charity care are not included in revenue.
Income taxes. The Agency has been recognized by the IRS as a not-for-profit corporation as described in
Section 501(c)(3) of the Internal Revenue Code (IRC) and is exempt from federal income taxes on related
income pursuant to Section 501(a) of the IRC.
Excess of revenue over expenses. The statement of operations includes excess of revenue over expenses. Changes
in unrestricted net assets which are excluded from excess of revenue over expenses, consistent with industry
practice, include unrealized gains and losses on investments other than trading securities, permanent transfers of assets to and from affiliates for other than goods and services, and contributions of long-lived assets
(including assets acquired using contributions which by donor restriction were to be used for the purposes
of acquiring such assets).
2.

Temporarily Restricted Net Assets

Temporarily restricted net assets are available for the following purposes:
20X7

20X6

Charity care
Purchase of equipment

$—
9,000

$5,000
—

$9,000

$5,000

Net assets were released from donor restrictions by incurring expenses satisfying the restricted purposes or
by occurrence of other events specified by donors:
20X7
Charity care expenditures
3.

20X6

$5,000

$—

Permanently Restricted Net Assets

Permanently restricted net assets are restricted in perpetuity, the income from which is expendable to support:
20X7
Program A activities
Any activities of the
Agency
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$10,000

$—

80,000

80,000

$90,000

$80,000

327

Illustrative Financial Statements

4.

Third-Party Rate Adjustments and Revenue

Approximately 38 percent in 20X7 and 37 percent in 20X6 of net patient service revenue was derived under
federal and state third-party reimbursement programs. These revenues are based, in part, on cost reimbursement principles and are subject to audit and retroactive adjustment by the respective third-party fiscal intermediaries. Laws and regulations governing these programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material
amount in the near term. The 20X7 net patient service revenue increased approximately $XXX due to removal of allowances previously estimated that are no longer necessary as a result of final settlements and
years that are no longer subject to audits, reviews, and investigations. The 20X6 net patient service revenue
decreased approximately $XXX due to prior-year retroactive adjustments in excess of amounts previously
estimated.
5.

Internally Designated Assets

The Board of Directors has designated investments aggregating $100,000 to be used for future major capital
improvements. Those assets are classified in the balance sheet as long-term investments.
6.

Long-Term Debt

Long-term debt at December 31, 20X7 and 20X6, is as follows:
20X7
Note payable to bank, interest at 15 percent, payable in
monthly installments of $2,200 per month, including
interest, collateralized by equipment with a
depreciated cost of $42,000
Less current maturities

20X6

$118,000
13,000

$131,000
13,000

$105,000

$118,000

Scheduled maturities of long-term debt at December 31, 20X7, are as follows:
Year Ending
December 31,
20X8
20X9
20Y0
20Y1
20Y2
Thereafter
Total

Amount
$13,000
13,000
13,000
13,000
13,000
53,000
$118,000
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Classification of Expenses
Program

Expenses incurred for the year
ended December 31, 20X7, were
for:
Salaries and benefits
Medical supplies and drugs
Insurance and other
Provision for bad debts
Depreciation
Interest
Total expenses

B

General and
Administrative

Total

A

C

$2,714,000
1,042,000
90,000
46,000
21,000
16,000

$1,363,000
511,000
58,000
16,000
5,000
10,000

$699,000
246,000

3,000

—

16,000
3,000

$3,929,000

$1,963,000

$978,000

$648,000

$340,000

$363,000
285,000

$289,000
32,000

30,000

Program
Total
Expenses incurred for the year
ended December 31, 20X6, were
for:
Salaries and benefits
Medical supplies and drugs
Insurance and other
Provision for bad debts
Depreciation
Interest
Total expenses

A

B

General and
Administrative

C

$1,835,000
675,000
83,000
21,000
15,000
19,000

$915,000
335,000
64,000
21,000
6,000
12,000

$463,000
211,000

$216,000
129,000

$241,000

5,000

—

9,000
2,000

$2,648,000

$1,353,000

$679,000

$345,000

$271,000

19,000

(The preparer of the financial statements may wish to include a brief description of the types of programs.)
8.

Charity Care

Charity care represented approximately 3 percent and 4 percent of visits in 20X7 and 20X6, respectively.
9.

Risks and Uncertainties Disclosures‡‡

10.

Pension Plan‡‡

11.

Postretirement Benefits‡‡

12.

Fair Value of Financial Statements‡‡

13.

Concentrations of Credit Risk‡‡

14.

Investments‡‡

‡‡

The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for the
not-for-profit hospital and, therefore, are not repeated here.
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ILLUSTRATIVE FINANCIAL STATEMENTS FOR A HEALTH MAINTENANCE
ORGANIZATION
.30
Sample Not-for-Profit Health Maintenance Organization
Balance Sheets*
June 30, 20X7 and 20X6

Assets
Current assets:
Cash and cash equivalents
Premiums receivable, net of allowance for doubtful
accounts of $36,000 in 20X7 and $42,000 in 20X6
Other receivables
Supplies
Prepaid expenses
Total current assets
Property and equipment, net
State guaranty fund deposit
Debt issuance costs, net of accumulated amortization of
$42,000 in 20X7 and $39,000 in 20X6
Total assets

20X7

20X6

$2,937,000

$1,021,000

358,000
263,000
190,000
197,000

407,000
261,000
184,000
99,000

3,945,000

1,972,000

5,756,000
150,000

5,626,000
150,000

18,000

21,000

$9,869,000

$7,769,000
(continued)

*
The fair value option subsections of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 825-10
permit all entities, including not-for-profit organizations, to choose to measure eligible items at fair value at specified election dates.
Notable eligible items include recognized financial assets and financial liabilities (except for those specifically prohibited), written loan
commitments, and rights and obligations under a warranty that is not a financial instrument (because it requires or permits the insurer
to provide goods or services rather than a cash payment) but whose terms permit the insurer to settle by paying a third party to provide
those goods or services. Prohibited recognized financial assets and liabilities include

a.

an investment in a subsidiary that the entity is required to consolidate.

b.

an interest in a variable interest entity that the entity is required to consolidate.

c.

employers and plans’ obligations (or assets representing net overfunded positions) for pension benefits, other postretirement
benefits (including health care and life insurance benefits), postemployment benefits, employee stock option and stock purchase plans, and certain other forms of deferred compensation arrangements, as defined by the applicable FASB pronouncements.

d.

financial assets and financial liabilities recognized under leases as defined in FASB ASC 840, Leases, excluding guarantees of a
third-party lease obligation or a contingent obligation arising from a cancelled lease.

e.

deposit liabilities, withdrawable on demand, of banks, savings and loan associations, credit unions, and other similar depository institutions.

f.

financial instruments that are, in whole or in part, classified by the issuer as a component of shareholder’s equity (including
temporary equity). An example is a convertible debt security with a noncontingent beneficial conversion feature.

Entities shall report assets and liabilities that are measured at fair value pursuant to the fair value option in this statement in a manner
that separates those reported fair values from the carrying amounts of similar assets and liabilities measured using another measurement
attribute. To accomplish that, an entity shall either
a.

present the aggregate of fair value and non-fair-value amounts in the same line item in the statement of financial position and
parenthetically disclose the amount measured at fair value included in the aggregate amount, or

b.

present two separate line items to display the fair value and non-fair-value carrying amounts.
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20X7
Liabilities and Net Assets
Current liabilities:
Unsecured 12 percent note payable to a bank
Current maturities of long-term debt
Accounts payable—medical services
Other accounts payable and accrued expenses
Unearned premium revenue
Total current liabilities
Long-term debt, less current maturities
Total liabilities
Net assets—unrestricted
Total liabilities and net assets
See accompanying notes to financial statements.
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20X6

$—
241,000
2,245,000
829,000
141,000

$44,000
109,000
1,471,000
661,000
202,000

3,456,000

2,487,000

4,295,000

2,382,000

7,751,000

4,869,000

2,118,000

2,900,000

$9,869,000

$7,769,000
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.31
Sample Not-for-Profit Health Maintenance Organization
Statements of Operations and Changes in Net Assets
Years Ended June 30, 20X7 and 20X6
20X7
Revenue:
Premiums earned
Coinsurance
Interest and other income
Total revenue
Expenses:
Salaries and benefits
Medical supplies and drugs
Insurance
Provision for bad debts
Depreciation
Interest
Total expenses
Operating income (loss)
Net assets, beginning of year
Net assets, end of year

20X6

$27,682,000
689,000
242,000

$22,500,000
500,000
100,000

28,613,000

23,100,000

16,154,000
8,507,000
3,963,000
19,000
367,000
385,000

13,328,000
5,988,000
2,463,000
20,000
336,000
375,000

29,395,000

22,510,000

(782,000)
2,900,000
$2,118,000

590,000
2,310,000
$2,900,000

See accompanying notes to financial statements.
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.32
Sample Not-for-Profit Health Maintenance Organization
Statements of Cash Flows
Years Ended June 30, 20X7 and 20X6
20X7
Cash flows from operating activities:
Cash received from premiums, stop-loss insurance
recoveries, and coinsurance
Cash paid to employees and to providers of health
care services
Interest and other income received
Interest paid
Net cash provided by operating activities
Cash flows from investing activities:
Capital expenditures

20X6

$28,969,000

$24,410,000

(28,405,000)
230,000
(382,000)

(22,818,000)
90,000
(372,000)

412,000

1,310,000

(497,000)

(121,000)

Net cash used in investing activities

(497,000)

(121,000)

Cash flows from financing activities:
Proceeds from long-term debt
Principal payments on long-term debt
Principal payments on note payable

2,300,000
(255,000)
(44,000)

—
(1,000,000)
—

2,001,000

(1,000,000)

Net cash provided by (used in) financing activities
Net increase in cash and cash equivalents
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of year
Reconciliation of change in net assets to net cash
provided by operating activities:
Change in net assets
Adjustments to reconcile change in net assets to net
cash provided by operating activities:
Depreciation and amortization
Provision for bad debts
(Increase) decrease in:
Premiums receivables
Other current assets
Increase (decrease) in:
Accounts payable—medical services
Other accounts payable and accrued expenses
Unearned premium revenue
Net cash provided by operating activities
See accompanying notes to financial statements.
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1,916,000
1,021,000

189,000
832,000

$2,937,000

$1,021,000

$(782,000)

$590,000

370,000
19,000

339,000
20,000

30,000
230,000

64,000
(93,000)

774,000
(168,000)
(61,000)

335,000
(60,000)
115,000

$412,000

$1,310,000
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Sample Not-for-Profit Health Maintenance Organization
Notes to Financial Statements19, †
June 30, 20X7 and 20X6
1.

Organization

The Sample Health Maintenance Organization (the HMO) was incorporated in 20X0 in New State as a notfor-profit corporation for the purpose of providing comprehensive health care services on a prepaid basis
and for the purpose of establishing and operating organized health maintenance and health care delivery
systems.
The HMO has been determined to be a qualified health maintenance organization under Title XIII of the
Public Health Service Act.
2.

Summary of Significant Accounting Policies20

Use of estimates. The preparation of financial statements in conformity with GAAP requires management to
make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues
and expenses during the reporting period. Actual results could differ from those estimates.
Cash and cash equivalents. Cash and cash equivalents include investments in highly liquid debt instruments
with an original maturity of three months or less.
Supplies. Inventories of drugs and other supplies are stated at the lower of cost (first-in, first-out) or market.
Property and equipment. Property and equipment are recorded at cost. Maintenance and repairs are charged
to expense, and betterments are capitalized. Property and equipment costing approximately $700,000 was
financed by health maintenance organization initial development grants received in 20X1 and 20X2 from the
U.S. Department of Health and Human Services (HHS). This property will be owned by the HMO as long
as the equipment and facilities are used for projects related to the objectives of the Public Health Service
Act.

19

See footnote 16.

†

FASB ASC 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value in generally
accepted accounting principles (GAAP), and expands disclosures about fair value measurements. This guidance applies under other
accounting pronouncements that require or permit fair value measurements, the FASB having previously concluded in those accounting
pronouncements that fair value is the relevant measurement attribute. Accordingly, FASB ASC 820 does not require any new fair value
measurements but the application of it will change current practice.
FASB ASC 820 retains the exchange price notion already established within GAAP but clarifies, among other matters, that fair value
is the price that would be received to sell the asset or paid to transfer the liability (for example, an exit price) and not the price that would
be paid to acquire the asset or paid to transfer the liability (for example, an entry price). Additionally, FASB ASC 820 establishes a fair
value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. Level 1 inputs are
quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the
measurement date and shall be used to measure fair value when available, with limited exceptions. Level 2 inputs are inputs other than
quoted prices included within level 1 that are observable for the asset or liability, either directly or indirectly, and may include, for
example, quoted prices for similar assets or liabilities in active markets. Level 3 inputs are unobservable inputs for the asset or liability.
Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for
situations in which there is little, if any, market activity. Unobservable inputs shall be developed based on the best information available
in the circumstances, which might include the reporting entity’s own data.
FASB ASC 820-10-50 expands disclosures about the use of fair value to measure assets and liabilities in interim and annual periods
subsequent to initial recognition. The disclosures focus on the fair value hierarchy and the effect of the measurements on earnings (or
changes in net assets) for the period. Entities are encouraged to combine the fair value information disclosed under this statement with
other required fair value information, including that required by FASB ASC 825-10-50 about financial instruments.
20

See footnote 5.
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Depreciation is computed using the straight-line method over the estimated useful lives of the related assets
as follows:
Building
Improvements
Data processing and laboratory equipment and
automobiles
Medical equipment
Office equipment

40 years
20–25 years
3–7 years
10 years
5–10 years

Amortization of debt issuance costs. Debt issuance costs are deferred and amortized using the effective interest
method over the term of the related debt.
Health care service cost recognition. The HMO contracts with various health care providers for the provision
of certain medical care services to its members. The HMO compensates these providers on a capitation basis.
As part of a cost control incentive program, the HMO retains up to 20 percent of the capitation as a risksharing fund. In the event of hospital utilization in excess of budget, those providers bear the risk to the
extent of 15 percent of the capitation fee. Operating expenses include all amounts incurred by the HMO
under the aforementioned contracts.
The cost of other health care services provided or contracted for is accrued in the period in which it is
provided to a member based in part on estimates, including an accrual for medical services provided but
not reported to the HMO.
Premiums revenue. Membership contracts are on a yearly basis subject to cancellation by the employer group
or the HMO upon 30 days written notice. Premiums are due monthly and are recognized as revenue during
the period in which the HMO is obligated to provide services to members.
Reinsurance (stop-loss insurance). Reinsurance premiums are reported as health care costs, and reinsurance
recoveries are reported as a reduction of related health care costs.
Federal income tax. The HMO is exempt from federal income taxes under Section 501(c)(4) of the Internal
Revenue Code; accordingly, no provision for federal income taxes has been made in the accompanying
financial statements.
3.

Property and Equipment

Property and equipment at June 30, 20X7 and 20X6, consists of the following:
20X7
Land
Buildings and improvements
Furniture and equipment
Less accumulated depreciation
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20X6

$300,000
5,473,000
1,786,000

$300,000
5,459,000
1,303,000

7,559,000
(1,803,000)

7,062,000
(1,436,000)

$5,756,000

$5,626,000
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4.

Long-Term Debt

Long-term debt is collateralized by assets with a depreciated cost of $4,943,000. A summary of long-term
debt at June 30, 20X7 and 20X6, follows.
20X7
HHS loan, interest at 7.5 percent, payable in monthly
installments of $50,000, including interest
HHS loan, interest at 9.25 percent, payable in monthly
installments of $10,000, including interest
Secured equipment loans, payable in monthly
installments of $15,000, including interest
Less current maturities

20X6

$2,020,000

$111,000

1,658,000

1,694,000

858,000

686,000

4,536,000
241,000

2,491,000
109,000

$4,295,000

$2,382,000

Scheduled principal payments on long-term debt are as follows:
Year Ending
December 31,
20X8
20X9
20Y0
20Y1
20Y2

Amount
$241,000
259,000
280,000
800,000
2,956,000
$4,536,000

5.

State Guarantee Fund Deposit

In August 20X4 the state in which the HMO is domiciled enacted legislation specifically governing HMOs.
Under this legislation, the corporation is required to maintain a deposit of $150,000 with the director of the
division of insurance of the state.
6.

Employee Retirement Plan

The HMO has a contributory defined contribution retirement plan covering substantially all employees.
Expense determined in accordance with the plan formula (4 percent to 10 percent of eligible covered compensation) was $354,000 and $275,000 for the years ended June 30, 20X5 and 20X4, respectively.
7.

Stop-Loss Insurance

The HMO entered into a stop-loss insurance agreement with an insurance company to limit its losses on
individual claims. Under the terms of this agreement, the insurance company will reimburse the HMO approximately 25 percent of the cost of each member’s annual hospital services, in excess of a $1,000 deductible, up to a lifetime limitation of $500,000 per member. In the event the HMO ceases operations, (a) plan
benefits will continue for members who are confined in an acute care hospital on the date of insolvency until
their discharge, and (b) plan benefits will continue for any other member until the end of the contract period
for which premiums have been paid.
Stop-loss insurance premiums of approximately $700,000 and $500,000 are included in insurance expense
(note 9) in 20X7 and 20X6 respectively. Approximately $600,000 and $400,000 in stop-loss insurance recoveries are deducted from insurance expense in 20X7 and 20X6, respectively.
Included in other receivables is approximately $50,000 recoverable from insurers.
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Malpractice Claims

Malpractice claims have been asserted against the HMO by various claimants. The claims are in various
stages of processing, and some may ultimately be brought to trial. In the opinion of counsel, the outcome of
these actions will not have a significant effect on the financial position or the operating income of the HMO.
Incidents occurring through June 30, 20X7, may result in the assertion of additional claims. Other claims
may be asserted arising from past services provided. Management believes that these claims, if asserted,
would be settled within the limits of insurance coverage.
9.

Classification of Expenses
20X7
Program activities
General and
administrative

10.

Risks and Uncertainties Disclosures‡‡

11.

Pension Plan‡‡

12.

Postretirement Benefits‡‡

13.

Fair Value of Financial Instruments‡‡

14.

Concentrations of Credit Risk‡‡

‡‡

20X6

26,921,000

20,909,000

2,474,000

1,601,000

$29,395,000

$22,510,000

The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for the
not-for-profit hospital and, therefore, are not repeated here.
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ILLUSTRATIVE FINANCIAL STATEMENTS FOR AN AMBULATORY CARE
ORGANIZATION
.34
Sample Not-for-Profit Ambulatory Care, Inc.
Balance Sheets*
December 31, 20X7 and 20X6
20X7
Assets
Current assets:
Cash
Patient accounts receivable, net of allowance for
doubtful accounts of $15,000 in 20X7 and $5,000 in
20X6
Estimated retroactive adjustments—third-party
payors
Accounts receivable—other
Supplies
Prepaid expenses and deposits
Total current assets

20X6

$65,000

$76,000

290,000

278,000

19,000
13,000
21,000
5,000

32,000
8,000
18,000
9,000

413,000

421,000
(continued)

*
The fair value option subsections of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 825-10
permit all entities, including not-for-profit organizations, to choose to measure eligible items at fair value at specified election dates.
Notable eligible items include recognized financial assets and financial liabilities (except for those specifically prohibited), written loan
commitments, and rights and obligations under a warranty that is not a financial instrument (because it requires or permits the insurer
to provide goods or services rather than a cash payment) but whose terms permit the insurer to settle by paying a third party to provide
those goods or services. Prohibited recognized financial assets and liabilities include

a.

an investment in a subsidiary that the entity is required to consolidate.

b.

an interest in a variable interest entity that the entity is required to consolidate.

c.

employers and plans’ obligations (or assets representing net overfunded positions) for pension benefits, other postretirement
benefits (including health care and life insurance benefits), postemployment benefits, employee stock option and stock purchase plans, and certain other forms of deferred compensation arrangements, as defined by the applicable FASB pronouncements.

d.

financial assets and financial liabilities recognized under leases as defined in FASB ASC 840, Leases, excluding guarantees of a
third-party lease obligation or a contingent obligation arising from a cancelled lease.

e.

deposit liabilities, withdrawable on demand, of banks, savings and loan associations, credit unions, and other similar depository institutions.

f.

financial instruments that are, in whole or in part, classified by the issuer as a component of shareholder’s equity (including
temporary equity). An example is a convertible debt security with a noncontingent beneficial conversion feature.

Entities shall report assets and liabilities that are measured at fair value pursuant to the fair value option in this statement in a manner
that separates those reported fair values from the carrying amounts of similar assets and liabilities measured using another measurement
attribute. To accomplish that, an entity shall either
a.

present the aggregate of fair value and non-fair-value amounts in the same line item in the statement of financial position and
parenthetically disclose the amount measured at fair value included in the aggregate amount, or

b.

present two separate line items to display the fair value and non-fair-value carrying amounts.
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20X7

20X6

Property and equipment, at cost:
Land
Land improvements
Buildings
Equipment

100,000
322,000
682,000
1,390,000

100,000
322,000
682,000
1,389,000

Less accumulated depreciation

2,494,000
217,000

2,493,000
100,000

2,277,000

2,393,000

14,000

5,000

$2,704,000

$2,819,000

$138,000
42,000
33,000

$144,000
77,000
22,000

30,000
—

24,000
1,000

243,000

268,000

10,000

10,000

253,000

278,000

2,451,000

2,541,000

$2,704,000

$2,819,000

Property and equipment, net
Other assets:
Advances receivable
Total assets
Liabilities and Net Assets
Current liabilities:
Notes payable
Accounts payable
Accrued payroll, benefits, and taxes
Estimated retroactive adjustments—third-party
payors
Financing advance from third-party payors
Total current liabilities
Guarantee liability
Total liabilities
Net assets—unrestricted
Total liabilities and net assets
See accompanying notes to financial statements.
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.35
Sample Not-for-Profit Ambulatory Care, Inc.
Statements of Operations and Changes in Net Assets
Years Ended December 31, 20X7 and 20X6
20X7

20X6

Revenue and gains:
Net patient service revenue
Other

$860,000
29,000

$357,000
15,000

Total revenue and gains

889,000

372,000

Expenses:
Salaries and benefits
Medical supplies and drugs
Insurance
Provision for bad debts
Depreciation
Interest

485,000
189,000
154,000
14,000
117,000
20,000

243,000
66,000
98,000
4,000
100,000
18,000

979,000

529,000

(90,000)
2,541,000

(157,000)
2,698,000

Total expenses
Operating loss
Net assets, beginning of year
Net assets, end of year

$2,451,000

$2,541,000

See accompanying notes to financial statements.
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.36
Sample Not-for-Profit Ambulatory Care, Inc.
Statements of Cash Flows
Years Ended December 31, 20X7 and 20X6
20X7
Cash flows from operating activities:
Cash received from patients and third-party payors
Cash received from others
Interest received
Interest paid
Cash paid to employees and suppliers
Net cash provided by (used in) operating activities

20X6

$866,000
21,000
3,000
(15,000)

$368,000
6,000
11,000
(16,000)

(870,000)

(432,000)

5,000

(63,000)

Cash flows from investing activities:
Purchase of equipment
Advances made to XYZ Affiliate

(1,000)
(9,000)

(4,000)
(5,000)

Net cash used in investing activities

(10,000)

(9,000)

Cash flows from financing activities:
Proceeds from notes payable
Payments on notes payable

—
(6,000)

144,000
—

(6,000)

144,000

Net increase (decrease) in cash
Cash, beginning of year

(11,000)
76,000

72,000
4,000

Cash, end of year

$65,000

$76,000

$(90,000)

$(157,000)

117,000
14,000

100,000
4,000

(12,000)
1,000

(19,000)
(2,000)

(24,000)
(1,000)

10,000
1,000

$5,000

$(63,000)

Net cash provided by (used in) financing activities

Reconciliation of change in net assets to net cash
provided by (used in) operating activities:
Change in net assets
Adjustments to reconcile change in net assets to net
cash provided by (used in) operating activities:
Depreciation
Provision for bad debts
(Increase) decrease in:
Patient accounts receivable
Other current assets
Increase (decrease) in:
Accounts payable and accrued payroll, benefits, and
taxes
Other current liabilities
Net cash provided by (used in) operating activities
See accompanying notes to financial statements.
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Sample Not-for-Profit Ambulatory Care, Inc.
Notes to Financial Statements†
December 31, 20X7 and 20X6
1.

Description of Organization and Summary of Significant Accounting Policies21

Organization. Ambulatory Care, Inc. was incorporated on September 7, 20X3, in New State, to operate an
ambulatory care health facility to treat or prevent injury and disease, to provide funds or to expend funds
to further the treatment or prevention of injury or disease, and to develop and participate in activities designed to promote the general health of the community.
Three area hospitals—ABC Hospital and Health Center, DEF Hospital, and GHI Hospital—entered into a
members’ agreement to develop this ambulatory care center. In accordance with this agreement, each hospital contributed capital of $947,000 to Ambulatory Care, Inc. Ambulatory Care, Inc. began operations in
October 20X3.
Use of estimates. The preparation of financial statements in conformity with GAAP requires management to
make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues
and expenses during the reporting period. Actual results could differ from those estimates.
Supplies. Supplies are stated at the lower of cost (first-in, first-out) or net realizable value.
Depreciation. Depreciation of property and equipment is computed on the straight-line method over the estimated lives of depreciable assets.
Third-party contractual adjustments. Retroactively calculated third-party contractual adjustments are accrued
on an estimated basis in the period the related services are rendered. Net patient service revenue is adjusted
as required in subsequent periods based on final settlements.
Net patient service revenue. Patient service revenue is reported at the estimated net realizable amounts from
patients, third-party payors, and others for services rendered.
Charity care. Ambulatory Care, Inc. has a policy of providing charity care to patients who are unable to pay.
Such patients are identified and related charges are estimated, based on financial information obtained from

†
FASB ASC 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value in generally
accepted accounting principles (GAAP), and expands disclosures about fair value measurements. This guidance applies under other
accounting pronouncements that require or permit fair value measurements, the FASB having previously concluded in those accounting
pronouncements that fair value is the relevant measurement attribute. Accordingly, FASB ASC 820 does not require any new fair value
measurements but the application of it will change current practice.

FASB ASC 820 retains the exchange price notion already established within GAAP but clarifies, among other matters, that fair value
is the price that would be received to sell the asset or paid to transfer the liability (for example, an exit price) and not the price that would
be paid to acquire the asset or paid to transfer the liability (for example, an entry price). Additionally, FASB ASC 820 establishes a fair
value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. Level 1 inputs are
quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the
measurement date and shall be used to measure fair value when available, with limited exceptions. Level 2 inputs are inputs other than
quoted prices included within level 1 that are observable for the asset or liability, either directly or indirectly, and may include, for
example, quoted prices for similar assets or liabilities in active markets. Level 3 inputs are unobservable inputs for the asset or liability.
Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for
situations in which there is little, if any, market activity. Unobservable inputs shall be developed based on the best information available
in the circumstances, which might include the reporting entity’s own data.
FASB ASC 820-10-50 expands disclosures about the use of fair value to measure assets and liabilities in interim and annual periods
subsequent to initial recognition. The disclosures focus on the fair value hierarchy and the effect of the measurements on earnings (or
changes in net assets) for the period. Entities are encouraged to combine the fair value information disclosed under this statement with
other required fair value information, including that required by FASB ASC 825-10-50 about financial instruments.
21

See footnote 5.
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the patient and subsequent analysis. Since management does not expect payment for charity care, the estimated charges are excluded from revenue.
Income taxes. Ambulatory Care, Inc. has been recognized by the Internal Revenue Service as a not-for-profit
corporation as described in Section 501(c)(3) of the Internal Revenue Code (IRC) and is exempt from federal
income taxes on related income pursuant to Section 501(a) of the IRC.
2.

Advances Receivable

In May 20X4, Ambulatory Care, Inc. entered into a five-year agreement with XYZ Affiliates (XYZ). Under
this agreement, XYZ is to provide emergency medical services as well as charge and bill each patient treated
at Ambulatory Care, Inc. Ambulatory Care, Inc. has guaranteed that XYZ will collect at least $18,000 per
month during the term of this agreement. In any month in which XYZ does not collect the minimum guarantee, Ambulatory Care, Inc. advances funds to XYZ to cover the deficiency. Such advances are to be repaid
to the extent XYZ’s net cash collections exceed the minimum guarantee amount. Management estimates that
the advances will be fully recovered in 20X8.
3.

Related-Party Transactions

During 20X3, Ambulatory Care, Inc. entered into a contract with one of the member hospitals (the managing
hospital) for the management of the business and affairs of Ambulatory Care, Inc. Under this agreement,
Ambulatory Care, Inc. pays $4,000 per month to the managing hospital. The agreement with the managing
hospital was to remain in effect through December 31, 20X5, but has been extended on a month-to-month
basis.
In addition, during 20X4 each hospital loaned $48,000 to Ambulatory Care, Inc. in the form of promissory
notes at an interest rate of prime rate plus 1 percent (effective rates of 10 percent and 9 percent in 20X7 and
20X6, respectively). Of the total $144,000 liability, $48,000 is payable on demand after November 28, 20X7,
to one member hospital, with the remaining portion ($96,000) payable on demand after December 8, 20X6,
to the other two member hospitals. During 20X7, Ambulatory Care, Inc. paid $2,000 to each member hospital, thereby reducing the obligation to $138,000.
4.

Revenue From Contracting Agencies

Ambulatory Care, Inc. participates as a provider of health care services to Blue Cross, Medicare, and County
Indigent Plan patients. Reimbursement for covered services is based on tentative payment rates. Final reimbursement is determined after submission of annual cost reports and audits thereof by the fiscal intermediaries. Provisions for estimated reimbursement adjustments are reported in the financial statements in
the period that the services are rendered.
Revenue from the Medicare program accounted for approximately XX percent for the year ended 20X7, and
XX percent for the year ended 20X6, of Ambulatory Care, Inc.’s net patient revenue. Laws and regulations
governing the Medicare program are extremely complex and subject to interpretation. As a result, there is
at least a reasonable possibility that recorded estimates will change by a material amount in the near term.
The 20X7 net patient service revenue increased approximately $XXX due to removal of allowances previously estimated that are no longer necessary as a result of final settlements and years that are no longer
subject to audits, reviews, and investigations. The 20X6 net patient service revenue decreased approximately
$XXX due to prior-year retroactive adjustments in excess of amounts previously estimated.
5.

Charity Care

Ambulatory Care, Inc. has a policy of providing charity care to indigent patients in emergency situations.
These services, which are excluded from revenues, amounted to $27,000 and $13,000 in 20X7 and 20X6,
respectively, when measured at Ambulatory Care, Inc.’s established rates.
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6.

Classification of Expenses
Program
Total

Expenses incurred for the year
ended December 31, 20X7, were
for:
Salaries and benefits
Medical supplies and drugs
Insurance
Provision for bad debts
Depreciation
Interest
Total expenses

A

B

C

General and
Administrative

$485,000
189,000
154,000
14,000
117,000
20,000

$216,000
98,000
79,000
9,000
100,000
9,000

$102,000
43,000
45,000
—
—
—

$121,000
48,000
14,000
5,000
17,000
—

$46,000
—
16,000
—
—
11,000

$979,000

$511,000

$190,000

$205,000

$73,000

Program
Total
Expenses incurred for the year
ended December 31, 20X6, were
for:
Salaries and benefits
Medical supplies and drugs
Insurance
Provision for bad debts
Depreciation
Interest
Total expenses

A

B

C

General and
Administrative

$243,000
66,000
98,000
4,000
100,000
18,000

$111,000
31,000
45,000
—
56,000
7,000

$46,000
15,000
19,000
4,000
—
—

$57,000
20,000
26,000
—
44,000
—

$29,000
—
8,000
—
—
11,000

$529,000

$250,000

$84,000

$147,000

$48,000

(The preparer of the financial statements may wish to include a brief description of the types of programs.)
7.

Risks and Uncertainties Disclosures‡‡

8.

Pension Plan‡‡

9.

Postretirement Benefits‡‡

10.

Fair Value of Financial Instruments‡‡

11.

Concentrations of Credit Risk‡‡

‡‡

The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for the
not-for-profit hospital and, therefore, are not repeated here.
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Your Opinion Matters
Thank you for selecting this publication for your accounting or auditing needs.
At the AICPA, we strive to provide the most useful publications available to the profession, which have been
produced with the highest quality. Responsiveness to our members and the profession as a whole is our
hallmark. We rely on feedback from our users to continually hone and improve our products.
Please take a few moments to let us know what you think of this edition. Does it meet your needs? Is it written
clearly? Is it comprehensive in its coverage? Is it easy to use? If not, how can we improve it?
Send your feedback by e-mail to A&APublications@aicpa.org.
Please note the name and edition of the publication, answers to the preceding questions, and anything else
you would like to share with us. Your feedback will help us improve subsequent editions and better serve
you.
Do you want to help even more?
Consider participating in a focus or advisory group related to this subject matter. If you are interested in, and
available for, participating in such a group, please be sure to include that information in your e-mail.
Thank you in advance for taking the time to write. We appreciate your feedback!

Additional Publications for Your Financial Reporting Library
Checklists and Illustrative Financial Statements

AICPA publishes a full range of Checklists to help you prepare financial statements and assist you in determining the
adequacy of disclosures in the financial statements you’re auditing.

AICPA Checklists include:
• Corporations
• Defined Benefit Pension Plans
• Defined Contribution Pension Plans
• Depository and Lending Institutions
• Health and Welfare Benefit Plans
• Health Care Entities
• Life and Health Insurance Entities
• Not-for-Profit Entities
• Property & Liability Insurance Entities
• State and Local Governments

Supplements to Corporations Checklist
• Real Estate Ventures and Construction Contractors
• Investment Companies

Audit and Accounting Guides – Industry Guides

Other Guides

• Airlines

• Analytical Procedures

• Brokers and Dealers in Securities
• Casinos

• Assessing and Responding to Audit
Risk In a Financial Statement Audit

• Construction Contractors

• Audit Sampling

• Depository and Lending Institutions: Banks and Savings
Institutions, Credit Unions, Finance Companies, and
Mortgage Companies

• Auditing Derivative Instruments,
Hedging Activities, and Investments
in Securities

• Employee Benefit Plans

• Auditing Revenue in Certain Industries

• Entities With Oil and Gas Producing Activities

• Compilation and Review Engagements

• Health Care Entities

• Government Auditing Standards and
Circular A-133 Audits

• Investment Companies
• Life & Health Insurance Entities

• Prospective Financial Information

• Not-for-Profit Entities
• Property and Liability Insurance Entities
• State and Local Governments

For these titles and other AICPA publications, sets, and bundles, get complete details - including table of
contents, excerpts, availability and ordering information – by visiting the AICPA Store at
www.cpa2biz.com/publications or call 1-888-777-7077

AICPA Online Professional Library
AICPA online professional library is an electronic research tool that combines the power and speed of the Web with
comprehensive accounting and auditing literature. Through this online subscription to the AICPA Complete Library, you’ll get:
• Robust search engine — helps you narrow down your research to find your results quickly
• Links between titles —no need to search for the related information, AICPA online professional library
links all of the relevant materials for quick access and answers
• Improved document referencing — more easily identify your location in the literature
• Quick Find — separates the literature by document type or subject matter so you can browse the materials
• Timely updates — new standards and conforming changes are added to keep you current with all of the
authoritative guidance

AICPA Complete Library includes the following:
• AICPA Professional Standards
• AICPA Technical Practice Aids
• AICPA Audit & Accounting Manual
• PCAOB Standards & Related Rules
• Accounting Trends & Techniques
• IFRS Accounting Trends & Techniques
• All current AICPA Audit and Accounting Guides
• All current Audit Risk Alerts
• All current Checklists and Illustrative Financial Statements

You can also add the FASB Accounting Standards Codification™ and the GASB Library

AICPA Complete Library with FASB Accounting Standards Codification™ and GASB
Library, one-year individual online subscription
No. WGLBY12

AICPA Complete Library and FASB Accounting Standards Codification™ ,
one-year individual online subscription
No. WFLBY12

AICPA Complete Library, one-year individual online subscription
No. WALBY12

AICPA online professional library offers a range of online subscription options
with pricing available for single products and single subscribers up to complete libraries for
multi users – log onto www.cpa2biz.com/library for details.

